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Short Abstract 
 
Quadruple helices, or G-quadruplexes, are DNA secondary structures found in 
guanine rich oligonucleotide sequences, having a natural propensity to self-associate 
in coplanar arrays of four guanines, stabilized by Hoogsteen hydrogen bonding. The 
scientific interest towards these particular DNA structures is mainly due to the 
presence of guanine rich domains, potentially able to form G-quadruplexes, in 
important regions of the human genome, as gene promoters and telomeres, and to 
the fact that the G-quadruplexes can constitute the scaffold of aptamers. Aptamers 
are short DNA or RNA fragments capable to bind with high affinity specific proteins, 
as for example thrombin or HIV-proteins. On these grounds, aptamers-based 
synthetic oligonucleotides can represent a new class of pharmacologically interesting 
molecules, characterized by a high selectivity of action. Furthermore, the G-
quadruplexes can have a potential use in nanotechnology. As a matter of fact, the 
overall quadruplex scaffold can exhibit several morphologies through intramolecular 
or intermolecular organization of G-rich oligonucleotide strands, which can form 
higher-order assemblies by multimerization between G-quadruplex units.  
 
In these contests, my research studies have been mainly focused on:  
 
1. Investigation of the most prominent biological properties of selected G-
quadruplexes and identification of bioactive sequences able to play a 
biological role as aptamers. 
 
2. Elucidation of the sequence-specific thermodynamic stability and physical-
chemical mechanisms that underlie the G-quadruplexes multimerization. 
 
Specifically, during my PhD research studies, I focused on anti-HIV aptamers, and 
Thrombin Binding Aptamer (TBA) with the aim to identify the structural features 
required for their biological activity and reaching the way to improve them.  
 
Furthermore, I identify the CGGXGGT oligonucleotide sequence (where X = A, C, G, 
or T) able to lead to the formation of higher order G-quadruplex assemblies, that can 
potentially be used as DNA-based nanostructures.  
 
In order to achieve these objectives, it has been necessary to exploit the synthesis 
and the structural characterization of quadruplex-forming oligonucleotides, the 
analysis of the sequence-specific thermodynamic stability, the physical-chemical 
properties and the structural features of resulting G-quadruplexes. Furthermore, as 
regard the studies about aptamers, the evaluation of the binding properties to the 
selected proteins, and bioassays to ascertain the biological properties of the 
synthesized complexes have been undertaken. 
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Long Abstract 
 
Le G-quadruplex sono strutture secondarie di acido deossiribonucleico che si 
formano in sequenze ricche di guanine. Tali guanine hanno una naturale 
propensione ad auto associarsi in quartetti complanari (o tetradi), e sono in grado di 
stabilizzarsi mediante legami a idrogeno di tipo Hoogsteen (1). Dalla prima 
identificazione delle G-quadruplex, avvenuta nel 1962, sono ormai passati 
cinquant’anni. Nonostante questo, l’interesse scientifico verso le G-quadruplex non si 
è mai esaurito ma è anzi cresciuto in maniera esponenziale, arrivando al suo apice 
proprio nei mesi scorsi, quando il gruppo di ricerca del prof. Balasubramanian ha 
pubblicato un articolo in Nature Chemistry, in cui ha descritto un metodo per la 
visualizzazione quantitativa in vivo delle G-quadruplex e fornito quindi prove 
sostanziali e dirette della loro naturale formazione all’interno del genoma umano (2). 
A parte questo, molto si è detto e molto si è scritto in questi anni sulle G-quadruplex. 
É ormai dimostrato che queste strutture siano coinvolte in diversi processi biologici, 
ed è per questo motivo che sono diventate il principale interesse scientifico di molti 
gruppi di ricerca specializzati in differenti campi: dalla biologia molecolare a quella 
cellulare, dalla fisica alla chimica.  
La presenza di domini ricchi di guanine, potenzialmente in grado di strutturarsi in  G-
quadruplex, sono presenti in importanti regioni del genoma umano, come ad 
esempio la porzione a singolo filamento dei telomeri  e diversi promotori genici, 
suggerendo pertanto un possibile ruolo delle strutture G-quadruplex nella 
regolazione dei processi replicativi e trascrizionali. Quello che però ha maggiormente 
stimolato la fantasia dei ricercatori, è stata la possibilità di andare ad interferire con i 
suddetti processi, al fine di ottenere delle strategie antitumorali valide da spendersi 
nell’inibizione dello sviluppo o della proliferazione delle cellule neoplastiche. Di 
seguito, e in breve, la descrizione delle due principali e potenziali strategie 
antitumorali che vedono il diretto coinvolgimento delle strutture G-quadruplex. 
Nelle cellule somatiche umane, la lunghezza dei telomeri diminuisce ad ogni evento 
di divisione cellulare, mentre l’inversione di questa degradazione, da parte di un 
enzima specializzato chiamato telomerasi, incrementa la capacità replicativa 
cellulare, determinando una proliferazione incontrollata; nella maggior parte delle 
cellule tumorali (85-90%) questo enzima è over-espresso (3). Poiché domini ricchi di 
guanine in grado di strutturarsi in G-quadruplex sono presenti a livello telomerico, e 
poiché la formazione delle G-quadruplex inibisce direttamente l’elongazione in vitro 
da parte della telomerasi, ligandi che possano selettivamente riconoscere e 
stabilizzare le strutture G-quadruplex possono interferire con l’elongazione dei 
telomeri, agendo come inibitori della telomerasi, e quindi come potenziali agenti 
antitumorali. 
Sulla base degli stessi principi, è riportato che le sequenze nucleotidiche ricche di 
guanine facenti parte dei promotori sono spesso in equilibrio tra una strutturazione a 
doppio filamento che favorisce la trascrizione, e una forma ripiegata a quadrupla 
elica, che invece ne inibisce la trascrizione (4). Quando a dover essere trascritto non 
è un gene ma un oncogene, in altre parole un gene che codifica per proteine che 
indirizzano la cellula verso lo sviluppo di un fenotipo neoplastico, la possibilità di 
poter bloccare il processo trascrizionale mediante la stabilizzazione della 
strutturazione a quadrupla elica, diventa estremamente interessante dal punto di 
vista farmacologico. Per questo motivo, negli ultimi anni si è amplificata anche la 
ricerca di specifici ligandi capaci di legarsi alle sequenze promotrici di importanti 
oncogeni, quali c-myc (5-9), c-kit (10, 11), and bcl-2 (12, 13); tali ligandi, in grado di 
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riconoscere e stabilizzare le strutture G-quadruplex, determinano l’inibizione della 
trascrizione degli oncogeni, e potrebbero quindi essere utilizzati come agenti 
antitumorali. 
Oltre a quanto accennato, ci sono altri due campi di applicazione che vedono come 
protagoniste le G-quadruplex: oligonucleotidi sintetici formanti G-quadruplex e 
nanostrutture a base di G-quadruplex, entrambe le categorie dalle applicazioni 
estremamente stimolanti. 
L’interesse per gli oligonucleotidi sintetici formanti G-quadruplex deriva 
principalmente dal fatto che essi possano costituire l’impalcatura degli aptameri. Gli 
aptameri sono piccole molecole di DNA o RNA a singolo filamento, che assumono 
specifiche strutturazioni tridimensionali per raggiungere un’altissima affinità di 
legame nei confronti di proteine specifiche, come ad esempio la trombina o alcune 
proteine dell’HIV, dimostrando così promettenti proprietà biologiche e possibili 
applicazioni farmacologiche (14). Una delle classi di aptameri a base G-quadruplex 
particolarmente studiata è quella degli aptameri leganti la trombina (Thrombin-
Binding Aptamer, TBA), capaci di legare una proteina fondamentale coinvolta nel 
processo di coagulazione, l’α-trombina, prevenendo così il processo patologico della 
trombosi (15, 16). È stato inoltre dimostrato che in questo caso la strutturazione in G-
quadruplex e la sua conseguente stabilità, sono requisiti essenziali all’esplicazione 
degli effetti biofisici e biologici del TBA (17).  
Un altro aptamero a base G-quadruplex è AS1411 (Antisoma, London, UK), un 
nucleotide 26-mer potenzialmente in grado di inibire la proliferazione delle cellule 
tumorali, che ha come target specifico la nucleolina, una proteina over-espressa sulla 
superficie delle cellule tumorali. Purtroppo la sperimentazione clinica di AS1411 in 
pazienti con leucemia mieloide acuta (AML) è stata bloccata in fase IIb a causa del 
tracollo finanziario dell’azienda produttrice. [fonte: http://www.fiercebiotech.com the 
biotech industry’s daily monitor]  
Altra grande famiglia è rappresentata dagli aptameri a base G-quadruplex sviluppati 
come potenziali farmaci anti-HIV, in grado di inibire le proteine essenziali del virus, 
coinvolte in diversi stadi del suo ciclo vitale. La ricerca in questo senso ha dato luogo 
a una vasta gamma di aptameri, principalmente diretti contro: 
 
 la glicoproteina di superficie virale coinvolta nel processo di ancoraggio e fusione 
del virus, nota come gp120.  
 l’enzima trascrittasi inversa (Reverse Transcriptase, RT) coinvolto nel processo di 
trascrizione inversa, quindi in grado di copiare l’RNA virale in un cDNA a doppio 
filamento previa integrazione nel genoma della cellula ospite. 
 l’enzima integrasi (Integrase, IN) coinvolto nel processo di integrazione del DNA 
virale all’interno del DNA della cellula ospite. 
 
Tra i vari aptameri a base G-quadruplex ad attività anti-HIV proposti e studiati in 
questi anni, i più efficienti si sono dimostrati l’oligonucleotide 17-mer 
GTGGTGGGTGGGTGGGT, anche noto come Zintevir, AR177 o T30177, così come 
due oligonucleotidi 16-mer (T30695 e 93del) e la sequenza più breve 
dell’oligonucleotide fosforotioato TTGGGGTT (ISIS 5320) (18). Particolare attenzione 
è stata richiamata dalla sequenza 6-mer di Hotoda TGGGAG, modificata in 5' 
mediante l’aggiunta di un gruppo dimetossitrietile (19). A partire da questa 
modificazione chimica, molte altre ne sono seguite con lo scopo di aumentare 
l’attività dell’aptamero, fino ad arrivare all’R-95288 caratterizzato dalla presenza di un 
gruppo 3,4-dibenzilossibenzil all’estremità 5' e un gruppo 2-idrossietilfosfato 
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all’estremità 3', che mostra l’attività biologica più potente e la citotossicità minore (20, 
21). Dal momento che la stabilità strutturale delle G-quadruplex formanti aptameri è 
strettamente correlata all’attività biologica dell’aptamero, diversi approcci sintetici 
sono stati proposti per migliorarne le caratteristiche chimico-fisiche, sia mediante 
l’introduzione di larghi sostituenti aromatici (22), sia mediante l’ancoraggio dei 
filamenti stessi a linker alchilici in grado di veicolarne la strutturazione in quadruplex, 
come proposto da Oliviero et al. (23, 24).  
Per quanto riguarda invece il campo nanotecnologico, le G-quadruplex presentano 
diverse proprietà che le rendono particolarmente interessanti. Tenendo presente che 
il fiorente campo delle nanotecnologie si basa sulla costruzione controllata di 
molecole su scala nanometrica o micrometrica, le G-quadruplex sono risultate le 
concorrenti ideali a questo scopo, grazie alla loro capacità di auto-assemblarsi in 
maniera ordinata e controllabile (25, 26). In quest’ambito le G-quadruplex sono state 
utilizzate sia per la costruzione di nanostrutture a base di DNA, quali G-wires, Frayed 
Wires e Synapses, sia per la costruzione di biosensori e nano-dispositivi. Nello 
specifico, i G-Wires sono dei polimeri di G-quadruplex identificati per la prima volta 
da Marsh ed Henderson. Originano dalla disposizione parallela di filamenti aventi 
sequenza d(G4T2G4), sono straordinariamente stabili ad alte temperature e hanno 
una lunghezza che può variare dai 10 ai 1000 nm (27). I Frayed Wires sono stati 
invece individuati da McGregor e collaboratori, si originano dalla sequenza d(G15A15), 
in cui le guanine vanno a costituire il nucleo principale della struttura, mentre le 
adenine si irradiano come bracci al di fuori della struttura (28). Sen e collaboratori 
hanno invece descritto un metodo per costruire nanostrutture a partire dalla 
connessione (synapsis, da qui il nome Synapses) tra due duplex di DNA (29). In 
questo caso, ciascun duplex contiene un “dominio sinaptico” costituito da coppie di 
guanine ingegnerizzate per facilitare la formazione delle G-tetradi e quindi portare 
alla dimerizzazione dei duplex. Per quanto riguarda invece i biosensori e le nano-
macchine a base di G-quadruplex, il principio di base è che gli aptameri a base G-
quadruplex, oltre ad essere utilizzati in campo terapeutico e diagnostico, possono 
avere anche un’applicazione pratica nel campo della chimica bioanalitica in qualità di 
biosensori. Difatti, data la loro altissima affinità di legame, gli aptameri a base G-
quadruplex possono essere utilizzati come fase stazionaria in cromatografie ed 
elettroforesi per la separazione di piccole molecole e proteine. McGown e 
collaboratori, ad esempio, hanno utilizzato questo principio per discriminare tra gli 
enantiomeri D,L del Trp o della Tyr o per separare pool di proteine simili che si 
differenziano per pochi amminoacidi (30). Un approccio diverso vede invece l’utilizzo 
delle sonde a Trasferimento di Energia di Risonanza della Fluorescenza (FRET), un 
metodo distanza-dipendente utilizzato in quest’ambito per il rilevamento dei cambi 
conformazionali. Sono implicate due sonde, un fluoroforo donatore e un cromoforo 
accettore rispettivamente legate alle estremità 3' e 5' di un oligonucleotide; quando le 
due sonde si trovano vicine nello spazio, la fluorescenza è annullata, quando invece 
si allontanano, per effetto di un cambio conformazionale, avviene un corrispondente 
aumento della fluorescenza. Takenaka e collaboratori, ad esempio, hanno utilizzato 
questo metodo per monitorare il passaggio da singolo filamento a struttura G-
quadruplex in base alla concentrazione di ioni K+ (31); analogamente, Li e Tan lo 
hanno utilizzato per monitorare in tempo reale i cambi conformazionali duplex-
quadruplex, valutando la suscettibilità del cambio in base alla concentrazione di 
diversi cationi, o alla presenza di ligandi e proteine (32).  
In questo contesto si è inserita la mia attività di ricerca e il mio lavoro di tesi si è 
focalizzato principalmente sull’identificazione e la caratterizzazione di:  
	  
	  
 
 
v 
 Aptameri a base G-quadruplex dotati di elevata attività anti-HIV 
Obiettivo di questo lavoro di ricerca: realizzazione di una piccola libreria di 
aptameri a base G-quadruplex, al fine di valutare l’effetto della sequenza di basi 
sull’attività anti-HIV.  
 
Nel 2010 Oliviero e collaboratori hanno proposto come nuovi aptameri anti-HIV a 
base G-quadruplex, degli oligonucleotidi di sequenza dTGGGAG, legati ad un 
linker tetraramificato (tetra-end-linked, TEL) (23). In questo lavoro, i TEL-aptameri 
sono stati preparati e analizzati per investigare l'influenza della posizione e della 
lunghezza del TEL, e la presenza di gruppi lipofili in posizione 5', sulle proprietà 
strutturali e biologiche. I risultati riportati hanno dimostrato che la presenza del 
TEL in posizione 3' e di un gruppo terz-butil-difenil-silil (TBDPS) in posizione 5' 
migliorano notevolmente la stabilità termica della G-quadruplex e la sua attività 
come aptamero anti-HIV. 
Partendo da questi presupposti, è stata effettuata la sintesi di TEL-ODN, aventi 
sequenza dTGGGXG (dove X = G, C o T), coniugati con un gruppo terz-butil-
difenil-silil (TBDPS) all’estremità 5' e al TEL all’estremità  3'. Lo scopo del lavoro è 
stato quello di sondare l'influenza dei diversi nucleotidi sulle proprietà strutturali e 
biologiche delle G-quadruplex risultanti, ed è stato accompagnato da studi di 
modellistica molecolare con lo scopo di valutare l'influenza dei diversi nucleotidi 
sulle interazioni tra gli aptameri e il loop V3 della proteina gp120 dell’HIV-1. I 
risultati ottenuti evidenziano che i nuovi aptameri hanno maggiore stabilità 
termica, maggiore velocità di strutturazione e valori di EC50 contro l’HIV-1 
compresi in un intervallo di 0,04-0,15 µM, nonché un’affinità per la proteina gp120 
dell’HIV-1 dello stesso ordine di grandezza (33).  
 
 Analoghi dell’Aptamero Legante la Trombina (Thrombin-Binding Aptamer, 
TBA) dotati di aumentata attività anticoagulante 
Obiettivo di questo lavoro di ricerca: aumento dell’attività anticoagulante del TBA 
mediante la modificazione di singole nucleobasi. 
 
Un nucleotide modificato, contenente un ciclo di cinque membri fuso sull’anello 
pirimidinico, è stato introdotto in posizione 7 o 12 nell’oligonucleotide formante il 
TBA, di sequenza dGGTTGGTGTGGTTGG. La caratterizzazione strutturale degli 
aptameri risultanti, TBA-T7b e TBA-T12b, effettuata mediante spettroscopia NMR 
e CD, ha evidenziato la loro capacità di ripiegarsi nella tipica strutturazione del 
TBA, ovvero una G-quadruplex antiparallela di tipo sedia. Le temperature di 
fusione apparenti registrate al CD indicano che l’introduzione del residuo aciclico, 
principalmente in posizione 7, migliora la stabilità termica della risultante G-
quadruplex rispetto al TBA. L’attività anticoagulante delle nuove molecole è stata 
poi valutata mediante saggio di tempo di protrombina (prothrombin time, PT), ed 
è risultato che l’analogo TBA-T7b fosse più potente rispetto al TBA nel prolungare 
il tempo di coagulazione. D’altra parte, nel saggio di fibrinogeno purificato, 
l’attività inibitoria della trombina di entrambe le sequenze modificate è risultata 
essere inferiore rispetto a quella del TBA, usando enzima umano, ma superiore 
con enzima bovino. Inoltre, le relazioni struttura-attività sono state indagate 
mediante studi computazionali e, nel loro insieme, nell’interazione aptamero-
proteina, i risultati ottenuti evidenziano il ruolo attivo dei residui T7 e T12 del TBA e 
la rilevanza di alcuni aminoacidi situati nell’esosito I anionico della trombina (34).  
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 Nanostrutture a base di DNA, costituite da dimeri di G-quadruplex 
Obiettivo di questo lavoro: realizzazione di una piccola libreria di nanostrutture 
costituite da dimeri di G-quadruplex. 
 
Mediante l’utilizzo di diverse tecniche analitiche, quali Risonanza Magnetica 
Nucleare (NMR), Spettrometria di Massa (MS), Dicroismo Circolare (CD), UV ed 
Elettroforesi su Gel di Poli-Acrilamide (PAGE) si è dimostrato che la sequenza 
dCGGXGGT (dove X = T, A, C o G) è in grado di strutturarsi in una nano-struttura 
di circa 4 nm, costituita da otto filamenti ben organizzati. Di fatto la formazione 
dell’ottamero avviene mediante un processo di dimerizzazione, che prevede 
l’impilamento 5'-5' di due subunità G-quadruplex tetramolecolari, mediante 
l’insolita formazione di un’ottade di tipo G(:C):G(:C):G(:C):(G:C) (35).  
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Chapter 1 
 
The G-quadruplex structures: general introduction and main applications 
 
Nucleic acids are highly flexible molecules than can adopt different conformational 
structures. While DNA is largely double helical and RNA is single stranded, guanine-
rich sequences can exist in alternative structural forms known as G-quadruplexes. G-
quadruplexes are unusual nucleic acid structures that can form within specific 
repetitive G-rich DNA or RNA sequences. They are characterized by the stacking of 
units known as G-tetrads, consisting of four guanines organized in a square planar 
arrangement. Each guanine is linked to the two adjacent ones by Hoogsteen 
hydrogen bonds, involving the amino and imino protons and the nitrogen N7 and 
oxygen O6 atoms (Figure 1). The stacking of G-tetrads is stabilized by monovalent 
cations that occupy the central cavities between the stacks, neutralizing the 
electrostatic repulsion of inwardly pointing guanine oxygens. (1)  
More than 50 years have passed since the disclosure of the G-quadruplex motif. 
Despite this, the scientific interest towards G-quadruplexes not only has never 
ended, but it rather has increased exponentially, reaching its peak just a few months 
ago, when the research group leaded by Prof. Balasubramanian published an article 
in Nature Chemistry describing a method for the quantitative visualization of G-
quadruplexes in vivo, thus making substantial and direct evidence of their natural 
formation in the human genome. (2) Several reports suggest that G-quadruplex 
structures may have important applications in several and different areas, ranging 
from medicinal chemistry to the nanotechnologies field, due to their possible 
formation in important G-rich regions of the human genome such as telomeres and 
gene promoters, and to the fact that they may be used as building blocks for novel 
DNA-based nanostructures, biosensors and nanodevices.  
 
 
Figure 1. Graphical representation of a G-tetrad and a G-quadruplex. 
 
 
1.1. Structural variability of G-quadruplex structures  
Although the core of G-quadruplexes always respect the G-tetrad formation, the 
global scaffold is subjected to high structural variability, due to the molecularity and 
the orientation of the strands, the number and type of possible connecting loops, and 
glycosidic conformation of the sugar bases (which can be either syn or anti type). 
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1.1.1. Topological classification of G-quadruplex structures 
The several G-quadruplex topologies can be classified into various groups depending 
on: i) the number of their strands, and thus classified into monomolecular (one 
strand), bimolecular (two strands) or tetramolecular (four strands); ii) the orientation 
of their strands, and thus they can be parallel, antiparallel or hybrids thereof; iii) the 
orientation of the connecting loops, if any, that can join adjacent strands (lateral 
loop), opposite strands (diagonal loop) or the bottom G-tetrad with the top G-tetrad 
(propeller loop) (Figures 2 and 3). 
 
Figure 2. Representation of some possible topologies for monomolecular (left), bimolecular (upper right), and 
tetramolecular (lower right) G-quadruplex structures. The arrowheads indicate the direction of the strands.  
 
 
 
Figure 3. From left to right: propeller loop, lateral loop, and diagonal loop. 
 
 
1.1.2. G-quadruplex DNA groove widths 
The G-quadruplex structures are not stacked linearly, but adopt a right-handed helix 
exposing four grooves, defined as the cavities bounded by the phosphodiester 
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backbones. The variation of groove-widths along the side of the quadruplex is due to 
the spacing between the DNA strands of the G-quadruplex, which depends by the 
conformation of base χ glycosidic torsion angles (3). This dihedral angle linkage χ is 
defined as O4'-C1'-N9-C4 for purines and O4'-C1'-N1-C2 for pyrimidine bases 
(Figure 4a). Glycosidic torsion angles in duplex DNA/RNA fall into two tightly 
confined conformations. The related orientations adopted by the stacked bases have 
significant consequences for the overall shape and depth of the DNA/RNA grooves, 
altering the width, shape, and hydrogen-bonding pattern. Two of the most common 
conformations observed in folded DNA structures are syn and anti, shown in Figure 
4b, where syn results from 0 < χ < 90° and anti from -120 < χ < 180° (4). 
 
Figure 4. (a) A ball and stick representation of a guanine nucleotide highlighting the three building blocks of DNA, 
the base, sugar (deoxyribose), and the phosphate group. (b) Guanine nucleotides showing both syn and anti 
glycosylic torsion angles χ [O4'-C1'-N9-C4]. The anti conformation is the lower energy arrangement. 
 
Notably, when a syn guanosine donates hydrogen bonds to a neighbouring anti 
guanosine, the groove formed between the two is extremely narrow; on the other 
hand, when the hydrogen bonding polarity between adjacent syn and anti 
guanosines is reversed, a very wide groove is formed (5). An intermediate width 
groove results when adjacent guanosines adopt the same glycosidic conformation. 
For instance, in a parallel four-stranded quadruplex, where all the guanine bases are 
in the anti conformation, the four grooves have approximately the same medium 
width (Figure 5a). In a monomolecular structure having lateral loops, the guanosines 
adopts an syn-anti-syn-anti conformation, with each syn guanosine donating 
hydrogen bonds to an adjacent anti guanosine, and accepting hydrogen bonds from 
the other adjacent guanosine (6), thus resulting in grooves of alternating wide-
narrow-wide-narrow widths (Figure 5b). Conversely, in a bimolecular quadruplex 
having diagonal loops, the guanosines adopt a syn-syn-anti-anti conformation, 
resulting in wide-medium-narrow-medium widths (Figure 5c).  
 
1.1.3 Metal ion coordination 
The thermodynamic stability of the G-quadruplex structures in the solution state is 
mainly due to the interaction of the G-quartets with specific metal ion.  
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c) 
 
 
Figure 5. Variations in glycosidic torsional angles and their effects on groove width in G-quadruplex structures. a) 
all anti, all medium widths b) syn-anti-syn-anti, wide-narrow-wide-narrow widths and c) syn-syn-anti-anti, wide-
medium-narrow-medium widths. 
 
 
Although the structure of the G-quartets appears to be stabilized by the hydrogen 
bonds, generally, these structures do not form in the absence of such metal ions. In 
effect, the central core of the G-quartets produces specific geometric arrangements 
of lone pairs of electrons from the four O6 of the guanines, which can coordinate a 
monovalent ion of the correct size, such as sodium or potassium, whose positioning 
depends on its nature. For instance, the smaller sodium ion can sit exactly at the 
center of the quartet, in the same plane formed by the oxygen atoms; on the 
contrary, the larger potassium requires a non planar component, and it lies between 
two such G-quartets, coordinating eight oxygen atoms with a bi-pyramidyl 
antiprismatic geometry (7).  
 
1.1.4 Beyond G-tetrads, novel tetrad pairing alignment 
A variety of alternative bases beyond guanines have been observed in G-quadruplex 
structures, and considerable effort has gone into defining these alignments. Keeping 
in mind that the standard view of G-quadruplex formation involves a scaffold 
stabilized by stacked G-tetrads, further non-guanine bases tetrads or mixed tetrads 
can coexist within the same structure (Figure 6) (8). For instance, a T tetrad has 
been found in a parallel tetraplex formed by the DNA sequence d-TGGTGGC 
containing two repeats of Saccaromyces cerevisiae telomere DNA (9). An A tetrad 
has been found in the truncated human telomeric DNA sequence d-AGGGT (10), 
and a C tetrad (11) has been observed in d-TGGGCGGT containing a repeat 
sequence from the SV40 viral genome. GCGC tetrads have been found in DNA 
tetraplexes with the repeat sequence d-GGGCT4GGGC that is observed in adeno-
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associated viral DNA and in human chromosome 19 and with the sequence d-
GGGCT3GGGC found in the fragile X syndrome triplet repeat (12). From a 
topological point of view, base tetrads may exhibit a cyclic, linear, or branched base-
base interaction pattern. 
 
Figure 6. H-bond patterns of cyclic base tetrads found in experimental tetraplex structures. a) GCGC, b) A4: N6-
H-N7 H-bonds, c) A4: N6-H-N1 H-bonds, d) C4: N4-H-O2 H-bonds, e) C4: N4-H-N3 H-bonds, f) T4. The full 
circles indicate the links to the sugar-phosphate backbone in nucleic acid tetraplex.  
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Almost all base tetrads known thus far adopt a cyclic structure (Figure 5). NMR-
based investigations of G-quadruplexes have also identified formation of A-(G-G-G-
G) pentads (13, 14), A-(G-G-G-G)-A hexads (15) and heptads (16, 17) (Figure 7). 
Such alignments essentially are composed of G-(A-G) triads, where one or more A 
residue(s) align(s) along one or more minor groove edge(s) of a G-tetrad. 
 
 
 
 
Figure 7. H-bond patterns of pentad (upper left), hexad (upper right), and heptad (lower) founded in experimental 
G-quadruplex structures. 
 
1.2 Biological relevance of G-quadruplex structures 
The presence of guanines-rich domains, potentially able to form G-quadruplex 
structures, are present in important regions of the human genome, such as the 
single-stranded portion of telomeres and different gene promoters, thus suggesting a 
possible role of the G-quadruplexes in the regulation of transcriptional and replicative 
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8 
processes. What has stimulated more the imagination of researchers has been the 
possibility of going to interfere with the just mentioned processes, by exploiting small 
organic molecules able to recognize and bind the guanines-rich domains, with the 
aim of promote and stabilize the G-quadruplex formation. In this way, interesting and 
potential anticancer strategies have come to light. 
For instance, in human somatic cells, telomere length decreases with each cell 
division event, while the inversion of this degradation, by a specialized enzyme called 
telomerase, increases the cell replicative capacity, resulting in an uncontrolled 
proliferation; in most cancer cells (85-90%), this enzyme is over-expressed (18). 
Since guanines-rich domains able to form G-quadruplex structures are present in the 
telomere, and since the formation of G-quadruplexes directly inhibits in vitro the 
telomerase activity, ligands that can selectively recognize and stabilize the G-
quadruplexes, can interfere with the elongation of telomeres, by acting as inhibitors 
of telomerase, and thus as potential antitumor agents (Figure 8). 
 
 
Figure 8. a) Ligands (blue) that bind to telomeric G-quadruplex (G4) are currently being analysed for their ability 
to influence telomere length by altering telomerase (yellow) activity. b) Ligands (blue) that bind to G-quadruplex 
(G4) of promoter sequences are postulated to block transcription by inhibiting polymerase (purple). 
 
On the basis of the same principles, it is reported that the guanines-rich domains in 
the nucleotide sequences of promoters are often in equilibrium between a double 
stranded structure, that promotes the transcription, and a quadruplex-folded form, 
that instead inhibits the transcription (19). When the transcription process does not 
involve a gene but an oncogene, that is a gene which codes for proteins that direct 
the cell towards a neoplastic phenotype, the possibility of being able to block the 
transcription process by stabilizing the quadruplex-folded form, becomes extremely 
interesting from a pharmacological point of view. For this reason, ligands able to 
recognize and stabilize the G-quadruplex structures in promoter sequences of 
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9 
important oncogenes, such as c-Myc (20-24), c-kit (25, 26), and bcl-2 (27, 28), may 
cause the inhibition of transcription, and may therefore be used as antineoplastic 
agents. 
 
1.3 G-quadruplex forming Aptamers  
Another extremely interesting field of application of G-quadruplex structures is that of 
synthetic G-quadruplex forming oligonucleotides. The interest towards this kind of 
oligonucleotides mainly derives from the fact that they may serve as the scaffold of 
aptamers. Aptamers are small DNA or RNA molecules able to assume specific three-
dimensional structuring in order to achieve a very high binding affinity towards 
specific proteins, such as thrombin or some HIV proteins, thus demonstrating 
promising biological properties and possible pharmacological applications (29). 
Particularly, one of the most studied G-quadruplex-based aptamer class is that of 
thrombin-binding aptamers (TBAs), which bind to α-thrombin, a key protein involved 
in the clotting process, preventing the pathological process of thrombosis (30, 31). It 
was also demonstrated that in this case the structuring in the G-quadruplex and its 
consequent stability, are essential requirements for the explication of biophysical and 
biological effects of TBA (32).  
The aptamer AS1411 (Antisoma, London, UK) is another synthetic G-quadruplex 
forming nucleotide potentially able to inhibit the proliferation of cancer cells. The 
specific target protein of AS1411 is the nucleolin, a protein located on the surface of 
cancer cells. Unfortunately, clinical trials of AS1411 in patients with acute myeloid 
leukaemia (AML) have been locked in phase IIb, due to the financial collapse of the 
producer company. [Source: http://www.fiercebiotech.com the biotech industry's daily 
monitor] 
Another large G-quadruplex-based aptamers class is that of potentially anti-HIV 
aptamers, that can inhibit the essential proteins of the HIV virus at different stages of 
its life cycle. Research in this sense has given rise to a wide range of aptamers, 
mainly directed against: 
 the viral surface glycoprotein involved in the process of anchoring and fusion of 
the virus, known as gp120. 
 the reverse transcriptase enzyme (Reverse Transcriptase, RT) involved in the 
process of reverse transcription, thus able to copy the viral RNA into a double-
stranded cDNA before its integration into the genome of the host cell. 
 the integrase enzyme (Integrase, IN) involved in the process of integration of viral 
DNA into the DNA of host cells. 
Among the several G-quadruplex-based aptamers proposed and studied for their 
potentially anti-HIV activity, the most efficient were the 17-mer oligonucleotide 
GTGGTGGGTGGGTGGGT, also known as Zintevir, AR177 or T30177, as well as 
two 16-mer oligonucleotides (T30695 and 93del) and the shorter phosphorothioate 
oligonucleotide sequence TTGGGGTT, also known as ISIS 5320 (Figure 9a) (33). 
Particular attention has been called by the Hotoda 6-mer TGGGAG sequence, 
modified to bear a dimethoxitrityl group linked to its 5' hydroxyl function (34). 
Subsequently, other modified ODNs were prepared and tested and the 6-mer bearing 
a 3,4-dibenzyloxybenzyl group at 5'-end and a 2-hydroxy-ethylphosphate at the 3'-
end, also known as R-95288 (Figure 9b), showed the most potent and less cytotoxic 
activity (35, 36).  
Since the structural stability of G-quadruplex-forming aptamers is closely related to 
the biological activity of the aptamer, different synthetic approaches have been 
proposed to improve the chemical-physical characteristics of the G-quadruplex 
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structures, either by the introduction of large aromatic substituents at the 3'- or 5'-end 
(37), either by the anchor of the filaments to alkyl tetra-end-linker (TEL) (38) able to 
direct the structuring of the G-quadruplex, as proposed for the aptamer TEL-
GAGGGT-TBDPS by Oliviero et al. in 2010 (Figure 9c) (39).  
 
  
 
 
Figure 9. Some of reported anti-HIV aptamers. a) Phosphorotioate ISIS 5320; b) R-95288, where p= 2-hydroxy-
ethylphosphate and DBB= 3,4-dibenzyloxybenzyl; c) TEL-GAGGGT-TBDPS, where TBDPS= terz-buthyl-
diphenyl-silil  
 
 
1.4 G-quadruplex structures in Nanotechnology 
The G-quadruplex structures have several properties that make them particularly 
interesting in the use in nanotechnology. Keeping in mind that the burgeoning field of 
nanotechnology is based on the controlled construction of molecules on micrometric 
or nanometric scale, the G-quadruplex represent the ideal competitors for this 
purpose, due to their ability of orderly and controllable self-assembly (40, 41). In this 
context, the G-quadruplex were used both for the construction of DNA-based 
nanostructures, such as G-wires, Frayed Wires and Synapses, both for the 
construction of biosensors and nano-devices. 
 
1.4.1 G-quadruplexes-based Nanostructures  
For duty of record, the G-Wires are G-quadruplex polymers, identified by Marsh and 
Henderson for the first time in 1994. G-wires originate from the parallel arrangement 
of strands having sequence d(G4T2G4); they are extraordinarily stable at high 
temperatures and they have a length that can vary from 10 to 1000 nm (42). In 1996, 
Macgregor and co-workers first identified the Frayed Wires, extended structures 
originated from the sequence d(G15A15), in which the guanines constitute the core of 
the structure, while the adenines radiate as arms outside of the structure (43). In the 
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same year, Sen and co-workers described a method to build nanostructures from the 
synapsis (hence the name Synapses) between two DNA duplexes (44). In this case, 
each duplex contains a "synaptic domain" consisting of guanines pairs engineered to 
facilitate the formation of G-tetrads and thus lead to dimerization of the duplexes. 
 
 
 
 
 
Figure 10. G-quadruplexes-based Nanostructures. a) G-wires formed by association of d(G4T2G4); b) Frayed 
wires formed by association of d(G15A15). The G residues make up the core, while the A15 arms radiate from the 
core; c) Synapsed DNA formed from G-quartet structures between duplex DNA strands containing G-G 
mismatches. 
 
1.4.2 G-quadruplexes-based Biosensors and Nanodevices  
The G-quadruplex-based aptamers, in addition to being used in therapeutic and 
diagnostic field, they also may have a practical application as biosensors in 
bioanalytical chemistry. In fact, given their high binding affinity, the G-quadruplex-
based aptamers can be used as stationary phase in chromatography and 
electrophoresis for the separation of small molecules and proteins. For instance, 
McGown and co-workers have used this principle to discriminate between the 
enantiomers D, L of Trp or Tyr or to separate pool of similar proteins that differ in a 
few amino acids (45). On the other hand, a different approach involves the use of 
Fluorescence Resonance Energy Transfer (FRET) probes, a distance-dependent 
method used for the detection of conformational changes. Two probes are involved, 
a donor fluorophore and an acceptor chromophore respectively linked to the 3'-end 
and 5'-end of an oligonucleotide; when the two probes are close in space, the 
fluorescence is quenched, when they move apart, as result of a conformational 
change, there is a corresponding increase in fluorescence. Takenaka and co-workers 
used this method to monitor the transition from single-stranded DNA into G-
quadruplex structure, according to the concentration of K+ ions (46); similarly, Li and 
Tan monitored in real time the conformational duplex-quadruplex switching, 
evaluating the susceptibility of the switch according to the concentration of different 
cations or in the presence of ligands and proteins (47).  
 
1.5 Aim of my research work 
In this context, my research activities involved the identification and the structural 
characterization of several biomolecules, such as DNA aptamers and nanostructures, 
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whose core architectures were based on G-quadruplex structures. Notably, I mainly 
focused my attention on: 
 G-quadruplex-based aptamers endowed with high anti-HIV activity 
The aim of this research was to achieve a small library of G-quadruplex-based 
aptamers, in order to assess the influence of different nucleotide sequences on the 
anti-HIV activity. 
 
In 2010, Oliviero and co-workers proposed some tetra-end-linked oligonucleotides 
(TEL-ODNs) containing the Hotoda’s sequence TGGGAG, as new modified 
aptamers with noteworthy anti-HIV activity (39). In this work, several TEL-ODNs were 
prepared and analysed in order to probe the influence of the lipophilic moieties and 
the TEL position on the structural and biological properties, and a complex lacking of 
the TEL moiety was used as reference for the evaluation of the thermal stability and 
the anti-HIV activity. The reported results showed that the presence of both the 5'-
tert-butyl-diphenyl-silyl (TBDPS) lipophilic groups and the 3'-TEL was necessary to 
dramatically improve the thermal stability of the aptamers and their anti-HIV-1 
activity. Furthermore, it was previously reported that Hotoda’s aptamers bind to the 
glycoprotein 120 hyper variable V3 loop (gp120 V3 loop) of the HIV-1 virus, thus 
inhibiting cell absorption and penetration by the virus (35). For this reason, the 
biological activity of TEL-ODNs was mainly related to two different factors: (a) the 
extent of interaction with the V3 loop and (b) the amount of G4 able to interact with 
target, that in turn is dependent on the quadruplex thermal stability, the kinetics of 
formation and the resistance to nucleases. As regards the first factor, molecular 
modelling studies reported in the above-mentioned work suggested that the V3 loop 
residues interact with the grooves and the sugar-phosphate backbones of the 
aptamer. Thus, the higher biological activity of TEL-ODNs was ascribed to both their 
enhanced thermal stability and to their monomolecular nature that improves the 
kinetics of formation. Furthermore, it should be taken into account that complexes 
showing the highest anti-HIV activities were characterized by capped 3'- and 5'-ends 
that definitively improve their resistance to exonucleases.  
 
Starting from these assumptions, the synthesis of TEL-ODNs, having TGGGXG 
(where X = G, C or T) sequences, conjugated with terz-buthyl-diphenyl-silil (TBDPS) 
groups attached to the 5'-end and linked to the TEL moiety on the 3'-end, has been 
undertaken to probe the influence of the different nucleotides on the structural and 
biological properties of such anti-HIV aptamers. Notably, during the period that I 
spent at the Centre of Cancer Research and Cell Biology (CCRCB) of the Queen’s 
University of Belfast, I performed molecular modelling studies useful to reveal the 
mechanism of action of the new synthesized aptamers, and investigate the influence 
of different nucleotides on the interactions with V3 loop of HIV. 
From the collected data, the new aptamers showed EC50 values against HIV-1 in the 
range of 0.04–0.15 µM as well as affinities for the HIV-1 gp120 envelope in the same 
order of magnitude (48).  
 
 Thrombin-Binding Aptamers (TBAs) Analogs with increased anticoagulant 
activity 
The aim of this research work was to achieve an increased anticoagulant activity of 
TBA through the modification of individual nucleobases. 
 
CHAPTER	  1	  
The	  G-­‐quadruplex	  structures	  
	  
	  
 
 
13 
A modified nucleotide, containing a five-member cycle fused on the pyrimidine ring, 
was introduced at position 7 or 12 of the 15-mer TBA-forming oligonucleotide 
dGGTTGGTGTGGTTGG. The structural characterization of the resulting aptamers, 
TBA-T7b and TBA-T12b, showed their ability to fold into the typical structuring of TBA, 
an antiparallel chair-like G-quadruplex. The apparent CD melting temperatures 
indicated that the introduction of the acyclic residue, mainly in position 7, improves 
the thermal stability of the resulting G-quadruplex with respect to TBA. The 
anticoagulant activity of the new molecules was then evaluated by the prothrombin 
time assay (PT assay),	   and it resulted that TBA-T7b is more potent than TBA in 
prolonging clotting time. On the other hand, in purified fibrinogen assay the thrombin 
inhibitory activity of both modified sequences was lower than that of TBA using 
human enzyme, whereas the potency trend was again reversed using bovine 
enzyme. Obtained structure−activity relationships were investigated by structural and 
computational studies. Taken together, the results reveal the active role of TBA 
residues T7 and T12 and the relevance of some amino acids located in the anion 
binding exosite I of the protein in aptamer−thrombin interaction (49).  
 
 DNA-based Nanostructures formed by G-quadruplexes dimers 
The aim of this research work was to achieve a small library of DNA-based 
nanostructures consisting of dimers of G-quadruplexes. 
 
Thanks to several analytical techniques, such as Nuclear Magnetic Resonance 
(NMR), mass spectrometry (MS), Circular Dichroism (CD), UV and gel 
electrophoresis of Poly-acrylamide (PAGE), it was proved that the sequence 
CGGXGGT (where X = T, A, C or G) can form a nanostructure of about 4 nm in 
length, consisting of eight well organized strands. This octamer formation takes place 
through a dimerization process, which is allowed by the 5'-5' stacking of two 
tetramolecular G-quadruplex subunits, and assisted by the formation of an unusual 
G(:C):G(:C):G(:C):G(:C) octad arrangement, involving C1 and G2 bases of each 
CGGXGGT strand (50).  
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Chapter 2 
New anti-HIV aptamers based on tetra-end-linked DNA G-quadruplexes 
The first stage of the HIV infection requires the entry of human immunodeficiency 
virus (HIV) into host cells. This stage involves the sequential interaction of the virion 
surface glycoprotein gp120 with the CD4 glycoprotein and a chemokine receptor, 
either CCR5 or CXCR4, on the host cell surface (1). The CD4 glycoprotein is 
expressed on the surface of T-lymphocytes, monocytes, dendritic cells and brain 
microglia, and its expression makes these cells a target for HIV in vivo. Furthermore, 
an interesting function of CD4 binding is to induce conformational changes in gp120 
that allow binding to the co-receptor, which is essential for viral entry (2). The third 
variable region of gp120 (from now on designated V3 loop) is a pivotal component of 
the co-receptor binding site, typically consisting of a 35 amino acid-loop (range 31 to 
39), closed by two cysteines that form a disulphide bridge. The crystal structure of 
gp120 complexed with the CD4 receptor and a neutralizing antibody (PDB ID 2B4C) 
revealed that the V3 loop is extended away from the gp120 protein and it is involved 
in co-receptor binding and selection, acting as a ‘‘molecular hook’’ that organizes 
associations within the viral spike (3).The importance of gp120 and the role of the V3 
loop in HIV-1 entry and pathogenesis have led to the recent pursuit of drugs targeted 
against it. One of the most studied alternatives is the use of aptamer technology (4). 
Aptamers are single stranded DNA or RNA molecules selected among large pools of 
nucleic acid sequences for their ability to bind selectively and with high affinity to a 
biomedically relevant target. For their properties, aptamers can be considered as the 
nucleic acid analogues of antibodies. Like the antibodies, several aptamers proved to 
be valuable diagnostic tools (5) and promising therapeutics (6, 7). In 1994 H. Hotoda 
(SA-1042) (8) and J. R. Wyatt (ISIS 5320) (9) independently reported the first anti-
HIV aptamers targeted against the V3 loop. In both cases the ODN sequences were 
chemically modified to improve their resistance against nucleases by capping the 5'-
ends with DMT groups (SA-1042) or by using the phosphorothioate backbone (ISIS 
5320). Subsequently, other analogues of SA-1042 were obtained and tested (10, 11), 
and the 6-mer TGGGAG ODN (known as ‘‘Hotoda’s sequence’’) bearing 3,4-
dibenzyloxybenzyl groups at the 5'-ends and 2-hydroxyethylphosphates at the 3'-
ends (R-95288) showed the highest anti-HIV activity (11). CD investigations on ISIS 
5320, R95288 and their analogues suggested their structuration into parallel 
tetramolecular quadruplexes. Following biophysical studies established that the 
presence of aromatic (12, 13) moieties at 5'- and/or 3'-ends of TGGGAG dramatically 
enhances the rate of formation of quadruplex complexes. Moreover, the overall 
stability of quadruplex complexes was found to correlate with the reported anti-HIV 
activity (12).  
In 2010, with the aim to overcome the unfavourable entropic factor and to stabilize 
the A-tetrad in Hotoda’s analogues, Oliviero et al. synthesized a series of new 
monomolecular anti-HIV aptamers by using the Tetra-End-Linker (TEL) strategy 
proposed by the same group in 2004 (14, 15). Several TEL-(TGGGAG)4 aptamers 
were prepared and analysed in order to probe the influence of lipophilic groups and 
TEL size and position on the structural and anti-HIV properties of the resulting TEL-
quadruplexes (16). The results showed that (i) the presence of the TEL at either 5'- or 
3' -ends was required for the anti-HIV activity, and (ii) lipophilic tert-butyldiphenylsilyl 
(TBDPS) groups at the 5'-ends strongly enhanced both the stability of TEL-
quadruplexes and their anti-HIV activity. The EC50 of the best aptamer (I, Fig. 1), 
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bearing TBDPS groups at the 5'-ends and the longer TEL at the 3'-ends was 0.082 ± 
0.04 µM. 
2.1 Results and Discussion 
With the aim to further improve the anti-HIV activity of TEL-ODN aptamers, we used I 
as a molecular synthon for the synthesis of a series of new TEL-ODN aptamers 
embodying the TGGGXG sequence (II–IV, Fig. 1). TEL-ODNs V and VI (a TEL-
(TGGGAG)4 analogue unable to form a TEL-quadruplex) were also synthesized and 
studied in order to investigate the role played by the G-tetrad at the 3'-terminus of 
TEL-quadruplexes I–IV and to further corroborate the requirement of quadruplex 
formation for the inhibition of HIV cytopathicity. In this communication we report the 
results of biophysical, biological and SAR studies performed on I–VI. 
 
Figure 1. Schematic representation of investigated TEL-ODNs. 
All products were synthesized and characterized following the previously described 
approach (14, 16). In order to verify that the presence of one (II–IV) or two (V) 
different bases did not affect the parallel quadruplex arrangement observed for the 
parent TEL-ODN I, CD measurements were performed (Fig. 2). The overall CD 
profiles, recorded in 100 mM K+ buffer, were in agreement with the formation of G-
quadruplex structures, showing two positive maxima at 220 and 260 nm and a 
negative minimum close to 240 nm, which are characteristic of head-to-tail 
arrangement of guanines, as typically found in parallel G-quadruplexes (17-19). 
Unexpectedly, CD spectra of VI were similar to those of a random coil, thus 
evidencing that the insertion of a propyl-phosphate moiety between the OH at 3'-ends 
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and TBDPS groups is detrimental for quadruplex stability. CD melting analyses on II–
IV confirmed the expected great thermal stability of the new TEL-quadruplexes (Fig. 
11 in 2.3.5). In fact, as for I, the apparent melting temperature of II–IV could not be 
determined since no derivatizable melting curve was obtained.  
The formation of thermally stable TEL-quadruplexes for II–IV was also confirmed by 
1H NMR evidence (Fig. 3 and 4). The G-quadruplex diagnostic exchange-protected 
imino proton signals were observed in all recorded spectra up to 90 °C (100 mM K+ 
buffer; H2O/D2O 9:1). As expected, the intensity of imino proton signals reflected the 
stability of the X-tetrad within the G-quadruplex structure. Stronger imino signals 
were observed for II (five stacked G-tetrads), whereas weaker imino signals were 
observed for I, III and IV due to the presence of the less stable A-, T- or C-tetrad, 
respectively, that accounts for the faster exchange of imino protons with the solvent. 
 
 
Figure 2. CD profiles of I-VI in 100 mM K+ buffer at 25°C. 
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Figure 3. 1H NMR spectra of I (first panel) and II (second panel) recorded in the temperature range 25-90 °C (100 
mM K+ buffer; H2O/D2O 9:1). 
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Figure 4. 1H NMR spectra of III (first panel) and IV (second panel) recorded in the temperature range 25-90 °C 
(100 mM K+ buffer; H2O/D2O 9:1). 
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The antiviral activity of II–IV against HIV-1 and HIV-2 was determined as previously 
reported for I (16) and is shown in Table 1. The binding properties of active aptamers 
II–IV to HIV-1 (IIIB) gp120 were also determined through Surface Plasmon 
Resonance (SPR) technology (Table 1; Fig. 5). All new TEL-(TGGGXG)4 aptamers 
reported (II–IV) retained potent anti-HIV-1 activity (nanomolar EC50 values). They 
displayed comparable on (ka) and off (kd) rates for HIV-1 gp120 binding resulting in 
very similar gp120 binding affinities (KD) to I, thus confirming that the residues of the 
gp120 V3 loop interact mainly with the grooves and the sugar–phosphate backbone 
of the aptamers. However, considering that the EC50’s of II and IV were significantly 
lower than those of I and III (0.039–0.041 versus 0.11–0.15 mM), and that V proved 
to be markedly less active notwithstanding its structuration in a stable TEL-
quadruplex structure, it has been hypothesized that some specific interactions 
between the X5G6 bases of I–IV and the V3 loop must occur. 
 
 
ODN 
EC50a (µM) 
HIV-1                      HIV-2  
SPR vs. HIV-1 (IIIB) gp120b 
 KD (nM)               ka (1/Ms)                       kd (1/s) 
I 0.11 ± 0.05 1.4 ± 0.9 256 ± 63 (1.72 ± 0.28) x 104 (4.31 ± 0.37) x 10-3 
II 0.041 ± 0.007 ≥ 2 183 ± 40 (2.40 ± 0.20) x 104 (4.35 ± 0.61) x 10-3 
III 0.15 ± 0.001 1.4 ± 0.87 248 ± 28 (2.55 ± 0.35) x 104 (6.29 ± 0.14) x 10-3 
IV 0.039 ± 0.005 0.73 ± 0.16 196 ± 0.16 (2.15 ± 0.40) x 104 (4.07 ± 0.71) x 10-3 
V ≥ 2 2 ̶ ̶ ̶ 
a EC50 represents the 50% effective concentration required to inhibit virus-induced cytopathicity in CEM cell 
cultures by 50%. b HIV-1 (IIIB) gp120 was obtained from recombinant-expressed gp120 in CHO cell cultures. 
 
 
Table 1. Anti-HIV and SPR studies on I–V. 
 
 
 
 
 
Figure 5. Kinetic analysis of interactions of compounds I-IV with recombinant HIV-(IIIB) gp120 expressed in CHO 
cell cultures using SPR technology. The experimental data (coloured curves) were fit using the 1:1 binding model 
(black lines) to determine the kinetic parameters. The data are a representative example of two independent 
experiments. 
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It is well described that binding of agents (i.e. monoclonal antibodies) to the viral 
envelope does not necessarily result in efficient virus neutralization. Their effect on 
viral infectivity depends on the molecular epitope that is recognized on gp120 (20). 
Thus, it seems that I and III bind nearly as efficiently to gp120 as II and IV but 
neutralize about 3-fold less efficiently HIV-1 possibly due to subtle differences in 
epitope recognition. Alternatively, it cannot be excluded that the different TEL-
quadruplexes have slightly different cellular uptake efficiencies or intracellular 
stability. 
To obtain insight into the nature of the atomistic interactions between the TEL-
aptamers I–IV and the V3 loop, we carried out molecular modelling studies by 
docking I–IV to the V3 loop of gp120 (PDB ID 2B4C). Our results revealed that (i) the 
V3 loop interacts with all aptamers with a similar binding mode involving the 3'-end 
tetrad and the TEL (Fig. 6), (ii) the type of nucleobases at the aptamer-V3 loop 
interface determines the chemical groups available for the interaction, and (iii) the 
number and type of interactions between the aptamer and the protein are responsible 
for the subtle differences in the binding energies (Table 2). 
 
                           
(TBDPS-5'TGGGAG3')4-TEL (I)  G-tetrad at 3’ terminus interactions 
                          
(TBDPS-5'TGGGGG3')4-TEL (II)  G-tetrad at 3’ terminus interactions 
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(TBDPS-5'TGGGTG3')4-TEL (III)  G-tetrad at 3’ terminus interactions 
                                 
(TBDPS-5'TGGGCG3')4-TEL (IV) G-tetrad at 3’ terminus interactions 
                          
(TBDPS-5'TGGGGT3')4-TEL (V)  T-tetrad at 3’ terminus interactions 
 
Figure 6. Molecular models of interactions between aptamers I-V and the V3 loop of gp120. The aptamers are 
drawn as lines, the V3 loop as cartoon and hydrogen bonding interactions between the V3 loop and the aptamers 
are drawn as dashed lines. 
10 
10 
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As reported by Honig and co-workers (21), charged residues are important in 
protein–DNA interactions. In this case, an important role is played by the side chain 
of residue R181 in the V3 loop that binds into the groove created by the 
phosphodiester backbone atoms (see Table 2). In particular, in II and IV, R181 
makes multiple interactions with both phosphates and purine bases (G5 and G6 in II, 
G6 in IV). Furthermore, the side chains of R190, T195 and E197 and the nitrogen 
backbone atom of T194 of the V3 loop interact with the oxygen atoms of the TEL, 
giving additional stability to the complexes. In the II–V3 loop complex, the side chain 
of Y193 and the nitrogen backbone atom of Y193, T195 and I198 established 
additional interactions with the TEL, thereby resulting in lower interaction energy of 
this complex with respect to the other ones (Table 2). It should also be noted that 
when the side chain of Y193 is involved in the interaction (I, II and IV), the resulting 
complexes are found to have a better biological activity. Thus, the G5 nucleobase in 
II presents additional points for hydrogen bonding with the V3 loop. This is not seen 
in other bases. Therefore we infer that the differences in activity can arise from the 
thermal stability of the structures. Furthermore, this is also rationalised by the SPR 
experiments.  	   G6-O6 X5-N3 G6-OP3’ G6-O3’/O4/O5’ T6-OP3’ X5-OP3’ X5-O3’/O4/O5’ TEL-O TEL-N 
Arg181/NH   	   	   	   	   	   	   	  
Arg181/NH2   	   	   	   	   	     
Lys182/N 	   	   	   	   	   	   	   	   	  
Lys182/O 	   	   	   	   	   	   	   	   	  
Ser183/OH 	   	   	   	   	   	   	   	   	  
Ile184/O 	   	   	   	   	   	   	   	   	  
Ile186/O 	   	   	   	   	   	   	   	   	  
Arg190/NH2   	   	   	   	   	   	   	  
Tyr193/N 	   	   	   	   	   	   	   	   	  
Tyr193/OH    	   	   	   	   	   	  
Thr194/N 	   	   	   	   	   	   	   	   	  
Thr195/N 	   	   	   	   	   	   	   	   	  
Thr195/OH 	   	   	   	   	   	   	   	   	  
Glu197/OH 	   	   	   	   	   	   	   	   	  
Ile198/N 	   	   	   	   	   	   	   	   	  
 
Table 2. Table of interactions among the residues of V3 loop and I (), II (), III (), IV () and V (). 
 
 
In order to better understand the structural features critical for the biological activity, 
we also carried out a molecular modelling study between the V3 loop and V, a 
quadruplex structure lacking marked anti-HIV activity. Our results revealed that the 
V3 loop interacts with V by using a different binding mode (Fig. 6). Differently from 
what was observed in the above-described complexes, V interacts with the V3 loop 
primarily via the TEL atoms and no atom of nucleobases is involved. Furthermore, 
except for R181, different residues of the V3 loop, such as K182, S183, I184, and 
I186, are involved in the interactions (Table 2). A plausible reason for the different 
binding mode of V is due to the presence of the T-tetrad at the 3'-terminus. As shown 
in Fig. 6, when there is a G-tetrad at the 3'-position, the oxygen atoms of guanines 
are involved in the interaction with the V3 loop through the side chains of R181 (and 
Y193 in the case of IV). In the V–V3 loop complex the methyl groups of the thymines 
are positioned in the groove formed by the phosphodiester backbone atoms, not 
allowing the formation of H bonds with R181 and Y193 of the V3 loop. All together, 
the structural evidence suggests that the T-tetrad at the 3'-position markedly affects 
the biological activity. In accordance with this finding and with the experimental data, 
the aptamer II showed the best docking score and the highest number of hydrogen 
bonds with the protein (Table 3). 
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Aptamer Interactions energy Number of H bonds 
I -24.11 8 
II -28.45 15 
III -13.74 9 
IV -28.09 11 
V -13.74 8 
 
Table 3. Interaction energies of top docks (Kcal mol-1) and number of H bonds between I–V and the V3 loop of 
gp120 
2.2 Conclusions 
The anti-HIV activity against HIV-1 and HIV-2 and the binding properties with HIV 
gp120 of a small library of new TEL-aptamers (II–IV) have been reported. Results 
from TEL-ODNs V and VI confirmed that the formation of a quadruplex species by 
the aptamer is required, but not sufficient to exert the anti-HIV activity. The docking 
data suggest that the interaction of the V3 loop with both the backbone and the TEL 
of the aptamers is required. Furthermore, the direct involvement of nucleobases in 
the interaction with the V3 loop gives additional stability to the complexes and results 
in a better biological activity. Overall, the here reported results expand our knowledge 
about anti-HIV G-quadruplexes and provide the rational basis for the design of novel 
anti-HIV aptamers with improved biological activity. 
2.3 Experimental Session 
2.3.1 General instrumentations 
Automated solid-phase oligonucleotide synthesis was performed on a 8909 DNA-
Synthesizer (Applied Biosystems). Mass spectra of TEL-ODNs were performed on a 
Bruker Autoflex I MALDI-TOF spectrometer using a picolinic/3-hydroxypicolinic acid 
mixture as the matrix. CD measurements were performed on a JASCO J-715 
spectropolarimeter equipped with a Peltier Thermostat JASCO ETC-505T using 0.1 
cm path length cuvettes. NMR spectra were acquired on Varian UNITYINOVA 500 
MHz, 700 MHz and Mercury Plus 400 MHz spectrometers and processed using the 
Varian VNMR software package. For the experiments in H2O, water suppression was 
achieved by including a double pulsed-field gradient spin-echo (DPFGSE) module 
(22, 23) in the pulse sequence prior to acquisition. Chemical shifts are reported in 
parts per million (δ) relative to the residual solvent signals. 
 
2.3.2 Synthesis of 3'-O-tert-butyldiphenylsilyl-propyl-1'-O-(2-cyanoethyl)-N,N'-
diisopropylphosphoramidite 
1,3-propandiol (1 g, 13.1 mmol) dissolved in 5 mL of dimethylformammide (DMF) 
was treated with imidazole (1.07 g, 15.7 mmol) and TBDPS-chloride (3.24 g, 11.8 
mmol) at 0°C under stirring at room temperature. After 2 h the reaction was 
quenched by addition of water and the resulting mixture was taken to dryness, 
dissolved in ethyl acetate (30 mL) and washed with water. The organic phase was 
dried over sodium sulphate, evaporated to oil and then purified by column 
chromatography (50 g Kieselgel 60H) eluted with esane/ethyl acetate 80:20 (v/v), 
giving 3.3 g (10.5 mmol, 80% yield) of the monosilylated 1,3-(O-TBDPS)-propandiol. 
1H-NMR (400 MHz; CD3OD): δ 7.67-7.66 (m, 4H, Ph), 7.45-7.37 (m, 6H, Ph), 3.78 (t, 
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J = 6.2 Hz, 2H, CH2O), 3.70 (t, J = 6.4 Hz, 2H, CH2O), 1.79 (quintuplet, J = 6.3 Hz, 
2H, CH2), 1.03 (s, 9H, tert-Bu). 
To the above product, dissolved in 20 mL of dry CH2Cl2, N,N-diisopropylethylammine 
(2.9 mL, 12.6 mmol) and 2-cyanoethyl-N,N’-diisopropylchlorophosphoramidite (2.81 
mL, 12.6 mmol) were added and the mixture was stirred at r.t. for 1h. The mixture 
was diluted with ethyl acetate (100 mL) and washed with saturated aq. sodium 
chloride (3 x 50 mL). The organic phase, dried over sodium sulphate and evaporated 
to an oil, was purified by column chromatography (10 g Kieselgel 60H) eluted with 
nesane/ethyl acetate/lutidine 90:9.5:0.5 (v/v) to give 3'-O-tert-butyldiphenylsilyl-
propyl-1'-O-(2-cyanoethyl)-N,N'-diisopropylphosphoramidite as a white powder (9.4 
mmol, 90% yield). 
1H-NMR (400 MHz; acetone-d6): δ 7.71-7.70 (m, 4H, Ph), 7.48-7.42 (m, 6H, Ph), 
3.88-3.76 (complex signal, 6H, 3 × CH2O), 3.67-3.58 (complex signal, 2H, 2 × CH), 
2.71 (t, J = 6.0 Hz, 2H, CH2CN), 1.88 (quintuplet, J = 6.1 Hz, 2H, CH2), 1.18 (d, J = 
6.8 Hz, 6H, isoPr), 1.15 (d, J = 6.8 Hz, 6H, iPr), 1.04 (s, 9H, tBu); 31P-NMR (202 
MHz; acetone-d6): δ 150.4 (s); HRESIMS: m/z 537.2672 [M+Na]+, 
C28H43N2NaO3PSi, requires 537.2678. 
2.3.3 Synthesis and MALDI-TOF spectra of TEL-ODNs  
The syntheses of TEL-ODNs I-V were performed using a solid-phase automated 
DNA synthesizer according to the previously described procedure (16). In the case of 
TEL-ODN VI, in the last coupling step the 3’-O-tertbutyldiphenylsilyl-propyl-1’-O-(2-
cyanoethyl)-N,N’-diisopropylphosphoramidite was used at 50 mg/mL in acetonitrile 
solution. After automated synthesis, the oligonucleotides were detached from the 
support and deprotected by using concentrated aqueous ammonia at 55 °C for 17 h. 
The combined filtrates and washings were dried, redissolved in water, analyzed and 
purified by HPLC on an anion exchange column (Macherey-Nagel, 1000-8/46, 4.4x50 
mm, 5 µm) using a linear gradient from 0 to 100% B in 30 min, flow rate = 1 mL/min 
and detection at 260 nm (buffer A: 20 mM NaH2PO4 aq. solution pH 7.0, containing 
20% (v/v) CH3CN; buffer B: 20 mM NaH2PO4 aq. solution pH 7.0, containing 1M 
NaCl and 20% (v/v) CH3CN. 
After HPLC purification, the oligonucleotide samples were desalted on a biogel 
column (BIORAD) eluted with H2O/CH3CH2OH (9:1 v/v). The isolated oligomers were 
characterized by MALDI TOF mass: 
 
I calculated: [M] = 9765.3; found [M+H]+ = 9764 
II calculated: [M] = 9829.3; found [M+H]+ = 9830 
III calculated: [M] = 9729.3; found [M+H]+ = 9730 
IV calculated: [M] = 9669.3; found [M+H]+ = 9669 
V calculated: [M] = 9729.3; found [M+H]+ = 9729 
VI calculated: [M] = 10316.1; found [M+H]+ = 10318  
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Figure 8. MALDI-TOF spectra (positive mode) of TEL-ODNs I-II. 
 
??????????
??????????????????
?
?
 
 
31 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. MALDI-TOF spectra (positive mode) of TEL-ODNs III-IV. 
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Figure 10. MALDI-TOF spectra (positive mode) of TEL-ODNs V-IV. 
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2.3.4 Preparation of quadruple helices (annealing) 
TEL-ODN samples were dissolved in 100 mM potassium buffer (10 mM KH2PO4 aq. 
solution containing 90 mM KCl, pH 7.0) and the corresponding quadruplexes were 
formed by heating at 90 °C for 5 min and slowly cooling at room temperature for 12 h. 
Samples were stored at 4°C for 24 h before measurements. TEL-ODNs 
concentrations were determined in water by measuring the absorbance at 260 nm at 
90 °C, using the nearest-neighbour calculated molar extinction coefficient of 
d[5'TGGGXG3'] (for I-IV and VI) or d[5'TGGGGT3'] (for V) multiplied by 4 (the 
number of strands in each TEL-ODN complex). A contribute of 8658 cm-1M-1 was 
added for each TBDPS group (24). 
 
I: calculated ε = 284632 cm-1M-1 
II: calculated ε = 272232 cm-1M-1 
III: calculated ε = 266232 cm-1M-1 
IV: calculated ε = 258232 cm-1M-1 
V: calculated ε = 265832 cm-1M-1 
VI: calculated ε = 284632 cm-1M-1 
2.3.5 CD spectroscopy measurements 
TEL-ODN samples (2×10-5 M) were annealed as described above and stored at 4°C 
overnight before measurements. CD spectra were recorded in the 360-200 nm 
wavelength range as an average of 5 scans (100 nm/min, 1 s response time, 1 nm 
bandwidth) and normalized by subtraction of the background scan containing only 
the buffer. Thermal denaturation experiments (Fig. 8) were carried out in the 
temperature range of 5-90 °C by monitoring CD values at 264 nm at a heating rate of 
0.5 °C/min. 
 
2.3.6 NMR spectroscopy measurements 
The NMR samples were prepared in 0.2 ml of buffer (90% H2O/10% D2O), containing 
0.1 M K+ at pH 7.0, and NMR spectra were recorded in the temperature range 25-90 
°C on Varian UNITYINOVA 700 MHz spectrometer.  
 
2.3.7 Biological evaluation assays 
The methodology of the anti-HIV assays was as follows: ~ 3 x 105 human CD4 T-
lymphocyte (CEM) cells were infected with 100 CCID50 of HIV(IIIB) or HIV-2(ROD)/ml 
and seeded in 200 µL wells of a 96-well microtiter plate containing appropriate 
dilutions of the test compounds. After 4 days of incubation at 37°C, HIV-induced 
syncytia formation in the CEM cell cultures was examined microscopically. Data 
represent the mean (± SD) of 3 independent experiments. 
 
2.3.8 Surface plasmon resonance (SPR) analysis 
Recombinant gp120 protein from HIV-1(IIIB) (ImmunoDiagnostics Inc., Woburn, MA) 
(produced by CHO cell cultures) was covalently immobilized on a CM5 sensor chip in 
10 mM sodium acetate, pH 4.0, using standard amine coupling chemistry. The chip 
density was 2345 RU (~19.5 fmol of gp120). A reference flow cell was used as a 
control for non-specific binding and refractive index changes. The experiment was 
performed at 25°C on a Biacore T200 instrument (GE Healthcare, Uppsala, Sweden). 
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The test compounds were serially diluted in HBS-P (10 mM HEPES, 150 mM NaCl 
and 0.05% surfactant P20; pH 7.4), covering a concentration range between 1.17 
and 4.69 µM. Samples were injected for 120 sec at a flow rate of 30 µl/min and the 
dissociation was followed for 180 sec. One duplicate sample and several buffer 
blanks were used as a control and as double referencing, respectively. The CM5 
sensor chip surface was regenerated with 1 injection of 50 mM NaOH. The 
experimental data were fit using the 1:1 binding model (Biacore T200 Evaluation 
software 1.0) to determine the binding kinetics. 
 
Figure 11: CD-melting curves of I-V recorded at 264 nm in 100 mM K+ buffer. 
 
2.3.9 Docking protocol 
The molecular models of TEL-ODNs were generated using the InsightII suite 
program (Accelrys, Inc), by employing the Biopolymer module, to make the 
quadruplexes, and the Builder module, to add the modified linkers at 3'- and 5'-ends. 
The molecular models were parameterized according to the AMBER force field and 
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then brought to their energetically minimized structures with Discovery3 module. The 
minimizations were performed using 1000 cycles of steepest descent method 
followed by conjugate gradient calculation until convergence at 0.1 rms was reached. 
A distance-dependent macroscopic dielectric constant of 4.0 and an infinite cut-off for 
non-bonded interactions were used to partially compensate for the lack of solvent. 
The Protein Data Bank was used to download the HIV gp120 protein (PDB ID 2B4C). 
All dockings between the V3 loop in gp120 and TEL-ODN were performed using the 
ZDOCK server (zdock.umassmed.edu), that evaluates Pairwise shape 
complementarity, desolvation and electrostatic energies using Fast Fourier 
Transform algorithm to search multiple binding possibilities for receptor and ligand. 
The output from the program is a list of transformation values for the docks, from 
which models can be generated. For each docking, a total of 2000 transformations 
were calculated, ranked based on internal scoring functions and presented through a 
global energy term. The best solution from each dock was chosen and further 
minimised to relieve any steric clashes that might have arisen in docking. No atoms 
were restrained during the minimization process. The minimized models were then 
visualized using the Pymol software and the electrostatic interactions between 
protein and aptamer were defined. 
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Chapter 3 
Thrombin-Binding Aptamer analogs with enhanced anticoagulant activity: the 
role of T7 and T12 residues on biological properties 
Thrombin is a sodium-activated allosteric enzyme playing a key role in blood 
coagulation. (1, 2) The complexity of thrombin function and regulation has gained this 
enzyme pre-eminence as the prototypic allosteric serine protease. (3-7) It clots blood 
by converting fibrinogen into fibrin, by activating factors V, VIII, and XIII, the latter 
being responsible for the cross-linking of fibrin fibers, and by promoting platelet 
aggregation. Because activation of factor V is required by activated factor X to cut 
prothrombin into thrombin, the synthesis of thrombin is in part modulated by its own 
blood concentration, thus providing a fast response to injury. Besides procoagulant 
stimuli, also anticoagulant stimuli can be triggered by thrombin via activation of 
protein C, under the allosteric control of the cofactor thrombomodulin. Moreover, 
thrombin inactivation and clearance in plasma can also be achieved by interaction 
with the serpin antithrombin and with the heparin cofactor II. Due to its central role in 
the coagulation cascade, malfunctions in the regulatory mechanism of thrombin 
activity cause pathological states such as haemorrhage or abnormal clot growth. 
Thrombosis and connected diseases are among the main causes of mortality in 
Western countries; (8, 9) thus, the discovery of molecules capable of modulating 
thrombin activity represents a major target for the development of anticoagulant 
strategies. (10) Aptamer technology has been efficiently employed to obtain new 
direct thrombin inhibitors by selecting thrombin-binding oligonucleotides. (11, 12) The 
term aptamer generally refers to a single-stranded oligonucleotide that binds to a 
selected protein and specifically inhibits one or more of its functions. The first 
reported consensus sequence able to inhibit thrombin activity was the 15-mer 
oligonucleotide (ON) GGTTGGTGTGGTTGG, usually known with the acronym TBA 
(thrombin-binding aptamer). (12) In the presence of thrombin and/or monovalent 
cations TBA folds into a specific three-dimensional structure that dictates its 
thrombin-binding affinity. The structures of TBA alone and in complex with thrombin 
were determined by NMR (13-15) and X-ray (16-18) methods, respectively. In all 
experimentally determined structures TBA adopted a monomolecular chair-like G-
quadruplex folding topology, consisting of two G-tetrads connected by one TGT loop 
and two TT loops. First, (17, 18) different TBA−thrombin X-ray complexes were 
reported, in which TBA adopted either the same folding as derived by NMR (PDB ID 
1HAO; Figure 1A) or a different one (PDB IDs 1HUT and 1HAP; Figure 1B), 
presenting a diverse positioning of the connecting loops. In these X-ray complexes, 
the aptamer interacts with distinct regions of two thrombin molecules, (i) the 
fibrinogen exosite (namely anion-binding exosite I, ABE I) and (ii) the heparin exosite 
(namely, ABE II) near the carboxylate terminal helix of a neighbouring thrombin. 
Thus, according to the adopted folding and the relative orientation with respect to 
thrombin, TBA bound to ABE I by using the TT loops (PDB ID 1HAO; Figure 1A) or 
the TGT loop (PDB IDs 1HUT and 1HAP; Figure 1B). A subsequent re-evaluation 
(19) of the diffraction data of TBA−thrombin complexes (17, 18) evidenced that the 
NMR-derived folding (Figure 1A) could fit all diffraction data if alternative aptamer 
orientations with respect to thrombin were considered. Indeed, according to the 
electron density maps, it was assumed that the oligonucleotide quartet region 
(including the DNA backbone) was correct as reported in the crystal structures, 
whereas, due to the D2 symmetry of the aptamer core, there are four distinct 
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possible orientations of the NMR folding that overlap with the core of the X-ray model 
(Figure 2). 
 
Figure 1. Schematic drawings of the X-ray derived G-quadruplex structures of TBA as reported in PDB IDs 1HAO 
(A) and 1HUT and 1HAP (B). In (A) TT loops span narrow grooves and TGT spans wide grooves, vice versa in 
(B). White and grey squares indicate G bases in anti and syn conformation, respectively. 
Figure 2. Representation of the four orientations of the NMR derived folding with respect to thrombin 
corresponding to the D2 symmetry of the quadruplex core assuming the same strand polarity of the X-ray 
complex. 
The re-evaluation of the X-ray complex gave similar results among orientations I−IV, 
but orientation III showed the best agreement with the experimental data. (19) 
Accordingly, different TBA−thrombin complexes in which the aptamer can bind ABE I 
through the TGT loop and ABE II through the TT loops (Figure 2, orientations I and 
II), or the other way around (Figure 2, orientations III and IV), are possible. 
Supporting this view, the newly released X-ray structures of thrombin−TBA−Na+ and 
thrombin−TBA−K+ complexes (PDB IDs 4DIH and 4DII, respectively) (16) showed 
the aptamer interacting with the enzyme assuming orientation IV (Figure 2). 
Moreover, the X-ray structure of human thrombin in complex with a modified TBA 
containing a 5'-5' inversion of the polarity site (3'GGT5'-5'TGGTGTGGTTGG3', 
namely mTBA) has also been reported (PDB ID 3QLP). (20) The X-ray complex 
revealed that the interaction occurs between the TT loops and ABE I (orientation III in 
Figure 2), whereas the TGT loop, particularly T7, is not involved in any relevant 
interaction with the protein. Despite the fact that mTBA binds to thrombin with higher 
affinity with respect to TBA, (21) it showed poor anticoagulant activity if compared to 
TBA in PT assay. (22) On the other hand, Toggle-25t, an RNA aptamer that contains 
2'-fluoropyrimidine nucleotides, and a 29-mer single-stranded DNA, designated 
DNA60-18 or HD22, bind selectively thrombin at ABE II and they also showed limited 
effect on clotting times. Because of their thrombin allostery, ABE I and ABE II 
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aptamers were used in combination to test their mixed effect on thrombin activity. 
(10, 23-26) The obtained results showed that synergistic anticoagulant effects could 
be achieved by mixing TBA with Toggle-25t or HD22 and by linking TBA to HD22 
with an appropriate-sized spacer. 
In this scenario, due to the symmetry of TBA and the complexity of the regulatory 
mechanism of thrombin, which includes a long-range allosteric linkage between ABE 
I and ABE II, (27, 28) the exact binding mode of aptamers to thrombin and its 
correlation with the observed biological activity is still a matter of debate. 
Nevertheless, biological results indicated that TBA exerts its anticoagulant activity 
mainly competing with fibrinogen at ABE I. (29) The phase I clinical trial for TBA 
demonstrated its positive pharmacokinetic profile in humans; however, clinical trials 
were halted after phase I due to suboptimal dosing profiles. (30) To optimize its 
anticoagulant properties, of particular interest is the enlargement of data gathering 
about TBA structure−activity relationships (SARs) through the development of new 
derivatives. In the nucleic acids research area the introduction of suitable 
modifications on natural oligonucleotide sequences represents a method widely 
employed to explore the relevance of single nucleotides both on secondary structure 
folding topology and on binding with target proteins. The explored modifications 
involve the nucleobases, (31, 32) the sugar−phosphate backbone, (33, 34) and the 
conjugation to flexible non-nucleotide linkers. (35-37) In our understanding of the 
bases of TBA−thrombin recognition, we previously developed new single-stranded 
TBA analogues, in which the acyclic nucleoside a (Figure 3) replaced, one at a time, 
all thymine residues along the aptamer sequence. (38)  
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Figure 3. Acyclic nucleosides mimicking T. The presence of the carbon atom marked with an asterisk causes the 
formation of two diastereomeric ONs when the nucleoside is inserted in the TBA sequence. 
The modification at position 7 in the T7G8T9 loop (herein TBA-T7a) gives rise to an 
ON that folds into a quadruplex structure that is more stable and active than the 
quadruplex structure formed by TBA. On the other hand, within the four ONs 
containing the acyclic nucleoside a at one position of TT loops, the ON modified at 
T12 (herein TBA-T12a) showed the most significant biological properties. (38) In line 
with data reported from other authors, (39) our results evidenced that modification at 
T7 and T12 along the TBA sequence can be fruitful to improve the biological activity. 
To investigate the role of the modification at T7 and T12 in affecting the structural 
stability and the biological activity, we synthesized two new modified TBAs, named 
TBA-T7b and TBA-T12b, which differed from the previously reported analogues only 
in the thymidine base coupled with the acyclic linker, which was bulked by fusing a 
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hydrophobic five member cycle with the pyrimidine ring (b, Figure 3). The abilities of 
TBA-T7b and TBA-T12b to fold into G-quadruplex structures, as well as their 
biological properties, were evaluated by CD and 1H NMR experiments and by PT and 
purified fibrinogen clotting assays, respectively. Finally, a computational study 
allowed the analysis of the obtained SARs. 
3.1 Results  
3.1.1 Synthesis of Monomer 6.  
The synthesis of the modified acyclic nucleoside phosphoramidite building block 6, 
used for the automated synthesis of TBA-T7b and TBA-T12b, is summarized in 
Scheme 1. The synthesis of N1-alkylated intermediate 3 was performed via 
Mitsunobu reaction (40) between 2, obtained as described under Experimental 
Section, and 1. The yields of this coupling reaction were strongly dependent on the 
initial temperature of the system and on the order in which the reagents were added. 
We found that temperatures lower than 30 °C were always detrimental to the reaction 
yield, and that higher yields (45−50%) were obtained by mild heating (30 °C) of a 
dioxane solution containing 2 and triphenylphosphine followed by addition of di-tert-
butylazodicarboxylate and finally a dioxane solution of protected linker 1 (100 µL of 
solvent per 1 mmol). The intermediate 4 was obtained by removing both the linker 
and nucleobase protecting groups from 3 using a one-pot procedure (see 
Experimental Section). Finally, 4 was functionalized to phosphoramidite building 
block 6 using standard procedure. The acyclic nucleoside 6 was inserted as a T 
mimic at position 7 or 12 along the TBA sequence to obtain TBA-T7b and TBA-T12b, 
respectively. 
 
 
 
 
Scheme 1. Synthesis of Monomer 6: (i) 1 0.94 g (5.9 mmol), 2 1.50 g (5.9 mmol), triphenylphosphine 2.28 g (8.7 
mmol), di-tert-butylazodicarboxylate 2.1 g (9.1 mmol), dry dioxane (70 mL), 24 h, 30°C, yields 43%; (ii) (a) 3 1.0 g 
(2.5 mmol), Dowex H+ 450 mg, MeOH/H2O (9:1 v/v) 100 mL; (b) aqueous NaOH (1.0 M, 5 mL) yields 98%; (iii) 4 
640 mg (2.5 mmol), 4,4'-dimethoxytrytylchloride 541 mg (1.6 mmol), 2,4-dimethylaminopyridine 15 mg (0.12 
mmol), pyridine (20 mL), acetonitrile (10 mL), 1.5 h, rt, yields 45%; (iv) 5 600 mg (1.1 mmol), 2-
cyanoethyldiisopropylchlorophosphoramidite 300 µL (1.2 mmol), DIPEA 600 µL (3.6 mmol), DCM (8 mL), 40 min, 
rt, yields 99%. 
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3.1.2 Structural Characterization  
TBA-T7b and TBA-T12b were characterized by circular dichroism (CD), CD melting, 
and 1H NMR for their ability to fold into G-quadruplexes. The introduction of the new 
acyclic nucleoside b at position 7 or 12 does not affect the overall G-quadruplex 
topology formed in solution. CD profiles of TBA-T7b and TBA-T12b are similar to 
those of TBA in both PBS and K+ buffer (left and right panels, respectively, in Figure 
4), showing maxima at about 208, 245, and 295 nm and a minimum at 267 nm.  
 
 
Figure 4. CD profiles in PBS (left) and in potassium phosphate buffer (right); [ON] = 2.0 × 10−5 M. 
 
 
 
 
Figure 5. 1H NMR spectra of TBA-T7b and TBA-T12b recorded at 25 °C in K+ buffer. 
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As expected, positive CD bands have higher molar ellipticities in K+ buffer than in 
PBS, according to the well-known dependence of G-quadruplex stabilities from the 
type of cations present in the buffer solution. (41, 42) The 1H NMR analysis, 
performed at temperatures in the range of 25−50 °C, confirmed that TBA-T7b and 
TBA-T12b form a stable G-quadruplex structure when annealed in K+ buffer. 
However, 1H NMR spectra appear more crowded than expected for a single 
quadruplex species, even at 25 °C (Figure 5), where only 14 aromatic signals and 8 
imino proton signals are expected. This finding was previously explained by 
considering that the replacement of a T residue with the acyclic nucleoside a 
produces two closely related diastereomeric G-quadruplex forming ONs. (38) 
Although both modified ONs show Tm values higher than that of TBA (Figure 6 and 
Table 1), the replacement of T7 with the acyclic nucleoside b stabilizes the resulting 
G-quadruplexes more efficiently than replacement of T12. 
 
Figure 6. CD melting curves of TBA and its analogues in potassium phosphate (continuous lines) or PBS (dotted 
lines) buffer. Concentration of each ON was 2.0 x 10−5 M. The curves were obtained by monitoring the variation of 
absorbance at 295 nm from 10 to 80 °C at 0.5 °C/min. 
                                          Tm (±0.5 °C) 
            ON                    PBS         K+ buffer 
TBA 33.0 50.0 
TBA-T12a 34.0a 51.0a 
TBA-T12b 34.5 51.5 
TBA-T7a 37.5a 54.0a 
TBA-T7b 37.5 54.0 
aData taken from ref 38 
 
Table 1. Tm values of TBA and its analogues. 
3.1.3 PT Assay  
The anticoagulant activity in the presence of all thrombin substrates and cofactors 
was evaluated by PT assay. PT analyses were performed at [ON] of 2 and 20 µM 
after 2 min of incubation with human plasma (Figure 7). To better understand the 
effects induced by the presence of nucleoside b on the anticoagulant activity, we 
compared the prolonging of clotting time caused by TBA-T7b and TBA-T12b with that 
of TBA and those of the previously reported (38) analogues TBA-T7a and TBA-T12a 
(Table 2). It is noteworthy that TBA-T7b prolonged the basal PT value to a 
significantly larger extent with respect to TBA and TBAT7a (Figure 7 and Table 2). 
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Replacement of nucleoside a for b was more effective also at position 12 (Table 2). 
In particular, TBA-T12b is less active than TBA at 2 µM, but showed a greater 
increase of activity at higher concentration, thus attaining that of TBA at 20 µM 
(Figure 7). To exclude that the observed activity of modified aptamers could be due 
to higher nuclease stability with respect to TBA, we repeated the experiments, 
changing the incubation time of TBA and analogues with plasma from 30 s to 15 min. 
PT results were almost unchanged for all sequences (data not shown). 
 
 
 
Figure 7. Concentration-dependent response, following 2 min ON incubation with human plasma at 2 (A) or 20 
µM (B) [ON]. PT values are expressed in seconds. Each measurement was performed in triplicate and is shown 
as the mean ± SEM. The basal PT time is 13.4 ± 0.2 s. 
 
 
ON PT valuea (20 µM) Fold increase 
TBA 53.68 ± 1.48 4.01 ± 0.70 
TBA-T7a 60.20 ± 1.38b 4.50 ± 0.60 
TBA-T7b 90.60 ± 5.26 6.77 ± 0.24 
TBA-T12a 44.83 ± 1.29b 3.35 ± 0.60 
TBA-T12b 55.20 ± 0.47 4.12 ± 0.20 
aPT values are expressed in seconds. bData taken from ref 38 
 
Table 2.	  PT values measured after 2 min of incubation using 20 µM ON concentration and fold increases of basal 
PT time (13.4 ± 0.2 s). 
 
3.1.4 Fibrinogen Assay Using Human and Bovine Thrombin 
The new ONs were subjected to purified fibrinogen clotting assay to evaluate their 
ability to inhibit the conversion of soluble fibrinogen into insoluble strands of fibrin in 
the absence of any other thrombin ligands/effectors (Figure 8 and Tables 3 and 4). 
The assay was performed using various concentrations of each aptamer. The 
purified fibrinogen solution was preincubated with the aptamer and the reactions 
were initiated by the addition of human thrombin and clotting times were recorded. 
The fibrinogen assay results evidenced that at all ON concentrations tested, the most 
efficient inhibitor is the unmodified TBA sequence (Figure 8A and Table 3), thus 
reversing the results gathered from the PT assay. To further investigate this 
CHAPTER	  3	  
TBA	  Analogues	  
	  
	  
 
 
46 
phenomenon, we performed the fibrinogen assay by using bovine thrombin, which 
differs from human thrombin in some residues of the fibrinogen-binding site (ABE I) 
that are crucial for TBA−thrombin interaction (see next paragraphs for details). By 
changing the source of the target enzyme, both modified sequences showed a 
substantial increase in their ability to inhibit thrombin activity (Figure 8B and Table 4), 
whereas the inhibitory activity of TBA was only slightly increased; as a consequence, 
TBA-T7b became again the best inhibitor. 
 
 
Figure 8. Effects of aptamers on human (A) and bovine (B) thrombin clotting time in fibrinogen solution. The 
results are expressed as the ratio of clotting times measured in the absence and in the presence of the aptamers. 
The effects are reported as a function of log [ON]. Each measurement was performed in triplicate and is shown as 
the mean ± SD. 
 
Prolonged clotting time (s) 
      ON         200 nM        300 nM         500 nM       750 nM     1000 nM 
TBA 18 ± 2.7 50 ± 2.3 137 ± 6.3 170 ± 24 170 ± 25 
TBA-T7b 10 ± 2.5 26 ± 2.3  120 ± 6.0 120 ± 22 140 ± 27 
TBA-T12b NAa 16.8 ± 0.71 98.9 ± 0.7 100 ± 30 100 ± 10 
aNot active 
 
Table 3. Prolonged fibrinogen clotting time results in presence of human thrombin. Each value was calculated 
subtracting the clotting time produced by thrombin alone from that measured in the presence of one of the 
aptamers. The measurements were performed preincubating for 1 min 200 µL of purified fibrinogen solution (2.0 
mg/mL in PBS) with various concentrations of aptamers. The reaction started by the addition of 100 µL of human 
thrombin solution (10 NIH per mL) and clotting time was recorded. In absence of any inhibitor, the measured 
clotting time for human thrombin was 24.9± 0.5 s. 
 
Prolonged clotting time (s) 
      ON         50 nM       100 nM      200 nM     300 nM      
TBA 4 ± 1.23 18 ± 1.5 36 ± 1.8 57 ± 3.7  
TBA-T7b 9 ± 3.3 50 ± 12  80 ± 12 120 ± 16  
TBA-T12b 9 ± 1.4 23 ± 2.5 57 ± 1.7 81 ± 3.8  
 
Table 4. Prolonged fibrinogen clotting time results in presence of bovine thrombin. Each value was calculated 
subtracting the clotting time produced by thrombin alone from that measured in the presence of one of the 
aptamers. The measurements were performed preincubating for 1 min 200 µL of purified fibrinogen solution (2.0 
mg/mL in PBS) with various concentrations of aptamers. The reaction started by the addition of 100 µL of bovine 
thrombin solution (10 NIH per mL) and clotting time was recorded. In absence of any inhibitor, the measured 
clotting time for bovine thrombin was 22.5± 1.2 s. 
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3.1.5 Conformational Search on TBA and Modified Analogues TBA-T7b and TBA-
T12b 
An extensive molecular modelling study, including molecular mechanics (MM) and 
dynamics (MD) calculations, was undertaken to analyse the SARs of new modified 
TBAs. In particular, to investigate the conformational properties of TBA and the new 
modified aptamers, a simulated annealing (SA) procedure followed by MM energy 
minimization was applied. Following the criteria described under Experimental 
Section, resulting conformers were analysed and each nucleotide of loops was 
classified on the basis of (i) χ torsional angle values, to identify the conformation of 
the glycosidic bond (i.e., syn, anti, or s/a); and (ii) the interatomic distance between 
its own centroid and that of the two G-tetrads, to investigate the position of loop 
nucleotides with respect to the guanine planes (i.e., “stacked” or “not-stacked”). 
Occurrence rates were calculated and compared to those obtained for TBA. Because 
the replacement of T7 and T12 residues with nucleoside b produced a mixture of 
diastereoisomers, characterized by S or R configuration at the acyclic linker, the 
occurrence rates reported in Tables 5 and 7 are the mean of the values obtained for 
the two diastereoisomers; single diastereoisomer values are reported in Tables 6 and 
8.  
 
3.1.6 Molecular Modelling Studies on Aptamer Interaction with Human and Bovine 
Thrombin  
With the aim of identifying the effects of the new structural modifications on 
aptamer−thrombin interactions, first, all possible aptamer-thrombin binding modes 
and the corresponding binding interactions were analysed (PDB IDs 1HAO, 1HAP, 
1HUT, 4DIH, and 4DII; see Experimental Section). 
 	  
 TBA 
   syn           anti           s/a 
TBA-T7b 
   syn           anti           s/a 
TBA-T12b 
   syn           anti           s/a 
T3 28.5 69.5 2.00 37.0 61.5 1.50 47.0 50.5 2.50 
T4 38.5 56.0 5.50 29.0 65.5 5.50 43.0 52.0 5.00 
T7a 39.0 59.5 1.50    36.0 62.5 1.50 
G8 39.5 38.0 22.5 35.0 46.5 18.5 34.5 44.0 21.5 
T9 41.5 50.0 8.50 34.0 57.0 9.00 42.0 51.0 7.00 
T12a 32.0 66.0 2.00 42.0 56.0 2.00    
T13 37.0 59.0 4.00 36.0 60.5 3.50 42.0 54.5 3.50 
aT7 residue in TBA-T7b, and T12 residue in TBA-T12b are replaced by the acyclic nucleoside b.  	  
Table 5. Calculated occurrence rates (percent) of syn, anti, and s/a conformers of TGT and TT glycosidic bonds. 
 
 TBA-T7b (S) 
  syn      anti       s/a 
TBA-T7b (R) 
syn      anti       s/a 
TBA-T12b (S) 
syn      anti       s/a 
TBA-T12b (R) 
syn      anti       s/a 
T3 40.5 57.5 2.00 33.5 65.5 1.00 46.5 51.0 2.50 47.0 50.0 3.00 
T4 28.0 66.0 6.00 30.0 65.0 5.00 37.0 57.0 6.00 49.5 47.0 3.50 
T7a - - - - - - 40.0 57.5 2.50 31.5 67.5 1.00 
G8 33.5 46.0 20.5 37.0 46.5 16.5 36.5 39.5 24.0 32.5 48.5 19.0 
T9 36.5 54.5 9.00 31.5 60.0 8.50 39.0 53.0 8.00 44.5 48.5 7.00 
T12a 42.0 55.5 2.50 42.0 56.0 2.00 - - - - - - 
T13 40.0 56.0 4.00 32.5 65.0 2.50 43.0 53.0 4.00 41.0 56.0 3.00 
aT7 residue in TBA-T7b (S) and TBA-T7b (R), and T12 residue in TBA-T12b (S) and TBA-T12b (R),  are replaced by 
the acyclic nucleoside b.  
 
Table 6. Calculated occurrence rates (%) of syn, anti, and s/a conformers of TGT and TT glycosidic bonds. 
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 TBA TBA-T7b TBA-T12b 
T3 62.5 33.0 39.0 
T4 46.0 60.0 65.0 
T7a 14.0 12.0 10.0 
G8 78.5 50.0 49.0 
T9 26.0 39.5 42.5 
T12a 33.5 37.0 29.0 
T13 38.0 40.5 29.0 
aT7 residue in TBA-T7b, and T12 residue 
 in TBA-T12b are replaced by the acyclic nucleoside b. 
 
Table 7. Calculated occurrence rates (percent) of conformers presenting TGT and TT nucleobases “stacked” on 
the guanine planes. 
 
 TBA-T7b (S) TBA-T7b (R) TBA-T12b (S)  TBA-T12b (R) 
T3 25.0 40.5 38.5 40.0 
T4 61.5 58.5 59.5 70.5 
T7a 6.5 18.0 14.0 6.50 
G8 25.5 74.5 49.5 49.0 
T9 52.0 27.0 47.5 37.5 
T12a 36.0 37.5 37.5 20.0 
T13 25.0 56.0 20.5 38.0 
aT7 residue in TBA-T7b (S) and TBA-T7b (R), and T12 residue in TBA-T12b (S) 
 and TBA-T12b (R),  are replaced by the acyclic nucleoside b. 
 
Table 8. Calculated occurrence rates (%) of conformers presenting TGT and TT nucleobases “stacked” on the 
guanine planes. 
 
This study revealed that the various binding orientations of TBA with respect to 
human thrombin (Figures 1 and 2) produced different binding modes in the crystal 
complexes sharing similar interactions with ABE I but involving different aptamer 
residues (Figure 9 and Table 9). Indeed, a thymine residue of TBA always interacts 
with ABE I hydrophobic cleft lined by Ile24, His71, Ile79 and Tyr117, but, depending 
on the binding mode, the interactions involve T3 (Figure 9 C, D), or T7 (Figure 9 A, B), 
or T12 (Figure 9 E, F). T7 interacts penetrating into the hydrophobic cleft more than 
T12 and T3 (Figure 9 F vs Figure 9 B, D); while the positioning of these latter resulted 
identical due to the symmetry of the two TT loops (Figure 9 B vs Figure 9 D). By 
consequence, a second ABE I subsite, including Gln38, Tyr76 and Ile82, interacts 
with T12 or T3, depending on the binding orientation (Figure 9 A−D). When the TGT 
loop binds to ABE I, the interaction with this second subsite is absent (Figure 9 E, F). 
Second, to identify the structural differences in TBA-binding site, experimentally 
determined structures of human and bovine thrombin were compared (PDB IDs are 
listed in the Experimental Section). Only three TBA-binding site residues, Ile24, 
Asn78, and Ile79, were mutated in bovine thrombin (Table 10), with no significant 
variation of the backbone structure (Figure 9). Human thrombin Asn78 residue 
(replaced by a lysine in bovine thrombin) interacts only with the TGT loop, 
establishing an Hbond interaction with the phosphate group of T9 (PDB IDs 1HUT 
and 1HAP; Figure 9 E, F and Table 9). On the contrary, the interactions with human 
ABE I hydrophobic cleft containing Ile24 and Ile79 are conserved in all crystal 
complexes and involve T3 or T7 or T12 depending on TBA-binding orientation (Figure 
9 and Table 9).  
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Figure 9. Cartoon (left) and 3D (right) structure of the different binding orientations of TBA with respect to human 
thrombin ABE I (green). (A, C, and E) Amino acid residues involved in TBA−thrombin interactions are evidenced 
in black; where mutated, the corresponding bovine residues are reported in red. The blue curve and straight 
arrows indicate loop nucleotides “stacked” or “not-stacked” on G-tetrad, respectively. (B) PDB ID 1HAO (TBA 
carbons = cyan); (D) PDB ID 4DIH (TBA carbons = yellow); (F) PDB ID 1HAP (TBA carbons = magenta). Protein 
carbons are colored in green, residues within TBA binding site that are mutated in bovine thrombin are shown and 
labeled. The nucleotides T3, T7, and T12 are evidenced as ball and stick. Heteroatoms are colored as follows: O 
= red; N = blue; P = magenta. Hydrogens are omitted for the sake of clarity. 
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1HAO TBA-thrombin 
X-ray complex 
4DIH TBA-thrombin 
X-ray complex 
Aptamer 
residue 
Thrombin 
residue Interaction 
Aptamer 
residue 
Thrombin 
residue Interaction 
T3 (O2) Gln 38 Hydrogen bonda T3 (N3) Glu 77 
Hydrogen 
bond 
T3 Tyr 76 π-π stacking T3 (O2) Gly 69 Hydrogen bonda 
T3 Ile 82 Hydrophobic T3 Ile 24 Ile 79 Hydrophobic 
T4 Tyr 76 T-shape T3 Hys 71 T-shape 
T4 (O2) Arg 75 Hydrogen bond T3 (O3') Tyr 117 
Hydrogen 
bond 
T12 Ile 24 Ile 79 Hydrophobic T3(O4) Arg 75 
Hydrogen 
bond 
T12 
(O3/O4) Tyr 117 
Hydrogen 
bond T4(O4) Arg 75 
Hydrogen 
bond 
T12 (N3) Glu 77 Hydrogen bond T4(O2) Arg 77A 
Hydrogen 
bond 
T12 His 71 T-shape T4 Ile 79 Hydrophobic 
T12 (O4) Arg 75 Hydrogen bonda G5 (O4') Arg 77A 
Hydrogen 
bond 
T13 (O4) Arg 75 Hydrogen bond T12 (O2) Gln 38 
Hydrogen 
bonda 
T13 (O2) Arg 77A Hydrogen bond T12 Tyr 76 π-π stacking 
   T12 Ile 82 Hydrophobic 
   T13(O2) Arg 75 Hydrogen bond 
   T13(O4) Tyr 76 Hydrogen bond 
   T13 Tyr 76 T-shape 
 
 
 
     
4DII TBA-thrombin 
X-ray complex 
1HAP TBA-thrombin 
X-ray complex 
Aptamer 
residue 
Thrombin 
residue Interaction 
Aptamer 
residue 
Thrombin 
residue Interaction 
T3 (O4) His 71 Hydrogen bond T7 (N3) 
Ile 24 
Ile 79 Hydrophobic 
T3 Ile 79 Hydrophobic T7 (O4) Gly 25 Lys 70 
Hydrogen 
bonda 
T3 Tyr 117 T-shape T7 Tyr 117 His 71 π-π stacking 
T4 (O4) Arg 75 Hydrogen bond T7 (N3) Glu 77 
Hydrogen 
bond 
T4 (O3') Asn 78 Hydrogen bond 
G8 
(O1P) Arg 75 Ion pair 
T4 Ile 79 Hydrophobic T3(O4) Arg 75 Hydrogen bond 
G5 (O4') Arg 77A Hydrogen bond T9 (O3') Arg 77A 
Hydrogen 
bond 
T12 Tyr 76 π-π stacking T9 (O1P) Asn 78 
Hydrogen 
bond 
T13 (O2) Arg 75 Hydrogen bond    
T13 (O4') Tyr 76 Hydrogen bond    
T13 Tyr 76 T-shape    
a Hydrogen bond through a water molecule 
 
Table 9. Binding interactions between TBA and human thrombin ABE I in X-ray complexes. 
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Human Thrombin Bovine Thrombin 
Ile 24a Val 24 
Met 26a Leu 26 
Asn 78a Lys 78 
Ile 79a Val 79 
a Amino acids within Å radius from any given TBA atom  
(PDB IDs: 1HAO, 1HAP, 1HUT, 4DIH and 4DII) 
 
Table 10. Mutated amino acid residues in human and bovine thrombin ABE I. The amino acid residues within 
TBA binding site are highlighted in bold. 
 
The replacement of these two isoleucine residues in human thrombin by two valine 
residues in the bovine homologue determines an enlargement of the employable 
volume within the ABE I cleft. We then calculated the occurrence rates of TBA, TBA-
T7b, and TBA-T12b SA/MM conformers presenting solvent accessible surface areas 
of residues 3, 7, and 12 equal to or greater than that of the corresponding residue of 
TBA binding the ABE I hydrophobic cleft in experimentally determined complexes 
(Table 11; single diastereoisomer values are reported in Table 12). Interestingly, the 
replacement of T7 and T12 with the acyclic nucleoside b determined in both cases a 
greater rate of conformations presenting a solvent-exposed conformation. Moreover, 
in agreement with the results reported in Tables 5 and 7, T3 is more exposed to the 
solvent in the new modified aptamers than in TBA. Finally, we calculated the 
occurrence rates of bioactive conformations of residues at positions 3, 7, and 12 
resulting from SA/MM calculations on TBA, TBA-T7b, and TBA-T12b (Figure 10 and 
Table 13; single diastereoisomer values are reported in Table 14).  
 
ON T3 T7a T12b 
TBA 16.5 85.0 36.5 
TBA-T7b 21.0 88.0 34.5 
TBA-T12b  22.0 76.0 50.0 
aT7 residue in TBA-T7b is replaced by the acyclic nucleoside b.  
bT12 residue in TBAT12b is replaced by the acyclic nucleoside b. 
 
Table 11. Occurrence rates (%) of TBA, TBA-T7b, and TBA-T12b SA/MM conformers presenting a solvent 
accessible surface area (Å2) of residues 3, 7, and 12 equal to or greater than that of the corresponding residue of 
TBA assuming the bioactive conformation at the ABE I hydrophobic cleft.  
 
ON T3 T7a T12b 
TBA-T7b (S) 23.5 85.0 33.5 
TBA-T7b (R) 19.0 91.0 35.5 
TBA-T12b (S) 22.0 72.0 47.5 
TBA-T12b (R) 22.0 80.5 52.0 
aT7 residue in TBA-T7b (S) and TBA-T7b (R) is replaced by the acyclic nucleoside b.  
bT12 residue in TBAT12b (S) and TBA-T12b (R) is replaced by the acyclic nucleoside b. 
 
Table 12. Occurrence rates (%) of TBA-T7b (S), TBA-T7b (R), TBA-T12b (S) and TBA-T12b (R) SA/MM 
conformers presenting a solvent accessible surface area (Å2) of residues 3, 7, and 12 equal to or greater than that 
of the corresponding residue of TBA assuming the bioactive conformation at the ABE I hydrophobic cleft.  
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With this aim, all obtained conformers were superimposed on the experimentally 
determined TBA−thrombin complexes by fitting the guanine tetrads to evaluate the 
overlap with the residue interacting with the ABE I hydrophobic cleft (see 
Experimental Section for details). Obtained results show that TBA-T7b presents an 
increased rate of bioactive conformations if compared to TBA; on the contrary, the 
substitution of T12 with b decreases the rate of bioactive conformations of T3 and T7.  
Interestingly, the replacement of T7 and T12 with the acyclic nucleoside b determined 
in both cases a greater rate of conformations presenting a solvent-exposed position 
able to drive the interaction with the ABE I hydrophobic cleft. Nevertheless, likely due 
to the higher flexibility of the TGT loop with respect to the TT loops, there is a higher 
occurrence rate of T7b assuming the ABE I bioactive conformation compared to T3 
and T12b (Table 13 and Figure 10). 
 
 
 
 
Figure 10. TBA (green; A-C), TBA-T7b (orange; D-F), and TBA-T12b (white; G-I) SA/MM conformers presenting 
residue 3, 7, or 12 assuming ABE I hydrophobic cleft binding conformation. Molecular models are superimposed 
on 4DIH (A, D, G; yellow), 1HAP (B, E, H; pink), or 1HAO (C, F, I; cyan) by fitting the guanine tetrads. All 
conformers of TBA and the mean of those obtained for the two diastereoisomers of TBA-T7b and TBA-T12b are 
shown. For the sake of clarity only the residue interacting with the ABE I hydrophobic cleft is displayed and 
hydrogens are omitted. Heteroatoms are colored as follows: O = red; N = blue; P = magenta.  
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ON T3 T7a T12b 
TBA 9.50 12.0 10.0 
TBA-T7b 8.00 14.0 13.5 
TBA-T12b  6.50 6.50 10.0 
aT7 residue in TBA-T7b is replaced by the acyclic nucleoside b.  
bT12 residue in TBAT12b is replaced by the acyclic nucleoside b. 
 
Table 13. Occurrence rates (%) of bioactive conformations at the ABE I hydrophobic cleft of residues at positions 
3, 7, and 12 resulting from SA/MM calculations. 
 
ON T3 T7a T12b 
TBA-T7b (S) 9.00 12.0 14.0 
TBA-T7b (R) 6.50 16.0 13.0 
TBA-T12b (S) 5.50 7.00 16.5 
TBA-T12b (R) 7.50 6.00 4.00 
aT7 residue in TBA-T7b (S) and TBA-T7b (R) is replaced by the acyclic nucleoside b.  
bT12 residue in TBAT12b (S) and TBA-T12b (R) is replaced by the acyclic nucleoside b. 
 
Table 14. Occurrence rates (%) of bioactive conformations at the ABE I hydrophobic cleft of residues at positions 
3, 7, and 12 resulting from SA/MM calculations on of TBA-T7b (S), TBA-T7b (R), TBA-T12b (S) and TBA-T12b (R). 
 
3.2 Discussion  
The introduction of a bulky five member cycle on the pyrimidine ring of the modified 
thymine residues of TBA-T7a and TBA-T12a  led to compounds (TBA-T7b  and TBA-
T12b ) able to fold into G-quadruplexes characterized by unaffected structural stability 
but showing different anticoagulant activity with respect to their parent compounds. 
(38) Because TBA-T7b  and TBA-T7a  show the same melting profile, with a Tm 
higher than that of TBA (Table 1), it can be concluded that the sole presence of the 
acyclic linker unit at position 7 is responsible for the structural stabilizing effect. 
Conformational analysis results indicate that the introduction of the acyclic linker at 
position 7 increased the solvent-exposed surface area (Table 13) of the modified 
residue and the rate of T4 and T13 conformations stacked on the guanine planes 
(Table 7). These data account for the nucleobase 7 always positioned outside the G-
quadruplex core and not involved in intramolecular interactions, as well as for the 
reported stabilizing role played by T4  and T13 on TBA structural stability. (13-15) In 
line with our results, a similar increase in Tm value has also been observed by 
replacing the sugar moiety of T7  with a different acyclic linker. (39) Interestingly, the 
fact that TBA-T7a and TBAT7b showed the same enhancement of the Tm value with 
respect to TBA is not correlated with their diverse anticoagulant activities. Indeed, 
although the anticoagulant activities of TBA-T7a and TBA-T7b are higher than that of 
TBA, TBA-T7b is more active than TBA-T7a (Figure 7). Furthermore, PT assay data 
show that the incorporation of nucleoside b was more effective than that of 
nucleoside a also at position 12 of TBA (Table 2). It was somehow surprising that the 
activity of TBA with respect to the new modified analogues is reversed in fibrinogen 
assay (Figure 8 A). It could be supposed that the introduction of an acyclic linker in 
the TBA phosphate backbone enhances the aptamers’ stability to nucleases, thus 
producing an increment of inhibitory effect in plasma tests. However, PT results were 
almost unaffected upon increasing of the incubation time of all sequences with 
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plasma (data not shown), thus suggesting that, in the explored conditions, nuclease 
stabilities and inhibitory activities are uncorrelated and that modifications at T7  
directly affect the interaction of aptamers with thrombin. Supporting this view, the use 
of bovine thrombin in fibrinogen assay changed again the activity trend. In particular, 
when tested toward bovine thrombin, the inhibitory activity of TBA-T7b  and TBA-T12b  
significantly increases, becoming much higher than that of TBA, which, on the 
contrary, is almost unchanged in both fibrinogen tests (Figure 8, panel A vs panel B). 
On this ground, subtle structural differences between human and bovine thrombin 
that specifically affect the binding with TBA-T7b and TBA-T12b must exist. The results 
from our molecular modelling study using both human and bovine thrombin revealed 
that the obtained SARs fit with the binding of modified nucleobases, T7b and T12b to 
thrombin ABE I. Indeed, within the TBA binding site, human thrombin differs from the 
bovine counterpart by only three amino acids located at ABE I (Table 10). 
Specifically, in the bovine enzyme two isoleucine residues are replaced by valine 
residues and an asparagine is mutated into a lysine. In the reported human thrombin-
TBA complexes, the isoleucine residues are involved in hydrophobic contacts with T3 
or T7 or T12, depending on the binding orientation of the aptamer (Figure 9). On the 
other hand, the asparagine residue is involved in H-bond interactions with the 
phosphate group linking G8 to T9 only when the TGT loop binds to ABE I (Tables 9 
and 10). In the new TBA derivatives TBA-T7b and TBA-T12b, the introduction of the 
acyclic linker facilitates the extension of the phosphate backbone toward the solvent 
and the penetration of the modified nucleobase within the ABE I hydrophobic cleft, 
thus amplifying the steric hindrance caused by the presence of the five member cycle 
on modified nucleobase b (Table 11 and Figure 10). Accordingly, the presence of the 
smaller Val24 and Val79 residues in bovine thrombin could explain the increased 
activity of the new modified TBA analogues for this enzyme. The observed higher 
activity of TBA-T7b is indeed correlated to the calculated higher rate of bioactive 
conformations at the ABE I hydrophobic cleft with respect to TBA and TBA-T12b 
(Table 13 and Figure 10). This hypothesis is supported by the previously reported 
activity of TBA-T7a and TBA-T12a, (38) which, lacking the steric bulk at the modified 
nucleoside, was more active in the fibrinogen assay using human thrombin. On the 
other hand, the charged group at the lysine side chain allows the establishment of an 
ionic interaction with the modified TGT phosphate backbone of TBA-T7b, likely 
contributing to the enhancement of inhibitory ability. On these bases, the apparent 
incongruence of PT and fibrinogen assay results, using human thrombin, can be 
interpreted by taking into account the effects of different aptamer binding modes on 
thrombin allostery. (3, 5-7) In the PT assay a number of thrombin ligands/effectors 
other than fibrinogen that are able to modulate thrombin activity are present, (1-5) 
(27, 43-45) thus driving different binding modes; the new modified aptamers could 
differently affect this ligand/effector binding network. In this scenario, it is noteworthy 
that the 65-84 thrombin loop, involved in specific interactions with the modified 
nucleobase of the new TBA derivatives according to our binding mode hypothesis, 
has been proved to be responsible for the allosteric long-range communication 
among ABE I, the catalytic site, and ABE II. (4, 28) Altogether, our results reveal the 
absence of a direct correlation between the structural stability and the anticoagulant 
property in our series of modified TBAs, suggesting that the role played by T7  
(placed in the TGT loop) and T12 (placed in the TT loop close to the 3' terminus) in 
the biological activity of TBA and its analogues could involve alternative aptamer 
binding modes and the complex and not yet fully understood allosteric mechanism of 
action of thrombin. 
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3.3 Conclusions 
Bringing together the so far acquired knowledge of the thrombin-TBA interaction and 
thrombin allosteric regulatory mechanism with our SAR data, we determined that the 
G-quadruplexes formed by the modified TBAs can bind the thrombin ABE I 
hydrophobic cleft by using either TGT or one of the two TT loops. Our results indicate 
that the incoherency of their behaviours in the two explored biological tests is due to 
the molecular process through which they exert the anticoagulant activity, which is 
surely more intricate than a competitive inhibition with the fibrinogen-binding site. 
Besides their high anticoagulant activity, these molecules represent valuable tools to 
further explore the complex regulatory mechanism of thrombin during plasma 
coagulation that is, as yet, not completely clarified. 
3.4 Experimental Session  
3.4.1 General Procedure 
Chemicals and anhydrous solvents were purchased from Fluka-Sigma-Aldrich. TLCs 
were run on Merck silica gel 60 F254 plates. Silica gel chromatography was 
performed by using Merck silica gel 60 (0.063-0.200 mm). An API 2000 (Applied 
Biosystem) mass spectrometer was used to perform the analyses of the 
intermediates and monomer 6. NMR experiments were recorded using Varian 
Mercury Plus 400 MHz and Varian UNITYINOVA 500 and 700 MHz spectrometers and 
processed using the Varian VNMR software package. Reagents and 
phosphoramidites for DNA synthesis were purchased from Glenn Research. ON 
syntheses were performed on a PerSeptive Biosystem Expedite DNA synthesizer. 
HPLC purifications and analyses were carried out using a JASCO PU-2089 Plus 
HPLC pump equipped with a JASCO BS-997-01 UV detector. The purity of the final 
products was determined as >95% by using a C-18 RP analytical column (C-18 
Purospher STAR, Merck) eluted by a gradient of CH3OH in H2O (from 0 to 100% in 
30 min). CD experiments were performed on a JASCO 715 spectropolarimeter 
equipped with a PTC-348 temperature controller. 
3.4.2 Synthesis of Monomer 6 
3.4.2.1 3-Benzoyl-6,7-dihydro-1H-cyclopenta-[d]-pyrimidine-2,4(3H,5H)-dione (2) 
Nucleobase 6,7-dihydro-1H-cyclopenta[d]pyrimidine-2,4(3H,5H)-dione was obtained 
as previously reported by Renault et al. (46) and converted in its N3 benzoyl 
derivative 2. (38) 1H NMR (400 MHz; mixture of CD3OD/CDCl3, 3:1 v/v): δ 7.75 (d, 
2H, J = 8.0 Hz), 7.60 (t, 1H, J = 8.0 Hz), 7.43 (t, 2H, J = 8.0 Hz), 3.03 (t, 2H, J = 7.3 
Hz), 2.67 (t, 2H, J = 7.3 Hz), 2.10 (q, 2H, J = 7.3 Hz) ppm. 13C NMR (100 MHz; 
mixture of CD3OD/CDCl3, 3:1 v/v): δ 169.3,166.3, 155.2, 147.3, 134.2, 132.2, 128.9, 
128.3, 127.5, 127.0, 113.4, 34.8, 30.5, 18.0 ppm. ESI Mass (positive mode): 257.1 
[M+H]+, 279.1 [M+Na]+ (calculated 256.1). 
 
3.4.2.2 3-Benzoyl-1-[(2,2,5-trimethyl-1,3-dioxan-5-yl)methyl]-6,7-dihydro-1H-
cyclopenta-[d]-pyrimidine-2,4(3H,5H)-dione (3) 
Compound 2 (1.5 g, 5.9 mmol) was suspended in 70 mL of dry dioxane at 30 °C in 
the presence of triphenylphosphine (2.28 g, 8.7 mmol) before the addition of di-tert-
butyl azodicarboxylate (2.1 g, 9.1 mmol). To the resultant mixture, after 10 min of 
stirring at room temperature, was added 5.9 mmol of 1 dissolved in dry dioxane (300 
µL). The reaction mixture was stirred at room temperature for 18 h under argon. The 
solution was concentrated under reduced pressure and the residue purified by 
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column chromatography on silica gel eluted with 95:5 Et2O/CH2Cl2 to give 3 as a 
white solid (yield 43%, Rf 0.70). 1H NMR (400 MHz; CDCl3): δ 7.98 (d, 2H, J = 8.0 
Hz), 7.60 (t, 1H, J = 8.0 Hz), 7.43 (t, 2H, J = 8.0 Hz), 4.0 (bs, 2H), 3.62 (m, 4H), 3.03 
(t, 2H, J = 7.3 Hz), 2.66 (t, 2H, J = 7.3 Hz), 2.09 (q, 2H, J = 7.3 Hz), 1.38 (s, 3H), 1.42 
(s, 3H), 0.87 (s, 3H) ppm. ESI Mass (positive mode): 399.2 [M+H]+, 421.2 [M+Na]+ 
(calculated 398.2). 
 
3.4.2.3 1-(3-hydroxy-2-(hydroxymethyl)-2-methylpropyl)-6,7-dihydro-1H-
cyclopenta-[d]-pyrimidine-2,4(3H,5H)-dione (4) 
Compound 3 (1.0 g, 2.5 mmol) was suspended in 9:1 MeOH/H2O (100 mL) 
containing 450 mg of Dowex 50WX8 (H+). After 8 h at room temperature, a NaOH 0.5 
M aqueous solution was slowly added to neutralization. The solution was filtered and, 
in turn, basified with NaOH 1.0 M (5 mL) to remove the N-3 benzoyl group from the 
nucleobase. After 12 h at room temperature, the pH of the reaction was neutralized, 
the solvent was evaporated under vacuum, and the residue was dissolved in MeOH 
and purified by HPLC (C-18 reversephase column, Grace Davison Discovery 
Sciences, eluted with ACN in H2O from 0 to 50% in 30 min) to give 4 as a white solid 
(yield 98%, elution time 15 min). 1H NMR (700 MHz; CD3OD): δ 3.80 (bs, 2H), 3.41 
(d, 2H, J = 11.4 Hz), 3.38 (d, 2H, J = 11.4 Hz), 3.03 (t, 2H, J = 7.3 Hz), 2.66 (t, 2H, J 
= 7.3 Hz), 2.09 (q, 2H, J = 7.3 Hz), 0.87 (s, 3H) ppm. 13C-NMR (175 MHz; CD3OD): δ 
163.8, 161.4, 155.7, 113.6, 66.6, 49.5, 44.0, 34.2, 28.2, 22.6, 17.8 ppm; NOESY (700 
MHz; CD3OD), fundamental NOE signal between 3.80 and 3.03 ppm that confirms 
the linker at the 1N position. ESI Mass (positive mode): 255.3 [M+H]+, 277.3 [M+Na]+, 
293.2 [M+K]+ (calculated 254.3). 
 
3.4.2.4 3-(4,4'-dimethoxy-trityl-oxy)-2-((2,4-dioxo-2,3,4,5,6,7-hexahydro-1H-
cyclopenta-[d]-pyrimidin-1-yl)methyl)-2-methylpropyl-2-cyanoethyl 
Diisopropylphosphoramidite (6)  
Compound 4 (640 mg, 2.5 mmol), 4,4'-dimethoxytrytyl chloride (541 mg, 1.6 mmol), 
and 4-dimethylaminopyridine (15.0 mg, 0.12 mmol) were dissolved in dry pyridine (20 
mL) and dry ACN (10 mL). The resulting solution was stirred at room temperature 
under argon for 1.5 h. Dry methanol (200 µL) was then added to quench the reaction. 
After 30 min under stirring, the solution was concentrated under reduced pressure 
and the residue purified by column chromatography on silica gel (eluted with 50:50:1 
EtOAc/hexane/Et3N) to give monodimethoxytritylated 5 as a clear yellow solid (44% 
yield from 4; Rf 0.51 in EtOAc/hexane 1:1 v/v). The solid (600 mg, 1.1 mmol) was 
dried in vacuo overnight before being dissolved in anhydrous DCM (8 mL) and 
diisopropylethylamine (600 µL, 3.6 mmol) under argon. Three hundred microliters of 
β-cyanoethyl diisopropylchlorophosphoramidite was then added (1.2 mmol). After 40 
min, the reaction was quenched by the addition of dry methanol (100 µL), diluted with 
ethyl acetate (15 mL), and finally washed with 10% sodium carbonate solution (15 
mL) and brine (15 mL). The organic layer was dried on magnesium sulfate and 
concentrated in vacuo. The residue was purified by silica gel chromatography eluted 
with DCM, ethyl acetate, and triethylamine (80:10:10). The fractions containing the 
product were collected and concentrated under vacuum, yielding 6 as a white foam 
(99% yield; Rf 0.65 in CHCl3/MeOH/TEA 97:3:0.05 v/v/v). 1H NMR (700 MHz; CDCl3): 
δ 7.90 (2H), 7.38 (3H), 7.35 (4H), 7.12 (1H), 6.85 (4H), 3.90 (2H), 3.70 (6H), 3.65 
(2H), 3.60 (2H), 3.45 (2H) 3.39-3.02 (2H), 2.60–2.45 (2H), 1.45(3H) 1.09 (6H), 1.04 ( 
6H) ppm. 13C-NMR (175 MHz; CDCl3): δ 158.6, 151.6, 147.3, 139.4, 135.1, 130.3, 
129.1, 127.8, 127.7, 127.1, 113.1, 64.4, 60.4, 55.2, 47.3, 33.6, 29.7, 27.6, 20.9, 19.3, 
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17.3 ppm. 31P NMR (200 MHz, CDCl3) δ 146.1 and 145.9 ppm. ESI Mass (positive 
mode): 757.9 [M+H]+, 779.9 [M+Na]+ (calculated 756.9).  
 
3.4.3 Synthesis of Oligomers  
TBA and analogues were synthesized by using standard solid phase DNA chemistry 
on controlled pore glass (CPG) support following the β-cyanoethyl phosphoramidite 
method. The oligomers were detached from the support and deprotected by 
treatment with an aqueous ammonia solution (33%) at 55 °C overnight. The 
combined filtrates and washings were concentrated under reduced pressure, 
dissolved in H2O, and purified by HPLC using an anionic exchange column eluted 
with a linear gradient (from 0 to 100% B in 30 min) of phosphate buffer at pH 7.0 (A, 
20 mM NaH2PO4 aqueous solution containing 20% CH3CN; B, 1.0 M NaCl, 20 mM 
NaH2PO4 aqueous solution containing 20% CH3CN). The oligomers were 
successively desalted by molecular exclusion chromatography on Biogel P-2 fine. 
The purity was checked on HPLC by using reverse phase column. The 
concentrations of the samples used in CD and UV experiments were determined by 
measuring the absorbance at 260 nm at 80 °C and using the open access program 
available on http://basic.northwestern.edu/biotools/OligoCalc.html. (47)  
 
3.4.4 NMR Experiments 
1D NMR spectra were acquired as 16384 data points with a recycle delay of 1.0 s at 
temperatures in the range of 2-50 °C. Data sets were zero filled to 32768 points prior 
to Fourier transformation and apodized with a shifted sine bell squared window 
function. The pulsed-field gradient DPFGSE (48, 49) sequence was used for H2O 
suppression. NMR samples of TBA-T7b and TBA-T12b (0.5 mM single-strand 
concentration) were prepared in 100 mM K+ buffer (H2O/D2O 9:1 v/v containing 90 
mM KCl, 10 mM KH2PO4, and 0.2 mM EDTA). 
 
3.4.5 CD Experiments 
To perform CD experiments, each ON was dissolved in the potassium (90 mM KCl, 
10 mM KH2PO4, pH 7.0) or PBS (Sigma-Aldrich; 10 mM phosphate buffer, 2.7 mM 
KCl, 137 mM NaCl, pH 7.4) phosphate buffer at the final ON concentration of 2.0 x 
10−5 M and submitted to the annealing procedure (heating at 90 °C and slowly 
cooling at room temperature). Before each experiment, the samples were 
equilibrated at 10 °C for 30 min. CD spectra were recorded from 200 to 360 at 100 
nm/min scanning rate, 16 s response, and 1.0 nm bandwidth. Each CD profile was 
obtained by taking the average of three scans from which the spectrum of 
background buffer was subtracted. CD melting curves were obtained by monitoring 
the variation of absorbance at 295 nm from 10 to 80 °C. Two melting experiments for 
each ON were recorded at 0.5 °C/min heating rate. 
 
3.4.6 Prothrombin (PT) Time 
PT time was measured by using a Koagulab MJ Coagulation System with a specific 
kit RecombiPlas Tin HemosIL (Instrumentation Laboratories, Lexington, MA, USA). 
The procedure was performed according to the manufacturer’s instructions. In our 
experimental protocol a time course of each ON or vehicle incubated with 100 µL of 
plasma at 37 °C has been performed. For the evaluation of PT at 20.0 µM, in the 
apposite microtube, 2.0 µL of the corresponding ON solution (1.0 x 10−3 M in PBS) or 
vehicle was added. The PT at final ON concentration of 2.0 µM was determined by 
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using 2.0 µL of a diluted ON solution (the initial ON solution 1.0 x 10−3 M in PBS was 
diluted at a final concentration of 1.0 x 10−4 M). Using six different incubation times 
from 30 s to 15 min (i.e., 30 s and 1, 2, 5, 10, and 15 min) 200 µL of the kit solution 
containing Recombiplastin was added with consequent activation of extrinsic 
pathway. The PT measurement, for each incubation time, was produced in triplicate, 
and the average and its standard error values were calculated. The basal clotting 
time was determined by measuring the clotting time in the absence of any ON. The 
fold increase of basal PT time was calculated as the ratio between the measured PT 
time in the presence of each ON and the basal PT value (13.4 ± 0.2 s). 
 
3.4.7 Purified Fibrinogen Clotting Assay 
ONs were incubated for 1min at 37 °C in 200 µL of buffer (20 mM tris acetate, 140 
mM NaCl, 2.7 mM KCl, 1.0 mM MgCl2, 1.0 mM CaCl2, pH 7.4) containing 2.0 mg/mL 
of fibrinogen (fibrinogen from human plasma, F 3879, Sigma-Aldrich). One hundred 
microliters of human (Sigma-Aldrich, T8885, human thrombin suitable for thrombin 
time test) or bovine (HemosIL, Thrombin Time Kit, Instrumentation Laboratories) 
thrombin (10 NIH per mL) was then added to the solution containing the fibrinogen 
and the ON. The time required to clot was measured using a Koagulab MJ 
Coagulation System. The clotting time of each ON was determined in triplicate at 
different concentrations. The basal clotting time was determined by measuring the 
clotting time in the absence of any ONs. Prolonged clotting time was obtained by 
subtracting the basal clotting value from each ON clotting time. The ratio of basal and 
prolonged clotting time versus log [ON] was reported. 
 
3.4.8 Molecular Modeling 
Molecular modeling calculations were performed on SGI Origin 200 8XR12000 and 
E4 Server Twin 2 x Dual Xeon 5520, equipped with two nodes. Each node was 2 x 
Intel Xeon QuadCore E5520, 2.26 GHz, 36 GB RAM. The molecular modeling 
graphics were carried out on SGI Octane 2 workstations. 
 
3.4.8.1 Conformational Analysis 
Experimentally determined structures of TBA alone (PDB ID 148D) and in complex 
with thrombin (PDB IDs 1HAO, 1HAP, and 1HUT) were downloaded from Protein 
Data Bank (PDB, http://www.rcsb.org/pdb/) and analyzed using the Homology 
module of Insight 2005 (Accelrys Software Inc., San Diego, CA, USA). Hydrogens 
were added to all of these structures considering a pH value of 7.4 (Biopolymer 
Module, Insight 2005). Because the replacement of T7 and T12 residues with 
nucleoside b produced a mixture of diastereoisomers characterized by S or R 
configuration at the acyclic linker, for each new TBA analogue TBA-T7b and TBA-
T12b, the two diastereoisomers were built by modifying the experimentally determined 
structure of TBA in complex with thrombin (PDB ID 1HAO; Insight2005 Builder 
module). Atomic potentials and charges were assigned using the CVFF force field.30 
The conformational space of TBA (PDB ID 1HAO) and the new modified analogues 
was sampled through 200 cycles of simulated annealing (SA) followed by molecular 
mechanics (MM) energy minimization. During the SA procedure, the temperature is 
altered in time increments from an initial temperature to a final temperature by 
adjusting the kinetic energy of the structure (by rescaling the velocities of the atoms). 
The following protocol was applied: the system was heated to 1000 °K over 2000 fs 
(time step of 1.0 fs); a temperature of 1000 °K was applied to the system for 2000 fs 
(time step of 1.0 fs) to surmount torsional barriers; successively, the temperature was 
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linearly reduced to 300 °K in 1000 fs (time step of 1.0 fs). Resulting conformations 
were then subjected to MM energy minimization within Insight 2005 Discover_3 
module (CVFF force field) until the maximum rms derivative was <0.001 kcal/Å, using 
a conjugate gradient (50) as the minimization algorithm.  
To reproduce the physiological environment where these molecules act and, to 
evaluate the effects of the implicit solvent, we sampled the conformational space 
through the combined procedure of SA/MM calculations, using the dielectric constant 
of the water (ε = 80r). Moreover, to allow a complete relaxation of the structures 
preserving the monomolecular chairlike G-quadruplex folding topology, during the 
entire course of SA/MM calculations, we applied a tether force of 100 kcal/Å2 to the 
guanine bases of two quartets. All resulting conformers were subsequently analyzed 
and loop nucleotides were classified on the bases of (i) glycosidic bond χ values, that 
is, 0° < χ < 90° = syn; −60° < χ < −180°= anti; (51, 52) 90°< χ <180° and −60° < χ < 
0° = s/a); (ii) the interatomic distance between the centroid of the ring atoms of the 
nucleobase of each loop nucleotide and the centroid of the ring atoms of the 
nucleobases of the two Gtetrads (Pseudo_Atom Define command, Biopolymer 
Module, Insight 2005). According to the latter parameter, the loop nucleotide was 
classified as “stacked” when the distance was <8 Å or as “not-stacked” when the 
distance was >12 Å, whereas a 3D visual inspection was needed to classify the 
nucleotide as “stacked” or “not-stacked” when the distance was between 8 and 12 
Å. A nucleotide termed “stacked” presented at least one nucleobase atom shielded 
by the G-tetrads; a nucleotide termed “not-stacked” presented no atoms shielded by 
the G-tetrads. Occurrence rates were calculated for TBA and for each 
diastereoisomer of the new analogues TBA-T7b and TBA-T12b. Because all 
experimental data refer to the mixture of the two diastereoisomers, the mean of the 
values obtained for the two diastereoisomers was also calculated. 
3.4.8.2 Structural and Bioinformatics Analysis  
To analyze the binding modes of TBAs and the corresponding aptamer-thrombin 
interactions, all of the experimentally determined structures of aptamers in complex 
with human thrombin were downloaded from Protein Data Bank: 1HAO, 1HAP, 
1HUT, 3DD2, 3QLP, 4DIH, and 4DII. On the other hand, to identify the structural 
differences in TBA binding site between human and bovine thrombin, additional 
structures of human (PDB IDs 1HXF, 1TB6, 1TMT, 1TMU, 1XMN, 3HTC, and 4HTC) 
and bovine (PDB IDs 1HRT, 1VIT, and 3PMA) thrombin, sharing similar ABE I and 
ABE II ligands, were selected and analyzed. Hydrogens were added to all of the PDB 
structures considering a pH value of 7.4 (Biopolymer Module, Insight 2005). All 
structures were superimposed by Cα atoms, and their sequences were extracted 
using the Homology module of Insight 2005 (Accelrys). On the other hand, the 
human (entry P00734) and bovine (entry P00735) prothrombin sequences were 
downloaded from the UniProt Knowledgebase (http://www.uniprot.org), and the 
sequence alignments were performed using Multiple_Sequence Alignment pulldown 
in the Insight 2005 Homology module. Moreover, for each ligand/enzyme complex, a 
subset around the ligands that consisted of all residues and water molecules having 
at least one atom within a 6 Å radius from any given ligand atom was defined. The 
created subsets were displayed and analyzed through a 3D visual inspection. The 
results of this analysis were compared with those obtained through the sequence 
alignments. Starting from the results obtained from this structural and bioinformatics 
analysis, to evaluate in detail the possibility of the residues at positions 3, 7, and 12 
to interact with thrombin ABE I hydrophobic cleft, the solvent-accessible surface area 
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of these nucleotides was evaluated by calculating the Connolly surface with a probe 
radius of 1.4 Å, which approximates the radius of a water molecule (Viewer Module, 
Insight 2005, Accelrys Software Inc.). In particular, the Connolly surface of the 
considered nucleotides was calculated for the TBA experimentally determined 
structures (PDB IDs 1HAO, 1HAP, 4DIH, and 4DII) and for all conformers of TBA and 
new modified analogues, resulting from SA/MM calculations. The TBA, TBA-T7b, and 
TBA-T12b SA/MM conformers presenting solvent-accessible surface areas of 
residues 3, 7, and 12 equal to or greater than that of the corresponding residue of 
TBA when interacting with the ABE I hydrophobic cleft in experimentally determined 
complexes (i.e., T3, 191.01 Å2; T7, 159.35 Å2; and T12, 180.59 Å2) were selected, and 
their occurrence rates were calculated. Because all experimental data refer to the 
mixture of the two diastereoisomers, the mean of the values obtained for the two 
diastereoisomers was also calculated. Finally, with the aim to calculate the 
occurrence rates of bioactive conformations of residues at position 3, 7, and 12 of 
TBA and new modified analogues TBA-T7b and TBA-T12b, all conformers, resulting 
from SA/MM calculations, were superimposed on the experimentally determined 
structures of TBA in complex with thrombin (PDB IDs 1HAO, 1HAP, 1HUT, 4DIH, 
and 4DII) by fitting heavy atoms of the guanine bases of two quartets, and the 
overlap with the residue interacting with the ABE I hydrophobic cleft (I1e24, His71, 
I1e79, and Tyr117) was evaluated. To assess the bioactive conformation of the 
residue at position 7, the orientation that allows residue 7 to be located in the same 
position of T7 of 1HAP or 1HUT crystal structure was considered (orientation II in 
Figure 2). The conformation of residues at positions 3, 7, and 12 was considered 
bioactive when the correspondent nucleobase was positioned within the ABE I 
hydrophobic cleft and presented at least one atom superimposed on T3 (PDB IDs 
4DIH and 4DII) or on T7 (PDB IDs 1HAP and 1HUT) or on T12 (PDB ID 1HAO), 
respectively. Occurrence rates of bioactive conformations of residues at positions 3, 
7, and 12 were then calculated. Because all experimental data refer to the mixture of 
the two diastereoisomers, the mean of the values obtained for the two 
diastereoisomers was also calculated. 
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Chapter 4 
 
DNA-based Nanostructures: dimers of G-quadruplexes via stacking of unusual 
G(:C):G(:C):G(:C):G(:C) octads 
 
Guanine-rich oligonucleotides can form a variety of G-quadruplex architectures 
involving stacked planar G-tetrads. The structural polymorphism of G-quadruplex 
topologies depends on the range of alternate strand orientations, loop connectivities, 
and syn-anti distribution of guanine bases around G-tetrads (1). Additional structural 
diversity arises from the accommodation of A-, T- or C-tetrads (2-4). Furthermore, 
several papers describing the higher order packing of intramolecular (5-7) or 
intermolecular (8, 9) DNA quadruplexes have also been published and higher order 
pairing alignments involving G-tetrads have been recently identified, such as pentads 
(10, 11), hexads (12), and heptads (8, 13) for sequences containing guanine 
stretches separated by adenine residues. One of the structural features required for 
quadruplex multimerization is the presence of a stretch of guanines at the 5'- or 3'-
termini of parallel G-quadruplexes, and various stacking modes (5'–5', 3'–3' and 3'–
5') have been proposed as a means for higher-order packaging of G-quadruplexes 
(14). These types of packaging have been reported to lead to higher ordered G-
quadruplexes assemblies by either the association of interlocked slipped strands (15) 
or by end-to-end stacking (9, 15). Understanding and controlling higher order 
structures formation is of prime importance for in vitro studies of oligonucleotides 
derived from biologically relevant sequences, and for the development of DNA-based 
nanostructures. In this respect, biomolecular self-assembly of the strongly interacting 
DNA bases provides a promising avenue, and the construction of specific higher 
order G-quadruplexes as DNA-based nanostructures may represent a key goal in the 
field of nanotechnologies. The main fundamental step to drive this topic from a 
laboratory curiosity towards the technologically relevant engineering is the achieving 
of control of self-folding and self-stimulated formation of these higher order G-
quadruplexes in solution as a function of their molecular composition (i.e., base 
sequence) and solution conditions (e.g., DNA and cations concentration)(16). 
Different experimental techniques may provide different views on the formation and 
structuring of higher order G-quadruplexes. For example, Polyacrylamide Gel 
Electrophoresis (PAGE) (17) and mass spectrometry (18-20) give indications on the 
molecular sizes of G-quadruplexes, while CD spectra are empirically used to 
speculate on the relative orientation of the strands constituting the G-tetrad core. So 
far, only NMR and X-ray crystallography can provide atomic-resolution structures of 
G-quadruplexes, and for NMR structural analysis of G-quadruplexes, unambiguous 
and model-independent spectral assignment approaches are required (21). 
In this context, the aim of this research work was to achieve a small library of DNA-
based nanostructures consisting of dimers of G-quadruplexes. Thanks to several 
analytical techniques, such as Nuclear Magnetic Resonance (NMR), mass 
spectrometry (MS), Circular Dichroism (CD), UV and PAGE, it was proved that the 
sequence CGGTGGT can form a nanostructure of about 4 nm in length, consisting of 
a ‘dimeric G-quadruplex’ (from now on 2Q), which is in fact an octamer of the 
sequence, coexisting in solution with minor amounts of other DNA secondary 
structures and with the single-stranded molecule. The octamer formation takes place 
through a dimerization process, which is allowed by the 5'-5' stacking of two 
‘monomeric G-quadruplexes’ (1Q) subunits, and assisted by the formation of an 
unusual G(:C):G(:C):G(:C):G(:C) octad arrangement, never reported before, involving 
??????????
?????????????????????????
?
?
 
 
66 
C1 and G2 bases of each CGGTGGT strand (22). Starting from these results, a 
speculation about the main features essentials to the dimerization process has been 
carried on, focusing the attention on ODN bases sequence and solution conditions. 
 
4.1 Results 
 
4.1.1 dCGGTGGT forms an octamer 
The formation of a higher order assembly than a tetramer by the DNA sequence 
dCGGTGGT was first noticed in native PAGE experiments. Figure 1a shows PAGE 
experiments on the following DNA sequences: TGGGGT annealed in 0.1 M 
potassium buffer (lane 1) used as a tetramolecular quadruplex ([dTGGGGT]4) size-
marker, CTGTGTT (lane 2) used as a single-stranded 7-mer marker, TGGTGGC 
(lanes 3 and 4), CGGTGGT (lanes 5 and 6) and CGGGGT (lanes 7 and 8). The 
sequence TGGTGGC migrates similarly to [dTGGGGT]4; whereas, the sequence 
CGGTGGT shows a major band migrating much slower. We conclude that 
TGGTGGC forms prevalently a tetrameric assembly, in agreement with the reported 
tetramer G-quadruplex formation for this sequence (23), whereas CGGTGGT forms a 
higher order assembly. The polarity of the sequence therefore appears crucial in the 
higher order structure formation.  
The migration profile of dCGGGGT has also been investigated to determine whether 
the additional central thymine played any role in the higher order structure formation. 
Two bands are observed for dCGGGGT, the faster one migrating as the tetrameric 
[dTGGGGT]4, and the slower one migrating like the structure formed by CGGTGGT. 
 
 
Figure 1. Stoichiometry of self-assemblies determined by (a) PAGE for sequences TGGGGT (lane 1), CTGTGTT 
(lane 2), TGGTGGC (lanes 3 and 4), CGGTGGT (lanes 5 and 6) and CGGGGT (lanes 7 and 8), and by (b–d) 
ESI-MS for TGGTGGC (b), CGGTGGT (c) and CGGGGT (d). In the peak annotation Gnz-, n indicates the number 
of strands and z indicates the charge. 
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As the PAGE results are similar in NH4+ and in K+ cations, we therefore used ESI-
MS, which can only be carried out in NH4+, to determine unambiguously the strand 
stoichiometry of the higher order assemblies formed by CGGTGGT and CGGGGT. 
The ESI-MS spectra of TGGTGGC, CGGTGGT and CGGGGT, each separately 
annealed at 6mM in 150 mM NH4OAc (pH = 7.0) and diluted to 80 µM final strand 
concentration, are shown in Figure 1b-d, respectively. All three sequences show 
peaks corresponding to a tetramolecular assembly (noted G4), but the spectra of 
CGGTGGT and CGGGGT also display peaks corresponding to an octameric 
assembly (noted G8). We therefore assign the slow migrating PAGE band to an 
octameric self-assembly. In terms of relative intensities, although native PAGE and 
ESI-MS experiments were performed on samples obtained by dilution of the same 
annealed stock solution, the octamer is the darkest band in the gels of CGGTGGT 
(lanes 5 and 6), whereas the ESI-MS peaks of the octamer have lower intensities 
than the tetramer peaks. The analysis of the electrospray response factors in the 
kinetics ESI-MS experiments (Figures 1b-d) indeed reveals the octamer has a lower 
ESI-MS response than the tetramer in the spectrometer used, and that the octamer is 
indeed the major species in solution. 
 
4.1.2 The octamer contains stacked G-tetrads 
All G-rich sequences studied here are expected to form G-quadruplex structures. 
Note that ‘G-quadruplex’ means that the structure contains stacked G-quartets, not 
necessarily that the assembly is a tetramer. CD was used to probe the relative 
orientation of the bases in the tetramer [TGGTGGC]4 and in the octamer 
[CGGTGGT]8. The overall CD profiles recorded in K+ (Figure 2a) and NH4+ (Figure 
2b) are in agreement with the formation of G-quadruplex structures (24, 25) both in 
K+ and NH4+ media, showing a positive maximum at about 260 nm and a negative 
minimum close to 240 nm, which are characteristics of head-to-tail arrangement of 
guanines, as typically found in parallel oligodeoxynucleotides G-quadruplexes (26-
28). Interestingly, the CD spectra of CGGTGGT also show a weak, but clearly visible 
negative band centered at 290 nm. This minimum suggests that additional base 
stacking interactions could be involved in the formation of the higher ordered 
quadruplex species by allowing the quadruplex multimerization via end-to-end 
stacking. A typical heteropolar stacking in G-quadruplexes formed by strands with no 
inverted polarity usually results in a positive band at 290 nm (27), but negative bands 
at 290 nm have been observed in octameric self-assemblies of lipophilic guanosine 
derivatives (29). The type of stacking present in our octamers could therefore 
resemble that present in those lipophilic octamers.  
 
Because the CD signature is peculiar and does not allow to conclude unambiguously 
to a G-quadruplex structure, we decided to probe cation incorporation into the 
octamer. Indeed, successive G-quartets incorporate monovalent cations (here K+ or 
NH4+) by coordination between eight guanines. High-resolution ESI-FTICRMS was 
used to count the number of ammonium cations per tetramer and per octamer 
(Figure 2c). Cation incorporation was found in all cases, confirming G-quadruplex 
formation both in the tetramer and the octamer. The major peaks correspond to three 
cations per tetramer [dCGGTGGT]4 and eight cations per octamer [dCGGTGGT]8. 
The number of cations is indicative of the number of stacked quartets. Interestingly, 
the tetramer [dCGGTGGT]4 contains three ammonium cations, whereas the tetramer 
[dTGGTGGC]4 contains four (data not shown), suggesting a structural difference 
depending on the strand polarity. However, the incorporation of eight ammonium 
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cations in the octamer suggests that within the octamer, each tetrameric subunit is 
now capable of incorporating four ammoniums cations. 
 
 
 
 
Figure 2. G-quadruplex formation probed by (a and b) CD in 100mM KCl (a) and 150mM NH4OAc (b) of the 
sequences CGGTGGT (solid line) and TGGTGGC (dotted line), and by (c) counting the number of ammonium 
cations incorporated in the tetramer (noted G4) and the octamer (noted G8) of CGGTGGT using high resolution 
ESI-FTICR mass spectrometry. 
 
4.1.3 Kinetics of octamer formation studied by ESI-MS 
We followed the kinetics of octamer formation from the CGGTGGT solution to 
monitor tetramer and octamer formation as a function of the time elapsed after 
ammonium acetate addition. This experiment is performed with an internal standard, 
and therefore also allows to ascertain the relative response of each species. Typical 
ESI-MS spectra recorded after different reaction times (1 h, 24 h and 17 days) are 
shown in Figure 3 (a-c). The relative intensity of the monomer (G1) decreases with 
time, the relative intensity of the tetramer (G4) first increases, then decreases, while 
the relative intensity of the octamer (G8) increases slowly, but nevertheless remains 
lower than the intensity of the tetramer (Figure 3d). Next, the mass balance equation 
procedure is used to calculate the relative response factors of the monomer, tetramer 
and octamer. The dimer and trimer response factors could not be evaluated because 
CHAPTER	  4	  
DNA-­‐based	  Nanostructures	  
	  
	  
 
 
69 
there are not enough independent equations to calculate them (their intensity 
variation profile is close to that of the monomer). Because they were minor species in 
the spectrum, they were ignored in the mass balance equation. We found that, in our 
experimental conditions, the response of the tetramer G4 (=Q1) is 8-fold larger than 
the response of the octamer G8 (=2Q), 2.9 times larger than the response of the 
monomer G1. Figure 3e is obtained from Figure 3d, after correction of the relative 
intensities by the relative response of each species (R(G1)/R(G4) = 0.348, R(G8)/R(G4) = 
0.125). Evolution of the concentrations of each species as a function of time shows 
that the octamer becomes the major species after ≈ 80 h, and is formed at > 80% 
after 168 h (7 days).  
 
 
Figure 3. Kinetics of dCGGTGGT octamer formation in ammonium acetate. The total strand concentration in the 
ageing solution was 6 µM (left at RT). The total dCGGTGGT concentration injected was 80 µM, with 10 µM dT6 as 
internal reference. (a-c) ESI-MS spectra obtained after 1h, 24h, and 17 days, respectively. (d) Time evolution of 
the intensity ratio of each species relative to the reference. (e) Time evolution of the concentrations of single 
strand, tetramer, and octamer, after correction for the relative response of each species (R(G1)/R(G4) = 0.348, 
R(G8)/R(G4) = 0.125). 
 
4.1.4 Influence of sample preparation procedure 
In all experiments described above, the octamer was obtained by annealing the 
strand CGGTGGT at 6 mM single-strand ODN concentration at pH = 7.0 in 100 mM 
K+ or 150mM NH4+. CD experiments carried out using a higher K+ concentration (1 
M) show that higher cation concentration further favours the formation of the 
structure characterized by the negative band at 290 nm (data not shown). We also 
tested the influence of the solution pH, to test whether cytosine protonation might 
favour the formation of the new structure, but no clear influence of pH was found 
(data not shown). However, because of the octamer stoichiometry, it is anticipated 
that the strand concentration upon annealing would have a great influence on the 
formation kinetics. Figure 4a shows the CD spectra recorded on CGGTGGT 
annealed at 6.0 mM or 0.2 mM ODN concentration in 1M K+. The presence of the 
negative band at 290 nm was strictly dependent from ODN concentration: it is 
present when the sample is annealed starting from the 6 mM stock solution, whereas 
it is not observed when the sample is obtained by annealing the 0.2 mM ODN (Figure 
4a). However, the CD spectrum of the species formed from the 0.2 mM ODN solution 
resembles that of a regular tetramolecular G-quadruplex. The influence of the strand 
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concentration, therefore, indicates slow formation kinetics for the octamer. To study 
the kinetics of octamer formation in the 6 mM stock solution, and to probe the nature 
of the reaction intermediates, we recorded ESI-MS spectra as a function of the time 
after addition of cation in the ODN solution, at room temperature. This experiment 
could be carried out only in ammonium acetate (150 mM). The details of the 
methodology, representative ESI-MS spectra at different reaction times, and the 
relative intensities are presented in Supplementary Figure 3. Briefly, the single-
stranded dT6 strand (0.75 mM) is added to the 6 mM single-stranded dCGGTGGT in 
water. Quadruplex formation is initiated by the addition of ammonium acetate (final 
concentration: 150 mM) at room temperature. At each time point, an aliquot of the 
sample is diluted to 80 µM final dCGGTGGT single strand concentration, and 
injected in the ESI-MS. We therefore assume that, once formed, the octamer resists 
the dilution step. The signal intensity of the reference is used to normalize the 
intensity variations of the dCGGTGGT monomer, tetramer and octamer signal, and 
deduce their respective response factors (Figure 3).  
Figure 4b presents the same data as Figures 3e, but showing the time evolution of 
the relative proportions of single strand, tetramer and octamer, after correction for the 
relative response of each species, expressed as the fraction of single strand in each 
form. The single strand is quickly converted into a tetramer, but the tetramer-to-
octamer conversion is slower. The dimerization is therefore the rate-limiting step in 
the octamer formation. The results also show that, although the octamer is not the 
most abundant peak in the mass spectra (see Figures 1b–d and 2c), it is 
nevertheless the predominant species. The predominance of the octamer at long 
time scales also confirms that, once formed, the octamer resists the dilution step.  
 
 
Figure 4. Influence of the sample preparation conditions on the octamer formation. (a) Influence of strand 
concentration: CD spectra of CGGTGGT in 1.0M K+ buffer annealed, respectively, at 6mM (solid line) and 200 
mM (dotted line) single-strand concentration. (b) Kinetics of tetramer and octamer formation of 6mM CGGTGGT 
in 150mM ammonium acetate at room temperature, as determined by time-resolved ESI-MS. 
 
4.1.5 NMR investigation of the octamer structure  
The 1H NMR spectrum of CGGTGGT in 100 mM K+ buffer at 25°C recorded 1 hour 
after the annealing (data not shown) is characterized by the presence of four well-
resolved signals in the 11.0–11.6 ppm region attributable to the exchange-protected 
imino protons involved in the formation of Hoogsteen hydrogen bonds of four G-
tetrads (30-32), in close analogy with what was previously observed for the parallel 
quadruplex structure formed by TGGTGGC (23). Furthermore, the count of 
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quadruplex NMR signals is the same as what must be expected for the NMR 
spectrum of the corresponding single strand, thus suggesting the formation of a 
highly symmetric parallel G-quadruplex possessing a 4-fold symmetry. However, the 
aromatic region of 1H NMR spectrum is populated by more than the expected seven 
signals belonging to the H8/H6 aromatic protons of nucleobases. In order to 
discriminate whether the minor peaks were due to sample impurities or to the 
coexistence in solution of alternative minor conformations of CGGTGGT, we 
recorded the 1H NMR spectrum also at 65°C, and the high-temperature spectrum 
was clearly in agreement with the second hypothesis as evidenced by the presence 
of just seven well-defined signals in the aromatic region of the spectrum. We 
therefore studied the influence of time elapsed after the annealing, of K+ 
concentration, and of pH (data not shown) on the 1D NMR spectra. In agreement 
with the CD data, the NMR results confirmed that the best medium for the structural 
study of the new octameric structure formed by CGGTGGT requires 1.0 M K+ and 
long folding times (Figure 5a), and that the change of pH from 7.0 to 4.5 does not 
affect the folding of the structure. The combined analysis of 2D NOESY and TOCSY 
spectra (700 MHz, 25°C, 1 M K+, 15 days after the annealing) allowed us to get the 
complete assignment (Table 1) of both exchangeable and non-exchangeable protons 
of CGGTGGT.  
 
 H6/H8 H5/CH3 NH NH2i H1' H2' H2'' H3' H4' H5'/H5'' 
C1 7.54 5.48   5.63 2.28 2.10 4.66 4.13 3.87/3.95 
G2 8.14  11.56 9.82 6.09 2.72 2.96 5.10 4.49 4.18 
G3 7.56  11.13 9.80 6.12 2.55 2.94 5.07 4.50 4.30 
T4 7.03 0.72 9.40  5.84 2.24 2.46 4.92 4.34 4.25 
G5 8.00  11.26 9.82 5.98 2.72 2.84 5.10 4.49 4.20/4.30 
G6 7.73  11.05 9.81 6.27 2.58 2.71 4.98 4.52 4.11/4.25 
T7 7.34 1.64   6.08 2.73 2.21 4.51 4.08 4.25 
 
Table 1. Proton chemical shift (ppm, relative to H2O at 4.78 ppm) for CGGTGGT at 25°C, pH 7.0, 1M K+. NH2i 
refers to the internal (i) H-bonded amino protons of guanosines. 
 
The sequential connectivities between the aromatic protons (Figure 5b) were traced, 
as well as the self and sequential NOE connectivities between H8/H6 base protons 
and H1', H2', H2'' and H3' sugar protons. The intensities of intranucleotide H8/H1' 
NOE cross-peaks (Figure 5c) indicate that all Gs adopt an anti glycosidic 
conformation. This finding together with the observation for each G-tetrad of a 
GiH8/GjN1H NOE cross-peak (Figure 5f), with i = j (where i and j represent the 
nucleotide labels), and with the observation of sequential G2N1H/G3N1H and 
G5N1H/G6N1H cross-peaks (Figure 5e), definitely allowed us to identify the 
presence of 4-fold symmetric parallel quadruplex moieties in the higher ordered 
structure formed by CGGTGGT when annealed in K+-containing buffer. In close 
analogy with what observed by Patel and Hosur for the quadruplex structure formed 
by TGGTGGC (23), we observed the formation of a central T-tetrad as ascertained 
by the appearance of the diagnostic T4NH/T4Me NOE cross-peak (Figure 5g) and 
supported by the observation of the strong shielding ring current experienced by T4 
methyl protons that are significantly upfield-shifted when compared to the 
corresponding signals of the ‘free’ T7 (0.72 versus 1.64 ppm). Although the overall 
observed NOEs account for a ‘classical’ tetramolecular parallel quadruplex, two 
peculiar NOE evidences drove us toward the disclosure of the higher ordered 
octamer structure.  
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Figure 5. Study of the octamer structure by NMR. (a) 1H-NMR spectra recorded at 25°C of CGGTGGT in 
H2O/D2O 9:1, annealed at 6mM strand concentration in 1M K+ at pH=7.0. (b–g) Expansions of 2D NOESY 
spectrum of CGGTGGT (25°C, 200 ms mixing time, 1M K+, pH=7.0). The sequential H8-H6 and self-peaks 
involving H' protons have been labeled in (b) and (c), respectively. (d) and (g) show NOE cross-peaks involving 
T4/T7 methyl protons and H8/H6 or imino and amino protons, respectively. The T-tetrad diagnostic peaks 
between T4Me and T4NH and sequential T4Me-G3NH, T4Me-G3NH2i and T4Me-G5NH are observable in panel 
(g). Imino-imino NOE correlations are shown in (e). The sequential imino-imino NOE correlations have been 
drawn in (e). NOE correlations between aromatic H8/H6 and imino and amino protons are shown in (f). 
 
 
 
 
 
 
Figure 6. 1D projection of 2D NOESY spectrum (25 °C, 200 ms mixing time) of CGGTGGT taken at 5.66 ppm, 
corresponding to C1 H1' protons. 
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In this regard, in Figure 6 it is shown the 1D cross-section of the NOESY spectrum 
(200 ms mixing time) of CGGTGGT taken at 5.66 ppm (C1H1' protons). This figure 
shows that the NOE between C1H1' and C1H5 has almost the same intensity than 
that between C1H1' and C1H6. These NOEs are in turn stronger than the sequential 
NOE C1H1'-G2H8, but weaker, as expected, than those between C1H1' and self 
H2'/H2''. The relative intensities of the aforementioned NOEs involving C1H1' require 
that the C1H1'-C1H5 distance is in the same range of the intranucleotide C1H1'-
C1H6 distance (2.31–3.74 Å depending on the glycosyl torsion angle). This 
experimental distance is compatible only with the occurrence of an intermolecular 
dipolar coupling between C1 bases, because the corresponding intranucleotide 
C1H1'-C1H5 distance would be in the range 4.64–5.49 Å.  
This finding, together with the observation of the very weak sequential NOE between 
C1H6 and G2H8 (marked with the arrow in Figure 5b), disclosed that, in the octamer, 
which is in fact a “dimeric G-quadruplex (2Q), each C1 base does not stack over the 
flanking G2 tetrad, as one may expect, but projects outside the quadruplex scaffold in 
such a way to allow dipolar couplings with one of the four C1 bases belonging to the 
other tetramer. This unusual arrangement might be favoured by the formation of 
additional C1NH2–G2N3 and G2NH2–C1N3 hydrogen bonds, thus allowing the 
formation of an unusual G2(:C1):G2(:C1):G2(:C1):G2(:C1) octad (Figure 11a) in each 
of the two tetrameric quadruplexes (1Q). 
 
4.1.6 Investigating the role of the central base on the structuring of the octamer. 
In summary, the above mentioned results allowed us to establish the optimal solution 
conditions for the self-folding and self-stimulated formation of the octamer 2Q: i) 
higher single-strand ODN concentration for the annealing step (6 mM better than 0.2 
mM) and ii) higher K+ concentration (1 M better than 0.1 M). Furthermore, we did not 
observe clear evidences of pH influence on quadruplex structuration in the pH range 
4.5-7.0. Starting from these results, a speculation about the role of the base 
sequence towards the dimerization process was carried out. Assuming the presence 
of C1 as a cardinal point for the formation of 2Q, the replacement of the middle base 
in dCGGTGGT sequence was undertaken, to evaluate its importance on the stability 
and rate of formation of the putative octamers; thus, dCGGAGGT (CA), dCGGCGGT 
(CC), and dCGGGGGT (CG) sequences were taken into account. All the samples 
were obtained by annealing the strands at 6 mM single-strand ODN concentration, 
and their structuration into quadruplex species were monitored by PAGE and 
spectrometric and spectroscopic measurements at different time-points from the 
annealing. Again, already at day 1 from the annealing, clear evidences about the 
formation of higher order assemblies were noticed in native PAGE experiments, as 
shown in Figure 7a. For this experiment, all sequences were annealed in 1M K+ 
buffer. CGGTGGT (Figure 7a, lane 1) was loaded on the gel at day 15 from the 
annealing, to be used as a 2Q marker, and T6 (lane 5) and TGGGGT (lane 6) were 
used as a single-stranded 6-mer and a tetramolecular quadruplex size-markers, 
respectively. All the CGGXGGT sequences taken into account (Figure 7a, lanes 2-4) 
showed a major band corresponding to the formation of 2Q-like secondary 
structures. In detail, the migration profile of CA showed a unique slow-migrating band 
(Figure 7a, lane 2), whereas two bands were observed for the migration profiles of 
CC and CG (Figure 7a, lanes 3 and 4). To verify unequivocally the strand 
stoichiometry of the structures, we performed mass spectrometry studies (ESI-MS) 
(Figure 7b-e). The ESI-MS spectra were recorded one day after the annealing under 
conditions that preserved non-covalent interactions. Interestingly, we observed mass 
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peaks corresponding to tetrameric assemblies (noted as Q) and also peaks 
corresponding to octameric assemblies (noted as 2Q), perfectly in line with what 
observed by PAGE data. Consequently, all the slower-migrating bands were ascribed 
to octameric self-assemblies. 
Melting profiles recorded by UV spectrophotometry at 295 nm (A295) revealed that all 
sequences presented a noteworthy thermal stability, with Tm in the range of 63-72 °C 
(Figure 8, on the left). Moreover, the CG sequence resulted to have a so marked 
thermal stability to not allowing the melting. To probe the relative formation of G-
quadruplex structures, as well as the orientation of the bases in the octamers, CD 
measurements were carried out. The overall CD profiles, recorded in K+ buffer after 1 
day from the annealing (Figure 8, on the right), showed a positive maximum close to 
260 nm and a negative minimum at about 240 nm, thus suggesting a head-to-tail 
arrangement of guanines, which is characteristic of parallel G-quadruplexes. 
 
 
 
 
Figure 7. Stoichiometry of self-assemblies determined by a) PAGE experiments after 1 day from the annealing, 
1M K+ buffer for sequences CGGTGGT (lane 1), CGGAGGT (lane 2), CGGCGGT (lane 3), CGGGGGT (lane 4), 
TTTTTT (lane 5), and TGGGGT (lane 6), and by (b-e) ESI-MS for CGGTGGT (b), CGGAGGT (c), CGGCGGT 
(d), CGGGGGT (e). In the peak annotation Gnz-, n indicates the number of strands and z indicates the charge.  
 
 
 
 
Figure 8. On the left: UV Melting profiles of CGGAGGT (red line, Tm = 65.2°C), CGGCGGT (green line, Tm = 
72.2°C), CGGTGGT (purple line, Tm = 63°C), and CGGGGGT (light blue line, no melting). On the right: CD 
profiles, after 1 day from the annealing, of CGGAGGT (red line), CGGCGGT (green line), CGGTGGT (purple 
line), and CGGGGGT (light blue line). 
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Furthermore, the CD profiles of CT, CA, and CC showed a peculiar negative band at 
about 290 nm. As previously discussed, this particular Cotton effect denotes the G-
quadruplex dimerization through a non-covalent 5'-5' stacking allowed by the head-
to-head stacking between G2-tetrads of two different tetramolecular parallel 
quadruplexes 1Q. In this context, a similar dimerization process was suggested for 
CA and CC sequences. As regards the CG sequence, no minimum at about 290 nm 
was observed, thus we do not exclude that a different dimerization process might 
occurs for this case.  
In order to monitor the structural behaviour of CA, CC, and CG during the time, we 
reacquired the CD and 1H NMR spectra at different time points after the annealing 
procedure (Figure 9). 
 
 
Figure 9: On the left: CD profiles after 1 hour (blue), 1 day (green), 7days (red) and 15 days (cyan) from the 
annealing of the sequences CGGAGGT (a), CGGCGGT (b), and CGGGGGT (c) sequences in K+ 1M. On the 
right: 1H NMR spectra recorded at 25°C of the sequences CGGAGGT (a), CGGCGGT (b), and CGGGGGT (c) 
sequences in H2O/D2O 9:1, after 7days (green) and 21 days (red) from the annealing, that occurs at 6mM ODN 
single-strand concentration in K+ 1M at pH = 7.0. 
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The 1H NMR spectra of CA showed that a single 2Q species was present in solution, 
whereas formation of multiple species was observed for CC and CG. Notably, CC 
also showed multiple bands in PAGE, while CG showed exclusively the Q and 2Q 
bands. In detail, 1H NMR spectra of CA show a unique, and highly symmetric G-
quadruplex conformation, characterized by four well-resolved NH resonances in the 
10.0-11.5 ppm region (consistent with the presence of four stable G-tetrads), and 
eight aromatic signals in the 7.0-8.5 ppm region. In this context, the unusual 
downfield shifted non-exchangeable resonance, detected at 9.20 ppm, accounted for 
A4-H2 protons, and it was diagnostic of a stabilised A-tetrad with a putative 6-NH2 to 
N1 hydrogen bonding geometry (see Figure 6c in Chapter 1), as reported by Searle 
et al. (3). Moreover, the signal at 9.20 ppm gave strong NOEs with G3NH1, and 
G5NH1, and appreciable NOEs with G3H8, A4H8, and G5H8 (data not shown), 
supporting the hypothesis that strong stacking interactions across G3-A4-G5 planes 
occurred. In addition to the above, the complete assignment (Table 2) of both 
exchangeable and non-exchangeable protons was obtained by the combined 
analysis of 2D NOESY and TOCSY spectra. For all nucleotides were traced self and 
sequential NOE connectivities from H8/H6 base protons to H1', H2'/H2'', and H3' 
sugar protons. Furthermore, the intensities of intranucleotide H8/H1' NOE cross-
peaks showed that all purine glycosidic torsion angles were in anti conformation (33, 
34). Taken together, the NMR features accounted for the presence of a parallel G-
quadruplex structure, as also supported by CD data.  
 
 
 H6/H8 H2/H5/Me NH NH2i H1' H2' H2'' H3' H4' H5'/H5'' 
C1 7.23 5.41 - 6.50 5.50 2.05 1.93  4.37 3.75/3.99 
G2 8.03 - 11.45 9.43/6.05 5.99 2.61 2.92    
G3 7.11 - 10.97 9.43/5.99 5.99 2.21 2.93    
A4 8.22 9.20 - - 5.99 2.77 2.60    
G5 8.00 - 10.38 9.34/5.42 6.03 2.59 2.69  4.21  
G6 7.63 - 10.61 9.34 6.14 2.47 2.59 4.89 4.46 3.97/4.17 
T7 7.25 1.56 - - 5.97 2.09 2.09 4.42 3.97  
 
Table 2. Proton chemical shift (ppm, relative to H2O at 4.78 ppm) for CA at 25°C, pH 7.0, 1M K+. NH2i refers to 
the internal (i) H-bonded amino protons of guanosines. 
 
 
Furthermore, the analysis of the intensity of NOE correlation peaks between the C1 
and G2 bases of CA, confirmed that the dimerization pathway of CA was similar to 
that of CT, via the formation of the unusual G2(:C1):G2(:C1):G2(:C1):G2(:C1) octad, 
with the difference that the former took place in a direct and faster manner. As 
concerned CC and CG sequences, the 1H NMR spectra were characterized by the 
presence of several signals in the 10.5–12.0 ppm region attributable to the exchange-
protected imino protons involved in the formation of Hoogsteen hydrogen bonds of 
four G-tetrads (30-32). Furthermore, the aromatic region of 1H NMR spectra were 
populated by more than the expected seven signals belonging to the H8/H6 aromatic 
protons of nucleobases, due to the coexistence in solution of alternative minor 
conformations. Thus, given the presence of more than one species in solution, and 
given that no species were selected as function of time or temperature, it was not 
possible to achieve the complete assignment of both exchangeable and non-
exchangeable protons for CC and CG species. 
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4.2 Discussion 
The structure adopted by the sequence dCGGTGGT must account for the following 
observations. It was a highly symmetrical octamer, formed from two parallel-stranded 
tetramers. In the octamer, each tetramer contained a central T-tetrad and the G-
tetrads were stacked in head-to-tail arrangement. However, at the octamer’s 
interface between the two tetramers, the stacking of the G-tetrads was likely to be 
different, as determined from CD. Interlocked structures like that formed by the 
(dGCGGTGGT)4 tetramer (35) were initially taken in consideration to build an 
octamer model, but were discarded due to NMR inconsistencies and symmetry-
related considerations. Unresponsiveness to pH changes also led us to discard 
structures involving protonated cytosines. The NOEs involving C1H1' point to the 
formation of a G2(:C1):G2(:C1):G2(:C1):G2(:C1) octad (Figure 10a) in each of the 
two tetrameric quadruplexes. The formation of the planar octad system would allow 
for further π - π stacking between C1 bases, thus adding more ‘hydrophobic glue’ 
between the two G-quadruplex tetramers that form the octamer. Figure 10b shows 
the energy minimized model of the octamer formed by stacking of two tetramers, 
each containing a 5'-G(:C):G(:C):G(:C):G(:C) octad. The details of molecular 
modelling are given in the Experimental Session. The overall topology of each 
tetramer is largely similar to that of the tetramolecular quadruplex formed by 
TGGTGGC (see Figure 8 in reference (23)), with the central T-tetrad causing a small 
decrease in the intertwining of the helices. Figure 10b also evidence that the octamer 
structure is very compact, regardless the presence of two stacked octads. These are 
seen to determine only a slight increase in the thickness of the octamer at the 
dimerization interface. Figure 10c–d shows the head-to-head stacking between the 
two octads (c) and the stacking between tetrads G2-G3 (d). Although C1 and G2 
bases involved in the stacked octads appear slightly rotated with respect to the tetrad 
plane, Figure 10c shows good stacking between the six-membered rings of G2 bases 
and between the stacked C1 bases. The electric transition moments corresponding 
to the guanine absorption band at approximately 250 nm are indicated in Figure 10c 
and d. The stacking interactions in the model allow to explain the CD data: G2-G3 
stacking resembles the standard head-to-tail stacking encountered in parallel 
stranded G-quadruplexes. However, the octad stacking gives rise to a heteropolar 
stacking that is distinct from those typically encountered in antiparallel G-
quadruplexes. Therefore, the negative CD band at 290 nm was interpreted as being 
due to the octad stacking shown in Figure 10c (29). One must note, however, that the 
formation of the octamer by the sequence dCGGTGGT is slow. ESI-MS kinetics 
experiments in ammonium acetate provide some insight into the mechanism of 
octamer formation. The first step is the formation of a tetramer that incorporates only 
three ammonium ions. This means either that the tetramer of [dCGGTGGT]4 has 
either a central or a terminal tetrad disrupted, or that the tetramer contain slipped 
strands and hence incomplete tetrad formation (36). The rate-limiting step is the 
conversion of tetramer to octamer, and in contrast with the tetramer, the octamer 
incorporates four cations per tetrameric subunit. We therefore conclude that the rate-
limiting step is the rearrangement of the tetramer into a fully aligned parallel structure 
that is amenable to octad formation and stacking thereof. 
Regarding the structure adopted by the sequence dCGGAGGT, the collected data 
were in agreement with those hitherto discussed. Also for CA the formation of a 
highly symmetrical octamer, formed from two parallel-stranded tetramers, took place. 
In the octamer, each tetramer contained a central A-tetrad, and the G-tetrads were 
stacked in head-to-tail arrangement. Also in this case, we founded evidences of the 
CHAPTER	  4	  
DNA-­‐based	  Nanostructures	  
	  
	  
 
 
78 
formation of a G2(:C1):G2(:C1):G2(:C1):G2(:C1) octad (Figure 10a) in each of the 
two tetrameric quadruplexes: i) the negative CD band at 290 nm due to the 
heteropolar stacking between the octads, and ii) the interquadruplexes NOEs 
involving C1H1' and C1H5. The peculiarities of the 2Q structure formed by CA lied in 
the rate of formation and in the high thermal stability. In this context, the PAGE data 
(Figure 7a) denoted the presence of a single structure, and the UV melting spectrum 
underlied the presence of a very stable structure with a melting temperature of about 
65 °C. Unlike CT and CC, the dimeric species of CA was selected already at day 1 
from the annealing, thus suggesting that the dimerization process does not provide 
for the formation of 1Q intermediates, as assumed for the dimerization process of 
CT. It stands to reason that this peculiar behaviour was due to the presence of the A-
tetrads. 
 
 
 
 
Figure 10. Structural model for the (dCGGTGGT)8 octamer. (a) Proposed structure of the 
G2(:C1):G2(:C1):G2(:C1):G2(:C1) octad. (b) Molecular model of the octamer: a different color was used for each 
ODN strand, and potassium ions appear as red crosses. (c) Detail of stacking of the octads. (d) Detail of stacking 
of G2–G3 tetrads. The transition moments of guanosines corresponding to the absorption band at approximately 
250nm are shown as colored bars in (c) and (d). 
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These confered additional stabilization to the 2Q structure, and seem to promote the 
formation of higher-order G-quadruplex structures. As regard the CC sequence, CD, 
MS, and PAGE data suggested that the 2Q-like octameric G-quadruplex complex 
was present in solution, but they also suggested that other different structures were 
also present. Therefore, it is conceivable that the 2Q structuring of CC was slower 
than those of CT and CA. Regarding CG, PAGE and MS data suggested the 
formation of a higher order G-quadruplex structure, but both CD and NMR could not 
confirm this finding. Specifically, two distinct bands attributable to a monomeric (Q) 
and a dimeric (2Q) species were visible in PAGE run, but the CD data did not allow 
to link the dimer formation to the head-to-head dimerization pathway. Furthermore, 
since the species in solution had a very high melting temperature (at 90°C there was 
still no fusion), it was not possible to select one of the two species as a function of 
temperature; similarly, no selection was made in function of time. Therefore, the 
formation of a higher order G-quadruplex structure was confirmed, but the 
dimerization process is still not clear.   
 
All together, these results therefore suggest that in the sequence CGGXGGT (where 
X = A, C, G, or T), the cytosine at 5'-end is capable of inducing the structuring of 
higher order structures by the formation of octads, and, when adenine is at central 
position, the structuring of the dimer occurs in a direct and faster manner, leading to 
the formation of the more stable nanostructure (Tm around 65°), among those one 
taken into account.  
 
4.3 Conclusions 
The present study demonstrates that the formation of a DNA-based nanostructure 
consisting of a dimer of tetramolecular G-quadruplexes (2Q) can occur when the 5'-
cytosine-ending CGGXGGT (where X = A, C, G, or T) DNA sequences are annealed 
in the presence of K+ ions. The NMR and molecular modelling data of CGGTGGT 
and CGGAGGT disclosed that the structuring of 2Q is allowed by the formation of 
one unusual octad arrangement, in each of the two 1Q units. Up to now, dimerization 
of G-quadruplexes had only be reported via guanine–adenine heptads (13), and 
recently via a shared uracil tetrad (37). This finding adds further possibilities for the 
design of novel quadruplex-based DNA functional nanostructures, and further 
complexity to the mechanisms of folding and assembly of G-rich sequences. It is 
particularly important for in vitro studies of artificially designed (e.g. aptamers) or 
biologically relevant sequences. 
 
4.4 Experimental Session  
 
4.4.1 DNA sample preparation 
DNA oligonucleotides TGGGGT, CTGTGTT, TGGTGGC, CGGTGGT, CGGGGT, 
CGGAGGT, CGGCGGT, CGGGGGT, and TTTTTT were chemically synthesized on 
an 8909 DNA/RNA synthesizer (Applied Biosystem), or purchased from Eurogentec 
(Belgium) for mass spectrometry experiments. DNA concentration expressed in 
strand molarity was calculated using a nearest-neighbour approximation for the 
absorption coefficients of the unfolded species. Ammonium acetate was obtained 
from a 5M solution from Fluka (Molecular Biology grade). Stock solutions of 6mM of 
each ODN were obtained by dissolving the lyophilized samples in 150mM NH4OAc or 
100mM and 1.0M K+ buffers (10mM KH2PO4 supplemented with 90mM or 990mM 
KCl, respectively). Hundred percent D2O (Armar chemicals) or H2O/D2O (9:1, v/v) 
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was used for the preparation of 6mM solutions to be used for NMR experiments. All 
ODN samples were annealed by heating at 90°C for 15 min and then cooling and 
storing at 5°C. The pH was adjusted to 7.0 or 4.5 using HCl/KOH or AcOH/NH4OH 
aqueous solutions before the annealing procedure. 
 
4.4.2 Polyacrylamide gel electrophoresis 
The molecular size of structures were probed using non denaturing polyacrylamide 
gel electrophoresis (PAGE) as previously described (23). ODN samples of 10 mM, 
obtained by diluting the annealed stock solutions just before the experiment, were 
loaded on a 15% polyacrylamide gel supplemented with 20mM of KCl or NH4OAc. 
Glycerol of 10% was added just before loading. The gels were run at 26°C at 
constant voltage (100 V) for 2.5 h. The bands were visualized by UV shadowing and 
after ‘Syber green’ coloration. 
 
4.4.3 Electrospray mass spectrometry 
A Q-TOF Ultima Global mass spectrometer (Waters, Manchester, UK) was used to 
characterize the samples in ammonium acetate, and to perform a kinetics 
experiment. ODN samples (80 mM single-strand concentration), obtained as 
described in the PAGE paragraph with the addition of 10% methanol, were infused at 
4 ml/min in the electrospray (ESI) source that was operated in negative ion mode 
(capillary voltage = -2.2 kV). Temperatures of ESI source and nitrogen desolvation 
gas were 80 °C and 100 °C, respectively. The source voltages were optimized for the 
best compromise to observe the single strand, tetramer and octamer: Cone = 80 V, 
RF Lens 1 = 80 V, collision energy = 10 V, source pressure = 3.06 mbar. For the 
kinetics experiments, the reference strand dT6 was added to the dCGGTGGT strand, 
so as to follow the intensities of the reactant (dCGGTGGT single strand, noted G1), 
the intermediates (dimer = G2, trimer = G3, tetramer = G4 = 1Q) and the product 
(octamer = G8 = 2Q) relative to that of the reference. The spectra were smoothed 
(mean function, 2 × 12 channels), background-substracted (polynomial order = 50, 
0.1% below curve, tolerance 0.010), centroided (peak width 20 channels, 
reconstructed area of the top 80% of the peak), and recalibrated using the reference 
as a lock mass (dT62- monoisotopic peak at m/z = 880.1530). The relative response 
factors of the monomer, the tetramer 1Q and the octamer 2Q were obtained by data 
processing as described elsewhere (38). Briefly, for each stoichiometry observed for 
dCGGTGGT, one charge state was selected based on the absence of possible 
overlap with other stoichiometries: G12- (four most intense isotopes), G23- (no 
ammonium adducts, to avoid overlap with [G4•(NH4)n]6-), G34- (no adducts), G45- (sum 
of all peaks from 0 to 4 NH4+ adducts), and G89- (uneven charge state to avoid 
overlap with tetramer, sum of all peaks from 2 to 9 NH4+ adducts). By assuming that 
the electrospray response of each CGGTGGT stoichiometry and dT6 are proportional 
throughout the experiment, and by using the mass balance equation applied to 
CGGTGGT (the total strand concentration being equal to 80 µM), the relative 
response factors of each stoichiometry can be determined. These response factors 
are then used to recalculate the concentration of each stoichiometry at each time 
point. The user’s choice of the charge state and/or adducts considered has no 
influence on the final results in terms of concentrations, because the calculated 
response factors provide the necessary correction (38). In addition, a Bruker Apex-
Qe9.4 T ESI-FTICR mass spectrometer was used to confirm the charge states from 
the isotopic distributions by recording high-resolution data, and to confirm the number 
of ammonium cations retained in each complex. The instrument voltages were 
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chosen so as to minimize collision-induced dissociation and therefore keep the non-
covalent complexes intact, including the inner ammonium cations: cap exit = -22 V, 
skimmer = -15 V, octapole offset = -4 V and coll cell trap = +4 V. 
 
4.4.4 Circular dichroism 
Circular dichroism (CD) spectra were measured at 25°C on a Jasco J-715 
spectropolarimeter equipped with a Peltier Jasco JPT423S, using a 0.1-cm path 
length quartz cuvette with a reaction volume of 500 µl. CD spectra were recorded at 
different time points after the annealing on 40 µM ODN samples annealed at strand 
concentration of 200 µM or 6.0 mM. Spectra were averaged over three scans. A 
buffer baseline was subtracted from each spectrum and the spectra were normalized 
to have zero at 360 nm. 
 
4.4.5 Nuclear magnetic resonance 
Nuclear magnetic resonance (NMR) data were collected on a Varian UNITYINOVA 500 
MHz spectrometer equipped with a broadband inverse probe with z-field gradient, 
and on a Varian UNITYINOVA 700 MHz spectrometer equipped with a triple resonance 
cryoprobe. The data were processed using the Varian VNMR software package. 
One-dimensional NMR spectra were acquired as 16384 data points with a recycle 
delay of 1.0 s at 5, 25 and 65°C. Data sets were zero filled to 32768 points prior to 
Fourier transformation and apodized with a shifted sine bell squared window function. 
Two-dimensional NMR spectra were all acquired at 25°C using a recycle delay of 1.2 
s. NOESY spectra were acquired with mixing times of 100, 200 and 300 ms. TOCSY 
spectra were recorded with the standard MLEV-17 spin-lock sequence and a mixing 
time of 80 ms. For the experiments in H2O, water suppression was achieved by 
including a double pulsed-field gradient spin-echo (DPFGSE) module (39, 40) in the 
pulse sequence prior to acquisition. In all 2D experiments, the time domain data 
consisted of 2048 complex points in t2 and 400 fids in t1 dimension. NMR samples 
were prepared at 6mM strand concentration in 0.6 ml of 100 mM or 1.0 M K+ buffer 
obtained as above described. Sequence-specific resonance assignments for 
CGGTGGT were obtained by using NOESY and TOCSY spectra following the 
standard procedure (41, 42). The self as well as sequential NOE connectivities from 
H8 to H1' and H2'/H2'' were traced for all the nucleotides. The connectivities followed 
the standard patterns as for B-DNA, apart from noticeable exceptions between C1 
and G2, and complete assignments of base and sugar protons was obtained. 
 
4.4.6 Molecular modeling 
The starting structure was generated using the builder module of Insight II (2005) 
program (Accelrys, Inc) on an Intel PC workstation running Red Hat Enterprise Linux. 
The model was parameterized according to the AMBER force-field, and calculations 
were performed using a distance-dependent macroscopic dielectric constant of 4.0 
and an infinite cut-off for non-bonded interactions to partially compensate for the lack 
of solvent. One of the two “monomer G-quadruplex” of 2Q was built using the 
coordinates of the NMR solution structure of [d(TGGTGGC)]4 tetramolecular 
quadruplex (PDB entry number 1EMQ) (23) as starting point. The four 5'-end T 
residues were replaced by deoxycytidines, while 3'-end C residues were replaced by 
deoxythimidines, then the G2(:C1):G2(:C1):G2(:C1):G2(:C1) octad was built by 
aligning the four C1 around the G2-tetrad plane in such a way that each C1 had its 
3'-OH close to the 5'-phosphate of the flanking G2, and its N3 and NH2 atoms close 
enough to the purine ring of G2 (belonging to the anti-clockwise-adjacent strand) to 
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form hydrogen bonds with G2-NH2 and G2-N3 atoms, respectively. Finally, each 
strand was completed by joining the C1 3'-OH with the G2 5'-phosphate. The 
coordinates of C1 and G2 atoms were then energy-minimized by using 1000 cycles 
of steepest descent method followed by conjugate gradient calculation until 
convergence at 0.001 rms was reached. Atoms of G3-T7 bases were kept frozen 
throughout the minimization. The resulting minimized structure was used to obtain 
the second “monomer quadruplex” by copy & paste. The 2Q model was then finally 
assembled by aligning the two identical quadruplexes head-to-head on top of each 
other with the standard B-DNA rise (3.4 Å) and twist (36°).  
The whole system was then subjected to 1000 cycles of steepest descent energy 
minimization followed by 2 ns of restrained molecular dynamics at 298 K. From the 
last nanosecond of the dynamic run, 11 different structures were selected on the 
basis of their low energies, proper covalent geometries and overall 4-fold symmetry. 
The selected structures were then subjected to restrained energy minimization with 
steepest descent and conjugate gradient methods until convergence to an rms 
gradient of 0.1 Kcal·mol-1 was reached. In these calculations 526 distance, 144 
hydrogen bond, and 32 glycosidic torsion angle constraints were used according to 
NMR data. NOE cross peaks were integrated and the intensities were translated into 
interproton distances using the intranucleotide C1-H5/C1-H6 cross peak intensity as 
the reference (2.46 Å). Cross peaks involving non-exchangeable protons were 
classified as strong (20 Kcal mol-1 Å-2 force constant), medium (10 Kcal mol-1 Å-2) and 
weak (5 Kcal mol-1 Å-2) on the basis of their relative intensities and the interproton 
distances were restrained to 1.8-3.0, 2.5-4.0 and 3.5-5.5 Å, respectively. Hydrogen 
bonds restraints were defined using upper and lower distance limits of 2.0 and 1.7 Å 
for hydrogen-acceptor distances, and 3.0 and 2.7 Å for donor-acceptor distances 
(100 Kcal mol-1 Å-2). Glycosidic torsion angles of guanosines were constrained to a 
range of -160°/-70° (200 Kcal mol-1 Å-2) as required for a G-quadruplex having all Gs 
in the anti orientation as arose from NOESY spectra. All restraints were finally 
removed and a further unrestrained energy minimization was performed as described 
above. The average RMSD value was 0.55. Finally, the length of the relaxed 
structure was measured and found equal to about 40 Å, or rather 4 nanometers.  
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This communication reports on the synthesis and biophysical,
biological and SAR studies of a small library of new anti-HIV
aptamers based on the tetra-end-linked G-quadruplex structure.
The new aptamers showed EC50 values against HIV-1 in the
range of 0.04–0.15 lM as well as affinities for the HIV-1 gp120
envelope in the same order of magnitude.
The first stage of the HIV infection requires the entry of
human immunodeficiency virus (HIV) into host cells. This
stage involves the sequential interaction of the virion surface
glycoprotein gp120 with the CD4 glycoprotein and a chemokine
receptor, either CCR5 or CXCR4, on the host cell surface.1 The
CD4 glycoprotein is expressed on the surface of T-lymphocytes,
monocytes, dendritic cells and brain microglia, and its expression
makes these cells a target for HIV in vivo. Furthermore, an
interesting function of CD4 binding is to induce conformational
changes in gp120 that allow binding to the co-receptor, which is
essential for viral entry.2 The third variable region of gp120
(from now on designated V3 loop) is a pivotal component of
the co-receptor binding site, typically consisting of a 35 amino
acid-loop (range 31 to 39), closed by two cysteines that form a
disulfide bridge. The crystal structure of gp120 complexed with
the CD4 receptor and a neutralizing antibody (PDB ID 2B4C)
revealed that the V3 loop is extended away from the gp120
protein and it is involved in co-receptor binding and selection,
acting as a ‘‘molecular hook’’ that organizes associations
within the viral spike.3 The importance of gp120 and the role
of the V3 loop in HIV-1 entry and pathogenesis have led to the
recent pursuit of drugs targeted against it. One of the most
studied alternatives is the use of aptamer technology.4 Aptamers
are single stranded DNA or RNA molecules selected among
large pools of nucleic acid sequences for their ability to bind
selectively and with high affinity to a biomedically relevant
target. For their properties, aptamers can be considered as the
nucleic acid analogues of antibodies. Like the antibodies,
several aptamers proved to be valuable diagnostic tools5 and
promising therapeutics.6,7
In 1994 H. Hotoda (SA-1042)8 and J. R. Wyatt (ISIS 5320)9
independently reported the first anti-HIV aptamers targeted
against the V3 loop. In both cases the ODN sequences were
chemically modified to improve their resistance against nucleases
by capping the 50-ends with DMT groups (SA-1042) or by using
the phosphorothioate backbone (ISIS 5320). Subsequently, other
analogues of SA-1042 were obtained and tested,10,11 and the 6-mer
TGGGAG ODN (known as ‘‘Hotoda’s sequence’’) bearing
3,4-dibenzyloxybenzyl groups at the 50-ends and 2-hydroxy-
ethylphosphates at the 30-ends (R-95288) showed the highest
anti-HIV activity.11 CD investigations on ISIS 5320, R95288
and their analogues suggested their structuration into parallel
tetramolecular quadruplexes. Following biophysical studies
established that the presence of aromatic12,13 moieties at 50-
and/or 30-ends of TGGGAG dramatically enhances the rate of
formation of quadruplex complexes. Moreover, the overall
stability of quadruplex complexes was found to correlate with
the reported anti-HIV activity.12
In 2010, with the aim to overcome the unfavourable entropic
factor and to stabilize the A-tetrad in Hotoda’s analogues, we
synthesized a series of new monomolecular anti-HIV aptamers
by using the Tetra-End-Linker (TEL) strategy proposed by
some of us in 2004.14,15 Several TEL-(TGGGAG)4 aptamers
were prepared and analyzed in order to probe the influence of
lipophilic groups and TEL size and position on the structural
and anti-HIV properties of the resulting TEL-quadruplexes.16
The results showed that (i) the presence of the TEL at either
50- or 30-ends was required for the anti-HIV activity, and (ii)
lipophilic tert-butyldiphenylsilyl (TBDPS) groups at the 50-ends
strongly enhanced both the stability of TEL-quadruplexes and
their anti-HIV activity. The EC50 of the best aptamer (I, Fig. 1),
bearing TBDPS groups at the 50-ends and the longer TEL at the
30-ends was 0.082 ! 0.04 mM.
With the aim to further improve the anti-HIV activity of
TEL-ODN aptamers, we used I as a molecular synthon for the
synthesis of a series of new TEL-ODN aptamers embodying
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the TGGGXG sequence (II–IV, Fig. 1). TEL-ODNs V and VI
(a TEL-(TGGGAG)4 analogue unable to form aTEL-quadruplex)
were also synthesized and studied in order to investigate the role
played by the G-tetrad at the 30-terminus of TEL-quadruplexes
I–IV and to further corroborate the requirement of quadruplex
formation for the inhibition of HIV cytopathicity. In this
communication we report the results of biophysical, biological
and SAR studies performed on I–VI.
All products were synthesized and characterized following
the previously described approach.14,16 In order to verify that
the presence of one (II–IV) or two (V) different bases did not
affect the parallel quadruplex arrangement observed for the
parent TEL-ODN I, CD measurements were performed
(Fig. S2 in ESIw). The overall CD profiles, recorded in
100 mM K+ buffer, were in agreement with the formation
of G-quadruplex structures, showing two positive maxima at
220 and 260 nm and a negative minimum close to 240 nm, which
are characteristic of head-to-tail arrangement of guanines, as
typically found in parallel G-quadruplexes.17–19 Unexpectedly,
CD spectra of VI were similar to those of a random coil, thus
evidencing that the insertion of a propylphosphate moiety
between the OH at 30-ends and TBDPS groups is detrimental
for quadruplex stability. CD melting analyses on II–IV
confirmed the expected great thermal stability of the new
TEL-quadruplexes (Fig. S3 in ESIw). In fact, as for I, the
apparent melting temperature of II–IV could not be determined
since no derivatizable melting curve was obtained.
The formation of thermally stable TEL-quadruplexes for
II–IV was also confirmed by 1H NMR evidence (Fig. S4 and
S5 in ESIw). The G-quadruplex diagnostic exchange-protected
imino proton signals were observed in all recorded spectra up
to 90 1C (100 mM K+ buffer; H2O/D2O 9 : 1). As expected,
the intensity of imino proton signals reflected the stability of
the X-tetrad within the G-quadruplex structure. Stronger
imino signals were observed for II (five stacked G-tetrads),
whereas weaker imino signals were observed for I, III and IV
due to the presence of the less stable A-, T- or C-tetrad,
respectively, that accounts for the faster exchange of imino
protons with the solvent.
The antiviral activity of II–IV against HIV-1 and HIV-2 was
determined as previously reported for I16 and is shown in Table 1.
The binding properties of active aptamers II–IV to HIV-1(IIIB)
gp120 were also determined through Surface Plasmon Resonance
(SPR) technology (Table 1; Fig. S6 in ESIw).
All new TEL-(TGGGXG)4 aptamers reported in this
communication (II–IV) retained potent anti-HIV-1 activity
(nanomolar EC50 values). They displayed comparable on
(ka) and off (kd) rates for HIV-1 gp120 binding resulting in
very similar gp120 binding affinities (KD) to I, thus confirming
that the residues of the gp120 V3 loop interact mainly with the
grooves and the sugar–phosphate backbone of the aptamers.
However, considering that the EC50’s of II and IV were
significantly lower than those of I and III (0.039–0.041 versus
0.11–0.15 mM), and that V proved to be markedly less active
notwithstanding its structuration in a stable TEL-quadruplex
structure, we hypothesized that some specific interactions between
the X5G6 bases of I–IV and the V3 loop must occur. It is well-
described that binding of agents (i.e.monoclonal antibodies) to the
viral envelope does not necessarily result in efficient virus neutra-
lization. Their effect on viral infectivity depends on the molecular
epitope that is recognized on gp120.20 Thus, it seems that I and III
bind nearly as efficiently to gp120 as II and IV but neutralize
B3-fold less efficiently HIV-1 possibly due to subtile differences
in epitope recognition. Alternatively, it cannot be excluded that
the different TEL-quadruplexes have slightly different cellular
uptake efficiencies or intracellular stability.
To obtain insight into the nature of the atomistic interactions
between the TEL-aptamers I–IV and the V3 loop, we carried
out molecular modelling studies by docking I–IV to the V3 loop
of gp120 (PDB ID 2B4C). Our results revealed that (i) the V3
loop interacts with all aptamers with a similar binding mode
involving the 30-end tetrad and the TEL (Fig. S7 in ESIw),
(ii) the type of nucleobases at the aptamer-V3 loop interface
determines the chemical groups available for the interaction,
and (iii) the number and type of interactions between the
aptamer and the protein are responsible for the subtle differences
in the binding energies (Table S1 in ESIw).
As reported by Honig and co-workers,21 charged residues
are important in protein–DNA interactions. In this case, an
important role is played by the side chain of residue R181 in the
V3 loop that binds into the groove created by the phosphodiester
Fig. 1 Schematic representation of investigated TEL-ODNs.
Table 1 Anti-HIV and SPR studies on I–V
ODN
EC50
a (mM) SPR vs. HIV-1(IIIB) gp120
b
HIV-1 HIV-2 KD (nM) ka (1/Ms) kd (1/s)
I 0.11 ! 0.05 1.4 ! 0.9 256 ! 63 (1.72 ! 0.28) " 104
(4.31 ! 0.37) " 10#3
II 0.041 ! 0.007 Z 2 183 ! 40 (2.40 ! 0.20) " 104
(4.35 ! 0.61) " 10#3
III 0.15 ! 0.0015 1.4 ! 0.87 248 ! 28 (2.55 ! 0.35) " 104
(6.29 ! 0.14) " 10#3
IV 0.039 ! 0.005 0.73 ! 0.16 196 ! 69 (2.15 ! 0.40) " 104
(4.07 ! 0.71) " 10#3
V Z 2 2 — —
a EC50 represents the 50% effective concentration required to inhibit
virus-induced cytopathicity in CEM cell cultures by 50%. b HIV-1(IIIB)
gp120 was obtained from recombinantly-expressed gp120 in CHO cell
cultures.
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backbone atoms (see Table S1 in ESIw). In particular, in II and
IV, R181 makes multiple interactions with both phosphates
and purine bases (G5 and G6 in II, G6 in IV). Furthermore,
the side chains of R190, T195 and E197 and the nitrogen
backbone atom of T194 of the V3 loop interact with the
oxygen atoms of the TEL, giving additional stability to the
complexes. In the II–V3 loop complex, the side chain of Y193
and the nitrogen backbone atom of Y193, T195 and I198
established additional interactions with the TEL, thereby
resulting in lower interaction energy of this complex with
respect to the other ones (Table 2). It should also be noted
that when the side chain of Y193 is involved in the interaction
(I, II and IV), the resulting complexes are found to have a
better biological activity. Thus, the G5 nucleobase in II
presents additional points for hydrogen bonding with the V3
loop. This is not seen in other bases. Therefore we infer that
the differences in activity can arise from the thermal stability
of the structures. Furthermore, this is also rationalised by the
SPR experiments.
In order to better understand the structural features critical
for the biological activity, we also carried out a molecular
modelling study between the V3 loop and V, a quadruplex
structure lacking marked anti-HIV activity. Our results revealed
that the V3 loop interacts with V by using a different binding
mode (Fig. S7 in ESIw). Differently from what was observed in
the above-described complexes, V interacts with the V3 loop
primarily via the TEL atoms and no atom of nucleobases is
involved. Furthermore, except for R181, different residues of
the V3 loop, such as K182, S183, I184, and I186, are involved in
the interactions (Table S1 in ESIw). A plausible reason for the
different binding mode of V is due to the presence of the
T-tetrad at the 30-terminus. As shown in Fig. S7 in ESIw, when
there is a G-tetrad at the 30-position, the oxygen atoms of
guanines are involved in the interaction with the V3 loop
through the side chains of R181 (and Y193 in the case of IV).
In the V–V3 loop complex the methyl groups of the thymines
are positioned in the groove formed by the phosphodiester
backbone atoms, not allowing the formation of H bonds with
R181 and Y193 of the V3 loop. All together, the structural
evidence suggests that the T-tetrad at the 30-position markedly
affects the biological activity. In accordance with this finding
and with the experimental data, the aptamer II showed the best
docking score and the highest number of hydrogen bonds with
the protein (Table 2).
The anti-HIV activity against HIV-1 and HIV-2 and the
binding properties with HIV gp120 of a small library of
new TEL-aptamers (II–IV) have been reported. Results from
TEL-ODNs V and VI confirmed that the formation of a
quadruplex species by the aptamer is required, but not sufficient
to exert the anti-HIV activity. The docking data suggest that the
interaction of the V3 loop with both the backbone and the
TEL of the aptamers is required. Furthermore, the direct
involvement of nucleobases in the interaction with the V3
loop gives additional stability to the complexes and results in a
better biological activity. Overall, the here reported results
expand our knowledge about anti-HIV G-quadruplexes and
provide the rational basis for the design of novel anti-HIV
aptamers with improved biological activity.
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Table 2 Interaction energies of top docks (Kcal mol#1) and number
of H bonds between I–V and the V3 loop of gp120
Aptamer Interactions energy Number of H bonds
I #24.11 8
II #28.45 15
III #13.74 9
IV #28.09 11
V #13.74 8
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ABSTRACT: An acyclic pyrimidine analogue, containing a ﬁve-member cycle fused on the
pyrimidine ring, was synthesized and introduced at position 7 or 12 of the 15-mer
oligodeoxynucleotide GGTTGGTGTGGTTGG, known as thrombin-binding aptamer (TBA).
Characterization by 1H NMR and CD spectroscopies of the resulting aptamers, TBA-T7b and
TBA-T12b, showed their ability to fold into the typical antiparallel chairlike G-quadruplex
structure formed by TBA. The apparent CD melting temperatures indicated that the
introduction of the acyclic residue, mainly at position 7, improves the thermal stability of
resulting G-quadruplexes with respect to TBA. The anticoagulant activity of the new molecules
was then valued in PT assay, and it resulted that TBA-T7b is more potent than TBA in
prolonging clotting time. On the other hand, in puriﬁed ﬁbrinogen assay the thrombin
inhibitory activity of both modiﬁed sequences was lower than that of TBA using human
enzyme, whereas the potency trend was again reversed using bovine enzyme. Obtained structure−activity relationships were
investigated by structural and computational studies. Taken together, these results reveal the active role of TBA residues T7 and
T12 and the relevance of some amino acids located in the anion binding exosite I of the protein in aptamer−thrombin interaction.
■ INTRODUCTION
Thrombin is a sodium-activated allosteric enzyme playing a key
role in blood coagulation.1a,b The complexity of thrombin
function and regulation has gained this enzyme pre-eminence
as the prototypic allosteric serine protease.2a−e It clots blood by
converting ﬁbrinogen into ﬁbrin, by activating factors V, VIII,
and XIII, the latter being responsible for the cross-linking of
ﬁbrin ﬁbers, and by promoting platelet aggregation. Because
activation of factor V is required by activated factor X to cut
prothrombin into thrombin, the synthesis of thrombin is in part
modulated by its own blood concentration, thus providing a
fast response to injury. Besides procoagulant stimuli, also
anticoagulant stimuli can be triggered by thrombin via
activation of protein C, under the allosteric control of the
cofactor thrombomodulin. Moreover, thrombin inactivation
and clearance in plasma can also be achieved by interaction
with the serpin antithrombin and with the heparin cofactor II.
Due to its central role in the coagulation cascade, malfunctions
in the regulatory mechanism of thrombin activity cause
pathological states such as hemorrhage or abnormal clot
growth. Thrombosis and connected diseases are among the
main causes of mortality in Western countries;3 thus, the
discovery of molecules capable of modulating thrombin activity
represents a major target for the development of anticoagulant
strategies.4 Aptamer technology has been eﬃciently employed
to obtain new direct thrombin inhibitors by selecting thrombin-
binding oligonucleotides.5 The term aptamer generally refers to
a single-stranded oligonucleotide that binds to a selected
protein and speciﬁcally inhibits one or more of its functions.
The ﬁrst reported consensus sequence able to inhibit thrombin
ac t i v i t y was the 15-mer o l i gonuc leo t ide (ON)
GGTTGGTGTGGTTGG, usually known with the acronym
TBA (thrombin-binding aptamer).5a In the presence of
thrombin and/or monovalent cations TBA folds into a speciﬁc
three-dimensional structure that dictates its thrombin-binding
aﬃnity. The structures of TBA alone and in complex with
thrombin were determined by NMR6 and X-ray7 methods,
respectively. In all experimentally determined structures TBA
adopted a monomolecular chairlike G-quadruplex folding
topology, consisting of two G-tetrads connected by one TGT
loop and two TT loops. First,7a,b diﬀerent TBA−thrombin X-
ray complexes were reported, in which TBA adopted either the
same folding as derived by NMR (PDB ID 1HAO; Figure 1A)
or a diﬀerent one (PDB IDs 1HUT and 1HAP; Figure 1B),
presenting a diverse positioning of the connecting loops.
In these X-ray complexes, the aptamer interacts with distinct
regions of two thrombin molecules, (i) the ﬁbrinogen exosite
(namely anion-binding exosite I, ABE I) and (ii) the heparin
exosite (namely, ABE II) near the carboxylate terminal helix of
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a neighboring thrombin. Thus, according to the adopted
folding and the relative orientation with respect to thrombin,
TBA bound to ABE I by using the TT loops (PDB ID 1HAO;
Figure 1A) or the TGT loop (PDB IDs 1HUT and 1HAP;
Figure 1B). A subsequent re-evaluation8 of the diﬀraction data
of TBA−thrombin complexes7a,b evidenced that the NMR-
derived folding (Figure 1A) could ﬁt all diﬀraction data if
alternative aptamer orientations with respect to thrombin were
considered. Indeed, according to the electron density maps, it
was assumed that the oligonucleotide quartet region (including
the DNA backbone) was correct as reported in the crystal
structures, whereas, due to the D2 symmetry of the aptamer
core, there are four distinct possible orientations of the NMR
folding that overlap with the core of the X-ray model (Figure
2). The re-evaluation of the X-ray complex gave similar results
among orientations I−IV, but orientation III showed the best
agreement with the experimental data.8
Accordingly, diﬀerent TBA−thrombin complexes in which
the aptamer can bind ABE I through the TGT loop and ABE II
through the TT loops (Figure 2, orientations I and II), or the
other way around (Figure 2, orientations III and IV), are
possible. Supporting this view, the newly released X-ray
structures of thrombin−TBA−Na+ and thrombin−TBA−K+
complexes (PDB IDs 4DIH and 4DII, respectively)7c showed
the aptamer interacting with the enzyme assuming orientation
IV (Figure 2). Moreover, the X-ray structure of human
thrombin in complex with a modiﬁed TBA containing a 5′-5′
i n v e r s i o n o f t h e p o l a r i t y s i t e ( 3 ′GGT 5 ′ -
5′TGGTGTGGTTGG3′, namely mTBA) has also been
reported (PDB ID 3QLP).9 The X-ray complex revealed that
the interaction occurs between the TT loops and ABE I
(orientation III in Figure 2), whereas the TGT loop,
particularly T7, is not involved in any relevant interaction
with the protein. Despite the fact that mTBA binds to thrombin
with higher aﬃnity with respect to TBA,10 it showed poor
anticoagulant activity if compared to TBA in PT assay.11 On
the other hand, Toggle-25t, an RNA aptamer that contains 2′-
ﬂuoropyrimidine nucleotides, and a 29-mer single-stranded
DNA, designated DNA60-18[29] or HD22, bind selectively
thrombin at ABE II and they also showed limited eﬀect on
clotting times.12 Because of their thrombin allostery, ABE I and
ABE II aptamers were used in combination to test their mixed
eﬀect on thrombin activity.4,13 The obtained results showed
that synergistic anticoagulant eﬀects can be achieved by mixing
TBA with Toggle-25t or HD22 and by linking TBA to HD22
with an appropriate-sized spacer.
In this scenario, due to the symmetry of TBA and the
complexity of the regulatory mechanism of thrombin, which
includes a long-range allosteric linkage between ABE I and ABE
II,14,15 the exact binding mode of aptamers to thrombin and its
correlation with the observed biological activity is still a matter
of debate. Nevertheless, biological results indicated that TBA
exerts its anticoagulant activity mainly competing with
ﬁbrinogen at ABE I.16 The phase I clinical trial for TBA
demonstrated its positive pharmacokinetic proﬁle in humans;
however, clinical trials were halted after phase I due to
suboptimal dosing proﬁles.17 To optimize its anticoagulant
properties, of particular interest is the enlargement of data
gathering about TBA structure−activity relationships (SARs)
through the development of new derivatives. In the nucleic
acids research area the introduction of suitable modiﬁcations on
natural oligonucleotide sequences represents a method widely
employed to explore the relevance of single nucleotides both on
secondary structure folding topology and on binding with
target proteins. The explored modiﬁcations involve the
nucleobases,18 the sugar−phosphate backbone,19 and the
conjugation to ﬂexible non-nucleotide linkers.20
In our understanding of the bases of TBA−thrombin
recognition, we previously developed new single-stranded
TBA analogues, in which the acyclic nucleoside a (Figure 3)
replaced, one at a time, all thymine residues along the aptamer
sequence.21
The modiﬁcation at position 7 in the T7G8T9 loop (herein
TBA-T7a) gives rise to an ON that folds into a quadruplex
structure that is more stable and active than the quadruplex
structure formed by TBA. On the other hand, within the four
ONs containing the acyclic nucleoside a at one position of TT
loops, the ON modiﬁed at T12 (herein TBA-T12a) showed the
Figure 1. Schematic drawings of the X-ray derived G-quadruplex
structures of TBA as reported in PDB IDs 1HAO (A) and 1HUT and
1HAP (B). In (A) TT loops span narrow grooves and TGT spans
wide grooves, vice versa in (B). White and gray squares indicate G
bases in anti and syn conformation, respectively.
Figure 2. Representation of the four orientations of the NMR derived folding with respect to thrombin corresponding to the D2 symmetry of the
quadruplex core assuming the same strand polarity of the X-ray complex.
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most signiﬁcant biological properties.21 In line with data
reported from other authors,22 our results evidenced that
modiﬁcation at T7 and T12 along the TBA sequence can be
fruitful to improve the biological activity.
To investigate the role of the modiﬁcation at T7 and T12 in
aﬀecting the structural stability and the biological activity, we
synthesized two new modiﬁed TBAs, named TBA-T7b and
TBA-T12b, which diﬀered from the previously reported
analogues only in the thymidine base coupled with the acyclic
linker, which was bulked by fusing a hydrophobic ﬁve member
cycle with the pyrimidine ring (b, Figure 3). The abilities of
TBA-T7b and TBA-T12b to fold into G-quadruplex structures,
as well as their biological properties, were evaluated by CD and
1H NMR experiments and by PT and puriﬁed ﬁbrinogen
clotting assays, respectively. Finally, a computational study
allowed the analysis of the obtained SARs.
■ RESULTS
Synthesis of Monomer 6. The synthesis of the modiﬁed
acyclic nucleoside phosphoramidite building block 6, used for
the automated synthesis of TBA-T7b and TBA-T12b, is
summarized in Scheme 1.
The synthesis of N1-alkylated intermediate 3 was performed
via Mitsunobu reaction23 between 2, obtained as described
under Experimental Section, and 1. The yields of this coupling
reaction were strongly dependent on the initial temperature of
the system and on the order in which the reagents were added.
We found that temperatures lower than 30 °C were always
detrimental to the reaction yield, and that higher yields (45−
50%) were obtained by mild heating (30 °C) of a dioxane
solution containing 2 and triphenylphosphine followed by
addition of di-tert-butylazodicarboxylate and ﬁnally a dioxane
solution of protected linker 1 (100 μL of solvent per 1 mmol).
The intermediate 4 was obtained by removing both the linker
and nucleobase protecting groups from 3 using a one-pot
procedure (see Experimental Section). Finally, 4 was function-
alized to phosphoramidite buiding block 6 using standard
procedure.
The acyclic nucleoside 6 was inserted as a T mimic at
position 7 or 12 along the TBA sequence to obtain TBA-T7b
and TBA-T12b, respectively.
Structural Characterization. TBA-T7b and TBA-T12b
were characterized by circular dichroism (CD), CD melting,
and 1H NMR for their ability to fold into G-quadruplexes. The
introduction of the new acyclic nucleoside b at position 7 or 12
does not aﬀect the overall G-quadruplex topology formed in
solution. CD proﬁles of TBA-T7b and TBA-T12b are similar to
those of TBA in both PBS and K+ buﬀer (left and right panels,
respectively, in Figure 4), showing maxima at about 208, 245,
and 295 nm and a minimum at 267 nm. As expected, positive
CD bands have higher molar ellipticities in K+ buﬀer than in
PBS, according to the well-known dependence of G-quadruplex
stabilities from the type of cations present in the buﬀer
solution.24
The 1H NMR analysis, performed at temperatures in the
range of 25−50 °C, conﬁrmed that TBA-T7b and TBA-T12b
form a stable G-quadruplex structure when annealed in K+
buﬀer. However, 1H NMR spectra appear more crowded than
expected for a single quadruplex species, even at 25 °C (Figure
5), where only 14 aromatic signals and 8 imino proton signals
are expected. This ﬁnding was previously explained by
considering that the replacement of a T residue with the
acyclic nucleoside a produces two closely related diastereomeric
G-quadruplex forming ONs.21
Although both modiﬁed ONs show Tm values higher than
that of TBA (Figure 6 and Table 1), the replacement of T7 with
the acyclic nucleoside b stabilizes the resulting G-quadruplexes
more eﬃciently than replacement of T12.
PT Assay. The anticoagulant activity in the presence of all
thrombin substrates and cofactors was evaluated by PT assay.
PT analyses were performed at [ON] of 2 and 20 μM after 2
min of incubation with human plasma (Figure 7).
To better understand the eﬀects induced by the presence of
nucleoside b on the anticoagulant activity, we compared the
prolonging of clotting time caused by TBA-T7b and TBA-T12b
with that of TBA and those of the previously reported21
analogues TBA-T7a and TBA-T12a (Table 2).
It is noteworthy that TBA-T7b prolonged the basal PT value
to a signiﬁcantly larger extent with respect to TBA and TBA-
T7a (Figure 7 and Table 2). Replacement of nucleoside a for b
was more eﬀective also at position 12 (Table 2). In particular,
TBA-T12b is less active than TBA at 2 μM, but showed a
Figure 3. Acyclic nucleosides mimicking T. The presence of the
carbon atom marked with an asterisk causes the formation of two
diastereomeric ONs when the nucleoside is inserted in the TBA
sequence.
Scheme 1. Synthesis of Monomer 6a
a(i) 1 0.94 g (5.9 mmol), 2 1.50 g (5.9 mmol), triphenylphosphine
2.28 g (8.7 mmol), di-tert-butylazodicarboxylate 2.1 g (9.1 mmol), dry
dioxane (70 mL), 24 h, 30°C, yields 43%; (ii) (a) 3 1.0 g (2.5 mmol),
Dowex H+ 450 mg, MeOH/H2O (9:1 v/v) 100 mL; (b) aqueous
NaOH (1.0 M, 5 mL) yields 98%; (iii) 4 640 mg (2.5 mmol), 4,4′-
dimethoxytrytylchloride 541 mg (1.6 mmol), 2,4-dimethylaminopyr-
idine 15 mg (0.12 mmol), pyridine (20 mL), acetonitrile (10 mL), 1.5
h, rt, yields 45%; (iv) 5 600 mg (1.1 mmol), 2-cyanoethyldiisopropyl-
chlorophosphoramidite 300 μL (1.2 mmol), DIPEA 600 μL (3.6
mmol), DCM (8 mL), 40 min, rt, yields 99%.
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greater increase of activity at higher concentration, thus
attaining that of TBA at 20 μM (Figure 7).
To exclude that the observed activity of modiﬁed aptamers
could be due to higher nuclease stability with respect to TBA,
we repeated the experiments, changing the incubation time of
TBA and analogues with plasma from 30 s to 15 min. PT
results were almost unchanged for all sequences (Supporting
Information, Figure 1SI).
Fibrinogen Assay Using Human and Bovine Throm-
bin. The new ONs were subjected to puriﬁed ﬁbrinogen
clotting assay to evaluate their ability to inhibit the conversion
of soluble ﬁbrinogen into insoluble strands of ﬁbrin in the
absence of any other thrombin ligands/eﬀectors (Figure 8 and
Tables 1SI and 2SI of the Supporting Information).
The assay was performed using various concentrations of
each aptamer. The puriﬁed ﬁbrinogen solution was preincu-
bated with the aptamer and the reactions were initiated by the
Figure 4. CD proﬁles in PBS (left) and in potassium phosphate buﬀer (right); [ON] = 2.0 × 10−5 M.
Figure 5. 1H NMR spectra of TBA-T7b and TBA-T12b recorded at 25 °C in K+ buﬀer.
Figure 6. CD melting curves of TBA and its analogues in potassium
phosphate (continuous lines) or PBS (dotted lines) buﬀer.
Concentration of each ON was 2.0 × 10−5 M. The curves were
obtained by monitoring the variation of absorbance at 295 nm from 10
to 80 °C at 0.5 °C/min.
Table 1. Tm Values of TBA and Its Analogues
Tm (±0.5 °C)
ON PBS K+ buﬀer
TBA 33.0 50.0
TBA-T12a 34.0
a 51.0a
TBA-T12b 34.5 51.5
TBA-T7a 37.5
a 54.0a
TBA-T7b 37.5 54.0
aData taken from ref 21.
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addition of human thrombin and clotting times were recorded.
The ﬁbrinogen assay results evidenced that at all ON
concentrations tested, the most eﬃcient inhibitor is the
unmodiﬁed TBA sequence (Figure 8A and Table 1SI of the
Supporting Information), thus reversing the results gathered
from the PT assay. To further investigate this phenomenon, we
performed the ﬁbrinogen assay by using bovine thrombin,
which diﬀers from human thrombin in some residues of the
ﬁbrinogen-binding site (ABE I) that are crucial for TBA−
thrombin interaction (see next paragraphs for details). By
changing the source of the target enzyme, both modiﬁed
sequences showed a substantial increase in their ability to
inhibit thrombin activity (Figure 8B and Table 2SI of the
Supporting Information), whereas the inhibitory activity of
TBA was only slightly increased; as a consequence, TBA-T7b
became again the best inhibitor.
Conformational Search on TBA and Modiﬁed Ana-
logues TBA-T7b and TBA-T12b. An extensive molecular
modeling study, including molecular mechanics (MM) and
dynamics (MD) calculations, was undertaken to analyze the
SARs of new modiﬁed TBAs.
In particular, to investigate the conformational properties of
TBA and the new modiﬁed aptamers, a simulated annealing
(SA) procedure followed by MM energy minimization was
applied. Following the criteria described under Experimental
Section, resulting conformers were analyzed and each
nucleotide of loops was classiﬁed on the basis of (i) χ torsional
angle values, to identify the conformation of the glycosidic
bond (i.e., syn, anti, or s/a); and (ii) the interatomic distance
between its own centroid and that of the two G-tetrads, to
investigate the position of loop nucleotides with respect to the
Figure 7. Concentration-dependent response, following 2 min ON incubation with human plasma at 2 (A) or 20 μM (B) [ON]. PT values are
expressed in seconds. Each measurement was performed in triplicate and is shown as the mean ± SEM. The basal PT time is 13.4 ± 0.2 s.
Table 2. PT Values Measured after 2 min of Incubation
Using 20 μM ON Concentration and Fold Increases of Basal
PT Time (13.4 ± 0.2 s)
ON PT valuea (20 μM) fold increase
TBA 53.68 ± 1.48 4.01 ± 0.70
TBA-T7a 60.20 ± 1.38
b 4.50 ± 0.60
TBA-T7b 90.60 ± 5.26 6.77 ± 0.24
TBA-T12a 44.83 ± 1.29
b 3.35 ± 0.60
TBA-T12b 55.20 ± 0.47 4.12 ± 0.20
aPT values are expressed in seconds. bData taken from ref 21.
Figure 8. Eﬀects of aptamers on human (A) and bovine (B) thrombin clotting time in ﬁbrinogen solution. The results are expressed as the ratio of
clotting times measured in the absence and in the presence of the aptamers. The eﬀects are reported as a function of log [ON]. Each measurement
was performed in triplicate and is shown as the mean ± SD.
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guanine planes (i.e., “stacked” or “not-stacked”). Occurrence
rates were calculated and compared to those obtained for TBA.
Because the replacement of T7 and T12 residues with nucleoside
b produced a mixture of diastereoisomers, characterized by S or
R conﬁguration at the acyclic linker, the occurrence rates
reported in Tables 3 and 4 are the mean of the values obtained
for the two diastereoisomers; single diastereoisomer values are
reported in Tables 3SI and 4SI of the Supporting Information.
The structural analysis evidenced that, although inducing
some variations, the introduced modiﬁcations at T7 and T12 did
not cause a reversal of the conformational preference of the
glycosidic bonds with respect to TBA (Table 3 and Table 3SI
of the Supporting Information). Consequently, in agreement
with previously reported NMR studies,6c TBA and modiﬁed
aptamers TBA-T7b and TBA-T12b conserved an overall
preference for the anti conformation of thymines in TGT
and TT loops.
With regard to the stacking of the TGT loop nucleobases on
the G-tetrads, TBA-T7b and TBA-T12b present an increased
stacking of T9 and a decreased stacking of G8 (Table 4 and
Table 4SI of the Supporting Information). Nevertheless, the
conformational features of the TGT loop still evidenced the
same trend of TBA with the following order of residue stacking
on the G-tetrads: G8 > T9 > T7.
The two modiﬁed analogues showed a similar conforma-
tional behavior at the T3T4 loop because, either in TBA-T7b or
in TBA-T12b, the rate of stacked conformation of T3 and T4
decreased and increased, respectively, with respect to TBA,
evidencing a conformational linkage between TGT and T3T4
loops. On the contrary, diﬀerent results were obtained for the
T12T13 loop. In fact, as expected, the substitution of T12 with
the acyclic nucleoside b (TBA-T12b) aﬀected the conforma-
tional ﬂexibility of the T12T13 loop, inducing a decreased
stacking rate of both nucleobases, which was not observed in
TBA-T7b (Table 4 and Table 4SI of the Supporting
Information). NMR studies performed on TBA6a revealed
that the positioning of T4 and T13 plays a key role in quadruplex
folding and stability; accordingly, due to the increased stacking
of T4 and T13 on the guanine planes, TBA-T7b was structurally
more stable than TBA in CD melting experiments (Table 1 and
Figure 6).
Molecular Modeling Studies on Aptamer Interaction
with Human and Bovine Thrombin. With the aim of
identifying the eﬀects of the new structural modiﬁcations on
aptamer−thrombin interactions, ﬁrst, all possible aptamer−
thrombin binding modes and the corresponding binding
interactions were analyzed (PDB IDs 1HAO, 1HAP, 1HUT,
4DIH, and 4DII; see Experimental Section). This study
revealed that the various binding orientations of TBA with
respect to human thrombin (Figures 1 and 2) produced
diﬀerent binding modes in the crystal complexes sharing similar
interactions with ABE I but involving diﬀerent aptamer residues
(Figure 9 and Table 5SI of the Supporting Information).
Indeed, a thymine residue of TBA always interacts with ABE
I hydrophobic cleft lined by Ile24, His71, Ile79 and Tyr117,
but, depending on the binding mode, the interactions involve
T3 (Figure 9C,D), or T7 (Figure 9A,B), or T12 (Figure 9E,F).
T7 interacts penetrating into the hydrophobic cleft more than
T12 and T3 (Figure 9F vs Figure 9B,D); while the positioning of
these latter resulted identical due to the symmetry of the two
TT loops (Figure 9B vs Figure 9D). By consequence, a second
ABE I subsite, including Gln38, Tyr76 and Ile82, interacts with
T12 or T3, depending on the binding orientation (Figure 9A−
D). When the TGT loop binds to ABE I, the interaction with
this second subsite is absent (Figure 9E,F).
Second, to identify the structural diﬀerences in TBA-binding
site, experimentally determined structures of human and bovine
thrombin were compared (PDB IDs are listed in the
Experimental Section). Only three TBA-binding site residues,
Ile24, Asn78, and Ile79, were mutated in bovine thrombin
(Supporting Information, Table 6SI), with no signiﬁcant
variation of the backbone structure (Figure 9). Human
thrombin Asn78 residue (replaced by a lysine in bovine
thrombin) interacts only with the TGT loop, establishing an H-
bond interaction with the phosphate group of T9 (PDB IDs
1HUT and 1HAP; Figure 9E,F and Table 5SI of the
Supporting Information). On the contrary, the interactions
with human ABE I hydrophobic cleft containing Ile24 and Ile79
are conserved in all crystal complexes and involve T3 or T7 or
T12 depending on TBA-binding orientation (Figure 9 and
Table 5SI of the Supporting Information). The replacement of
these two isoleucine residues in human thrombin by two valine
residues in the bovine homologue determines an enlargement
of the employable volume within the ABE I cleft.
Table 3. Calculated Occurrence Rates (Percent) of syn, anti, and s/a Conformers of TGT and TT Glycosidic Bonds
TBA TBA-T7b TBA-T12b
syn anti s/a syn anti s/a syn anti s/a
T3 28.5 69.5 2.00 37.0 61.5 1.50 47.0 50.5 2.50
T4 38.5 56.0 5.50 29.0 65.5 5.50 43.0 52.0 5.00
T7
a 39.0 59.5 1.50 36.0 62.5 1.50
G8 39.5 38.0 22.5 35.0 46.5 18.5 34.5 44.0 21.5
T9 41.5 50.0 8.50 34.0 57.0 9.00 42.0 51.0 7.00
T12
b 32.0 66.0 2.00 42.0 56.0 2.00
T13 37.0 59.0 4.00 36.0 60.5 3.50 42.0 54.5 3.50
aT7 residue in TBA-T7b is replaced by the acyclic nucleoside b.
bT12 residue in TBA-T12b is replaced by the acyclic nucleoside b.
Table 4. Calculated Occurrence Rates (Percent) of
Conformers Presenting TGT and TT Nucleobases “Stacked”
on the Guanine Planes
TBA TBA-T7b TBA-T12b
T3 62.5 33.0 39.0
T4 46.0 60.0 65.0
T7
a 14.0 12.0 10.0
G8 78.5 50.0 49.0
T9 26.0 39.5 42.5
T12
b 33.5 37.0 29.0
T13 38.0 40.5 29.0
aT7 residue in TBA-T7b is replaced by the acyclic nucleoside b.
bT12
residue in TBA-T12b is replaced by the acyclic nucleoside b.
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We then calculated the occurrence rates of TBA, TBA-T7b,
and TBA-T12b SA/MM conformers presenting solvent-
accessible surface areas of residues 3, 7, and 12 equal to or
greater than that of the corresponding residue of TBA binding
the ABE I hydrophobic cleft in experimentally determined
complexes (Table 5; single diastereoisomer values are reported
in Table 7SI of the Supporting Information).
Interestingly, the replacement of T7 and T12 with the acyclic
nucleoside b determined in both cases a greater rate of
conformations presenting a solvent-exposed conformation.
Moreover, in agreement with the results reported in Tables 3
and 4, T3 is more exposed to the solvent in the new modiﬁed
aptamers than in TBA.
Finally, we calculated the occurrence rates of bioactive
conformations of residues at positions 3, 7, and 12 resulting
from SA/MM calculations on TBA, TBA-T7b, and TBA-T12b
(Figure 10 and Table 6; single diastereoisomer values are
reported in Table 8SI of the Supporting Information).
With this aim, all obtained conformers were superimposed
on the experimentally determined TBA−thrombin complexes
by ﬁtting the guanine tetrads to evaluate the overlap with the
residue interacting with the ABE I hydrophobic cleft (see
Experimental Section for details). Obtained results show that
TBA-T7b presents an increased rate of bioactive conformations
if compared to TBA; on the contrary, the substitution of T12
with b decreases the rate of bioactive conformations of T3 and
T7.
Interestingly, the replacement of T7 and T12 with the acyclic
nucleoside b determined in both cases a greater rate of
conformations presenting a solvent-exposed position able to
drive the interaction with the ABE I hydrophobic cleft.
Nevertheless, likely due to the higher ﬂexibility of the TGT
loop with respect to the TT loops, there is a higher occurrence
rate of T7b assuming the ABE I bioactive conformation
compared to T3 and T12b (Table 6 and Figure 10).
■ DISCUSSION
The introduction of a bulky ﬁve member cycle on the
pyrimidine ring of the modiﬁed thymine residues of TBA-T7a
and TBA-T12a led to compounds (TBA-T7b and TBA-T12b)
able to fold into G-quadruplexes characterized by unaﬀected
structural stability but showing diﬀerent anticoagulant activity
with respect to their parent compounds.21 Because TBA-T7b
and TBA-T7a show the same melting proﬁle, with a Tm higher
than that of TBA (Table 1), it can be concluded that the sole
presence of the acyclic linker unit at position 7 is responsible
for the structural stabilizing eﬀect. Conformational analysis
results indicate that the introduction of the acyclic linker at
position 7 increased the solvent-exposed surface area (Table 6)
of the modiﬁed residue and the rate of T4 and T13
conformations stacked on the guanine planes (Table 4).
These data account for the nucleobase 7 always positioned
outside the G-quadruplex core and not involved in intra-
molecular interactions, as well as for the reported stabilizing
role played by T4 and T13 on TBA structural stability.
6 In line
with our results, a similar increase in Tm value has also been
observed by replacing the sugar moiety of T7 with a diﬀerent
acyclic linker.22 Interestingly, the fact that TBA-T7a and TBA-
T7b showed the same enhancement of the Tm value with
respect to TBA is not correlated with their diverse
anticoagulant activities. Indeed, although the anticoagulant
activities of TBA-T7a and TBA-T7b are higher than that of
TBA, TBA-T7b is more active than TBA-T7a (Figure 7).
Furthermore, PT assay data show that the incorporation of
Figure 9. Cartoon (left) and 3D (right) structure of the diﬀerent
binding orientations of TBA with respect to human thrombin ABE I
(green). (A, C, and E) Amino acid residues involved in TBA−
thrombin interactions are evidenced in black; where mutated, the
corresponding bovine residues are reported in red. The blue curve and
straight arrows indicate loop nucleotides “stacked” or “not-stacked” on
G-tetrad, respectively. (B) PDB ID 1HAO (TBA carbons = cyan); (D)
PDB ID 4DIH (TBA carbons = yellow); (F) PDB ID 1HAP (TBA
carbons = magenta). Protein carbons are colored in green, residues
within TBA binding site that are mutated in bovine thrombin are
shown and labeled. The nucleotides T3, T7, and T12 are evidenced as
ball and stick. Heteroatoms are colored as follows: O = red; N = blue;
P = magenta. Hydrogens are omitted for the sake of clarity.
Table 5. Occurrence Rates (Percent) of TBA, TBA-T7b, and
TBA-T12b SA/MM Conformers Presenting a Solvent-
Accessible Surface Area (Å2) of Residues 3, 7, and 12 Equal
to or Greater than That of the Corresponding Residue of
TBA Assuming the Bioactive Conformation at the ABE I
Hydrophobic Cleft
ON T3 T7
a T12
b
TBA 16.5 85.0 36.5
TBA-T7b 21.0 88.0 34.5
TBA-T12b 22.0 76.0 50.0
aT7 residue in TBA-T7b is replaced by the acyclic nucleoside b.
bT12
residue in TBA-T12b is replaced by the acyclic nucleoside b.
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nucleoside b was more eﬀective than that of nucleoside a also at
position 12 of TBA (Table 2). It was somehow surprising that
the activity of TBA with respect to the new modiﬁed analogues
is reversed in ﬁbrinogen assay (Figure 8A). It could be
supposed that the introduction of an acyclic linker in the TBA
phosphate backbone enhances the aptamers’ stability to
nucleases, thus producing an increment of inhibitory eﬀect in
plasma tests. However, PT results were almost unaﬀected upon
increasing of the incubation time of all sequences with plasma
(Supporting Information, Figure 1SI), thus suggesting that, in
the explored conditions, nuclease stabilities and inhibitory
activities are uncorrelated and that modiﬁcations at T7 directly
aﬀect the interaction of aptamers with thrombin. Supporting
this view, the use of bovine thrombin in ﬁbrinogen assay
changed again the activity trend. In particular, when tested
toward bovine thrombin, the inhibitory activity of TBA-T7b
and TBA-T12b signiﬁcantly increases, becoming much higher
than that of TBA, which, on the contrary, is almost unchanged
in both ﬁbrinogen tests (Figure 8, panel A vs panel B). On this
ground, subtle structural diﬀerences between human and
bovine thrombin that speciﬁcally aﬀect the binding with
TBA-T7b and TBA-T12b must exist. The results from our
molecular modeling study using both human and bovine
thrombin revealed that the obtained SARs ﬁt with the binding
of modiﬁed nucleobases, T7b and T12b to thrombin ABE I.
Indeed, within the TBA binding site, human thrombin diﬀers
from the bovine counterpart by only three amino acids located
at ABE I (Supporting Information, Table 6SI). Speciﬁcally, in
the bovine enzyme two isoleucine residues are replaced by
valine residues and an asparagine is mutated into a lysine. In the
reported human thrombin−TBA complexes, the isoleucine
residues are involved in hydrophobic contacts with T3 or T7 or
T12, depending on the binding orientation of the aptamer
(Figure 9). On the other hand, the asparagine residue is
involved in H-bond interactions with the phosphate group
linking G8 to T9 only when the TGT loop binds to ABE I
(Supporting Information, Tables 5SI and 6SI). In the new TBA
derivatives TBA-T7b and TBA-T12b, the introduction of the
acyclic linker facilitates the extension of the phosphate
Figure 10. TBA (green; A−C), TBA-T7b (orange; D−F), and TBA-T12b (white; G−I) SA/MM conformers presenting residue 3, 7, or 12 assuming
ABE I hydrophobic cleft binding conformation. Molecular models are superimposed on 4DIH (A, D, G; yellow), 1HAP (B, E, H; pink), or 1HAO
(C, F, I; cyan) by ﬁtting the guanine tetrads. All conformers of TBA and the mean of those obtained for the two diastereoisomers of TBA-T7b and
TBA-T12b are shown. For the sake of clarity only the residue interacting with the ABE I hydrophobic cleft is displayed and hydrogens are omitted.
Heteroatoms are colored as follows: O = red; N = blue; P = magenta.
Table 6. Occurrence Rates (Percent) of Bioactive
Conformations at the ABE I Hydrophobic Cleft of Residues
at Positions 3, 7, and 12 Resulting from SA/MM
Calculations
ON T3 T7
a T12
b
TBA 9.50 12.0 10.0
TBA-T7b 8.00 14.0 13.5
TBA-T12b 6.50 6.50 10.0
aT7 residue in TBA-T7b is replaced by the acyclic nucleoside b.
bT12
residue in TBA-T12b is replaced by the acyclic nucleoside b.
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backbone toward the solvent and the penetration of the
modiﬁed nucleobase within the ABE I hydrophobic cleft, thus
amplifying the steric hindrance caused by the presence of the
ﬁve member cycle on modiﬁed nucleobase b (Table 5 and
Figure 10). Accordingly, the presence of the smaller Val24 and
Val79 residues in bovine thrombin could explain the increased
activity of the new modiﬁed TBA analogues for this enzyme.
The observed higher activity of TBA-T7b is indeed correlated
to the calculated higher rate of bioactive conformations at the
ABE I hydrophobic cleft with respect to TBA and TBA-T12b
(Table 6 and Figure 10). This hypothesis is supported by the
previously reported activity of TBA-T7a and TBA-T12a,
21
which, lacking the steric bulk at the modiﬁed nucleoside, was
more active in the ﬁbrinogen assay using human thrombin. On
the other hand, the charged group at the lysine side chain
allows the establishment of an ionic interaction with the
modiﬁed TGT phosphate backbone of TBA-T7b, likely
contributing to the enhancement of inhibitory ability.
On these bases, the apparent incongruence of PT and
ﬁbrinogen assay results, using human thrombin, can be
interpreted by taking into account the eﬀects of diﬀerent
aptamer binding modes on thrombin allostery.2 In the PT assay
a number of thrombin ligands/eﬀectors other than ﬁbrinogen
that are able to modulate thrombin activity are
present,1,2,14,25,26 thus driving diﬀerent binding modes; the
new modiﬁed aptamers could diﬀerently aﬀect this ligand/
eﬀector binding network. In this scenario, it is noteworthy that
the 65−84 thrombin loop, involved in speciﬁc interactions with
the modiﬁed nucleobase of the new TBA derivatives according
to our binding mode hypothesis, has been proved to be
responsible for the allosteric long-range communication among
ABE I, the catalytic site, and ABE II.2e,15
Altogether, our results reveal the absence of a direct
correlation between the structural stability and the anticoagu-
lant property in our series of modiﬁed TBAs, suggesting that
the role played by T7 (placed in the TGT loop) and T12
(placed in the TT loop close to the 3′ terminus) in the
biological activity of TBA and its analogues could involve
alternative aptamer binding modes and the complex and not yet
fully understood allosteric mechanism of action of thrombin.
■ CONCLUSIONS
Bringing together the so far acquired knowledge of the
thrombin−TBA interaction and thrombin allosteric regulatory
mechanism with our SAR data, we determined that the G-
quadruplexes formed by the modiﬁed TBAs can bind the
thrombin ABE I hydrophobic cleft by using either TGT or one
of the two TT loops. Our results indicate that the incoherency
of their behaviors in the two explored biological tests is due to
the molecular process through which they exert the
anticoagulant activity, which is surely more intricate than a
competitive inhibition with the ﬁbrinogen-binding site. Besides
their high anticoagulant activity, these molecules represent
valuable tools to further explore the complex regulatory
mechanism of thrombin during plasma coagulation that is, as
yet, not completely clariﬁed.
■ EXPERIMENTAL SECTION
General Procedure. Chemicals and anhydrous solvents were
purchased from Fluka-Sigma-Aldrich. TLCs were run on Merck silica
gel 60 F254 plates. Silica gel chromatography was performed by using
Merck silica gel 60 (0.063−0.200 mm). An API 2000 (Applied
Biosystem) mass spectrometer was used to perform the analyses of the
intermediates and monomer 6. NMR experiments were recorded using
Varian Mercury Plus 400 MHz and Varian UNITYINOVA 500 and 700
MHz spectrometers and processed using the Varian VNMR software
package. Reagents and phosphoramidites for DNA synthesis were
purchased from Glenn Research. ON syntheses were performed on a
PerSeptive Biosystem Expedite DNA synthesizer. HPLC puriﬁcations
and analyses were carried out using a JASCO PU-2089 Plus HPLC
pump equipped with a JASCO BS-997-01 UV detector. The purity of
the ﬁnal products was determined as >95% by using a C-18 RP
analytical column (C-18 Purospher STAR, Merck) eluted by a gradient
of CH3OH in H2O (from 0 to 100% in 30 min). CD experiments were
performed on a JASCO 715 spectropolarimeter equipped with a PTC-
348 temperature controller.
Synthesis of Monomer 6. (a) 3-Benzoyl-6,7-dihydro-1H-
cyclopenta[d]pyrimidine-2,4(3H,5H)-dione (2). Nucleobase 6,7-dihy-
dro-1H-cyclopenta[d]pyrimidine-2,4(3H,5H)-dione was obtained as
previously reported by Renault et al.27 and converted in its N3 benzoyl
derivative 2.21 1H NMR (400 MHz; mixture of CD3OD and CDCl3),
δ 7.75 (d, J = 8.0 Hz, 2H), 7.60 (t, J = 8.0 Hz, 1H), 7.43 (t, J = 8.0 Hz,
2H), 3.03 (t, J = 7.3 Hz, 2H), 2.67 (t, J = 7.3 Hz, 2H), 2.10 (q, J = 7.3
Hz, 2H); 13C NMR (100 MHz; mixture of CD3OD and CDCl3), δ
169.3, 166.3, 155.2, 147.3, 134.2, 132.2, 128.9, 128.3, 127.5, 127.0,
113.4, 34.8, 30.5, 18.0. ESI mass (positive mode), calculated 256.1;
found 257.1 [M + H]+, 279.1 [M + Na]+.
(b) 3-Benzoyl-1-[(2,2,5-trimethyl-1,3-dioxan-5-yl)methyl]-6,7-di-
hydro-1H-cyclopenta[d]pyrimidine-2,4(3H,5H)-dione (3). Com-
pound 2 (1.5 g, 5.9 mmol) was suspended in 70 mL of dry dioxane
at 30 °C in the presence of triphenylphosphine (2.28 g, 8.7 mmol)
before the addition of di-tert-butyl azodicarboxylate (2.1 g, 9.1 mmol).
To the resultant mixture, after 10 min of stirring at room temperature,
was added 5.9 mmol of 1 dissolved in dry dioxane (300 μL). The
reaction mixture was stirred at room temperature for 18 h under
argon. The solution was concentrated under reduced pressure and the
residue puriﬁed by column chromatography on silica gel eluted with
95:5 Et2O/CH2Cl2 to give 3 as a white solid (yield 43%, Rf 0.70).
1H
NMR (400 MHz; CDCl3), δ 7.98 (d, J = 8.0 Hz, 2H), 7.60 (t, J = 8.0
Hz, 1H), 7.43 (t, J = 8.0 Hz, 2H), 4.0 (bs, 2H), 3.62 (m, 4H), 3.03 (t, J
= 7.3 Hz, 2H), 2.66 (t, J = 7.3 Hz, 2H), 2.09 (q, J = 7.3 Hz, 2H), 1.38
(s, 3H), 1.42 (s, 3H), 0.87 (s, 3H). ESI mass (positive mode),
calculated 398.2; found 399.2 [M + H]+, 421.2 [M + Na]+.
(c) 1-(3-Hydroxy-2-(hydroxymethyl)-2-methylpropyl)-6,7-dihy-
dro-1H-cyclopenta[d]pyrimidine-2,4(3H,5H)-dione (4). Compound
3 (1.0 g, 2.5 mmol) was suspended in 9:1 MeOH/H2O (100 mL)
containing 450 mg of Dowex 50WX8 (H+). After 8 h at room
temperature, a NaOH 0.5 M aqueous solution was slowly added to
neutralization. The solution was ﬁltered and, in turn, basiﬁed with
NaOH 1.0 M (5 mL) to remove the N-3 benzoyl group from the
nucleobase. After 12 h at room temperature, the pH of the reaction
was neutralized, the solvent was evaporated under vacuum, and the
residue was dissolved in MeOH and puriﬁed by HPLC (C-18 reverse-
phase column, Grace Davison Discovery Sciences, eluted with ACN in
H2O from 0 to 50% in 30 min) to give 4 as a white solid (yield 98%,
elution time 15 min). 1H NMR (700 MHz; CD3OD), δ 3.80 (bs, 2H),
3.41 (d, J = 11.4 Hz, 2H), 3.38 (d, J = 11.4 Hz, 2H), 3.03 (t, J = 7.3
Hz, 2H), 2.66 (t, J = 7.3 Hz, 2H), 2.09 (q, J = 7.3 Hz, 2H), 0.87 (s,
3H); 13C NMR (175 MHz; CD3OD), δ 163.8, 161.4, 155.7, 113.6,
66.6, 49.5, 44.0, 34.2, 28.2, 22.6, 17.8; NOESY (700 MHz; CD3OD),
fundamental NOE signal between 3.80 and 3.03 ppm that conﬁrms the
linker at the 1N position. ESI mass (positive mode), calculated 254.1;
found, 255.3 [M + H]+, 277.3 [M + Na]+, 293.2 [M + K]+.
(d) 3-(Bis(4-methoxyphenyl)(phenyl)methoxy)-2-((2,4-dioxo-
3,4,6,7-tetrahydrohydro-1H-cyclopenta[d]pyrimidin-1-yl)methyl)-2-
methylpropyl-2-cyanoethyl Diisopropylphosphoramidite (6). Com-
pound 4 (640 mg, 2.5 mmol), 4,4′-dimethoxytrytyl chloride (541 mg,
1.6 mmol), and 4-dimethylaminopyridine (15.0 mg, 0.12 mmol) were
dissolved in dry pyridine (20 mL) and dry ACN (10 mL). The
resulting solution was stirred at room temperature under argon for 1.5
h. Dry methanol (200 μL) was then added to quench the reaction.
After 30 min under stirring, the solution was concentrated under
reduced pressure and the residue puriﬁed by column chromatography
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on silica gel (eluted with 50:50:1 EtOAc/hexane/Et3N) to give
monodimethoxytritylated 5 as a clear yellow solid (44% yield from 4;
Rf 0.51 in EtOAc/hexane 1:1 v/v). The solid (600 mg, 1.1 mmol) was
dried in vacuo overnight before being dissolved in anhydrous DCM (8
mL) and diisopropylethylamine (600 μL, 3.6 mmol) under argon.
Three hundred microliters of β-cyanoethyl diisopropylchlorophos-
phoramidite was then added (1.2 mmol). After 40 min, the reaction
was quenched by the addition of dry methanol (100 μL), diluted with
ethyl acetate (15 mL), and ﬁnally washed with 10% sodium carbonate
solution (15 mL) and brine (15 mL). The organic layer was dried on
magnesium sulfate and concentrated in vacuo. The residue was
puriﬁed by silica gel chromatography eluted with DCM, ethyl acetate,
and triethylamine (80:10:10). The fractions containing the product
were collected and concentrated under vacuum, yielding 6 as a white
foam (99% yield; Rf 0.65 in CHCl3/MeOH/TEA 97:3:0.05 v/v/v).
1H
NMR (700 MHz; CDCl3), δ 7.90 (2H), 7.38 (2H), 7.35 (4H), 7.12
(1H), 6.85 (4H), 3.90 (2H), 3.70 (6H), 3.65 (2H), 3.60 (2H), 3.45
(2H), 3.39−3.02 (4H), 2.60−2.45 (4H), 2.16 (2H), 1.45 (3H), 1.09
(6H), 1.04 (6H); 13C NMR (175 MHz; CDCl3), δ 158.6, 151.6, 147.3,
139.4, 135.1, 130.3, 129.1, 127.8, 127.7, 127.1, 113.1, 64.4, 60.4, 55.2,
47.3, 33.6, 29.7, 27.6, 20.9, 19.3, 17.3; 31P NMR (202 MHz, CDCl3), δ
146.1 and 145.9. ESI mass (positive mode), calculated 756.3; found
757.9 [M + H]+, 779.9 [M + Na]+.
Synthesis of Oligomers. TBA and analogues were synthesized by
using standard solid phase DNA chemistry on controlled pore glass
(CPG) support following the β-cyanoethyl phosphoramidite method.
The oligomers were detached from the support and deprotected by
treatment with an aqueous ammonia solution (33%) at 55 °C
overnight. The combined ﬁltrates and washings were concentrated
under reduced pressure, dissolved in H2O, and puriﬁed by HPLC
using an anionic exchange column eluted with a linear gradient (from
0 to 100% B in 30 min) of phosphate buﬀer at pH 7.0 (A, 20 mM
NaH2PO4 aqueous solution containing 20% CH3CN; B, 1.0 M NaCl,
20 mM NaH2PO4 aqueous solution containing 20% CH3CN). The
oligomers were successively desalted by molecular exclusion
chromatography on Biogel P-2 ﬁne. The purity was checked on
HPLC by using reverse phase column (Supporting Information, Figure
2SI). The concentrations of the samples used in CD and UV
experiments were determined by measuring the absorbance at 260 nm
at 80 °C and using the open access program available on http://basic.
northwestern.edu/biotools/OligoCalc.html.28
NMR Experiments. 1D NMR spectra were acquired as 16384 data
points with a recycle delay of 1.0 s at temperatures in the range of 2−
50 °C. Data sets were zero ﬁlled to 32768 points prior to Fourier
transformation and apodized with a shifted sine bell squared window
function. The pulsed-ﬁeld gradient DPFGSE29 sequence was used for
H2O suppression. NMR samples of TBA-T7b and TBA-T12b (0.5 mM
single-strand concentration) were prepared in 100 mM K+ buﬀer
(H2O/D2O 9:1 v/v containing 90 mM KCl, 10 mM KH2PO4, and 0.2
mM EDTA).
CD Experiments. To perform CD experiments, each ON was
dissolved in the potassium (90 mM KCl, 10 mM KH2PO4, pH 7.0) or
PBS (Sigma-Aldrich; 10 mM phosphate buﬀer, 2.7 mM KCl, 137 mM
NaCl, pH 7.4) phosphate buﬀer at the ﬁnal ON concentration of 2.0 ×
10−5 M and submitted to the annealing procedure (heating at 90 °C
and slowly cooling at room temperature). Before each experiment, the
samples were equilibrated at 10 °C for 30 min. CD spectra were
recorded from 200 to 360 at 100 nm/min scanning rate, 16 s response,
and 1.0 nm bandwidth. Each CD proﬁle was obtained by taking the
average of three scans from which the spectrum of background buﬀer
was subtracted. CD melting curves were obtained by monitoring the
variation of absorbance at 295 nm from 10 to 80 °C. Two melting
experiments for each ON were recorded at 0.5 °C/min heating rate.
Prothrombin (PT) Time. PT time was measured by using a
Koagulab MJ Coagulation System with a speciﬁc kit RecombiPlas Tin
HemosIL (Instrumentation Laboratories, Lexington, MA, USA). The
procedure was performed according to the manufacturer’s instructions.
In our experimental protocol a time course of each ON or vehicle
incubated with 100 μL of plasma at 37 °C has been performed. For the
evaluation of PT at 20.0 μM, in the apposite microtube, 2.0 μL of the
corresponding ON solution (1.0 × 10−3 M in PBS) or vehicle was
added. The PT at ﬁnal ON concentration of 2.0 μM was determined
by using 2.0 μL of a diluted ON solution (the initial ON solution 1.0 ×
10−3 M in PBS was diluted at a ﬁnal concentration of 1.0 × 10−4 M).
Using six diﬀerent incubation times from 30 s to 15 min (i.e., 30 s and
1, 2, 5, 10, and 15 min) 200 μL of the kit solution containing
Recombiplastin was added with consequent activation of extrinsic
pathway. The PT measurement, for each incubation time, was
produced in triplicate, and the average and its standard error values
were calculated. The basal clotting time was determined by measuring
the clotting time in the absence of any ON. The fold increase of basal
PT time was calculated as the ratio between the measured PT time in
the presence of each ON and the basal PT value (13.4 ± 0.2 s).
Puriﬁed Fibrinogen Clotting Assay. ONs were incubated for 1
min at 37 °C in 200 μL of buﬀer (20 mM tris acetate, 140 mM NaCl,
2.7 mM KCl, 1.0 mM MgCl2, 1.0 mM CaCl2, pH 7.4) containing 2.0
mg/mL of ﬁbrinogen (ﬁbrinogen from human plasma, F 3879, Sigma-
Aldrich). One hundred microliters of human (Sigma-Aldrich, T8885,
human thrombin suitable for thrombin time test) or bovine
(HemosIL, Thrombin Time Kit, Instrumentation Laboratories)
thrombin (10 NIH per mL) was then added to the solution containing
the ﬁbrinogen and the ON. The time required to clot was measured
using a Koagulab MJ Coagulation System. The clotting time of each
ON was determined in triplicate at diﬀerent concentrations. The basal
clotting time was determined by measuring the clotting time in the
absence of any ONs. Prolonged clotting time was obtained by
subtracting the basal clotting value from each ON clotting time. The
ratio of basal and prolonged clotting time versus log [ON] was
reported.
Molecular Modeling. Molecular modeling calculations were
performed on SGI Origin 200 8XR12000 and E4 Server Twin 2 x
Dual Xeon 5520, equipped with two nodes. Each node was 2 x Intel
Xeon QuadCore E5520, 2.26 GHz, 36 GB RAM. The molecular
modeling graphics were carried out on SGI Octane 2 workstations.
(a) Conformational Analysis. Experimentally determined struc-
tures of TBA alone (PDB ID 148D) and in complex with thrombin
(PDB IDs 1HAO, 1HAP, and 1HUT) were downloaded from Protein
Data Bank (PDB, http://www.rcsb.org/pdb/) and analyzed using the
Homology module of Insight 2005 (Accelrys Software Inc., San Diego,
CA, USA). Hydrogens were added to all of these structures
considering a pH value of 7.4 (Biopolymer Module, Insight 2005).
Because the replacement of T7 and T12 residues with nucleoside b
produced a mixture of diastereoisomers characterized by S or R
conﬁguration at the acyclic linker, for each new TBA analogue TBA-
T7b and TBA-T12b, the two diastereoisomers were built by modifying
the experimentally determined structure of TBA in complex with
thrombin (PDB ID 1HAO; Insight2005 Builder module). Atomic
potentials and charges were assigned using the CVFF force ﬁeld.30
The conformational space of TBA (PDB ID 1HAO) and the new
modiﬁed analogues was sampled through 200 cycles of simulated
annealing (SA) followed by molecular mechanics (MM) energy
minimization. During the SA procedure, the temperature is altered in
time increments from an initial temperature to a ﬁnal temperature by
adjusting the kinetic energy of the structure (by rescaling the velocities
of the atoms). The following protocol was applied: the system was
heated to 1000 K over 2000 fs (time step of 1.0 fs); a temperature of
1000 K was applied to the system for 2000 fs (time step of 1.0 fs) to
surmount torsional barriers; successively, the temperature was linearly
reduced to 300 K in 1000 fs (time step of 1.0 fs). Resulting
conformations were then subjected to MM energy minimization
within Insight 2005 Discover_3 module (CVFF force ﬁeld) until the
maximum rms derivative was <0.001 kcal/Å, using a conjugate
gradient31 as the minimization algorithm.
To reproduce the physiological environment where these molecules
act and, to evaluate the eﬀects of the implicit solvent, we sampled the
conformational space through the combined procedure of SA/MM
calculations, using the dielectric constant of the water (ε = 80r).
Moreover, to allow a complete relaxation of the structures preserving
the monomolecular chairlike G-quadruplex folding topology, during
Journal of Medicinal Chemistry Article
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the entire course of SA/MM calculations, we applied a tether force of
100 kcal/Å2 to the guanine bases of two quartets.
All resulting conformers were subsequently analyzed and loop
nucleotides were classiﬁed on the bases of (i) glycosidic bond χ values,
that is, 0° < χ < 90° = syn; −60° < χ < −180°= anti;32 90°< χ <180°
and −60° < χ < 0° = s/a); (ii) the interatomic distance between the
centroid of the ring atoms of the nucleobase of each loop nucleotide
and the centroid of the ring atoms of the nucleobases of the two G-
tetrads (Pseudo_Atom Deﬁne command, Biopolymer Module, Insight
2005). According to the latter parameter, the loop nucleotide was
classiﬁed as “stacked” when the distance was <8 Å or as “not-stacked”
when the distance was >12 Å, whereas a 3D visual inspection was
needed to classify the nucleotide as “stacked” or “not-stacked” when
the distance was between 8 and 12 Å. A nucleotide termed “stacked”
presented at least one nucleobase atom shielded by the G-tetrads; a
nucleotide termed “not-stacked” presented no atoms shielded by the
G-tetrads. Occurrence rates were calculated for TBA and for each
diastereoisomer of the new analogues TBA-T7b and TBA-T12b.
Because all experimental data refer to the mixture of the two
diastereoisomers, the mean of the values obtained for the two
diastereoisomers was also calculated.
(b) Structural and Bioinformatics Analysis. To analyze the binding
modes of TBAs and the corresponding aptamer−thrombin inter-
actions, all of the experimentally determined structures of aptamers in
complex with human thrombin were downloaded from Protein Data
Bank: 1HAO, 1HAP, 1HUT, 3DD2, 3QLP, 4DIH, and 4DII. On the
other hand, to identify the structural diﬀerences in TBA binding site
between human and bovine thrombin, additional structures of human
(PDB IDs 1HXF, 1TB6, 1TMT, 1TMU, 1XMN, 3HTC, and 4HTC)
and bovine (PDB IDs 1HRT, 1VIT, and 3PMA) thrombin, sharing
similar ABE I and ABE II ligands, were selected and analyzed.
Hydrogens were added to all of the PDB structures considering a pH
value of 7.4 (Biopolymer Module, Insight 2005). All structures were
superimposed by Cα atoms, and their sequences were extracted using
the Homology module of Insight 2005 (Accelrys). On the other hand,
the human (entry P00734) and bovine (entry P00735) prothrombin
sequences were downloaded from the UniProt Knowledgebase
(http://www.uniprot.org), and the sequence alignments were
performed using Multiple_Sequence Alignment pulldown in the
Insight 2005 Homology module. Moreover, for each ligand/enzyme
complex, a subset around the ligands that consisted of all residues and
water molecules having at least one atom within a 6 Å radius from any
given ligand atom was deﬁned. The created subsets were displayed and
analyzed through a 3D visual inspection. The results of this analysis
were compared with those obtained through the sequence alignments.
Starting from the results obtained from this structural and
bioinformatics analysis, to evaluate in detail the possibility of the
residues at positions 3, 7, and 12 to interact with thrombin ABE I
hydrophobic cleft, the solvent-accessible surface area of these
nucleotides was evaluated by calculating the Connolly surface with a
probe radius of 1.4 Å, which approximates the radius of a water
molecule (Viewer Module, Insight 2005, Accelrys Software Inc.). In
particular, the Connolly surface of the considered nucleotides was
calculated for the TBA experimentally determined structures (PDB
IDs 1HAO, 1HAP, 4DIH, and 4DII) and for all conformers of TBA
and new modiﬁed analogues, resulting from SA/MM calculations.
The TBA, TBA-T7b, and TBA-T12b SA/MM conformers presenting
solvent-accessible surface areas of residues 3, 7, and 12 equal to or
greater than that of the corresponding residue of TBA when
interacting with the ABE I hydrophobic cleft in experimentally
determined complexes (i.e., T3, 191.01 Å
2; T7, 159.35 Å
2; and T12,
180.59 Å2) were selected, and their occurrence rates were calculated.
Because all experimental data refer to the mixture of the two
diastereoisomers, the mean of the values obtained for the two
diastereoisomers was also calculated.
Finally, with the aim to calculate the occurrence rates of bioactive
conformations of residues at position 3, 7, and 12 of TBA and new
modiﬁed analogues TBA-T7b and TBA-T12b, all conformers, resulting
from SA/MM calculations, were superimposed on the experimentally
determined structures of TBA in complex with thrombin (PDB IDs
1HAO, 1HAP, 1HUT, 4DIH, and 4DII) by ﬁtting heavy atoms of the
guanine bases of two quartets, and the overlap with the residue
interacting with the ABE I hydrophobic cleft (I1e24, His71, I1e79, and
Tyr117) was evaluated. To assess the bioactive conformation of the
residue at position 7, the orientation that allows residue 7 to be located
in the same position of T7 of 1HAP or 1HUT crystal structure was
considered (orientation II in Figure 2).
The conformation of residues at positions 3, 7, and 12 was
considered bioactive when the correspondent nucleobase was
positioned within the ABE I hydrophobic cleft and presented at
least one atom superimposed on T3 (PDB IDs 4DIH and 4DII) or on
T7 (PDB IDs 1HAP and 1HUT) or on T12 (PDB ID 1HAO),
respectively. Occurrence rates of bioactive conformations of residues at
positions 3, 7, and 12 were then calculated. Because all experimental
data refer to the mixture of the two diastereoisomers, the mean of the
values obtained for the two diastereoisomers was also calculated.
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ABSTRACT
Among non-canonical DNA secondary structures,
G-quadruplexes are currently widely studied be-
cause of their probable involvement in many pivotal
biological roles, and for their potential use in nano-
technology. The overall quadruplex scaffold can ex-
hibit several morphologies through intramolecular
or intermolecular organization of G-rich oligodeox-
yribonucleic acid strands. In particular, several
G-rich strands can form higher order assemblies
by multimerization between several G-quadruplex
units. Here, we report on the identification of a
novel dimerization pathway. Our Nuclear magnetic
resonance, circular dichroism, UV, gel electrophor-
esis and mass spectrometry studies on the DNA
sequence dCGGTGGT demonstrate that this se-
quence forms an octamer when annealed in pres-
ence of K+ or NH4
+ ions, through the 50-50 stacking
of two tetramolecular G-quadruplex subunits via
unusual G(:C):G(:C):G(:C):G(:C) octads.
INTRODUCTION
G-quadruplexes are unique structures formed by Hoogsteen-
type base pairing between four guanines and involving
chelation of a metal ion. G-quadruplexes are typically
formed by intramolecular folding of guanine-rich oligo-
nucleotide (GRO) sequences or by intermolecular associ-
ation of two or four sequences leading to the formation of
dimeric or tetrameric complexes (1). The biological im-
portance of these structures is 3-fold: (i) the occurrence of
short G-rich sequences able to fold into G-quadruplex
structures at the ends of telomeric DNA in eukaryotic
chromosomes (2,3); (ii) the high prevalence of G-rich
sequences in a large number of eukaryotic and prokaryotic
genomes, and the increasing number of G-quadruplexes
arising from these sequences (2,4,5); and (iii) their presence
in the scaffold of several aptamers that have the ability to
selectively bind to biologically relevant proteins and small
molecules (6–10).
G-quadruplexes have the ability to form an array of con-
formations differing in structural features such as the mo-
lecularity, the relative orientation of the strands, the size
of the loops connecting the strands and the glycosidic con-
formation of guanosine residues (syn or anti) (11). Further
structural diversity arises from the quadruplex capacity to
accommodate A-, T- and C-tetrads (12–14), as well as tet-
rads formed by modified residues (15,16). Moreover, in
the last few years, several papers describing the higher
order packing of intramolecular (17–19) or intermolecular
(20,21) DNA quadruplexes have also been published.
Particular attention has been devoted to the understand-
ing of mechanisms responsible for the self-organization of
human telomeric DNA into higher ordered G-quadruplex
structures (17,19,22). Knowledge of such mechanisms is
precious for shedding light on the in vivo role of quad-
ruplex DNA as well as for the design of supramolecular
DNA structures provided with novel functionalities.
Understanding and controlling higher order structure for-
mation is also of prime importance for in vitro studies of
oligonucleotides derived from biologically relevant se-
quences, and for controlling the aggregation state of oligo-
nucleotide aptamers aimed at therapeutic applications.
One of the identified structural moieties required for
quadruplex dimerization is the presence of a stretch of
guanines at the 50- or 30-termini of parallel G-quadruplex-
forming GROs. These types of GROs have been reported
to form higher ordered ‘dimer G-quadruplexes’ by either
the association of interlocked slipped strands (23) or by
end-to-end stacking (20,23). The presence of even a single
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base other than G at 50- or 30-termini has been reported to
prevent the dimerization. In this context, we report here
the results of our structural investigations on the sequence
CGGTGGT under different conditions of oligodeoxy-
nucleotide (ODN) concentration, pH and salts. We
observe that the sequence folds into a ‘dimeric
G-quadruplex’ (from now on 2Q), which is in fact an
octamer of the sequence, coexisting in solution with
minor amounts of other DNA secondary structures and
with the single-stranded molecule. This higher ordered
structure is obtained by head-to-head stacking between
two G(:C):G(:C):G(:C):G(:C) octads, each belonging
to one of the two ‘monomeric G-quadruplexes’ (1Q), as
ascertained from the results described below.
MATERIALS AND METHODS
DNA sample preparation
DNA oligonucleotides TGGGGT, CTGTGTT, TGGTG
GC, CGGTGGT and CGGGGT were chemically synthe-
sized on an 8909 DNA/RNA synthesizer (Applied
Biosystem), or purchased from Eurogentec (Belgium) for
mass spectrometry experiments. DNA concentration
expressed in strand molarity was calculated using a
nearest-neighbor approximation for the absorption coeffi-
cients of the unfolded species. Ammonium acetate was
obtained from a 5M solution from Fluka (Molecular
Biology grade). Stock solutions of 6mM of each ODN
were obtained by dissolving the lyophilized samples in
150mM NH4OAc or 100mM and 1.0M K
+ buffers
(10mM KH2PO4 supplemented with 90mM or 990mM
KCl, respectively). Hundred percent D2O (Armar chem-
icals) or H2O/D2O (9:1, v/v) was used for the preparation
of 6mM solutions to be used for NMR experiments. All
ODN samples were annealed by heating at 90!C for
15min and then cooling and storing at 5!C. The pH was
adjusted to 7.0 or 4.5 using HCl/KOH or AcOH/NH4OH
aqueous solutions before the annealing procedure.
Polyacrylamide gel electrophoresis
The molecular size of structures were probed using non-
denaturing polyacrylamide gel electrophoresis (PAGE) as
previously described (24). ODN samples of 10 mM,
obtained by diluting the annealed stock solutions just
before the experiment, were loaded on a 15% polyacryl-
amide gel supplemented with 20mM of KCl or NH4OAc.
Glycerol of 10% was added just before loading. The gels
were run at 26!C at constant voltage (100V) for 2.5 h. The
bands were visualized by UV shadowing and after ‘Syber
green’ coloration.
Electrospray mass spectrometry
A Q-TOF Ultima Global mass spectrometer (Waters,
Manchester, UK) was used to characterize the samples
in ammonium acetate, and to perform a kinetics experi-
ment. ODN samples (80 mM single-strand concentration),
obtained as described in the PAGE paragraph with the
addition of 10% methanol, were infused at 4 ml/min in
the electrospray (ESI) source that was operated in
negative ion mode (capillary voltage="2.2 kV).
Temperatures of ESI source and nitrogen desolvation gas
were 80!C and 100!C, respectively. The source voltages
were optimized for the best compromise to observe the
single strand, tetramer and octamer: cone=80V, RF
Lens 1=80V, collision energy=10V and source pres-
sure=3.06mbar. For the kinetics experiments, the refer-
ence strand dT6 was added to the dCGGTGGT strand, so
as to follow the intensities of the reactant (dCGGTGGT
single strand, noted G1), the intermediates (dimer=G2,
trimer=G3, tetramer=G4 = 1Q) and the product
(octamer=G8= 2Q) relative to that of the reference.
The method for obtaining relative response factors of
the monomer, the tetramer 1Q and the octamer 2Q
compared to the reference is described elsewhere (25),
and the details of its application in the present case are
given in Supplementary Data. In addition, a Bruker
Apex-Qe9.4 T ESI-FTICR mass spectrometer was used
to confirm the charge states from the isotopic distributions
by recording high-resolution data, and to confirm the
number of ammonium cations retained in each complex.
The instrument voltages were chosen so as to minimize
collision-induced dissociation and therefore keep the
non-covalent complexes intact, including the inner
ammonium cations: cap exit="22V, skimmer="15V,
octapole offset="4V and coll cell trap=+4V.
Circular dichroism
Circular dichroism (CD) spectra were measured at 25!C
on a Jasco J-715 spectropolarimeter equipped with a
Peltier Jasco JPT423S, using a 0.1-cm path length quartz
cuvette with a reaction volume of 500 ml. CD spectra were
recorded at different time points after the annealing on
40 mM ODN samples annealed at strand concentration of
200 mMor 6.0mM. Spectra were averaged over three scans.
A buffer baseline was subtracted from each spectrum and
the spectra were normalized to have zero at 360 nm.
Nuclear magnetic resonance
Nuclear magnetic resonance (NMR) data were collected
on a Varian UNITYINOVA 500MHz spectrometer
equipped with a broadband inverse probe with z-field
gradient, and on a Varian UNITYINOVA 700MHz spec-
trometer equipped with a triple resonance cryoprobe. The
data were processed using the Varian VNMR software
package. One-dimensional NMR spectra were acquired
as 16 384 data points with a recycle delay of 1.0 s at 5, 25
and 65!C. Data sets were zero filled to 32768 points prior to
Fourier transformation and apodized with a shifted sine bell
squared window function. Two-dimensional NMR spectra
were all acquired at 25!C using a recycle delay of 1.2 s.
NOESY spectra were acquired with mixing times of 100,
200 and 300ms. TOCSY spectra were recorded with the
standard MLEV-17 spin-lock sequence and a mixing time
of 80ms. For the experiments in H2O, water suppression
was achieved by including a double pulsed-field gradient
spin-echo (DPFGSE) module (26,27) in the pulse sequence
prior to acquisition. In all 2D experiments, the time
domain data consisted of 2048 complex points in t2 and
400 fids in t1 dimension. NMR samples were prepared at
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6mM strand concentration in 0.6ml of 100mM or 1.0M
K+ buffer obtained as above described. Sequence-specific
resonance assignments for CGGTGGT were obtained by
using NOESY and TOCSY spectra following the standard
procedure (28,29). The self as well as sequential NOE
connectivities from H8 to H10 and H20/H200 were traced
for all the nucleotides. The connectivities followed the
standard patterns as for B-DNA, apart from noticeable
exceptions between C1 and G2, and complete assignments
of base and sugar protons was obtained.
Molecular modeling
The starting structure was generated using the builder
module of Insight II (2005) program (Accelrys, Inc) on
an Intel PC workstation running Red Hat Enterprise
Linux. The model was parameterized according to the
AMBER force-field, and calculations were performed
using a distance-dependent macroscopic dielectric constant
of 4.0 and an infinite cut-off for non-bonded interactions
to partially compensate for the lack of solvent. The details
of model building and energy minimization are given in
Supplementary Data.
RESULTS
dCGGTGGT forms an octamer
The formation of a higher order assembly than a tetramer
by the DNA sequence dCGGTGGT was first noticed in
native PAGE experiments. Figure 1a shows PAGE
experiments on the following DNA sequences: TGGGG
T annealed in 0.1M potassium buffer (lane 1) used as a
tetramolecular quadruplex ([dTGGGGT]4) size-marker, C
TGTGTT (lane 2) used as a single-stranded 7-mer marker,
TGGTGGC (lanes 3 and 4), CGGTGGT (lanes 5 and 6)
and CGGGGT (lanes 7 and 8). The sequence TGGTGGC
migrates similarly to [dTGGGGT]4; whereas, the sequence
CGGTGGT shows a major band migrating much slower.
We conclude that TGGTGGC forms prevalently a tetra-
meric assembly, in agreement with the reported tetramer
G-quadruplex formation for this sequence (30), whereas C
GGTGGT forms a higher order assembly. The polarity of
the sequence therefore appears crucial in the higher order
structure formation. The migration profile of dCGGGGT
has also been investigated to determine whether the add-
itional central thymine played any role in the higher order
structure formation. Two bands are observed for dCGGG
GT, the faster one migrating as the tetrameric [dTGGGG
T]4, and the slower one migrating like the structure formed
by CGGTGGT.
As the PAGE results are similar in NH4
+ and in K+
cations, we therefore used ESI-MS, which can only be
carried out in NH4
+, to determine unambiguously the
strand stoichiometry of the higher order assemblies
formed by CGGTGGT and CGGGGT. The ESI-MS
spectra of TGGTGGC, CGGTGGT and CGGGGT,
each separately annealed at 6mM in 150mM NH4OAc
(pH=7.0) and diluted to 80 mM final strand concentra-
tion, are shown in Figure 1b–d, respectively. All three se-
quences show peaks corresponding to a tetramolecular
Figure 1. Stoichiometry of self-assemblies determined by (a) PAGE for sequences TGGGGT (lane 1), CTGTGTT (lane 2), TGGTGGC (lanes 3 and
4), CGGTGGT (lanes 5 and 6) and CGGGGT (lanes 7 and 8), and by (b–d) ESI-MS for TGGTGGC (b), CGGTGGT (c) and CGGGGT (d). In the
peak annotation Gn
z-, n indicates the number of strands and z indicates the charge.
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assembly (noted G4), but the spectra of CGGTGGT and
CGGGGT also display peaks corresponding to an octa-
meric assembly (noted G8). We therefore assign the slow
migrating PAGE band to an octameric self-assembly. In
terms of relative intensities, although native PAGE and
ESI-MS experiments were performed on samples obtained
by dilution of the same annealed stock solution, the
octamer is the darkest band in the gels of CGGTGGT
(lanes 5 and 6), whereas the ESI-MS peaks of the octamer
have lower intensities than the tetramer peaks. The
analysis of the electrospray response factors in the kinetics
ESI-MS experiments (see below and Supplementary
Figure S2) indeed reveals the octamer has a lower
ESI-MS response than the tetramer in the spectrometer
used, and that the octamer is indeed the major species in
solution.
The octamer contains stacked G-tetrads
All G-rich sequences studied here are expected to form
G-quadruplex structures. Note that ‘G-quadruplex’ means
that the structure contains stacked G-quartets, not neces-
sarily that the assembly is a tetramer. CD was used to
probe the relative orientation of the bases in the tetramer
[TGGTGGC]4 and in the octamer [CGGTGGT]8. The
overall CD profiles recorded in K+ (Figure 2a) and
NH4
+ (Figure 2b) are in agreement with the formation of
G-quadruplex structures (31,32) both in K+ and NH4
+
media, showing a positive maximum at about 260 nm
and a negative minimum close to 240 nm, which are char-
acteristics of head-to-tail arrangement of guanines, as
typically found in parallel oligodeoxynucleotides
G-quadruplexes (33–35). Interestingly, the CD spectra of
CGGTGGT also show a weak, but clearly visible negative
band centered at 290 nm. This minimum suggests that
additional base stacking interactions could be involved
in the formation of the higher ordered quadruplex species
by allowing the quadruplex multimerization via end-
to-end stacking. A typical heteropolar stacking in
G-quadruplexes formed by strands with no inverted
polarity usually results in a positive band at 290 nm (34),
but negative bands at 290 nm have been observed in
octameric self-assemblies of lipophilic guanosine deriva-
tives (36). The type of stacking present in our octamers
could therefore resemble that present in those lipophilic
octamers.
Figure 2. G-quadruplex formation probed by (a and b) CD in 100mM KCl (a) and 150mM NH4OAc (b) of the sequences CGGTGGT (solid line)
and TGGTGGC (dotted line), and by (c) counting the number of ammonium cations incorporated in the tetramer (noted G4) and the octamer
(noted G8) of CGGTGGT using high resolution ESI-FTICR mass spectrometry.
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Because the CD signature is peculiar and does not allow
to conclude unambiguously to a G-quadruplex structure,
we decided to probe cation incorporation into the octamer.
Indeed, successive G-quartets incorporate monovalent
cations (here K+ or NH4
+) by coordination between
eight guanines. High-resolution ESI-FTICRMS was used
to count the number of ammonium cations per tetramer
and per octamer (Figure 2c). Cation incorporation was
found in all cases, confirming G-quadruplex formation
both in the tetramer and the octamer. The major peaks
correspond to three cations per tetramer [dCGGTGGT]4
and eight cations per octamer [dCGGTGGT]8. The
number of cations is indicative of the number of stacked
quartets. Interestingly, the tetramer [dCGGTGGT]4
contains three ammonium cations, whereas the tetramer
[dTGGTGGC]4 contains four (data not shown), suggest-
ing a structural difference depending on the strand polar-
ity. However, the incorporation of eight ammonium
cations in the octamer suggests that within the octamer,
each tetrameric subunit is now capable of incorporating
four ammoniums cations.
Influence of sample preparation procedure
In all experiments described above, the octamer was
obtained by annealing the strand CGGTGGT at 6mM
single-strand ODN concentration at pH =7.0 in
100mM K+ or 150mM NH4
+. CD experiments carried
out using a higher K+ concentration (1M) show that
higher cation concentration further favors the formation
of the structure characterized by the negative band at
290 nm (Supplementary Figure S1). We also tested the
influence of the solution pH, to test whether cytosine
protonation might favor the formation of the new struc-
ture, but no clear influence of pH was found (see
Supplementary Figure S1 and NMR results described
below and in Supplementary Figure S4).
However, because of the octamer stoichiometry, we
anticipated that the strand concentration upon annealing
would have a great influence on the formation kinetics.
Figure 3a shows the CD spectra recorded on CGGTGG
T annealed at 6.0mM or 0.2mM ODN concentration in
1M K+. The presence of the negative band at 290 nm was
strictly dependent from ODN concentration: it is present
when the sample is annealed starting from the 6mM stock
solution, whereas it is not observed when the sample is
obtained by annealing the 0.2mM ODN (Figure 3a).
However, the CD spectrum of the species formed from
the 0.2mM ODN solution resembles that of a regular
tetramolecular G-quadruplex. The influence of the
strand concentration, therefore, indicates slow formation
kinetics for the octamer.
To study the kinetics of octamer formation in the 6mM
stock solution, and to probe the nature of the reaction
intermediates, we recorded ESI-MS spectra as a function
of the time after addition of cation in the ODN solution,
at room temperature. This experiment could be carried
out only in ammonium acetate (150mM). The details of
the methodology, representative ESI-MS spectra at
different reaction times, and the relative intensities are
presented in Supplementary Figure S2. Briefly, the
single-stranded dT6 strand (0.75mM) is added to the
6mM single-stranded dCGGTGGT in water.
Quadruplex formation is initiated by the addition of
ammonium acetate (final concentration: 150mM) at
room temperature. At each time point, an aliquot of the
sample is diluted to 80 mM final dCGGTGGT single-
strand concentration, and injected in the ESI-MS. We
therefore assume that, once formed, the octamer resists
the dilution step. The signal intensity of the reference is
used to normalize the intensity variations of the dCGGTG
GT monomer, tetramer and octamer signal, and deduce
their respective response factors (see Supplementary
Figure S2). Figure 3b shows the time evolution of the
relative proportions of single strand, tetramer and
octamer, after correction for the relative response of
each species, expressed as the fraction of single strand in
each form. The single strand is quickly converted into a
tetramer, but the tetramer-to-octamer conversion is
slower. The dimerization is therefore the rate-limiting
step in the octamer formation. The results also show that,
although the octamer is not the most abundant peak in the
mass spectra (see Figures 1b–d and 2c), it is nevertheless
the predominant species. The predominance of the
octamer at long time scales also confirms that, once
formed, the octamer resists the dilution step.
Figure 3. Influence of the sample preparation conditions on the
octamer formation. (a) Influence of strand concentration: CD spectra
of CGGTGGT in 1.0M K+ buffer annealed, respectively, at 6mM
(solid line) and 200 mM (dotted line) single-strand concentration. (b)
Kinetics of tetramer and octamer formation of 6mM CGGTGGT in
150mM ammonium acetate at room temperature, as determined by
time-resolved ESI-MS.
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NMR investigation of the octamer structure
The 1H NMR spectrum of CGGTGGT in 100mM K+
buffer at 25!C recorded 1 h after the annealing
(Supplementary Figure S3, bottom left) is characterized
by the presence of four well-resolved signals in the
11.0–11.6 ppm region attributable to the exchange-
protected imino protons involved in the formation of
Hoogsteen hydrogen bonds of four G-tetrads (37–39), in
close analogy with what was previously observed for the
parallel quadruplex structure formed by TGGTGGC (30).
Furthermore, the count of quadruplex NMR signals is
the same as what must be expected for the NMR
spectrum of the corresponding single strand, thus suggest-
ing the formation of a highly symmetric parallel
G-quadruplex possessing a 4-fold symmetry. However,
the aromatic region of 1H NMR spectrum is populated
by more than the expected seven signals belonging to the
H8/H6 aromatic protons of nucleobases. In order to dis-
criminate whether the minor peaks were due to sample
impurities or to the coexistence in solution of alternative
minor conformations of CGGTGGT, we recorded the 1H
NMR spectrum also at 65!C, and the high-temperature
spectrum was clearly in agreement with the second hy-
pothesis as evidenced by the presence of just seven well-
defined signals in the aromatic region of the spectrum. We
therefore studied the influence of time elapsed after the an-
nealing (Supplementary Figure S3), of K+ concentration
(Supplementary Figure S3), and of pH (Supplementary
Figure S4) on the 1D NMR spectra. In agreement with
the CD data, the NMR results confirmed that the best
medium for the structural study of the new octameric
structure formed by CGGTGGT requires 1.0M K+ and
long folding times (Figure 4a), and that the change of pH
from 7.0 to 4.5 does not affect the folding of the structure.
Figure 4. Study of the octamer structure by NMR. (a) 1H-NMR spectra recorded at 25!C of CGGTGGT in H2O/D2O 9:1, annealed at 6mM strand
concentration in 1M K+at pH=7.0. (b–g) Expansions of 2D NOESY spectrum of CGGTGGT (25!C, 200ms mixing time, 1M K+, pH=7.0). The
sequential H8-H6 and self-peaks involving H10 protons have been labeled in (b) and (c), respectively. (d) and (g) show NOE cross-peaks involving T4/
T7 methyl protons and H8/H6 or imino and amino protons, respectively. The T-tetrad diagnostic peaks between T4Me and T4NH and sequential
T4Me-G3NH, T4Me-G3NH2i and T4Me-G5NH are observable in panel (g). Imino–imino NOE correlations are shown in (e). The sequential imino–
imino NOE correlations have been drawn in (e). NOE correlations between aromatic H8/H6 and imino and amino protons are shown in (f).
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The combined analysis of 2D NOESY and TOCSY
spectra (700MHz, 25!C, 1M K+, 15 days after the anneal-
ing) allowed us to get the complete assignment (Table 1) of
both exchangeable and non-exchangeable protons of CG
GTGGT. The sequential connectivities between the aro-
matic protons (Figure 4b) were traced, as well as the self
and sequential NOE connectivities between H8/H6 base
protons and H10, H20, H200and H30 sugar protons. The
intensities of intranucleotide H8/H10 NOE cross-peaks
(Figure 4c) indicate that all Gs adopt an anti glycosidic
conformation. This finding together with the observation
for each G-tetrad of a GiH8/GjN1H NOE cross-peak
(Figure 4f), with i= j (where i and j represent the nucleotide
labels), and with the observation of sequential G2N1H/
G3N1H and G5N1H/G6N1H cross-peaks (Figure 4e),
definitely allowed us to identify the presence of 4-fold sym-
metric parallel quadruplex moieties in the higher ordered
structure formed by CGGTGGT when annealed in K+-
containing buffer. In close analogy with what observed by
Patel,P.K. and Hosur,R.V. for the quadruplex structure
formed by TGGTGGC (30), we observed the formation
of a central T-tetrad as ascertained by the appearance of
the diagnostic T4NH/T4Me NOE cross-peak (Figure 4g)
and supported by the observation of the strong shield-
ing ring current experienced by T4 methyl protons that
are significantly upfield-shifted when compared to the
corresponding signals of the ‘free’ T7 (0.72 versus
1.64 ppm).
Although the overall observed NOEs account for a
‘classical’ tetramolecular parallel quadruplex, two peculiar
NOE evidences drove us toward the disclosure of the
higher ordered octamer structure. In Supplementary
Figure S5, we show the 1D cross-section of the NOESY
spectrum (200ms mixing time) of CGGTGGT taken at
5.66 ppm (C1H10 protons). This figure shows that the
NOE between C1H10 and C1H5 has almost the same in-
tensity than that between C1H10 and C1H6. These NOEs
are in turn stronger than the sequential NOE C1H10-
G2H8, but weaker, as expected, than those between
C1H10 and self H20/H200. The relative intensities of the
aforementioned NOEs involving C1H10 require that
the C1H10-C1H5 distance is in the same range of
the intranucleotide C1H10-C1H6 distance (2.31–3.74 A˚ de-
pending on the glycosyl torsion angle). This experimental
distance is compatible only with the occurrence of an inter-
molecular dipolar coupling between C1 bases, because
the corresponding intranucleotide C1H10-C1H5 distance
would be in the range 4.64–5.49 A˚. This finding, together
with the observation of the very weak sequential NOE
between C1H6 and G2H8 (marked with the arrow in
Figure 4b), disclosed that, in the octamer, each C1 base
does not stack over the flanking G2 tetrad, as one may
expect, but projects outside the quadruplex scaffold in
such a way to allow dipolar couplings with one of the
four C1 bases belonging to the other tetramer. This
unusual arrangement might be favored by the formation
of additional C1NH2–G2N3 and G2NH2–C1N3
hydrogen bonds, thus allowing the formation of an un-
usual G2(:C1):G2(:C1):G2(:C1):G2(:C1) octad (Figure 5a)
in each of the two tetrameric quadruplexes (1Q).
DISCUSSION
The structure adopted by the sequence dCGGTGGT must
account for the following observations. It is a highly sym-
metrical octamer, formed from two parallel-stranded tetra-
mers. In the octamer, each tetramer contains a central
T-tetrad and the G-tetrads are stacked in head-to-tail ar-
rangement. However, at the octamer’s interface between
the two tetramers, the stacking of the G-tetrads is likely to
be different, as determined from CD.
Interlocked structures like that formed by the (dGCGG
TGGT)4 tetramer (40) were initially taken in consider-
ation to build an octamer model, but were discarded due
to NMR inconsistencies and symmetry-related consider-
ations. Unresponsiveness to pH changes also led us to
discard structures involving protonated cytosines. The
NOEs involving C1H10 point to the formation of a
G2(:C1):G2(:C1):G2(:C1):G2(:C1) octad (Figure 5a) in
each of the two tetrameric quadruplexes. The formation
of the planar octad system would allow for further p–p
stacking between C1 bases, thus adding more ‘hydropho-
bic glue’ between the two G-quadruplex tetramers that
form the octamer.
Figure 5b shows the energy minimized model of the
octamer formed by stacking of two tetramers, each con-
taining a 50- G(:C):G(:C):G(:C):G(:C) octad. The details
of molecular modeling are given in Supplementary
Figure S6, and additional ribbon and space-filled views
of the model are shown in Supplementary Figure S6.
The overall topology of each tetramer is largely similar
to that of the tetramolecular quadruplex formed by TG
GTGGC (see Figure 8 in reference 30), with the central
T-tetrad causing a small decrease in the intertwining of the
helices. Space filling views (Supplementary Figure S6) also
evidence that the octamer structure is very compact, re-
gardless the presence of two stacked octads. These are seen
to determine only a slight increase in the thickness of the
octamer at the dimerization interface.
Figure 5c–d also shows the head-to-head stacking be-
tween the two octads (c) and the stacking between tetrads
G2-G3 (d). The stacking between tetrads G3-T4 and T4-G5
steps is shown in Supplementary Figure S7. Although
C1 and G2 bases involved in the stacked octads appear
slightly rotated with respect to the tetrad plane, Figure 5c
shows good stacking between the six-membered rings of
G2 bases and between the stacked C1 bases. The electric
Table 1. Proton chemical shifta (ppm) for 2Q at 25!C, pH7.0, 1M
K+
H6/H8 H5/CH3 NH NH2i
b H1’ H2’ H2’’ H3’ H4’ H5’/H5’’
C1 7.54 5.48 5.63 2.28 2.10 4.66 4.13 3.87–3.95
G2 8.14 11.56 9.82 6.09 2.72 2.96 5.10 4.49 4.18
G3 7.56 11.13 9.80 6.12 2.55 2.94 5.07 4.50 4.30
T4 7.03 0.72 9.40 5.84 2.24 2.46 4.92 4.34 4.25
G5 8.00 11.26 9.82 5.98 2.72 2.84 5.10 4.49 4.20–4.30
G6 7.73 11.05 9.81 6.27 2.58 2.71 4.98 4.52 4.11–4.25
T7 7.34 1.64 6.08 2.73 2.21 4.51 4.08 4.25
aRelative to H2O at 4.78 ppm.
bNH2i refers to the internal (i) H-bonded amino protons of guanosines.
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transition moments corresponding to the guanine absorp-
tion band at approximately 250 nm are indicated in
Figure 5c and d. The stacking interactions in the model
allow to explain the CD data: G2-G3 stacking resembles
the standard head-to-tail stacking encountered in parallel-
stranded G-quadruplexes. However, the octad stacking
gives rise to a heteropolar stacking that is distinct from
those typically encountered in antiparallel
G-quadruplexes. We, therefore, interpret the negative
CD band at 290 nm as being due to the octad stacking
shown in Figure 5c (36). Interestingly, a similar weak
negative CD band at 290 nm was also observed, but not
discussed, by Mastugami et al. (41) in the dimer formed by
d(GGAGGAGGAGGA), which contains stacked G(:A):
G(:A):G(:A):G heptads at the dimerization interface.
Our results therefore suggest that, like adenine, cytosine
is also capable of inducing the formation of higher order
structures by the formation of octads. One must note,
however, that the formation of the octamer by the
sequence dCGGTGGT is slow. ESI-MS kinetics experi-
ments in ammonium acetate provide some insight into
the mechanism of octamer formation. The first step is
the formation of a tetramer that incorporates only three
ammonium ions. This means either that the tetramer of
[dCGGTGGT]4 has either a central or a terminal tetrad
disrupted, or that the tetramer contain slipped strands and
hence incomplete tetrad formation (42). The rate-limiting
step is the conversion of tetramer to octamer, and in con-
trast with the tetramer, the octamer incorporates four
cations per tetrameric subunit. We therefore conclude
Figure 5. Structural model for the (dCGGTGGT)8 octamer. (a) Proposed structure of the G2(:C1):G2(:C1):G2(:C1):G2(:C1) octad. (b) Molecular
model of the octamer: a different color was used for each ODN strand, and potassium ions appear as red crosses. (c) Detail of stacking of the octads.
(d) Detail of stacking of G2–G3 tetrads. The transition moments of guanosines corresponding to the absorption band at approximately 250 nm are
shown as colored bars in (c) and (d).
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that the rate-limiting step is the rearrangement of the
tetramer into a fully aligned parallel structure that is amen-
able to octad formation and stacking thereof. Further ex-
periments with various sequences are underway to probe
the effect of the central T-tetrad on stability and rate of
formation of octamers.
CONCLUSIONS
In summary, the present study demonstrates that the for-
mation of a quadruplex dimer (2Q) can occur when the
50-cytosine-ending CGGTGGT DNA sequence, but not
the inverted TGGTGGC sequence, is annealed in the
presence of K+ or NH4
+ ions. The NMR and molecular
modeling data disclosed that the formation of 2Q is
allowed by the formation of an unusual octad arrange-
ment, in each of the two 1Q units, involving C1 and G2
bases of each CGGTGGT strand. Up to now, dimeriza-
tion of G-quadruplexes had only be reported via guanine–
adenine heptads (41), and recently via a shared uracil
tetrad (43). Our finding of G-quadruplex dimerization
with 50-cytosine containing strands adds further possibili-
ties for the design of novel quadruplex-based DNA func-
tional nanostructures, and further complexity to the
mechanisms of folding and assembly of G-rich sequences.
It is particularly important for in vitro studies of artifi-
cially designed (e.g. aptamers) or biologically relevant
sequences.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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Mutations in the cytochrome p450 (CYP)21A2 gene, which encodes
the enzyme steroid 21-hydroxylase, cause the majority of cases in
congenital adrenal hyperplasia, an autosomal recessive disorder. To
date, more than 100 CYP21A2mutations have been reported. These
mutations can be associated either with severe salt-wasting or sim-
ple virilizing phenotypes or with milder nonclassical phenotypes.
Not all CYP21A2 mutations have, however, been characterized bio-
chemically, and the clinical consequences of these mutations remain
unknown. Using the crystal structure of its bovine homolog as
a template, we have constructed a humanized model of CYP21A2
to provide comprehensive structural explanations for the clinical
manifestations caused by each of the known disease-causing mis-
sense mutations in CYP21A2. Mutations that affect membrane an-
choring, disrupt heme and/or substrate binding, or impair stability
of CYP21A2 cause complete loss of function and salt-wasting dis-
ease. In contrast, mutations altering the transmembrane region or
conserved hydrophobic patches cause up to a 98% reduction in en-
zyme activity and simple virilizing disease. Mild nonclassical disease
can result from interference in oxidoreductase interactions, salt-
bridge and hydrogen-bonding networks, and nonconserved hydro-
phobic clusters. A simple in silico evaluation of previously uncharac-
terized gene mutations could, thus, potentially help predict the
often diverse phenotypes of a monogenic disorder.
structure–phenotype correlation | molecular modeling |
CYP21A2 structural analysis
Congenital adrenal hyperplasia (CAH) is an autosomal re-cessive disorder, with an overall incidence of 1:15,000 live
births worldwide (1). Up to 95% of cases arise from mutations in
the cytochrome p450 (CYP) 21A2 (CYP21A2) gene, which enc-
odes the enzyme steroid 21-hydroxylase. Classical CAH is char-
acterized by a complete or near-complete loss of enzyme activity,
which leads to salt-wasting (SW) or simple virilizing (SV) CAH.
SW CAH patients display impaired cortisol synthesis, signs of
hyperandrogenemia, and features of aldosterone deﬁciency. In
contrast, in SV CAH, patients have sufﬁcient aldosterone to
maintain sodium homeostasis. However, because of the shunting
of cortisol precursors through the adrenal androgen biosynthetic
pathway resulting in the formation of testosterone and dihy-
drotestosterone, patients display signs of hyperandrogenemia
with impaired fertility. Female newborns in both SW and SV
forms of CAH have ambiguous genitalia.
Nonclassical (NC) CAH is observed in 1 in 100 subjects in
a heterogeneous population, for example, in New York City,
with patients generally displaying a mild and variable phenotype
because of a ∼20–60% retention of 21-hydroxylase activity.
Ethnic-speciﬁc frequency indicates that among Eastern Euro-
pean Jews, 1 in 27 subjects have NC CAH, making it the most
frequent autosomal disorder in humans. The newborn females
do not have ambiguous genitalia, whereas females postnatally
often exhibit hirsutism, oligomenorrhea, and impaired fertility.
In males, hyperandrogenism is difﬁcult to detect and often only
comes to attention in adulthood owing to short stature and im-
paired fertility (2).
CYP21 genes are a part of the RP-C4-CYP21-TNX module
and are located within the major histocompatibility complex on
chromosome 6 (3). CYP21A2 is present 30 kb downstream of its
nonfunctional pseudogene CYP21A1. Importantly, however, the
two genes share 98% nucleotide homology in the exonic regions
and 96% nucleotide homology in the intronic regions (3). Com-
mon CYP21A2 mutations arise from gene recombination with
CYP21A1, gross gene deletions, and point mutations (4). How-
ever, about 5% of CAH patients do not harbor mutations arising
from recombination. From our own work over the past three
decades, and from the work of others, over 100 CYP21A2 muta-
tions have been cataloged. In most cases, genotypes and pheno-
types are correlated (5). However, in rare instances, genotype–
phenotype discordance has been reported (6).
We present data demonstrating that a molecular characteriza-
tion of CYP21A2 mutations can be used to predict clinical phe-
notype and disease severity based upon changes it brings in the
structure of the enzyme, steroid 21 hydroxylase. Previously, mo-
lecular models of the human CYP21A2 protein structure have
been constructed using bacterial CYP102A1 (7) and rabbit
CYP2C5 (8) as templates. Structural analyses of CYP21A2
mutants have been performed using these two templates (9–15).
Other templates, such as the human CYP2C8, were also used as
homology models of CYP21A2 (16).
Recently, the bovine CYP21A2 crystal structure has become
available (17). We have, thus, constructed a humanized model of
CYP21A2 and mapped disease-causing mutations to investigate
the structural role of all known mutations in CYP21A2. Here, we
provide full structural explanations for clinical manifestations
observed in patients of CAH with varied mutations. We also
highlight structural criteria that might allow the prediction of
clinical severity through such in silico modeling.
Results
Humanized Model of CYP21A2. Bovine and the human sequences
share 79% sequence identity. The human model of CYP21A2
was constructed by aligning bovine and human sequences and
extracting structural features from the bovine template (17). An
alignment of six cytochrome P450 proteins involved in steroid
biosynthesis was also carried out to identify conserved structural
elements (Fig. S1).
The derived human CYP21A2 model exhibits the character-
istic triangular prism shape, containing 16 helices and 9 β-sheets
(Fig. S2). All conserved structural motifs and elements are ca-
nonical to steroid-synthesizing cytochrome P450 proteins. A single
heme prosthetic molecule is positioned centrally and is sur-
rounded by B0-C loop, I-helix, K-K0 region, and a Cys-pocket. The
structural elements that enclose heme in a closed binding cavity
are the most conserved. There are 23 amino acid residues that lie
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within 3.5 Å and additional 12 residues that lie within 5 Å of the
heme moiety (Fig. S3).
Similar to the bovine CYP21A2 crystal structure, our model
suggests that 17-hydroxyprogesterone (17OHP) can bind to the
human structure on two well-deﬁned regions. The proximal sub-
strate-binding site lies in front of the I-helix and is located over the
heme-binding region. Residues V100, S108, L109, V197, L198,
W201, I230, R233, V286, D287, G291, T295, V359, L363, S468,
and V469 lie within 5 Å of the proximal substrate-binding cavity;
17OHP docks at an angle of ∼45° to the plane of heme. The
substrate is oriented in a way that the C-21 lies just over the heme
iron at a distance of 4.5 Å. The distance between C-17 and the
center of heme is 5.2 Å. In contrast, in the distal substrate-binding
site is 14.6 Å from the heme molecule, and the ligand binds near
the gate of its entrance channel. The substrate cavity of this site has
residues L39, L63, G64, L65, Q66, V68, P94, Q207, D210, V211,
L361, A362, P364, V383, I385, V440, and C467 lying within 5 Å.
Mutations Causing SW CAH. CYP21A2 mutations, including frame-
shift mutations, which cause abrupt truncations of the protein and
severely impair enzymatic function, cause SW CAH (Table S1).
Here, we focus on missense point mutations that cause SW by
several mechanisms (Table S1).
Altered membrane anchoring. CYP21A2 is anchored to the endo-
plasmic reticular membrane by the ﬁrst 25 residues through
a helix (Fig S2C). Mutations that disrupt this anchoring will result
in SWCAH. Importantly, changes to the start codon, for example
M1 to I/V/L, are not tolerated. SW disease is also a feature of the
P30Emutation. In this case, the close contact (2.4 Å) between the
carbon of P30 in the N-terminal loop and the side chain of Y376
within the β5-β6 hairpin loop is critical for protein folding (18).
P30E disrupts this interaction, leading to structural instability. A
distinct mechanism is in play when G56 is mutated to Arg. No-
tably, G56 lies on the loop between the A-helix and β1-sheet and
is preceded by F55, which interacts with the membrane. Together
with P57, G56 forms the hinge between the membrane interacting
N terminus and rest of the protein. The substitution of G56 with
a polar and rigid Arg residue disrupts the hinge affecting the
interactions of CYP21A2 with the membrane.
Disruption of heme and/or substrate binding. Mutations that disrupt
the binding of heme, which is the cofactor of CYP21A2, cause
SW CAH. Residues R91 and R426 form hydrogen bonds with
the propionate chains of the heme moiety; this not only orients
the heme in the protein but is also involved in the electron
transfer (19). Replacement of R426 with a hydrophobic residue,
as in the R426C mutation, disrupts this interaction rendering
the protein nonfunctional and causing SW CAH (Fig. 1A). The
propionate chain of heme also interacts with residue R91, which
is adjacent to G90 located in B-B0 loop. A mutation of G90 to
valine will affect the ability of R91 to hydrogen bond with heme,
causing SW CAH (Fig. 1A). The presence of glycine at this po-
sition introduces ﬂexibility to the loop, allowing R90 to position
and interact with heme. In contrast, the mutation of a hydro-
phobic leucine residue to a polar arginine residue in L107 and
L353, both of which interact directly with heme, is not tolerated
and will cause SW CAH (Fig. 1A).
Highly conserved residues in close proximity to the heme- and/
or the proximal substrate-binding sites, such as T295 involved in
proton transfer (20), when mutated will lead to SW CAH. An-
other residue A362, also in proximity to heme and the distal
substrate-binding sites, when mutated to valine, causes SW CAH
(Fig. 1A). This results from steric clashes with heme attributable
to its slightly bulkier side chain, which abrogates enzyme activity.
Another residue H365 is located within 3.5 Å of heme and
makes hydrogen bonds with its propionate carboxylate group (Fig.
1A). Disruption of this hydrogen bonding in the H365Y mutation
leads to SW. On the proximal side of heme, lying adjacent to the
K-helix is residue R356. Separated by a distance of 3.5 Å, it forms
a hydrogen bond with Q389; this interaction maintains spatial
conﬁguration and tertiary structure of the CYP21A2 enzyme.
When R356 is mutated to a proline, these interactions are dis-
rupted, and additional steric clashes with neighboring residues,
render the enzyme inactive causing SW CAH.
CYP21A2 mutations that speciﬁcally disrupt one of the two
substrate-binding regions invariably cause SW CAH. Lining the
proximal substrate-binding site are the conserved residues G291
and G292, which provide ﬂexibility to the I-helix and facilitate
kinking and swiveling (21). Their mutation into bulkier residues,
namely G291S/C/R and G292D, causes clashes within this pocket,
Fig. 1. Structural determinants of CYP21A2 muta-
tions causing salt-wasting CAH. (A) Residues that are
within 3.5 Å of heme- or substrate-binding site, when
mutated result in SW CAH. R91, R426, and H365 form
hydrogen bonds with the propionate chain of heme
and, thus, prevent misalignment in an enclosed envi-
ronment. (B) Mutations of residues that result in dis-
ruption of the tertiary structure results in SW CAH.
(Ba) V139E mutation is not tolerated in a small hy-
drophobic pocket. (Bb) Disruption of the pi-pi stacking
interactions destabilizes the structural elements. (Bc)
A bulkier leucine side chain is not accepted for P386.
(Bd) Q481P results in the extensive loss of hydrogen-
bonding networks. (C) Mutation of residues forming
salt-bridge interactions and hydrogen-bonding net-
works that enable maintenance of tertiary structural
elements when mutated result in SW CAH. Salt-bridge
interactions between R316-D407 (Ca), R366-D111 (Cb),
R444-E140 (Cc), and hydrogen bonding between
the highly conserved Glu-Xaa-Xaa-Arg (EXXR) motif
formed by E351-R354-R408 (Cd) are shown.
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causing SWCAH. Similarly, the gate of the distal substrate-binding
site is ﬂanked by G64, which, when mutated to a glutamate with
a longer side chain, prevents substrate entry causing SW CAH.
Impairment of structural stability. The loss of hydrophobic inter-
actions of CYP21A2 impairs protein stability and the organiza-
tion of its secondary structures, resulting in an inactive enzyme
and SW CAH. Because residue Y59 is located in a hydrophobic
pocket formed by residues from the A-helix and the β1- and β2-
sheets, its mutation to asparagine disrupts the hydrophobicity of
this region resulting in loss of function (Fig. 1B). Hydrophobicity
is also disrupted when V139, a D-helix conserved residue, upon
its mutation to glutamate, fails to interact with residues V440
and L436 on the L-helix. Furthermore, charge repulsions be-
tween the side chain of mutated V139E and E437 of the E-helix
render the protein unstable and inactive causing SW CAH (Fig.
1B). Similarly, residue P386, located in a very hydrophobic
pocket on the β7-sheet, when mutated to the polar and bulkier
residue arginine, will cause the disruption of hydrophobicity and
protein instability. Disruption of pi-pi stacking among the inter-
acting residues W302, F306, and F404 by their mutation into
nonaromatic residues, such as in W302R/S and F404S, prevents
stable packing interactions (Fig. 1B), resulting in SW CAH.
Protein inactivation can also occur when conformational
ﬂexibility is impaired, mostly because of the introduction of
bulkier residues. For example, the sharp fold between the E-
and F-helices, where G178 is located, can only accommodate the
smallest residue. Even the mutation of glycine to alanine will
hinder the ﬂexibility of this fold. Similarly, G375 is present on
the turn of β5-β6 hairpin. Its mutation to a more rigid residue,
serine, will likewise impair ﬂexibility of the fold, rendering the
protein unstable. The mutation T450P likewise reduces ﬂexi-
bility of β8-sheet, which helps stabilize the very long C-terminal
loop. Structural elements in CYP21A2 are also maintained in
position by a set of hydrogen bonds between the C-terminal
residue Q481, Q318 (J-helix), and backbone carbonyl oxygens of
L446 and Q447 (L-helix). When Q481 is mutated to proline, de-
stabilization of the structure renders the protein inactive (Fig. 1B).
Other substitutions where leucine is mutated to proline, such as
in L142P (D-helix), L166P (E-helix), L167P (E-helix), L261P (H-
helix), and L446P (L-helix), also cause helical disruption and de-
stabilization of secondary structures. This is because the respective
leucine residues are positioned in the middle of the helices.
Finally, the mutation of residues that form salt-bridge inter-
actions and assist in maintaining tertiary structural elements of
CYP21A2 also lead to SW CAH (Fig. 1C and Table S2). R366
(β4-sheet) forms a salt bridge with D111 (B0-C loop), and its
mutation to cysteine will disrupt this salt-bridge interaction,
causing protein inactivation (Fig. 1C). In contrast, R354 hydro-
gen bonds with the side chains of E351 and R408 (E-R-R triad)
and with the backbone atoms of P401 and W405 (K0-L loop).
Mutation of R354 will, therefore, disrupt a network of hydrogen
bond interactions and destabilize the protein (Fig. 1C). R408C/L
mutations would likewise destabilize structural elements because
of the extensive loss of hydrogen bonds.
Mutations Causing SV CAH. SV CAH is observed in 25% of clas-
sical CAH cases and can be mapped to two sets of structural
aberrations that cause up to a 98% reduction of CYP21A2 ac-
tivity: alterations in the transmembrane region and changes to
conserved hydrophobic patches.
The membrane anchoring helix must enter the hydrophobic
endoplasmic reticular membrane to allow for CYP21A2 to be
active. Mutation of a semiconserved helix residue, A15, to a polar
threonine prevents optimal anchoring, thus resulting in a gross
reduction but not abrogation of enzyme activity and causing SV
CAH (compare with SW CAH, above). Proximal to the anchor-
ing helix, is residue H38, which lies in the loop between the N
terminus and the A-helix and hydrogen bonds with Y47. When
mutated to a nonpolar leucine, hydrogen bonds are disrupted
resulting in SV CAH.
Hydrophobic patches regulate inter- and intraprotein inter-
actions (22), and their disruption in several mutations causes
a near loss of enzyme activity and SV CAH. First, the highly
conserved residue I77 sits in a hydrophobic pocket formed with
residues from L71 (β2-sheets), M81 (B-helix), A391 (β4-sheet–
K0-helix), L388 (K0-helix), L419 and C423 (loop between K0-L
helices). Its replacement by a polar residue, such as threonine,
disrupts the hydrophobic environment (Fig. 2A). Second, the
conserved residue C169 makes hydrophobic interactions with the
loop between E-F helices and F-helix. Its mutation to arginine
alters the region’s hydrophobicity. Third, the mutation of I172,
which forms a hydrophobic pocket with M186 and M187 residues
of F-helix, to asparagine causes a loss of the hydrophobic pocket.
Fourth, hydrophobicity is also lost when interactions between
V281, present on the I-helix, and the H-helix are disrupted in the
V281G mutation. The helix is also rendered unstable due to the
high conformational ﬂexibility imparted by glycine. Finally, L363
and A434 lie very close to heme and contribute to the hydro-
phobic environment of the heme-binding site (compare with SW
CAH). Although mutations L363W and A434V conserve this
hydrophobicity, they cause steric clashes with the heme because
Fig. 2. Structural determinants of CYP21A2 mutations causing SV and NC
CAH. (A) I77 and I317, which are surrounded by hydrophobic residues.
Mutations of I77 or I317 (cyan sticks) result in disruption of hydrophobicity.
Whereas mutation I77T results in SV CAH, L317M/V causes NC CAH (because
valine and methionine are both hydrophobic residues that can be tolerated
at this position). (B) Positively charged resides that have been implicated in
the binding of oxidoreductase. Mutation of these residues causes NC CAH.
All of these residues are present on the same face of CYP21A2. (C) Disrup-
tion of salt-bridge and hydrogen bonding interactions that result in localized
destabilization of structure causes NC CAH. Salt-bridge interactions between
R149-E162 (Ca), R479-E163 (Cb), R136-D407 (Cc), R435-E431 (Cd), R483-D322
(Ce), and hydrogen-bonding network between G35-H62 and G67 (Cf).
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of replacement by a bulkier residue. Thus, a near-complete rather
than a complete loss of enzyme activity ensues.
Other mutations that alter the charge on and/or the size of
individual residues can result in steric clashes and conformational
instability within certain parts of the CYP21A2 molecule. These
relatively localized alterations can cause grossly reduced enzyme
activity and SV CAH. For example, E320 is a highly conserved
residue on a negatively charged Glu-Glu-Leu-Asp (EELD) motif
(22, 23). In the E320K mutation, a change from acidic to basic
residue alters the charge on the motif. Likewise, replacement of
R408 with histidine, when the latter is not protonated, prevents
normal hydrogen bonding with E351 and R354. Another residue
P432 lies adjacent to the loop that contains invariant C428, which
binds heme and P432 to optimally position the loop. Its mutation
to leucine makes the structure more ﬂexible and prevents cysteine
from being presented to heme. In contrast, the mutation of G424
to serine imparts rigidity to the loop between K0- and L-helix.
Examples of steric hindrance include the L300F and L308F
mutations. Both residues are present in a very constricted space
on I-helix, so that their mutation to a bulky phenylalanine causes
localized destabilization of secondary structure. Finally, P463
mutation to leucine interferes with the conformation of the β8-β9
loop with the subsequent closure of substrate entrance channel.
Mutations Causing Nonclassical CAH. The following mutation-in-
duced aberrations in protein structure signiﬁcantly reduce
CYP21A2 activity (2).
Oxidoreductase Interactions. The oxidation of steroidogenic sub-
strates by CYP21A2 requires delivery of two electrons from P450
oxidoreductase (POR). Both charged and hydrophobic residues
on the proximal surface of cytochrome P450 are involved in in-
teraction with POR (24). The basic residues on the surface of
CYP21A2, namely K121, R132, R341, R339, and R369, are
known to interact with the acidic residues on POR (8, 17). All of
these positively charged residues are also aligned to one face of
the protein (Fig. 2B). When these residues are mutated (K121Q,
R132C, R339H, R341W/P, and R369Q), the positively charged
side chain of the interacting residue is lost. The strength of in-
teraction with POR is affected, which results in mild, NC CAH.
Salt-bridge and hydrogen-bonding networks. CYP21A2 has many hy-
drogen bonds and salt bridges that stabilize the overall tertiary
structure of the protein. Mutations of nonconserved residues
participating in these interactions mainly cause NC CAH (Fig.
2C). For example, H62 hydrogen bonds with the backbone of
G35 (adjacent to the N-terminal loop) and side chain of G67 (β2-
sheet). Substitution of histidine by hydrophobic leucine (H62L)
may disrupt hydrogen bonding to reduce, but not eliminate, en-
zyme activity. Likewise, R149C, D407N, E431K, R435C, D322G,
R479L, and R483Q/P mutations correspond to changes in resi-
dues that contribute in salt-bridge formation, including R149 (D-
helix)–E162 (E-helix), R316 (J-helix)–D407 (K0-helix), E431 (L-
helix)–R435 (L-helix), R479 (β9)–E163 (E-helix), and R483 (C-
terminal)–D322 (J-helix). When these residues are mutated, salt-
bridge formation will be prevented resulting in a localized, as
opposed to global, destabilization of tertiary structure (Table S2).
Additionally, the introduction of a bulkier side chain than the
native residue causes NC CAH. Thus, the mutations H119R,
R124H, T168N, I194N, I230T, V249A, A265V, S301Y, A265C,
V304M, and N387K show side-chain steric clashes with the
neighboring residues.
Nonconserved hydrophobic clusters. The introduction of a single
polar residue in a hydrophobic cluster will obliterate its hydro-
phobicity and destabilize the local environment. For example,
I171 is located in a hydrophobic region, and its mutation to as-
paragine will disrupt the hydrophobic cluster. Similarly, P459 sits
in a hydrophobic pocket, surrounded by V305 and L308 (I-helix),
L458 (β8-β9 loop), and M473 and P475 (β8-β9 loop). P453 is
likewise positioned in a hydrophobic pocket surrounded by L308
(I-Helix), L452 (β8-sheet), L458 (β8-β9 loop). Furthermore,
A391 sits in a hydrophobic pocket, surrounded by L388, L419,
and I77. Mutations A391T, P453S, and P459H will all disrupt
hydrophobicity of their respective regions. In contrast, L317 is
present in a region with tight packing in a hydrophobic pocket
surrounded by a leucine cluster formed by L307 (I-helix); I313
(J-helix); L321 (loop between J-K helices); and L344, L345,
L442, and L446 (K-helix). Its mutation to a methionine or valine
disrupts the optimal packing of side chains but does not alter the
hydrophobic environment.
Other mild mutations. Certain mutations result in mild disease,
because the mutated residues are either reasonably well tolerated
or the disrupted interactions are compensated by other residues.
These mutations, therefore, variably reduce, but do not grossly
lower or eliminate, enzyme activity. For example, P30 is present
near the transmembrane region and, along with P31 and P34,
forms the hinge to orient protein away from membrane. Its
mutation to leucine, a hydrophobic residue, is tolerated and only
somewhat reduces enzyme activity. Residue V281 is present on
the I-helix in a very constricted space. When mutated to leucine,
the increase in chain length results in steric clashes that are rel-
atively modest and, thus, cause mild NC CAH. Although the
mutation Y47C disables hydrogen bonding with H38, the in-
teraction is compensated by a weak His-Cys interaction, similar
to that observed in glutamine amidotransferases (25). Mutation
R224W is mild because tryptophan can still interact with the
phosphate head group through its nitrogen atom (26). Although
another mutation R233G/K may prevent R233 from binding to
the 3-keto oxygen of the proximal 17OHP in the proper orien-
tation, it does not inﬂuence protein activity signiﬁcantly, resulting
in minimal phenotype.
Structural Implications of Previously Uncharacterized Mutations.
In Fig. 3, we document structural aberrations in previously
uncharacterized mutations on the basis of changes that each
mutation brings to the humanized model of CYP21A2. The
classiﬁcation of these mutations is based on an exhaustive se-
quence and structural analysis of all CAH-causing mutations.
Discussion
Although newborn screening for CAH is becoming used in-
creasingly, difﬁculties regarding prediction of clinical phenotype
remain (1). We have used computational modeling to perform
an exhaustive sequence–structure–clinical outcome analysis of
known and previously unreported missense CYP21A2 mutations
as they relate to the phenotype and severity of CAH. We show
that this in silico approach can predict the extent of loss of
function of the steroidogenic CYP21A2 enzyme. With certain
mutations, varying degrees of loss of function have been con-
ﬁrmed biochemically by overexpressing the mutated enzyme in
vitro (27–32), whereas, in other cases, the extent to which the
enzyme is disrupted remains unknown.
We ﬁnd that enzyme activity is completely lost in silico,
resulting in SW CAH when mutations alter the heme-binding or
substrate-binding pocket, disrupt membrane anchoring of the
enzyme, or cause gross structural instability by interfering with
protein scaffolding. This accounts for ∼35% of residues around
the heme- and ligand-binding sites. However, mutations that
occur near the transmembrane domain or in conserved hydro-
phobic patches other than the heme- and substrate-binding region
result in a near-complete loss of enzyme activity, with less severe,
SV disease. In contrast, mutations disrupting nonconserved hy-
drophobic clusters, salt-bridge interactions, hydrogen bonding, or
oxidoreductase interactions or those that are tolerated sterically
or compensated by other residues, produce milder, NC disease.
Of these, eight are present on the surface, whereas the rest lie
within the core of the protein. We, thus, infer that there is overall
concordance between the extent and type of structural disruption
of CYP21A2 and the clinical phenotype and severity of CAH.
There are, however, several exceptions to this concordance.
First, single-point mutations to polar or nonpolar residues can
show distinct clinical presentations. For example, R356 (K-helix)
is located near the heme-binding site and interacts with Q389
(K0-helix) and Q462 (β8-β9) to maintain secondary structural
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elements. Its mutation to hydrophobic tyrosine or proline leads
to SW CAH, because hydrogen bonding is completely lost.
However, when R356 mutates to glutamine, partial hydrogen
bonding may still be preserved, so that the R356Q mutation
exhibits SV CAH. Similarly R408C/L mutation causes SW CAH,
whereas R408H leads to SV CAH. Likewise, because R408
makes extensive hydrogen-bonding network with E351 and R354
(E-R-R triad), different substitutions may yield distinct clinical
phenotypes.
Second, although the analysis presented in this study is based
on individual point mutations, compound mutations may pro-
duce severe SW disease, even if the individual mutation is rela-
tively mild. For example, the three mutations I236N, V237E, and
M239K in CYP21A2 gene, which arise from homologous re-
combination between the CYP21A1 pseudogene and CYP21A2,
occur as a cluster in the same patient. When individually mutated
to asparagine, I236 does not signiﬁcantly disrupt structure.
Similarly, although the M239K mutation causes charge repul-
sions between K239 and H235 side chains, it does not disrupt the
structure signiﬁcantly. However, the V237E is highly disruptive:
it modiﬁes the hydrophobic region and alters conformation of
the substrate-binding site, resulting in loss of function of the
enzyme. Thus, compound mutations of these residues, namely
I236N, V237E, and M239K, cause SW CAH.
Finally, because CAH is a recessive disorder, phenotype can
vary between homozygous and heterozygous mutations. L166 is
present in the middle of the E-helix. Similarly to L167P mutation,
L166P can lead to SW, because proline in the middle of the helix
destabilizes the structure. However, L166P has been observed as
NC CAH in a patient with V281L mutation on the other allele.
The clinical outcome in this casemay be attributable to the V281L
mutation, which is, in itself, reported to exhibit NC CAH phe-
notype. Thus, although our analysis predicts the severity of a given
mutation in CAH, variations can be observed when compound
and heterozygous mutations are under consideration.
Even with the above caveats, the results of our analysis of 113
missense mutations in terms of changes they bring to the struc-
ture of CYP21A2 is compatible with our observations in clinical
practice. Indeed, many of the phenotypes of the mutation have
been well ascertained by experienced clinicians.
Fig. 3. Previously unreported CYP21A2 mutations.
Previously unreported missense mutations, namely
S113Y/F, V305D, F306V, L307V, R316L, L321P, E351K,
R366H, G381S, P386L, F404L, R408H, R426P, L433P, and
R444P are shown. The location of the mutated residue
and the impact each mutation has on protein structure
and the predicted clinical outcomes are shown.
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Monogenic disorders, such as CAH, Gaucher, and many
others, are often characterized by diverse clinical phenotypes,
toward which there are oftentimes no ready explanations. Par-
ticularly with the advent of tools through which fetal DNA from
maternal plasma can be sequenced, it is now possible to obtain
genotype information very early during gestation. This in silico
computational approach may help clinicians to attribute a phe-
notype, hence facilitating prenatal therapeutic decisions.
Methods
The amino acid sequence for human CYP21A2 was taken from UniProt (ac-
cession no. P08686). The sequence from the bovine CYP21A2 crystal structure
[Protein Data Bank ID code 3QZ1 (17)] was extracted and aligned with the
human sequence using ClustalX (33) (overall sequence similarity, 79%). The
sequence conservation in the heme-binding cavity, between human and
bovine, is 95%. The alignment revealed that the initial 28 residues at the
N-terminal did not have a corresponding structural template and were,
therefore, built separately.
Models of human CYP21A2 were generated using MODELLER version
9.10 (34, 35), and stereochemical properties evaluated using the program
PROCHECK version 3.5.4 (36). The ﬁnal model was chosen based on low-
energy function and a low Cα rmsd overlap between the bovine template
and the humanized model. The model was constructed with the spatial
position of heme and ligands retained in their respective binding sites. This
was based on the assumption that the ligands and cofactor interact in
a similar manner in the human as in the bovine crystal structure; this com-
parison replicates all conserved interactions from the template into the
model. Several rounds of energy minimization were carried out to obtain
a ﬁnal low-energy conformation with no steric clashes between side chains.
The ﬁnal Cα rmsd between the bovine template and the humanized model
was 0.22 Å (Fig. S4).
The ﬁrst 28 residues corresponding to the N-terminal region including the
membrane-anchoring α-helix were constructed after secondary structure
prediction using PSIPRED (37). Residues 1–25 were modeled in a canonical
α-helical conformation, whereas residues 26–28, which connect the an-
choring transmembrane helix to the ﬁrst residue in the model, were built in
a random-coil conformation using MODELLER. The orientation and position
of the model, with respect to the lipid bilayer, was obtained using the
membrane self-assembly coarse-grained dynamics protocol by Cojocaru
et al. (38). This permits unbiased orientation of the protein in the mem-
brane, which is not achievable via atomistic simulations. At the end of 1 μs,
the coarse-grained model was converted to atomistic resolution using the
reverse-conversion protocol (39) and further subjected to restraint-free
molecular-dynamics simulations to test the stability of the model (SI
Methods). The molecular graphics images were generated using PyMOL
(www.pymol.org).
Mutations were identiﬁed from the Human Cytochrome P450 Allele No-
menclature database (www.cypalleles.ki.se). Redundancies were removed,
and clinical conditions were cross-evaluated with respect to the original
publications (Table S1).
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Insight Into the Conformational Arrangement of a Bis-THF Diol
Compound Through 2D-NMR Studies and X-Ray Structural
Analysis
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Received: 3 August 2011 /Accepted: 3 December 2011 / Published online: 18 December 2011
! Springer Science+Business Media, LLC 2011
Abstract The conformational arrangement of an all-threo
bis-THF diol compound, synthesized through the RuO4-
catalysed oxidative bis-cyclization of farnesyl acetate, was
determined via crystallographic analysis and detailed 2D-
NMR solution studies. The bis-THF compound crystallizes
in the orthorhombic Pbca space group, with unit cell para-
meters a = 10.496(1), b = 17.974(1), c = 19.777(2) A˚,
Z = 8. The final refinement converged to R1 = 0.0484 for
4714 independent observed reflections having I[2r(I).
There is a good agreement between the solution molecular
conformation determined by 2D-NMR and the X-ray
molecular conformation. The molecule adopts a folded, horse
shoe-type conformation both in solution and in the crystal,
that suggests aptitude to coordinate cations. Additionally, in
the crystals, the molecular conformation is stabilized by
intramolecular and intermolecular H-bonding.
Keywords Bis-tetrahydrofuran !
Oxidative bis-cyclization ! RuO4 ! X-ray ! 2D-NMR
Introduction
Tetrahydrofuran-containing compounds are widely dis-
tributed in nature. For example, 2,5-disubstituted THF
fragments are commonly encountered in a variety of bio-
logically active substances such as polyether ionophores,
squalene-derived polycyclic polyether metabolites (oxa-
squalenoids) as well as Annonaceous acetogenins, a large
group of plant-derived metabolites displaying a wide range
of biological activities [1–5]. It is well known that the
biological activity of polyether ionophores is directly
related to their ability to selectively bind physiologically
important metal cations via coordination with various
oxygen atoms of the molecule and transport them through
biological membranes [6]. As a result, the cation equilib-
rium through the cell membrane is altered resulting in
various activities such as antibiotic, antimalarial and
insecticide activity, among others.
Previous studies carried out mostly on natural THF-
containing compounds belonging to one of the above
classes or their analogues have demonstrated that both
adjacent and non-adjacent poly-THF compounds often
possess cation complexation and transport abilities. In
particular, Kodama and coworkers [7] have shown that the
triterpene polyether 14-deacetyl eurylene, isolated from the
wood of Euricoma longifolia, and its non-natural analogues
11-epi-eurylene, 11-epi-14-deacetyleurylene (Fig. 1), all
embodying two non-adjacent THF rings, possess K?
transport ability. These authors and others suggested that
the cytotoxicity of these substances is related to their
complexation ability. Itokawa and coworkers [8] proposed
that a relationship exists between the cytotoxicity and the
conformation of 14-deacetyl eurylene, and structurally
related longilene peroxide and teurilene, also isolated from
the above organism. Based on X-ray criystallographic
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analyses and NOE experiments they showed that these
compounds possess folded, ‘‘horse shoe’’, conformation.
Later Morimoto et al. [9] suggested that the cytotoxic
activity displayed by these compounds may be attributed to
their ability to bind physiologically important cations such
as Ca2? and Mg2? possibly due to their folded conforma-
tion. Indeed, eurylene [8] (Fig. 1), another representative
of this class of substances, possessing and extended con-
formation, has essentially no cytotoxic activity.
Morimoto et al. [9] synthesised three isomeric tris-THF
diol compounds (Fig. 2) and carried out cation transport
experiments demonstrating that all three compounds pos-
sess cation transport ability for Na? and K?. Furthermore,
it has been suggested that the biological activities of
Annonaceous acetogenins involving THF rings may be
attributed to their ability to bind physiologically important
cations such as Ca2? [10–14] (Fig. 2). Indeed, mimics of
bis-THF acetogenins such as bullatacin, possessing a
variety of functionalised side chains, have been shown to
selectively bind Ca2? or Mg2? [11, 15].
Based on this ground, we were interested to test the
cation complexation ability of some poly-THF compounds
structurally related to the above substances, previously
synthesized in our laboratories through ruthenium-medi-
ated chemistry. In particular, we have previously demon-
strated that adjacently linked bis-, tris- and even more
complex poly-THF compounds can be easily synthesized in
a single step via the oxidative polycyclization of all-trans
isoprenoid polyenes such as farnesyl acetate, geranylgera-
nyl acetate, squalene or ad hoc synthesised all-E linear
polyenes (Scheme 1) [15–21].
It is interesting to note that, owing to postulated bio-
genetic pathways leading to the above natural substances as
well as epoxide chemistry used for the synthesis of
unnatural analogues, almost all the bis- or tris-THF com-
pounds examined for cation complexation and/or transport
ability possess erhytro inter-THF relationships, whereas no
studies have been accomplished on poly-THF compounds
possessing all-threo inter-THF relationships such as com-
pounds 4–6. As a part of our ongoing interest in oxidative
processes mediated by transition metal oxo-species [22–24]
and in particular on the derivatization and biological
properties of mono and poly-THF compounds [3, 15–22,
25–27], we report here solid state X-ray and solution
2D-NMR studies on bis-THF diol 4 (Scheme 1) synthe-
sized as previously reported [15].
Experimental
General Methods
All reagents were purchased (Aldrich and Fluka) at the
highest commercial quality and used without further puri-
fication. Reactions were monitored by thin-layer chroma-
tography carried out on precoated silica gel plates (Merck
60, F254, 0.25 mm thick). Merck silica gel (Kieselgel,
particle size 0.063–0.200 mm) was used for column chro-
matography. HPLC separations were carried out on a Varian
2510 apparatus equipped with a Waters R403 dual cell dif-
ferential refractometer using Phenomenex 250 9 10 mm
column. NMR experiments were performed on Varian
Mercury Plus 400 spectrometer in CDCl3. Proton chemical
shifts were referenced to the residual CHCl3 signal
(7.26 ppm); 13C-NMR chemical shifts were referenced to
the solvent (77.0 ppm). J values are in Hz. Abbreviations for
signal coupling are as follows: s, singlet; d, doublet; t, triplet;
q, quartet; m, multiplet.
OO OAc OAcH
OH
H OH
OOH
OH
H OH
H O H OH
OHOH
OH
H O H OH
OHOH
OH
OHHOO
Eurylene
14-deacetyl eurylene (1) R1= -OAc, R2=H;
11-epi-eurylene (2) R1= -OAc, R2=OAc;
11-epi-14-deacetyl eurylene (3) R1= -OAc, R2=Hβ
β
α
11 14
11 14
R1 R2
Teurilene
Longilene peroxide
Fig. 1 Some cytotoxic triterpene poly-tetrahydrofurans
H O HOHOHOH OH
H O HOHOHOH OH
H O HOHOHOH OH
HOHOH
Annonaceous acetogenin 
analogues
R1
R2
R1
R2
R1 = OH, NHAc
R2 = CH3, (CH2)8CH3, 
(OCH2CH2)2OEt
Fig. 2 Synthetic tris-tetrahydrofurans possessing cation transport
abilities (left) and Annonaceous acetogenins analogues (right) able
to bind Ca2? and/or Mg2?
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X-Ray Crystallography
Single crystals of 4 were obtained from a CHCl3 solution by
slow evaporation of the solvent. Data were collected at
ambient temperature on a Bruker-Nonius Kappa-CCD dif-
fractometer using graphite monochromated MoKa radiation
(k = 0.71073 A˚). Unit cell parameters were determined by
least squares refinement of the h angles of 143 strong
reflections in the range 3.501"\ h\ 22.763". Data reduc-
tion and multi-scan absorption correction were done using
SADABS program [28]. The structure was solved by direct
methods (SIR97 program [29]) and refined by the full matrix
least-squares method onF2 using SHELXL-97 program [30]
with the aid of the program WinGX [31]. Non-hydrogen
atoms were refined anisotropically. H atoms of hydroxyl
groups were located in difference Fourier maps and refined
with Uiso = 1.2 Ueq of the carrier atom. The positions of the
other H atoms were determined stereochemically and
refined by the riding model with Uiso = 1.2 Ueq of the car-
rier atom (1.5 Ueq for H atoms of methyl groups). Ring
puckering coordinates [32] were determined using the pro-
gram PARST [33]. The analysis of the crystal packing and
the drawing of the molecule were performed using the
programs Mercury [34] and ORTEP [35]. Crystal and
refinement data are summarized in Table 1. CCDC refer-
ence number 836567 contain the supplementary crystallo-
graphic data for 4. These data can be obtained free of charge
at www.ccdc.cam.ac.uk/data_request/cif.
Results and Discussion
Our initial investigation was addressed to 4 (Scheme 1), a
product synthesised in large amounts from farnesyl acetate,
a commercially available substance. X-ray analysis and
detailed 2D-NMR studies allowed us to determine the
preferential conformation of the molecule demonstrating
that 4 adopts similar folded spatial arrangements both in
solution and in the crystal.
In particular, a full set of 2D-NMR experiments
[(COSY; HMBC, HSQC, HSQCTOCSY, TOCSY,
NOESY (Fig. 3)] was carried out at 400 MHz in CDCl3
solution that allowed the complete assignment of the 1H
and 13C resonances to the pertinent protons and carbons of
the molecule (Table 2).
A summary of significant NOESY correlations are
shown in Fig. 4. In particular, the presence of a NOESY
correlation between H-6 and Me-14 indicated that A and B
THF rings are almost orthogonally oriented with respect to
each other, while a NOESY cross peak between Me-13 and
Ha-9 is in agreement with a staggered conformation of the
2-hydroxypropyl side-chain with respect to the A THF
ring, the C-11 OH group being oriented toward the bottom
side of the molecule. In addition, NOESY correlations
OOOOOOH OHH H H H H H
OAc
OH OO OHH H
O
O
OAc
HHHHOH
OO OAc
OH
Squalene cis/cis/trans/trans/trans
RuO4(cat.)/NaIO4
(E,E)-Farnesyl acetate
RuO4(cat.)/NaIO4
4
5
99
cis
RuO4 (cat.)/NaIO4
6Linear all-E 1,5,9-triene cis
cis
cis
1
236710
11
12
13
14 15
16
17
A B
Scheme 1 Representative examples of the oxidative polycyclization of isoprenoid and linear polyenes catalyzed by ruthenium tetroxide
Table 1 Crystal data and refinement details of 4
Empirical formula C17H30O6
Formula weight 330.41
Temperature 297(2) K
Radiation, wavelength MoKa, 0.71073 A˚
Color Colourless
Crystal size 0.50 9 0.50 9 0.50 mm
Crystal system, space group Orthorhombic, Pbca
a 10.496(1) A˚
b 17.974(1) A˚
c 19.777(2) A˚
Volume 3725.4(6) A˚3
Z, calculated density 8, 1.178 Mg/m3
Absorption coefficient 0.088 mm-1
Theta range for data collection 3.16–27.50"
Reflections collected/unique 21,126/4,147 [Rint = 0.0297]
Reflections with I[ 2r(I) 4,714
Number of parameters 219
Goodness-of-fit on F2 1.073
R indices [I[ 2r(I)] R1 = 0.0484, wR2 = 0.1183
R indices (all data) R1 = 0.0796, wR2 = 0.1390
Largest diff. peak and hole 0.189, -0.199 e/A˚3
362 J Chem Crystallogr (2012) 42:360–365
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between Me-14 and H-10 and Me-15 and H-6 confirmed
the previously determined cis configuration of the two THF
rings in 4. The rest of the NOESY contacts indicated that
the two THF oxygens and the two hydroxyl oxygens all
protrude toward the inner part of the molecule that there-
fore possess a folded conformation (Fig. 4).
The X-ray molecular structure of 4 is reported in Fig. 5,
selected torsion angles are given in Table 3. It is clearly
shown that in both THF rings the 2,5 substituents are in cis
configuration with respect to each other. Owing to this
stereochemistry and to the torsion angles around the bonds
C2–C3, C6–C7 and C10–C11, the molecule adopts a bent,
horse-shoe-type shape, with hydroxy oxygens placed in the
inner part and the two THF ring oriented substantially
perpendicular to each other (the dihedral angle between the
mean planes is 88.53(7)"), as found in the solution con-
formation. In addition, the staggered conformation of the
2-hydroxypropyl tail with respect to the adjacent THF ring
is also observed in the X-ray molecular structure. So, the
Fig. 3 NOESY spectrum of 4
in CDCl3 (25 "C) recorded at
400 MHz
Table 2 Carbon and Proton assignments of 4
d 13C d 1Ha (J, mult.) d
1Hb
1 65.7 4.20 (dd, 11.4, 2.7) 3.97 (dd, 11.4, 8.4)
2 75.0 3.65 (dd, 8.3, 2.8)
3 83.9
4 35.3 1.63 (m) 2.03 (m)
5 27.1 1.91 (m) 1.96 (m)
6 83.3 3.89 (dd, 6.3, 5.5)
7 83.3
8 34.4 2.12 (m) 1.55 (m)
9 25.7 1.94 (m) 1.85 (m)
10 84.8 3.75 (dd, 7.1, 7.1)
11 71.1
12 27.7 1.22 (s)
13 25.3 1.06 (s)
14 23.6 1.10 (s)
15 21.7 1.15 (s)
16 171.1
17 20.9 2.04 (s)
2 9 OH 3.00–3.10
O
Me
Me
Me
H
H
H
H
H
OH
H
O
H
H
Me
OH
O
Me
O
H H
H
H
H
14
6
12
13
9
3
1
10
15
A
B
Fig. 4 Summary of some significant 400 MHz NOESY correlations
for 4
Fig. 5 ORTEP drawing of 4. Thermal ellipsoids are drawn at 30%
probability level. The intramolecular hydrogen bond is shown as
dashed line
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accurate X-ray molecular structure of 4 in the solid state
confirms the general features of the molecular structure in
solution as deduced by 2D-NMR experiments.
The molecular conformation in the solid state is further
stabilized by an intramolecular H bond between O5–H donor
and O4 acceptor (Table 4). Ring puckering coordinates of the
two THF rings are given in Table 5, and they indicate that the
ring (O2, C3, C4, C5, C6) is in envelope conformation, while
the other is basically in twisted conformation.
In the crystals, molecules are associated in dimers
through intermolecular H bonding between O4–H donor
and O5 acceptor. In this way, R4
4(8) ring patterns are
formed across crystallographic inversion centres, Fig. 6.
A head-to-tail arrangement of molecules in chains run-
ning along c is achieved through weak H bonding between
C13–H donor and carbonyl oxygen acceptor O6, see
Table 4 and Fig. 7.
Conclusions
In summary, in the present study we have determined the
conformational arrangement of a bis-THF diol compound.
Both the solution and the solid-state conformation is folded
as observed for similar bis-THF compounds possessing
cytotoxic activity and cation transport ability. This is a
promising result that prompts us to carry out further study
on this compound to determine its possible cation com-
plexation ability as well as its cytotoxic activity.
Supplementary Material
All crystallographic data have been deposited at the Cam-
bridge Crystallographic Data Centre (CCDC). Deposition
number is CCDC 836567. These data can be obtained free of
charge from www.ccdc.cam.ac.uk/data_request/cif.
Table 3 Selected torsion angles (") of 4 (e.s.d.’s in parentheses)
O5–C2–C3–O2 52.4(2)
O2–C6–C7–O3 67.1(2)
O3–C10–C11–O4 -69.2(2)
Table 4 Hydrogen bonding geometry of 4 (e.s.d.’s in parentheses)
D–H!!!A D–H (A˚) H!!!A (A˚) D!!!A (A˚) D–H!!!A (")
O4–H!!!O5a 0.82(2) 1.99(2) 2.800(2) 170(2)
O5–H!!!O4b 0.86(2) 1.97(2) 2.781(2) 157(2)
C13–H!!!O6c 0.96 2.502 3.451(3) 170
Symmetry code: a -x ? 2, -y ? 1, -z ? 1; b x, y, z; c -x ? 3/2,
-y ? 1, z ? 1/2
Table 5 Ring puckering coordinates of 4 (e.s.d.’s in parentheses)
Ring q2 (A˚) u 2 (")
(O2, C3, C4, C5, C6) 0.353(2) 6.1(2)
(O3, C7, C8, C9, C10) 0.367(2) 195.4(3)
Fig. 6 Dimer of H-bonded molecules through a crystallographic
inversion center. Dashed lines marks the R4
4(8) motif (i = -x ? 2,
-y ? 1, -z ? 1). Methyl and methylene H atoms are not shown for
clarity
Fig. 7 Partial crystal packing of 4 showing a chain formed by weak
H bonding
364 J Chem Crystallogr (2012) 42:360–365
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Tetrahydrofuran Compounds and Synthesis of Umbelactone
Vincenzo Piccialli,*[a] Sabrina Zaccaria,[a] Giorgia Oliviero,[b] Stefano D’Errico,[b]
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The catalytic system PCC (cat.)/H5IO6 has been used to oxi-
dise mono- and polytetrahydrofuran compounds. New oxi-
dative pathways are disclosed. 2,2,5-Trisubstituted THF rings
are converted into dicarbonyl compounds through oxidative
cleavage of the C2–C3 bond. Cyclic enol ethers appear to
be intermediate species in this process. Oxidation of 2,2,5-
trisubstituted α-keto-THF compounds proceeds with the oxi-
dative cleavage of the C2(THF)–C=O bond to give 1,4-di-
ketones with degraded carbon backbones. Attack of the oxi-
dant on 2,5-disubstituted THF rings leads to 1,4-diketones
Introduction
Pyridinium chlorochromate (PCC) is a well-known rea-
gent employed in an array of oxidising processes.[1] This oxi-
dant is usually used either in stoichiometric or in excess
amounts to oxidise a variety of functional groups. In con-
trast, the use of PCC in catalytic amounts has received little
attention to date[2,3] even though chromium(VI) species are
known to be carcinogenic and environmentally hazardous
and the use of substoichiometric amounts of such a reagent
would therefore be highly desirable. In this respect, the cata-
lytic system PCC (cat.)/H5IO6 is particularly appealing, al-
though it has been employed in only a few cases.[2,3] As a
part of our ongoing interest in oxidative processes mediated
by transition metal oxo species[4] and in particular in the
synthesis of new THF-containing compounds,[5] we report
here on the oxidation of mono- and poly-THF compounds
with the PCC (cat.)/H5IO6 (chlorochromatoperiodate,
CCP) system, which has led to the discovery of new types
of useful oxidative transformations involving THF ring sys-
tems. A similarity between the oxidative behaviour of PCC
and that of RuO4, which further supported our recent find-
ings in the chemistry of these oxo species, has also
emerged.[5a,5b]
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containing intact THF carbon frameworks. Oxidation of com-
plex poly-THF substrates, containing up to five THF rings,
allows access to new poly-THF compounds through regiose-
lective THF oxidation along the poly-THF backbones. A
mechanistic explanation of the new processes consistent with
the reported reactivity of PCC and the isolation of some
minor products of the process is provided. The synthesis of
racemic umbelactone, an antiviral natural butenolide metab-
olite, has been carried out by use of the developed chemistry.
Results and Discussion
Oxidation of Poly-THF Compounds – Preliminary Results
In a preliminary experiment devised to test the reactivi-
ties of tetrahydrofuran-containing substances with PCC,
penta-THF dibenzoate 2 (Scheme 1), containing five dif-
ferently substituted and configured THF rings, was investi-
gated. The synthesis of 2 was accomplished by a RuO4-cata-
lysed oxidative polycyclization protocol starting from squal-
ene, previously developed in our laboratory,[5i,5f] followed
by benzoylation of the tertiary hydroxy groups in the ini-
tially formed penta-THF diol 1 under standard conditions
(BzCl, DMAP, CH2Cl2).
Treatment of 2 with PCC under classical oxidising condi-
tions (excess PCC/AcOH, CH2Cl2, Scheme 2)[5b] gave the
two isomeric tetra-THF compounds 3 and 4 (overall 32%
yield), originating from the oxidative cleavage of the C2–C3
bonds in either the D or the B THF rings of 2, respectively.
The rest of the material for mass balance was made up of
polar substances possibly derived by side- or over-oxidation
processes due to the presence of various THF rings prone
to attack by the oxidant. The structures of 3 and 4 were
determined by a full set of 2D NMR experiments recorded
at high fields. Although the process proceeded with a rather
low yield and could not be forced to completion under these
conditions, the ability of PCC to oxidise the THF ring had
been confirmed.
Our next goal was to test the reactivity of 2 in the pres-
ence of the catalytic system PCC (cat.)/H5IO6 (Scheme 3).
From previous studies[6] it is thought that the combination
of PCC and H5IO6 generates chlorochromatoperiodate
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Scheme 1. Synthesis of penta-THF dibenzoate 2.
Scheme 2. Cleavage products from the oxidation of penta-THF di-
benzoate 2 with PCC/AcOH.
(CCP, Scheme 3), an oxidising agent more powerful than
PCC itself. It was hoped that the use of a more reactive
reagent such as this might possibly reduce reaction times
and force the process to completion. The oxidation was ini-
tially carried out in CH3CN at 0 °C with 1 mol-% of PCC
and 4 equiv. of periodic acid (Scheme 3, conditions A). The
process was indeed much cleaner under these conditions
and overall improved yields of acids 3 and 4 (3: 40%; 4:
4%) were obtained in a shorter time (3 h). Importantly, the
two isomers were now obtained in a ca. 10:1 ratio in favour
of 3. With regard to the attack of the oxidant at the D
ring of the poly-THF system of 2, the observed enhanced
regioselectivity was probably due both to the increased
steric demand of the CCP and to the different configura-
tions of the involved rings (ring B: cis; ring D: trans). Under
these conditions the process was still incomplete and
stopped at 80% conversion. Addition of a further 1 mol-%
PCC and 1 equiv. of H5IO6 (conditions B) forced the pro-
cess to completion at the expense of a slight reduction in
the overall yield (3 + 4 38%; 3/4 10:1) presumably due to
the over-oxidation of 3 and 4 themselves, as indicated by
the presence of polar products, probably related to 3 and/or
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4, in the reaction mixture (NMR, HPLC and MS analyses).
Smaller amounts of these side products were also formed
under conditions A.
Scheme 3. Oxidation of penta-THF dibenzoate 2 with PCC (cat.)/
H5IO6.
To test the above oxidising system further, the oxidation
of tris-THF tetrabenzoate 5 (Scheme 4), a structurally “sim-
plified” substrate related to 2, was then carried out. Com-
pound 5 was obtained by benzoylation of the corresponding
tetrol (prepared in turn from penta-THF 1 through a short
degradative sequence developed in a previous study con-
ducted by our group[5f]). Interestingly, in this case the three
major products 6–8, two of them – acids 6 and 7 – structur-
ally related to 3 and 4 and all originating from attack of
the oxidant at the central THF ring, were obtained. In this
case 4 equiv. of H5IO6 were sufficient to drive the process
to completion. 2D NMR experiments were carried out to
determine the stereostructures of 6–8. A new feature of this
process was the formation of the 1,4-diketone 8 through a
different oxidative route featuring the oxidation of both the
angular carbons of the central THF ring in 5, not observed
in the oxidation of penta-THF 2. 1,4-Diketones are easily
transformed into five-membered heterocycles, so substances
such as 8 might be synthetically useful to access new types
of rare mixed poly-THF/heterocycle compounds.
Catalytic Oxidation of Tetrahydrofuran Compounds
Scheme 4. Oxidation of tris-THF tetrabenzoate 5.
The parent penta-THF 2 can be obtained in a single step
in multi-gram amounts from cheap and commercially avail-
able squalene, so the oxidative degradation of its penta-
THF backbone can allow facile access to stereochemically
definite and functionalised cis-cis-trans and trans-trans-
trans tris-THF compounds by hydrolysis of the inter-THF
ester functions in either 3 or 4 (Scheme 5). Likewise, new
functionalised cis or trans mono-THF systems can be ob-
tained from 6 and 7 by hydrolysis (Scheme 5). Given litera-
ture precedents, it can be presumed that at least some of
these substances should be useful for further cytotoxic ac-
tivity studies and also for synthetic purposes.[7]
Scheme 5. Functionalised new all-threo mono- and tris-THF sys-
tems accessible through hydrolysis of poly-THF compounds 3, 4,
6 and 7.
A further simplification of the poly-THF substrate was
achieved by conversion of the tetrol corresponding to 5 into
bis-lactone 9 (Scheme 6) through a previously developed
degradative sequence.[5f] Interestingly, oxidation of this
compound under the same conditions as used for 5 led to
1,4-diketone 10 (45% yield) through the oxidative opening
of the THF ring, whereas no acid corresponding to com-
pounds 6/7 was observed.
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Scheme 6. Oxidation of THF-dilactone 9.
The above results indicated that the oxidation of complex
poly-THF compounds containing both di- and trisubsti-
tuted THF rings proceeds through two main routes. Oxidat-
ive cleavage of the C2–C3 bond is preferred when a 2,2,5-
trisubstituted THF ring is involved, as in the oxidation of
2. A second route leads to 1,4-diketones, such as 8 and 10,
through the attack of the oxidant at a 2,5-disubstituted
THF ring and oxidation of both its angular carbon atoms,
as in the oxidations of 5 and 9.
Oxidation of Mono-THF Compounds
With the aim of making the above process synthetically
useful, the oxidation of some mono-THF compounds,
based on the di- and trisubstituted THF motifs present in
previously studied poly-THF compounds, was tested. cis-
THF 11 (Table 1), obtained by benzoylation of the corre-
sponding diol, in turn synthesized by RuO4-catalyzed oxi-
dative cyclization of geranyl benzoate,[8] was initially chosen
as a model compound to find the best conditions for the
oxidative process. Oxidation of 11 under previously em-
ployed conditions [PCC (2 mol-%), H5IO6 (4 equiv.), 0 °C]
gave acid 12, analogous to compounds 3/4 and 6/7 obtained
from more complex substrates, in a 54% yield (Table 1, En-
try 1), although longer reaction times were required. The
process was then carried out at room temp. with the same
amounts of catalysts and co-oxidant, leading to 12 in a sim-
ilar 55% yield in only 3 h (Entry 2). Improved yields (80%)
and further reduced reaction times (45 min) were achieved
by increasing the catalyst amount to 5% (Entry 3). Increas-
ing of the catalyst amount to 10% resulted in a similar yield
and further reduced times (78%, 30 min, Entry 4). Further
increasing of the catalyst up to stoichiometric amounts (50–
Table 1. Optimization of the process on a model 2,2,5-trisubstituted
THF compound.
Entry PCC H5IO6 Time Yield of
[mol-%] [equiv.] 12[a] [%]
1[b] 2 4 19 h 54
2 2 4 3 h 55
3 5 4 45 min 80[c]
4 10 4 30 min 78
5 50 4 30 min 62
6 100 4 30 min 37
[a] Estimated by 1H NMR examination of the crude mixture.
[b] Carried out at 0 °C. [c] Isolated yield.
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100%) only resulted in diminished yields (Entries 5 and 6).
Finally, the effect of addition of water to the process was
tested. Although the related system CrO3(cat.)/H5IO6 has
been successfully used to oxidise alcohols cleanly in wet
CH3CN (0.75 vol.-% water)[9] in our case we have observed
that addition of water (2–5 vol.-%) is detrimental, causing
the process to stop at 10–20% conversion.
Oxidation of mono-THF compounds structurally related
to 11 under the optimized conditions was then carried out
(Scheme 7). cis-THF compounds 14, 16 and 24 were syn-
thesized by benzoylation of the corresponding THF diols,
in turn obtained by RuO4-catalysed oxidative cyclization of
trans,trans-2,6-dimethyl-2,6-octadiene-1,8-diol diacetate,[5j]
methyl geranate[5j] and hexa-1,5-diene,[8] respectively, as re-
ported. trans-THF 19 was obtained by benzoylation of the
corresponding THF diol, a minor product from the oxidat-
ive cyclization of geranyl benzoate.[10] THF 20 was synthe-
sized from 11 through a short sequence. In particular, selec-
tive removal of both the primary and secondary benzoates
in 11 with K2CO3 in MeOH proceeded cleanly to give the
corresponding diol. Oxidative cleavage of the diol system
by treatment with silica-supported NaIO4[11] in CH2Cl2, fol-
lowed by borohydride reduction and benzoylation, afforded
dibenzoate 20 in 43% yield (over four steps). Ketone 22 was
obtained by TPAP-catalysed oxidative cyclization of geranyl
acetate[5g] followed by benzoylation.
Scheme 7. Oxidation of functionalised 2,5-disubstituted and 2,2,5-
trisubstituted THF compounds. i) PCC (5 mol-%), H5IO6
(4 equiv.), CH3CN, room temp., 1 h; ii) PCC (2 mol-%), H5IO6
(4 equiv.), CH3CN, room temp., 40 min.
CCP oxidation of cis-THF diacetate 14 and trans-THF
19 gave acids 15 and 12, respectively, in 65–70% yields. The
methoxycarbonyl derivative 16 unexpectedly afforded the
corresponding acid in a diminished 30% yield, the major
product of the process being lactone 18, analogous to 13,
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derived from the oxidative removal of the dimethylated left-
hand side chain. This side process is unusual but is reminis-
cent of the oxidative cleavage of a similar substrate.[3] This
type of lactone is also the main side product of the process
carried out on all the other substrates. Similarly, the THF
derivative 20 gave acid 21 in 65% yield.
In another experiment, α-keto THF 22 was oxidised. In
this case the presence of a keto group adjacent to the THF
ring induced removal of the side chain through the oxidat-
ive cleavage of the C(THF)2–C=O bond to give 1,4-diket-
one 23 in good yields.
Finally, the reactivity of the 2,5-disubstituted cis-mono-
THF 24 was tested. Pleasingly, 1,4-diketone 25 was ob-
tained in a nearly quantitative yield (98%) even when the
amount of PCC was reduced to 2 mol-%, This process is
particularly appealing because it allows, when coupled with
the oxidative cyclization of 1,5-dienes, the transformation
of the latter into bis-ketols in a regioselective manner. This
experiment and the oxidation of the more complex disubsti-
tuted mono-THF 9 demonstrated that for substrates con-
taining only a 2,5-disubstituted THF ring the preferred
route is the one leading to 1,4-diketones.
Isolation of Minor Products and Mechanistic
Considerations
A plausible mechanistic route based on the known reac-
tivity of PCC and related oxo species such as RuO4[5a] was
hypothesised to explain the formation of the above com-
pounds. In particular, a pathway leading to compound 12
is shown in Scheme 8, but it also applies to the formation
of the analogous compounds 3/4, 6/7, 15, 17 and 21. It is
likely that the process begins with the attack of CCP,
formed by elimination of water from PCC and periodic
acid, at the angular C–H bond of the THF ring to give the
mixed chromium ester intermediate 26. This step is conceiv-
ably a [3+2] addition of the O=Cr=O portion of the oxidant
to the angular C–H bond of the THF ring, as also hypoth-
esised for the RuO4 oxidation of neoisocedrane oxide,[12] a
sesquiterpene containing a THF ring. It is reported that the
oxidation of the THF ring in this substance proceeds
through the intramolecular insertion of an oxoruthenium
bond into the angular C–H bond of the THF ring. In ad-
dition, it has been suggested that attack of transition metal
oxo species such as OsO4 and RuO4 to C–H bonds of al-
kanes also proceeds through a [3+2] addition of a C–H
bond across an O=M=O unit,[13] through a mechanism
analogous to the one now widely accepted for alkene bishy-
droxylation. In the next step, chromium ester 26 would give
rise to cyclic enol ether 27 through an elimination step de-
livering a low-valent chromium species that would then be
reoxidised to CCP by H5IO6. However, it cannot be ex-
cluded that the first step of the process could proceed
through hydride abstraction from the angular C–H bond
(not shown) by the same O=Cr=O portion of CCP to give
an intermediate carbocation (actually an oxonium ion)
which could then collapse to form enol ether 27. This would
Catalytic Oxidation of Tetrahydrofuran Compounds
Scheme 8. A plausible catalytic cycle explaining the formation of acid 12.
be consistent with the mechanism proposed by Lee and
van den Engh for the RuO4 oxidation of tetrahydrofuran to
γ-butyrolactone,[14] in which the initially formed carbonium
ion and RuVI oxo species recombine to give an intermediate
ester similar to 26.
Whereas PCC is unable to cleave isolated (unactivated)
carbon-carbon double bonds, oxidative cleavages of both
cyclic and acyclic enol ethers to esters with PCC have been
reported.[15] In particular, the conversion of 27 to the final
dicarbonyl compound 12 is thought to proceed through the
formation of the chromium diester intermediate 28, by a
second [3+2] addition step. Oxidative cleavage to afford al-
dehyde 29, followed by oxidation, eventually generates acid
12. The conversion of 27 to 29 agrees well with the pre-
viously observed oxidative cleavage of cyclic enol ethers
lacking α-hydrogen atoms.[15a,15c] Finally, formation of lact-
one 13, the main side-product of the oxidation of 11
(Table 1), can be seen to originate from the oxidative re-
moval of the dimethyl benzoate side chain. It has previously
been observed that THF rings bearing a tertiary (free)
alcohol functions undergo similar oxidative cleavage with
CCP to give γ-lactones[3] such as 13, via C-2 chromium es-
ter intermediates. It is conceivable that a similar route could
be responsible for the C2–C3 oxidative cleavage in a chro-
mium ester intermediate possibly formed by further evol-
ution of 26 (Scheme 9). This interaction is supported by the
complete absence of hydrolysis of the primary and second-
ary benzoate functions present in the same molecule.
Scheme 9. Formation of lactone 13 by side-chain removal in inter-
mediate 26.
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To support the mechanistic path shown in Scheme 8, a
careful examination of the minor products formed during
the oxidation of penta-THF 2, both with PCC/AcOH and
with CCP, was undertaken. HPLC analyses (direct and re-
versed-phase modes) led to the identification of the three
side-products 30–32 (Figure 1) in both processes. Their
structures give strong support for the proposed mechanism
and their formation could be interpreted through routes
consistent with those given for the main oxidation products.
Figure 1. Minor products obtained from the oxidation of penta-
THF dibenzoate 2.
In particular, the presence of the oxidised B ring in 30
strongly suggested that it is formed on the pathway leading
to acid 4, as shown in Scheme 10. On this pathway, acid 4
and ketol 30 would be formed by attack of CCP at the
angular C7–H bond in the THF ring B of 2 via intermedi-
ates 33, 34 and 35 as seen for the oxidation of 11. Com-
pound 35 would follow route a to give acid 4 through the
oxidative cleavage of the C7–C8 bond. Alternatively, its oxi-
dative opening would give ketol 30 through route b. The
isolation of 30 furnishes the first indirect support for the
previously hypothesised[16] formation of chromium diester
intermediates, such as 35, during the oxidative cleavage of
enol ethers with PCC, and strongly supports the involve-
ment of enol ether 34.
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Scheme 10. Formation of compounds 4 and 30.
Acid 3 (see Scheme 3) would in turn originate in a similar
way by attack of CCP at the C18–H of the THF ring D in
2 whereas acids 6 and 7 (see Scheme 4) would be formed by
attack of the oxidant at the central C ring in the tris-THF
5.
With regard to the minor compounds 31 and 32 (Fig-
ure 1), it seems likely that they could originate from 2 in
the same route leading to 3 or 4 (Scheme 11). In particular,
the oxidative cleavage of the C6–C7 bond in 2 could occur
in the chromium ester intermediate 33 through an elimi-
nation step now involving both the A and the B rings. This
step accounts well for the formation of the C-7 lactone
function in 31 with generation once again of an enol ether
species, compound 36, that is then oxidatively cleaved to
the dicarbonyl compound 32 via chromium diester 37, as
previously seen. The configuration of 31 has not been deter-
mined, so its formation might follow either the depicted
route, through attack of the oxidant at the C7-H and oxi-
dation of ring B, or an analogous pathway in which the
D ring is oxidised by attack at the C18–H bond (pathway
not shown) and cleavage of the C18–C19 bond connecting
rings D and E.
By the same line of reasoning, the formation of diketone
23 from 22 (Scheme 12) can be explained by the assumption
that the initially formed chromium ester 38 collapses to the
dicarbonyl species 39, the α-ketol portion of which un-
dergoes oxidative cleavage to give 23 through a known pro-
cess.
The formation of 1,4-diketone 25 from 24 is shown in
Scheme 13. In particular, CCP could attack one of the
angular C–H bonds in 24 in the usual way to give chro-
mium ester 40. Opening of this would then follow to give
ketol 41 (route a) with simultaneous production of a chro-
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Scheme 11. A mechanistic explanation for the formation of com-
pounds 31 and 32.
Scheme 12. A catalytic cycle for the formation of diketone 23.
mium species, the oxidation of which would regenerate
CCP, closing the catalytic cycle. CCP oxidation of the
alcohol function in 41[2a] would eventually give 1,4-diketone
25. Formation of the related 1,4-diketones 8 (Scheme 4) and
10 (Scheme 6) can be explained in a similar manner. It
should be noted that the possible competing path giving
rise to an enol ether species (compound 42, Scheme 13,
route b) from 40 is completely suppressed in this case. It is
worth noting that the chemical behaviour of PCC in this
Scheme 13. A catalytic cycle for the formation of 1,4-diketone 25.
Catalytic Oxidation of Tetrahydrofuran Compounds
Scheme 14. Synthesis of umbelactone.
transformation parallels that displayed by RuO4. In fact,
in a similar transformation, 2,5-dimethyl-tetrahydrofuran is
reported to undergo oxidative opening by the RuO2(cat.)/
NaIO4 system to afford hexane-2,5-dione.[17]
Synthesis of Umbelactone
As an application of the developed oxidative procedure,
a short synthesis of racemic umbelactone was carried out.
Umbelactone is a γ-butenolide natural product, isolated
from ethanolic extracts of Memecylon umbellatum Brum,[18]
that exhibited antiviral activity against the Ranikhet disease
virus as well as spasmolytic and antiamphetamine activity.
This substance has been the subject of various syntheses
both in racemic and in enantiopure form.[19]
Our oxidation of trisubstituted THFs such as 11 de-
scribed above allows access to elaborated 3,4,5-trioxygen-
ated acids. In particular, compound 12 derived from 11 was
seen as a good starting product for the synthesis of umbel-
actone (Scheme 14). Tribenzoate 12 was converted into tri-
hydroxyacid 43 in high yield by treatment with K2CO3 in
MeOH. Successive treatment of crude 43 with CH2N2 gave
transient methyl ester 44, which spontaneously cyclised to
the γ-lactone 45 in 90% yield (81% from 12). The primary
hydroxy group in 45 was then protected as the TBS ether
(compound 46) by treatment with TBSCl/imidazole in
DMF (96% yield).[20] Dehydration of 46 was accomplished
with SOCl2/pyridine to give silylated umbelactone 47 in
95% yield. Lastly, desilylation of 47 with Et3N·3HF in
THF cleanly gave umbelactone 48 (92% yield).
Our synthetic route to umbelactone is short and highly
efficient and does not require carbon-carbon bond-forming
steps. In addition, it can be made enantioselective to give
both the umbelactone enantiomers because mono-THF tri-
benzoate 11 (Table 1), the immediate precursor of 12, can
be obtained in both enantiomeric forms from commercially
available geraniol in high yields and enantiomeric purity.[21]
Studies directed towards this goal, as well as exploitation
of the above chemistry for the preparation of further func-
tionalised butenolides, are ongoing.
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Conclusions
In summary, we have examined the oxidative behaviour
of some mono- and poly-THF compounds with the cata-
lytic system PCC (cat.)/H5IO6. Novel oxidative pathways
leading to the modification/degradation of the THF ring,
as well as of the poly-THF backbone, have been disclosed.
Plausible hypotheses, consistent with the known reactivity
of PCC, have been put forward to explain the new oxidative
routes. In particular, attack of the oxidant at the angular C–
H bond of the target THF ring with formation of a mixed
chromium ester is thought to be the first event. Two main
routes then follow. Oxidative carbon-carbon bond cleavage,
to give dicarbonyl products, occurs when 2,2,5-trisubsti-
tuted THFs are oxidised. The isolation of some minor side
products of the process strongly supports the formation of
cyclic enol ether intermediates in this transformation. With
2,5-disubstituted mono-THFs, THF ring opening, with no
C–C bond cleavage, is observed. 1,4-Diketones, useful
building blocks in organic synthesis,[22] are obtained in this
case. The latter transformation proceeds with a remarkable,
nearly quantitative yield. A third route, leading to the oxi-
dative cleavage of a C-2 side-chain, operates when the THF
ring is flanked by a ketone function. Finally, the above re-
sults provide further support for the previously observed
similarity of the chemical oxidative behaviour of PCC and
of RuO4 toward THF-containing substances.[5a] Further de-
velopment of the chemistry presented here is currently on-
going.
Experimental Section
General: All reagents were purchased in the highest commercial
quality and used without further purification. Petroleum ether had
a boiling range of 40–70 °C. Reactions were monitored by thin-
layer chromatography carried out on precoated silica gel plates
(Merck 60, F254, 0.25 mm thick). Merck silica gel (Kieselgel 40,
particle size 0.063–0.200 mm) was used for column chromatog-
raphy. Na2SO4 was used as a drying agent for aqueous workup.
HPLC separations were carried out with a Varian 2510 apparatus
fitted with a Waters R403 dual cell differential refractometer with
use of Phenomenex 250!10 mm and 250!4.6 mm (both 5 µ) and
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LiChrosorb RP-18 250!4.0 mm columns. NMR experiments were
performed with Varian Unity Inova 700, Varian Unity Inova 500,
Varian Mercury Plus 400, and Gemini 200 spectrometers in CDCl3.
Proton chemical shifts were referenced to the residual CHCl3 signal
(δ =7.26 ppm). 13C NMR chemical shifts were referenced to the
solvent (δ =77.0 ppm). Abbreviations for signal coupling are as fol-
lows: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet, br,
broad. IR spectra were recorded with a Jasco FT-IR 430 spectro-
photometer. High-resolution MS was recorded with a Bruker
APEX II FT-ICR mass spectrometer with use of ESI. For com-
pounds 2–4, 30 and 31 the numbering previously given[5f] for penta-
THF 1 is used.
Syntheses of Poly-THFs 2, 5 and 9: Penta-THF 1, the tetrol precur-
sor of 5 and dilactone 9 were synthesized as described previously.[5f]
Compound 1 was benzoylated as follows. Benzoyl chloride
(15 equiv., 6.75 mmol, 785 µL) and DMAP (30 equiv., 3.5 mmol,
11.6 g) were added to 1 (236 mg, 0.45 mmol) dissolved in CH2Cl2
(10 mL) and the mixture was stirred at room temp. for 30 h. Water
(2 mL) was added and the mixture was stirred for 15 min in a water
bath and then taken to dryness. The residue was taken up in
CH2Cl2 and washed with a sat. NaHCO3 solution and water. The
organic phase was dried, filtered and concentrated in vacuo to give
an oily product that was chromatographed on silica gel with elution
with petroleum ether/Et2O (8:2) to give dibenzoyl penta-THF 2
(264 mg, 80%). Further purification of 2 was carried out by HPLC
(250!10 mm column; flow: 2.5 mLmin–1, hexane/EtOAc 75:25).
Penta-THF Dibenzoate 2: Oil. 1H NMR (200 MHz, CDCl3): δ =
8.05–7.92 (m, 4 H), 7.58–7.35 (m, 6 H), 4.25–4.15 (m, 2 H), 4.02–
3.75 (4 H, overlapped multiplets), 2.33–1.49 (20 H, partly over-
lapped to some methyl protons), 1.64 (s, 3 H), 1.60 (s, 6 H), 1.58,
1.23, 1.16, 1.15, 1.11 (3 H each, singlets, 5! Me) ppm. 13C NMR
(50 MHz, CDCl3): δ = 165.54, 165.45, 132.3, 132.2, 131.9, 131.7,
129.2, 128.0, 86.1, 85.7, 85.1, 84.9, 84.4, 84.3, 83.83, 83.78, 83.5,
83.3, 82.5, 34.4, 34.3, 34.1, 32.5, 27.6, 26.9, 26.8, 26.7, 26.5, 24.7,
24.0, 23.4, 23.2, 23.0, 22.6, 21.3, 21.1 ppm. IR (neat): ν˜max = 1712
(C=O benzoates), 1285, 710 cm–1. HRMS (ESI): calcd. for
C44H60NaO9 [M + Na]+ 755.4135; found 755.4144.
The tris-THF tetrol corresponding to 5 was benzoylated as de-
scribed for 1. Benzoyl chloride (15 equiv., 2.6 mmol, 305 µL) and
DMAP (60 equiv., 10.4 mmol, 1.3 g) were added to the tetrol
(77.0 mg, 0.173 mmol) dissolved in CH2Cl2 (2.0 mL) and the mix-
ture was heated at reflux for 10 h. The mixture was worked up as
for 1 to give an oily product. Column chromatography on silica gel
with elution with petroleum ether/Et2O (8:2) gave tetrabenzoyl tris-
THF 5 (108 mg, 73%).
Tris-THF Tetrabenzoate 5: Oil. 1H NMR (400 MHz, CDCl3): δ =
8.16–7.95 (m, 8 H), 7.64–7.45 (m, 4 H), 7.45–7.32 (m, 8 H), 4.54
(dd, J = 6.6, 6.6 Hz, 1 H), 4.32 (m, 5 H), 3.89–3.74 (m, 2 H),
2.33–2.07 (7 H, overlapped multiplets), 2.01–1.73 (13 H, overlapped
multiplets) 1.63, 1.57, 1.12, 1.08 (3 H each, singlets, 4! Me) ppm.
13C NMR (100 MHz, CDCl3): δ = 166.50, 166.46, 165.6, 132.80,
132.78, 132.50, 132.46, 131.7, 131.6, 130.26, 130.24, 129.5, 129.4,
128.26, 128.24, 128.16, 128.15, 85.9, 85.3, 85.2, 84.7, 84.4, 83.9,
83.7, 81.4, 65.2, 65.1, 34.6, 34.4, 31.9, 31.5, 27.5, 27.2, 26.92, 26.86,
24.3, 23.7, 23.5, 23.1, 20.4, 20.0 ppm. IR (neat): ν˜max = 1714 (C=O
benzoates), 1275, 710 cm–1. HRMS (ESI): calcd. for C52H60NaO11
[M + Na]+ 883.4033; found 883.4028.
Oxidation of 2 with PCC/AcOH: PCC (5 equiv., 2.5 mmol, 537 mg)
and AcOH (70 equiv., 35 mmol, 2 mL) were added to a solution of
2 (365 mg, 0.50 mmol) in CH2Cl2 (16 mL) and the resulting mix-
ture was heated at reflux for 16 h. A saturated aqueous NaHCO3
solution was added and the organic phase was washed with water,
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dried and concentrated in vacuo to give a yellow oil. Filtration on
a silica gel pad (eluent CHCl3/MeOH 9:1) afforded an oily product
(350 mg). Further elution with CHCl3/MeOH (8:2) gave a complex
mixture of polar products (57 mg) that was not studied further. The
first eluted fraction was separated by HPLC (250!10 mm column;
flow: 2.5 mLmin–1; eluent: hexane/EtOAc 75:25) to give unreacted
2 (128 mg) and slightly impure compounds 3 and 4. Analytical
HPLC (250!4.6 mm column; flow: 1.0 mLmin–1; 3 mg/injection,
hexane/EtOAc 75:25) afforded major acid 3 (58.4 mg, 25%, tR =
11.5 min) and minor acid 4 (16.3 mg, 7%, tR = 10.0 min).
Acid 3 (Major Isomer): Oil. 1H NMR (700 MHz, CDCl3): δ = 7.95
(br. d, J = 7.6 Hz, 4 H), 7.52 (br. t, J = 7.4 Hz, 2 H), 7.41 (br. t, J
= 7.7 Hz, 4 H), 4.38 (dd, J = 7.3, 7.3 Hz, 1 H), 4.25 (dd, J = 7.4,
7.4 Hz, 1 H), 4.13 (br. dd, J = 7.4, 7.4 Hz, 1 H), 4.01 (dd, J = 10.0,
5.3 Hz, 1 H), 3.94 (dd, J = 9.0, 6.3 Hz, 1 H), 3.25 (d, J = 14.9 Hz,
1 H), 2.97 (d, J = 14.9 Hz, 1 H), 2.36 (ddd, J = 13.0, 8.4, 5.5 Hz,
1 H), 2.07–1.81 (14 H, overlapped multiplets), 1.69 (m, 1 H), 1.62,
1.61, 1.59, 1.56, 1.54, 1.50, 1.20, 1.13 (3 H each, singlets, 8!
Me) ppm. 13C NMR (175 MHz, CDCl3): δ = 174.4, 171.9, 165.7,
165.6, 132.6, 132.5, 131.85, 131. 78, 129.42, 129.37, 128.25, 128.20,
86.4, 85.5, 85.3, 84.6, 84.5, 83.9, 83.6, 83.2, 82.8, 81.9, 42.2, 36.5,
34.5, 32.9, 27.9, 27.2, 26.7, 26.6, 26.0, 24.3, 23.14, 23.09, 22.8, 22.3,
21.5, 21.41, 21.38 ppm. IR (neat): ν˜max = 3600–2400 (OH), 1714
(C=O of benzoates, ester and acid), 1288, 712 cm–1. HRMS (ESI):
calcd. for C44H58NaO12 [M + Na]+ 801.3826; found 801.3819.
Acid 4 (Minor Isomer): Oil. 1H NMR (400 MHz, CDCl3): δ = 7.9
(br. d, J = 7.4 Hz, 4 H), 7.51 (br. t, J = 7.3 Hz, 2 H), 7.40 (br. t, J
= 7.4 Hz, 4 H), 4.35 (dd, J = 7.2, 7.2 Hz, 1 H), 4.24 (dd, J = 9.3,
5.9 Hz, 1 H), 4.07–3.99 (m, 2 H), 3.55 (dd, J = 7.2, 7.2 Hz, 1 H),
3.31 (d, J = 15.0 Hz, 1 H), 2.98 (d, J = 15.0 Hz, 1 H), 2.61–2.53
(m, 1 H), 2.19–2.10 (m, 1 H), 2.05–1.76 (14 H, overlapped mul-
tiplets), 1.64, 1.63, 1.60, 1.59, 1.48, 1.47, 1.15, 1.12 (3 H each, sing-
lets, 8!Me) ppm. 13C NMR (100 MHz, CDCl3): δ = 174.8, 172.9,
165.8, 165.7, 132.6, 132.4, 132.0, 131.7, 129.5, 129.4, 128.19,
128.16, 86.3, 86.0, 85.8, 85.5, 85.1, 84.3, 83.9, 83.8, 83.7, 83.4, 81.5,
43.0, 36.4, 34.7, 34.4, 26.95, 26.88, 26.82, 25.2, 24.1, 23.0, 22.7,
21.7 ppm. IR (neat): ν˜max = 3600–2400 (OH), 1712 (C=O of benzo-
ates, ester and acid), 1287, 712 cm–1. HRMS (ESI): calcd. for
C44H58NaO12 [M + Na]+ 801.3826; found 801.3835.
Oxidation of 2 with PCC (cat.)/H5IO6: PCC (2 mol-%, 700 µL of a
0.01  stock solution in acetonitrile) was added at 0 °C with vigor-
ous stirring to a suspension of H5IO6 (4 equiv., 78.8 mg,
0.35 mmol) in acetonitrile (1.5 mL). After 5 min, compound 2
(61 mg, 0.083 mmol) dissolved in acetonitrile (650 µL) was added.
After 3 h, CH2Cl2 (1.5 mL) was added followed by ethanol (40 µL)
and the mixture was taken to dryness. Filtration through a short
pad of sodium thiosulfate adsorbed on silica[3] (CHCl3/MeOH 9:1)
gave an oily product (50 mg). Further elution with CHCl3/MeOH
(8:2) gave a mixture of polar products (14 mg) that was not studied
further. The first eluted fraction was separated as described above
for the analogous process with PCC/AcOH to give compounds 3
(20.6 mg, 40%) and 4 (2.2 mg, 4%), along with slightly impure
ketol 30 (tR = 5.0 min), lactone 31 (tR = 13.5 min) and 32 (tR =
16.5 min). A further reversed-phase HPLC run (250!4.0 mm col-
umn; flow: 1.0 mLmin–1; 2 mg/injection) was required to obtain
pure 30 (MeCN/H2O 9:1, 4.6 mg, 2%, tR = 14.0 min), 31 (MeCN/
H2O 85:15, 3.0 mg, 2%, tR = 5.2 min) and 32 (MeCN/H2O 8:2,
1.0 mg, 1%, tR = 2.0 min).
Ketol 30: Oil. 1H NMR (700 MHz, CDCl3): δ = 7.99 (d, J = 6.9 Hz,
2 H), 7.98 (d, J = 6.5 Hz, 2 H), 7.52 (t, J = 7.3 Hz, 2 H), 7.43 (t,
J = 7.7 Hz, 2 H), 7.40 (t, J = 7.6 Hz, 2 H), 4.33 (br. s, 1 H, OH),
4.16 (dd, J = 9.2, 6.0 Hz, 1 H), 4.10 (dd, J = 8.2, 7.0 Hz, 1 H), 3.89
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(m, 1 H), 3.72 (m, 2 H), 2.66 (ddd, J = 12.7, 10.5, 5.4 Hz, 1 H),
2.55 (d, J = 16.9 Hz, 1 H), 2.44 (d, J = 16.9 Hz, 1 H), 2.18 (ddd,
J = 12.3, 9.3, 8.2 Hz, 1 H), 2.03–1.83 (12 H, overlapped multiplets),
1.71–1.61 (m, 2 H), 1.60 (s, 6 H, 2! Me),1.58, 1.55, 1.36, 1.29,
1.14, 1.07 (3 H each, singlets, 6! Me) ppm. 13C NMR (175 MHz,
CDCl3): δ = 212.7, 165.8, 165.7, 132.6, 132.4, 132.0, 131.6, 129.6,
129.4, 128.2, 128.1, 101.7, 86.4, 85.9, 85.70, 85.68, 85.65, 84.3,
83.51, 83.46, 83.2, 82.9, 77.8, 48.4, 35.1, 34.4, 31.8, 27.0, 26.86,
26.83, 26.81, 26.0, 24.6, 24.4, 22.82, 22.79, 22.74, 22.2, 21.6,
20.1 ppm. IR (neat): ν˜max = 3301 (broad, OH), 1712 (C=O of benz-
oates and ketone), 1287, 712 cm–1. HRMS (ESI): calcd. for
C44H58NaO11 [M + Na]+ 785.3877; found 785.3884.
Lactone 31: Oil. 1H NMR (500 MHz, CDCl3): δ = 7.96 (br. d, J =
7.0 Hz, 2 H), 7.53 (br. t, J = 7.4 Hz, 1 H), 7.41 (br. t, J = 7.5 Hz,
2 H), 4.25 (dd, J = 7.0, 7.0 Hz, 1 H), 3.94 (dd, J = 9.0, 6.2 Hz, 1
H), 3.88 (dd, J = 7.2, 7.2 Hz, 1 H), 3.78 (dd, J = 9.4, 5.1 Hz, 1 H),
2.80 (ddd, J = 17.4, 10.1, 10.2 Hz, 1 H), 2.47 (ddd, J = 17.4, 10.6,
3.5 Hz, 1 H), 2.39 (ddd, J = 13.9, 10.7, 3.5 Hz, 1 H), 2.09–1.65 (13
H, overlapped multiplets), 1.63, 1.58, 1.31, 1.22, 1.11 (3 H each,
singlets, 5! Me) ppm. 13C NMR (100 MHz, CDCl3): δ = 177.6,
165.7, 132.5, 131.9, 129.4, 128.2, 86.5, 85.7, 85.2, 84.6, 84.0, 83.6,
83.4, 82.7, 35.0, 32.7, 29.8, 27.8, 27.3, 26.8, 26.6, 23.5, 23.3, 23.2,
23.0, 22.9, 21.3 ppm. IR (neat): ν˜max = 1773 (C=O lactone), 1711
(C=O benzoate), 1288, 1071, 713 cm–1. HRMS (ESI): calcd. for
C29H40NaO7 [M + Na]+ 523.2672; found 523.2668.
Acid 32: Oil. 1H NMR (500 MHz, CDCl3): δ = 7.97 (br. d, J =
7.3 Hz, 2 H), 7.55 (br. t, 1 H, J = 7.3 Hz), 7.44 (br. t, 2 H, J =
7.7 Hz), 5.62 (dd, 1 H, J = 9.3, 3.1 Hz), 2.86 (dd, 1 H, J = 16.1,
3.2 Hz), 2.74 (dd, 1 H, J = 16.1, 9.4 Hz), 2.11 (s, 3 H), 1.66, 1.65
(3 H each, singlets, 2! Me) ppm. 13C NMR (100 MHz, CDCl3): δ
= 175.2, 170.1, 165.1, 133.0, 131.1, 129.5, 128.4, 82.4, 73.9, 34.9,
22.4, 21.7, 20.9 ppm. IR (neat): ν˜max = 3600–2400 (OH), 1744
(C=O acetate), 1715 (C=O benzoate and acid), 1283, 712 cm–1.
HRMS (ESI): calcd. for C15H18NaO6 [M + Na]+ 317.1001; found
317.1009.
Oxidation of 5 with PCC (cat.)/H5IO6: PCC (1 mol-%, 38 µL of a
0.01  stock solution in acetonitrile) was added at 0 °C with vigor-
ous stirring to a suspension of H5IO6 (4 equiv., 0.15 mmol,
34.2 mg) in acetonitrile (600 µL). After 5 min, compound 5
(32.3 mg, 0.037 mmol) dissolved in acetonitrile (150 µL) was added.
After 2 h, a further 1 mol-% PCC was added and the mixture was
kept at 0 °C for an additional 1 h. CH2Cl2 (700 µL) was then added
followed by ethanol (40 µL) and the mixture was taken to dryness.
Filtration through a short pad of sodium thiosulfate adsorbed on
silica (CHCl3/MeOH 9:1) gave an oily product (19 mg). Separation
by HPLC (250!4.6 mm column; flow: 1.0 mLmin–1; 1 mg/injec-
tion, hexane/EtOAc 75:25) gave compounds 6 (10.0 mg, 30%), 7
(2.0 mg, 6%) and 8 (2.9 mg, 9%).
Acid 6 (Major Isomer): Oil. 1H NMR (400 MHz, CDCl3): δ = 8.02
(d, J = 8.2 Hz, 4 H), 7.96 (d, J = 8.0 Hz, 4 H), 7.55–7.45 (m, 4 H),
7.44–7.38 (m, 8 H), 5.40 (dd, J = 9.7, 3.1 Hz, 1 H), 4.49 (dd, J =
8.5, 6.2 Hz, 1 H), 4.44 (dd, J = 7.4, 7.4 Hz, 1 H), 4.40–4.28 (4 H,
overlapped multiplets), 2.73 (dd, J = 15.8, 3.0 Hz, 1 H), 2.64 (dd,
J = 15.8, 9.8 Hz, 1 H), 2.37 (ddd, J = 12.6, 7.9, 6.0 Hz, 1 H), 2.29–
2.19 (m, 2 H), 2.17–2.00 (m, 2 H), 1.98–1.58 (12 H, overlapped
multiplets), 1.57, 1.55, 1.45, 1.19 (3 H each, singlets, 4!Me) ppm.
13C NMR (100 MHz, CDCl3): δ = 174.2, 173.4, 166.8, 166.6, 165.8,
165.6, 132.93, 132. 87, 132.7, 131.5, 131.4, 130.26, 130.21, 129.6,
129.55, 129.50, 128.32, 128.27, 85.2, 85.0, 83.9, 83.5, 83.3, 81.3,
75.0, 65.3, 65.0, 36.1, 35.7, 33.7, 31.6, 31.5, 26.9, 25.9, 24.1, 23.5,
23.2, 22.7, 20.4, 20.2 ppm. IR (neat): ν˜max = 3600–2400 (OH), 1717
(C=O benzoates, ester and acid), 1279, 1119, 710 cm–1. HRMS
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(ESI): calcd. for C52H58NaO14 [M + Na]+ 929.3724; found
929.3736.
Acid 7 (Minor Isomer): Oil. 1H NMR (400 MHz, CDCl3): δ = 8.04
(br. d, J = 7.0 Hz, 2 H), 8.02 (br. d, J = 5.5 Hz, 2 H), 7.98 (br. d,
J = 8.0 Hz, 4 H), 7.53 (m, 4 H), 7.41 (m, 8 H), 5.41 (dd, J = 6.1,
6.1 Hz, 1 H), 4.64 (dd, J = 7.4, 7.4 Hz, 1 H), 4.49–4.44 (m, 5 H),
2.63 (dd, J = 15.7, 7.3 Hz, 1 H), 2.56 (dd, J = 15.8, 5.9 Hz, 1 H),
2.44 (br. ddd, J = 12.5, 5.5, 5.5 Hz, 1 H), 2.23–1.70 (16 H, over-
lapped multiplets), 1.64, 1.53, 1.44, 1.28 (3 H each, singlets, 4!
Me) ppm. 13C NMR (100 MHz, CDCl3): δ = 172.9, 171.3, 167.2,
167.0, 165.8, 165.7, 133.03, 132.98, 132.7, 132.6, 131.6, 131.4,
130.1, 129.64, 129.57, 129.4, 128.34, 128.29, 85.3, 84.6, 84.3, 84.1,
83.9, 83.5, 74.9, 65.5, 65.3, 36.5, 35.0, 33.4, 32.0, 31.1, 26.9, 26.3,
24.8, 24.4, 23.6, 23.2, 20.8, 20.6 ppm. IR (neat): ν˜max = 3600–2400
(OH), 1714 (C=O benzoates, ester and acid), 1277, 1113, 711 cm–1.
HRMS (ESI): calcd. for C52H58NaO14 [M + Na]+ 929.3724; found
929.3742.
Diketone 8: Oil. 1H NMR (200 MHz, CDCl3): δ = 8.10–7.91 (m, 8
H), 7.62–7.32 (m, 12 H), 4.54–4.24 (6 H, overlapped multiplets),
3.17–2.94 (m, 1 H), 2.94–1.68 (19 H, overlapped multiplets), 1.63
(s, 6 H), 1.37 (s, 3 H), 1.34 (s, 3 H) ppm. 13C NMR (100 MHz,
CDCl3): δ = 214.0, 212.7, 166.5, 165.7, 132.8, 132.7, 131.6, 131.4,
130.35, 130.31, 129.55, 129.53, 129.48, 129.43, 128.35, 128.31, 88.9,
88.7, 84.93, 84.92, 84.2, 83.4, 65.0, 35.2, 34.8, 32.3, 31.8, 30.8, 29.9,
26.3, 24.2, 23.7, 23.55, 23.51, 20.6, 20.4 ppm. IR (neat): ν˜max =
1710 (C=O benzoates and ketones), 1274, 1111, 710 cm–1. HRMS
(ESI): calcd. for C52H58NaO12 [M + Na]+ 897.3826; found
897.3815.
Oxidation of 9: PCC (2 mol-% , 80 µL of a 0.01  stock solution
in acetonitrile) was added at 0 °C with vigorous stirring to a sus-
pension of H5IO6 (4 equiv., 0.15 mmol, 35.4 mg) in acetonitrile
(600 µL). After 5 min, compound 9 (10.4 mg, 0.039 mmol) dis-
solved in acetonitrile (150 µL) was added. After 3.5 h, CH2Cl2
(750 µL) was added followed by ethanol (40 µL) and the mixture
was taken to dryness. Filtration through a short pad of sodium
thiosulfate adsorbed on silica (CHCl3/MeOH 9:1) gave almost pure
10 as an oil. Further purification by HPLC (250!4.6 mm column;
flow: 1.0 mLmin–1; CHCL3/MeOH 98:2, tr = 4.0 min) gave pure
10 (4.3 mg, 45%).
Compound 10: Oil. 1H NMR (500 MHz, CDCl3): δ = 3.01–2.92 (m,
2 H), 2.92–2.82 (m, 2 H), 2.65–2.53 (m, 6 H), 2.12–2.04 (m, 2 H),
1.55 (s, 6 H, 2!Me) ppm. 13C NMR (125 MHz, CDCl3): δ = 209.2
(2 C), 175.9 (2 C), 89.2 (2 C), 31.3 (2 C), 31.0 (2 C), 28.2 (2 C),
23.6 (2 C) ppm. IR (neat): ν˜max = 1774 (C=O lactones), 1717 (C=O
ketones) cm–1. HRMS (ESI): calcd. for C14H18NaO6 [M + Na]+
305.1001; found 305.1008.
Synthesis of Mono-THFs 11, 14, 16, 19, 22 and 24: The title com-
pounds were obtained by benzoylation of the corresponding THF
diols (synthesized as described previously[5g,5j,8,10]). Purification of
these compounds was achieved by column chromatography with
the following eluents: 11 (petroleum ether/diethyl ether 9:1), 14 (pe-
troleum ether/diethyl ether 1:1), 16 (petroleum ether/diethyl ether
6:4), 19 (petroleum ether/diethyl ether 1:1), 22 (40:70 petroleum
ether/diethyl ether 8:2), 24 (hexane/EtOAc 8:2).
Compound 11: Oil. 1H NMR: (200 MHz, CDCl3): δ = 8.13–7.88
(m, 6 H), 7.68–7.28 (m, 9 H), 5.65 (dd, J = 8.8, 2.9 Hz, 1 H), 4.80
(dd, J = 12.2, 2.9 Hz, 1 H), 4.59 (dd, J = 12.2, 8.8 Hz, 1 H), 4.33
(dd, J = 6.3 Hz, 1 H), 2.27–1.74 (m, 4 H), 1.67 (s, 3 H), 1.64 (s, 3
H), 1.43 (s, 3 H) ppm. 13C NMR (50 MHz, CDCl3): δ = 166.4,
166.0, 165.6, 133.0, 132.9, 132.5, 131.6, 129.8, 129.65 (2 C), 129.63,
129.5 (2 C), 129.3 (2 C), 128.4 (2 C), 128.3 (2 C), 128.2 (2 C), 83.5,
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83.0, 82.8, 76.2, 63.9, 34.6, 26.9, 23.6, 23.2, 21.3 ppm. IR (neat):
ν˜max = 1719 (C=O benzoates), 1281, 1111, 709 cm–1. HRMS (ESI):
calcd. for C31H32NaO7 [M + Na]+ 539.2046; found 539.2038.
Compound 14: Oil. 1H NMR (200 MHz, CDCl3): δ = 8.00 (m, 4
H), 7.66–7.30 (m, 6 H), 5.46 (dd, J = 8.8, 2.6 Hz, 1 H), 4.78–4.20
(5 H, overlapped multiplets), 2.15–1.88 (10 H, including two acetate
singlets at 2.02 and 1.96), 1.67 (s, 3 H), 1.36 (s, 3 H) ppm. 13C
NMR (50 MHz, CDCl3): δ = 170.9, 170.5, 166.1, 165.6, 133.1,
132.8, 131.0, 129.7 (2 C), 129.6 (3 C), 128.5 (2 C), 128.3 (2 C), 83.2,
83.0, 80.4, 76.1, 65.2, 63.3, 34.5, 26.8, 23.5, 20.80 (2 C), 18.9 ppm.
IR (neat): ν˜max = 1740 (C=O acetates), 1721 (C=O benzoates),
1275, 712 cm–1. HRMS (ESI): calcd. for C28H32NaO9 [M + Na]+
535.1944; found 535.1963.
Compound 16: Oil. 1H NMR (200 MHz, CDCl3): δ = 8.07 (d, J =
8.5 Hz, 2 H), 7.96 (d, J = 7.1 Hz, 2 H), 7.64–7.29 (m, 6 H), 5.20
(s, 1 H), 4.33 (dd, J = 7.7, 6.9 Hz, 1 H), 3.72 (s, 3 H), 2.56–2.38
(m, 1 H), 2.19–1.75 (m, 3 H), 1.61 (s, 3 H), 1.59 (s, 3 H), 1.46 (s, 3
H) ppm. 13C NMR (50 MHz, CDCl3): δ = 168.6, 166.0, 165.7,
133.3, 132.5, 131.6, 129.8 (3 C), 129.4 (2 C), 128.4 (2 C), 128.2 (2
C), 83.5, 83.3, 82.8, 78.0, 52.2, 34.3, 26.5, 23.4, 23.0, 21.3 ppm.
IR (neat): ν˜max = 1713 (C=O benzoates and CO2Me), 1285, 1113,
710 cm–1. HRMS (ESI): calcd. for C25H28NaO7 [M + Na]+
463.1733; found 463.1717.
Compound 19: Oil. 1H NMR (200 MHz, CDCl3): δ = 8.07 (d, J =
7.7 Hz, 2 H), 7.96 (d, J = 8.2 Hz, 4 H), 7.64–7.30 (m, 9 H), 5.65
(dd, J = 8.6, 2.7 Hz, 1 H), 4.75 (dd, J = 11.9, 2.8 Hz, 1 H), 4.55
(dd, J = 11.9, 8.6 Hz, 1 H), 4.32 (dd, J = 8.1, 6.6 Hz, 1 H), 2.27–
1.68 (m, 4 H), 1.60 (s, 6 H), 1.45 (s, 3 H) ppm. 13C NMR (50 MHz,
CDCl3): δ = 166.5, 166.0, 165.7, 133.04, 133.02, 132.4, 131.9, 130.1,
129.72 (2 C), 129.70, 129.6 (2 C), 129.4 (2 C), 128.4 (2 C), 128.3 (2
C), 128.2 (2 C), 85.5, 83.03, 83.01, 76.1, 64.0, 34.8, 26.7, 24.1, 22.6,
21.5 ppm. IR (neat): ν˜max = 1712 (C=O benzoates), 1278, 1109,
708 cm–1. HRMS (ESI): calcd. for C31H32NaO7 [M + Na]+
539.2046; found 539.2055.
Compound 22: Oil. 1H NMR (200 MHz, CDCl3): δ = 7.96–7.87 (d,
J = 6.9 Hz, 2 H), 7.59–7.35 (m, 3 H), 5.04 (AB system, J = 17.8 Hz,
2 H), 4.20 (dd, J = 7.2 Hz, 1 H), 2.54–2.39 (m, 1 H), 2.13–1.77 (6
H, overlapped multiplets including the acetate singlet at 2.08), 1.71
(s, 3 H), 1.61 (s, 3 H), 1.41 (s, 3 H) ppm. 13C NMR (50 MHz,
CDCl3): δ = 206.5, 170.2, 165.7, 132.7, 131.4, 129.3 (2 C), 128.4 (2
C), 88.5, 85.9, 82.7, 65.7, 35.4, 26.0, 23.6, 22.8, 22.6, 20.4 ppm. IR
(neat): ν˜max = 1735 (C=O acetate), 1716 (C=O benzoate and
ketone), 1289, 712 cm–1. HRMS (ESI): calcd. for C19H24NaO6 [M
+ Na]+ 371.1471; found 371.1489.
Compound 24: Oil. 1H NMR (500 MHz, CDCl3): δ = 8.05 (br. d, J
= 8.4 Hz, 4 H), 7.55 (br. t, J = 7.4 Hz, 2 H), 7.42 (br. t, J = 7.8 Hz,
4 H), 4.42 (2 H, overlapped multiplets), 4.39–4.32 (4 H, overlapped
multiplets), 2.12 (m, 2 H), 1.89 (m, 2 H) ppm. 13C NMR (50 MHz,
CDCl3): δ = 166.4 (2 C), 132.9 (2 C), 130.0 (2 C), 129.6 (4 C), 128.3
(4 C), 77.5 (2 C), 66.6 (2 C), 27.8 (2 C) ppm. IR (neat): ν˜max =
1715 (C=O benzoates), 1268, 709 cm–1. HRMS (ESI): calcd. for
C20H20NaO5 [M + Na]+ 363.1208; found 363.1220.
Synthesis of 20: K2CO3 (2 equiv., 0.4 mmol, 55 mg) was added to
compound 11 (106 mg, 0.20 mmol) dissolved in MeOH (5 mL) and
the mixture was stirred at room temp. for 1.5 h. Water (1 mL) was
added followed by acetic acid up to neutrality. The mixture was
taken to dryness in vacuo and the solid was partitioned between a
sat. NaHCO3 solution and EtOAc. The organic phase was washed
with water, dried and concentrated to give an oily product
(65.9 mg).
NaIO4 supported on wet silica (2.4 equiv., 0.47 mmol, 746 mg;
0.64 mmolg–1) was added to the crude product obtained above, dis-
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solved in CH2Cl2 (5 mL), and the mixture was stirred for 30 min
at room temp. The reaction mixture was filtered, the solid was thor-
oughly washed with CH2Cl2, and the filtrate was taken to dryness
to give an oily product.
Sodium borohydride (two spatula tips) was added to the above oil
(55.1 mg), dissolved in EtOH (4 mL). After 30 min, acetic acid was
added dropwise until no gas evolution was observed. The mixture
was filtered and the filtrate was taken to dryness to give an oily
product.
The above oil (33.0 mg, 0.12 mmol) was dissolved in pyridine
(500 µL) and benzoyl chloride (1.1 equiv., 0.13 mmol, 15 µL) was
added. After 1 h, water (100 µL) was added and the mixture was
taken to dryness. Purification by preparative TLC (hexane/EtOAc
1:1) yielded pure 20 (33.0 mg, 43% over four steps).
Compound 20: Oil. 1H NMR (200 MHz, CDCl3): δ = 8.06 (d, J =
7.0 Hz, 2 H), 7.98 (d, J = 6.9 Hz, 2 H), 7.61–7.33 (6 H, overlapped
multiplets), 4.38 (d, J = 11.1 Hz, 1 H), 4.31 (m, 1 H), 4.20 (d, J =
11.1 Hz, 1 H), 2.20–1.73 (m, 4 H), 1.64 (s, 3 H), 1.61 (s, 3 H), 1.38
(s, 3 H) ppm. 13C NMR (50 MHz, CDCl3): δ = 166.4, 165.7, 133.0,
132.5, 131.7, 130.1, 129.5 (2 C), 129.4 (2 C), 128.3 (2 C), 128.2 (2
C), 83.8, 83.4, 81.8, 69.7, 34.5, 26.8, 24.1, 23.0, 21.4 ppm. IR (neat):
ν˜max = 1712 (C=O benzoates), 1277, 1112, 709 cm–1. HRMS (ESI):
calcd. for C23H26NaO5 [M + Na]+ 405.1678; found 405.1670.
General Reaction Procedure for the Oxidation of Mono-THF Com-
pounds 11, 14, 16, 19, 20, 22 and 24: PCC (5 mol-%, from a 0.01 
stock solution in acetonitrile) was added at room temp. with vigor-
ous stirring to a suspension of H5IO6 (4 equiv.) in acetonitrile. Af-
ter 5 min the mono-THF compound (1 equiv.) dissolved in acetoni-
trile was added. The overall volume of acetonitrile was such that
the final concentration of the solution was 0.05 . After complete
consumption of the starting material (TLC monitoring, usually 45–
60 min), ethanol (excess) was added and stirring was continued un-
til the colour of the solution had turned from yellow to green. Silica
(excess) was then added and the solvent was evaporated in vacuo
to give a fine powder that was loaded on the top of a silica gel
column. Elution with CHCl3/MeOH (9:1) allowed recovery of the
acid that proved to be pure enough for successive spectral studies
and/or synthetic steps.
Compound 11 (112.0 mg, 0.22 mmol) was subjected to the stan-
dard oxidative procedure to give the crude acid as a yellow oil. It
was purified by column chromatography (CH2Cl2/MeOH 95:5) to
yield 12 (99 mg, 80%) and lactone 13 (8.0 mg, 10%) as oils.
Compound 12: Oil. 1H NMR: (200 MHz, CDCl3): δ = 8.00 (d, J =
7.7 Hz, 2 H), 7.87 (m, 4 H), 7.57–7.28 (m, 9 H), 5.89 (dd, J = 7.8,
3.1 Hz, 1 H), 4.74 (dd, J = 12.2, 3.1 Hz, 1 H), 4.45 (dd, J = 12.2,
7.8 Hz, 1 H), 3.24 (AB system, J = 15.6 Hz, 2 H), 1.86 (s, 3 H),
1.71 (s, 6 H) ppm. 13C NMR (50 MHz, CDCl3): δ = 174.1, 171.1,
166.0, 165.5, 165.2, 133.15, 133.12, 133.0, 129.8, 129.6 (6 C), 129.5,
129.3, 128.35 (4 C), 128.28 (2 C), 82.0, 79.0, 74.6, 62.8, 39.2, 24.55,
24.46, 21.3 ppm. IR (neat): ν˜max = 3600–2400 (OH), 1717 (C=O
benzoates, ester and acid), 1282, 1107, 709 cm–1. HRMS (ESI):
calcd. for C31H30NaO10 [M + Na]+ 585.1737; found 585.1723.
Compound 13: Oil. 1H NMR (200 MHz, CDCl3): δ = 8.04 (d, J =
7.9 Hz, 2 H), 7.92 (d, J = 8.0 Hz, 2 H), 7.67–7.31 (m, 6 H), 5.66
(dd, J = 8.3, 3.2 Hz, 1 H), 4.85 (dd, J = 12.1, 3.2 Hz, 1 H), 4.52
(dd, J = 12.1, 8.3 Hz, 1 H), 2.61 (t, J = 7.6 Hz, 2 H), 2.37 (ddd, J
= 13.1, 7.6, 7.6 Hz, 1 H), 2.08 (ddd, J = 13.1, 9.5, 9.5 Hz, 1 H),
1.66 (s, 3 H) ppm. 13C NMR (50 MHz, CDCl3): δ = 176.2, 166.2,
165.5, 133.7, 133.2, 129.9 (2 C), 129.6 (2 C), 129.4, 128.9, 128.7 (2
C), 128.4 (2 C), 85.2, 75.6, 62.8, 31.5, 28.9, 24.2 ppm. IR (neat):
ν˜max = 1778 (C=O lactone), 1721 (C=O benzoates), 1259, 709 cm–1.
Catalytic Oxidation of Tetrahydrofuran Compounds
HRMS (ESI): calcd. for C21H20NaO6 [M + Na]+ 391.1158; found
391.1167.
Compound 14 (13.5 mg, 0.026 mmol) was subjected to the stan-
dard oxidative procedure to give the crude acid as an oil. This was
purified by column chromatography (CH2Cl2/MeOH 95:5) to yield
15 (9.4 mg, 65%) as an oil.
Compound 15: Oil. 1H NMR (200 MHz, CDCl3): δ = 8.0 (m, 4 H),
7.65–7.29 (m, 6 H), 5.75 (dd, J = 7.8, 2.9 Hz, 1 H), 4.67–4.49 (m,
3 H), 4.21 (dd, J = 12.1, 7.8 Hz, 1 H), 3.20 (AB system, J =
15.7 Hz, 2 H), 2.09 (s, 3 H, acetate), 1.94 (s, 3 H, acetate), 1.85 (s,
3 H), 1.73 (s, 3 H) ppm. 13C NMR (50 MHz, CDCl3): δ = 172.4,
172.3, 170.5, 170.3, 165.24, 165.17, 133.4, 133.3, 130.1, 129.8 (2 C),
129.7 (2 C), 129.6, 128.5 (4 C), 82.8, 79.4, 74.3, 66.0, 62.2, 38.9,
21.1, 20.71, 20.68, 19.7 ppm. IR (neat): ν˜max = 3600–2400 (OH),
1740 (shoulder, C=O acetates) 1721 (C=O benzoates, ester and
acid), 1273, 1226, 711 cm–1. HRMS (ESI): calcd. for C28H30NaO12
[M + Na]+ 581.1635; found 581.1651.
Compound 16 (23.8 mg, 0.050 mmol) was subjected to the stan-
dard oxidative procedure to give an oil, which was separated by
column chromatography (CH2Cl2 to CH2Cl2/MeOH 95:5) to yield
acid 17 (7.3 mg, 30%) and lactone 18 (6.4 mg, 45%) as oils.
Compound 17: Oil. 1H NMR (400 MHz, CDCl3): δ = 8.02–7.89 (m,
4 H), 7.61–7.44 (m, 2 H), 7.44–7.29 (m, 4 H), 5.69 (s, 1 H), 3.64 (s,
3 H), 3.42 (d, J = 16.2 Hz, 1 H), 3.27 (d, J = 16.2 Hz, 1 H), 1.91
(s, 3 H), 1.65 (s, 3 H), 1.63 (s, 3 H) ppm. 13C NMR (100 MHz,
CDCl3): δ = 171.4, 171.0, 167.4, 165.4, 165.2, 133.4, 133.1, 130.2,
129.85, 129.84 (2 C), 129.6 (2 C), 128.4 (2 C)128.2 (2 C), 81.1, 78.8,
75.8, 52.4, 39.0, 24.6, 24.1, 20.7 ppm. IR (neat): ν˜max = 3600–2400
(OH), 1719 (C=O benzoates, esters and acid), 1287, 1110, 712 cm–1.
HRMS (ESI): calcd. for C25H26NaO10 [M + Na]+ 509.1424; found
509.1418.
Compound 18: Oil. 1H NMR (200 MHz, CDCl3): δ = 8.06, (d, J =
7.0 Hz, 2 H), 7.63 (t, J = 6.5 Hz, 1 H), 7.48 (t, J = 7.7 Hz, 2 H),
5.26 (s, 1 H), 3.80 (s, 3 H), 2.76–2.52 (m, 3 H), 2.20–2.01 (m, 1 H),
1.65 (s, 3 H) ppm. 13C NMR (50 MHz, CDCl3): δ = 175.6, 167.3,
165.5, 133.8, 129.9 c, 128.6 (3 C), 84.3, 77.2, 52.9, 30.9, 28.7,
23.8 ppm. IR (neat): ν˜max = 1781 (C=O lactone), 1726 (C=O benz-
oate and CO2Me), 1271, 1112, 714 cm–1. HRMS (ESI): calcd. for
C15H16NaO6 [M + Na]+ 315.0845; found 315.0853.
Compound 19 (9.7 mg, 0.019 mmol) was subjected to the standard
oxidative procedure to give the crude acid as an oil. This was puri-
fied by column chromatography (CH2Cl2/MeOH 95:5) to yield 12
(7.3 mg, 70%).
Compound 20 (31.0 mg, 0.081 mmol) was subjected to the stan-
dard oxidative procedure to give the crude acid as an oil. This was
purified by column chromatography (CH2Cl2/MeOH 95:5) to yield
21 (21.5 mg, 65%) as an oil.
Compound 21: Oil. 1H NMR (200 MHz, CDCl3): δ = 7.94 (m, 4
H), 7.60–7.44 (m, 2 H), 7.42–7.28 (m, 4 H), 4.60 (AB system, J =
11.7 Hz, 2 H), 3.12 (br. s, 2 H), 1.71 (s, 3 H), 1.64 (s, 6 H) ppm.
13C NMR (50 MHz, CDCl3): δ = 174.9, 171.3, 165.8, 165.4, 133.05,
133.02, 129.8, 129.65, 129.6 (2 C), 129.5 (2 C), 128.35 (2 C), 128.30
(2 C), 80.4, 78.9, 67.5, 39.9, 24.5 (2 C), 21.0 ppm. IR (neat): ν˜max
= 3600–2400 (OH), 1716 (C=O benzoates, ester and acid), 1284,
1109, 710 cm–1. HRMS (ESI): calcd. for C23H24NaO8 [M + Na]+
451.1369; found 451.1360.
Compound 22 (10.1 mg, 0.029 mmol) was subjected to the stan-
dard oxidative procedure to give an oil, which was purified by
HPLC (hexane/EtOAc 7:3) to yield 1,4-diketone 23 (5.3 mg, 70%),
as an oil.
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Compound 23: Oil. 1H NMR (200 MHz, CDCl3): δ = 8.04 (d, J =
8.3 Hz, 2 H), 7.59 (t, J = 7.2 Hz, 1 H), 7.45 (t, J = 7.7 Hz, 2 H),
2.78 (m, 4 H), 2.19 (s, 3 H), 1.65 (s, 6 H) ppm. 13C NMR (50 MHz,
CDCl3): δ = 207.8, 207.3, 165.9, 133.4, 129.8 (2 C), 129.4, 128.4 (2
C), 84.2, 37.0, 30.1, 30.0, 23.8 (2 C) ppm. IR (neat): ν˜max = 1715
(C=O benzoate and ketones), 1287, 714 cm–1. HRMS (ESI): calcd.
for C15H18NaO4 [M + Na]+ 285.1103; found 285.1109.
Compound 24 (107.0 mg, 0.31 mmol) was subjected to the stan-
dard oxidative procedure with PCC (2 mol-%) to give 1,4-diketone
25 (109 mg, 98%).
Compound 25: Amorphous solid. 1H NMR (200 MHz, CDCl3): δ
= 8.09 (d, J = 7.2 Hz, 4 H), 7.58 (t, J = 7.5 Hz, 2 H), 7.45 (t, J =
7.7 Hz, 4 H), 4.95 (s, 4 H), 2.87 (s, 4 H) ppm. 13C NMR (50 MHz,
CDCl3): δ = 202.7 (2 C), 165.8 (2 C), 133.5 (2 C), 129.9 (4 C), 129.0
(2 C), 128.4 (4 C), 68.3 (2 C), 32.0 (2 C) ppm. IR (neat): ν˜max =
1713 (C=O benzoates and ketones), 1275, 715 cm–1. HRMS (ESI):
calcd. for C20H18NaO6 [M + Na]+ 377.1001; found 377.1015.
Synthesis of Umbelactone
Trihydroxy Acid 43: K2CO3 (2.0 equiv. 58 mg, 0.42 mmol) was
added to acid 12 (118.1 mg, 0.21 mmol), dissolved in MeOH
(5 mL), and the mixture was stirred at room temp. for 2.5 h. Water
(1 mL) was added followed by acetic acid up to neutrality. The
mixture was taken to dryness in vacuo and the solid was parti-
tioned between a sat. NaHCO3 solution and EtOAc. The organic
phase was washed with water, dried and concentrated to give 43
(31.2 mg, 90%), which was used in the next step without further
purification.
Compound 43: 1H NMR (500 MHz, CD3OD): δ = 3.78 (dd, J =
10.9, 2.5 Hz, 1 H), 3.58 (dd, J = 10.9, 7.9 Hz, 1 H), 3.53 (dd, J =
7.9, 2.5 Hz, 1 H), 2.49 (d, J = 14.9 Hz, 1 H), 2.35 (d, J = 14.9 Hz,
1 H), 1.36 (s, 3 H) ppm. 13C NMR (125 MHz, CD3OD): δ = 180.6,
79.0, 73.5, 63.9, 45.6, 24.7 ppm. HRMS (ESI): calcd. for
C6H12NaO5 [M + Na]+ 187.0582; found 187.0590.
Dihydroxylactone 45: Excess CH2N2 in Et2O was added to tri-
hydroxy acid 43 (30.0 mg, 0.18 mmol), dissolved in MeOH (4 mL),
until a yellow colour persisted. The mixture was stirred for a fur-
ther 10 min and the excess of CH2N2 was then destroyed by drop-
wise addition of acetic acid until the solution became colourless.
The mixture was taken to dryness to give an oil, which was purified
by column chromatography (CH2Cl2/MeOH 9:1) to yield lactone
45 (23.5 mg, 90%) as a clear oil.
Compound 45: Oil. 1H NMR (200 MHz, CDCl3): δ = 4.30 (dd, J =
6.0, 4.4 Hz, 1 H), 3.86 (m, 2 H), 2.77 (d, J = 17.2 Hz, 1 H), 2.50
(d, J = 17.2 Hz, 1 H), 1.44 (s, 3 H) ppm. 13C NMR (50 MHz,
CDCl3): δ = 177.9, 90.1, 75.7, 61.0, 45.6, 24.5 ppm. IR (neat): ν˜max
= 3408 (broad, OHs), 1771 (C=O lactone) cm–1. HRMS (ESI):
calcd. for C6H10NaO4 [M + Na]+ 169.0477; found 169.0472.
Silylated Lactone 46: Imidazole (3.0 equiv., 28.6 mg, 0.42 mmol)
and tert-butyldimethylsilyl chloride (1.5 equiv., 31.5 mg,
0.21 mmol) were added to lactone 45 (21.3 mg, 0.14 mmol), dis-
solved in DMF (300 µL), and the mixture was stirred for 2.5 h at
room temp. MeOH (500 µL) was then added and stirring was con-
tinued for 30 min. The reaction mixture was concentrated on silica
and purified by column chromatography (hexane/EtOAc 1:1) to
yield compound 46 (34.9 mg, 96%) as a clear oil.
Compound 46: Oil. 1H NMR (200 MHz, CDCl3): δ = 4.19 (dd, J =
3.8, 2.8 Hz, 1 H), 4.12 (dd, J = 11.8, 2.8 Hz, 1 H), 4.02 (dd, J =
11.8, 3.8 Hz, 1 H), 3.66 (br. s, 1 H), 2.73 (d, J = 17.6 Hz, 1 H),
2.57 (d, J = 17.6 Hz, 1 H), 1.49 (s, 3 H), 0.90 (s, 9 H), 0.12 (s, 6
H) ppm. 13C NMR (50 MHz, CDCl3): δ = 174.7, 85.5, 75.4, 61.8,
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44.9, 26.7, 25.7 (3 C), 18.1, –5.6, –5.7 ppm. IR (neat): ν˜max = 3447
(broad, OH), 1782 (C=O lactone) cm–1. HRMS (ESI): calcd. for
C12H24NaO4Si [M + Na]+ 283.1342; found 283.1339.
Unsaturated Lactone 47: Thionyl chloride (5 equiv., 0.55 mmol,
40 µL) was added to lactone 46 (30.0 mg, 0.11 mmol), dissolved in
pyridine (500 µL), and the mixture was stirred at 0 °C for 30 min.
Water (500 µL) was added and the reaction mixture was evaporated
in vacuo to give an oily product. Column chromatography (hexane/
EtOAc 8:2) yielded compound 47 (25.3 mg, 95%) as a clear oil.
Compound 47: Oil. 1H NMR (500 MHz, CDCl3): δ = 5.83 (br. s, 1
H), 4.82 (br. s, 1 H), 3.94 (dd, J = 11.3, 3.7 Hz, 1 H), 3.90 (dd, J
= 11.3, 3.5 Hz, 1 H), 2.10 (s, 3 H), 0.85 (s, 9 H), 0.06 (s, 3 H), 0.05
(s, 3 H) ppm. 13C NMR (125 MHz, CDCl3): δ = 173.2, 166.7,
118.1, 84.7, 61.7, 25.7 (3 C), 18.1, 14.1, –5.5, –5.6 ppm. IR (neat):
ν˜max = 1759 (C=O α,β-unsaturated lactone), 1132, 837, 778 cm–1.
HRMS (ESI): calcd. for C12H22NaO3Si [M + Na]+ 265.1236; found
265.1244.
Umbelactone (48): Et3N·3HF (20 equiv., 270 µL) was added to lac-
tone 47 (20.2 mg, 0.083 mmol), dissolved in dry THF (1 mL), and
the mixture was stirred for 2.5 h at room temp. Et3N (500 µL) was
then added and the mixture was taken to dryness. The residue was
co-evaporated with Et3N (2!500 µL) and MeOH (3!500 µL) and
concentrated to give an oil, which was purified by column
chromatography (EtOAc) to yield umbelactone 48 (9.8 mg, 92%)
as a clear oil.
Compound 48: Oil. 1H NMR (200 MHz, CDCl3): δ = 5.89 (br. s, 1
H), 4.91 (br. s, 1 H), 4.07 (dd, J = 12.7, 2.9 Hz, 1 H), 3.77 (dd, J
= 12.7, 3.9 Hz, 1 H), 2.11 (s, 3 H) ppm. 13C NMR (50 MHz,
CDCl3): δ = 172.8, 165.8, 118.3, 85.0, 61.5, 14.0 ppm. IR (neat):
ν˜max = 3404 (broad OH), 2921, 2851, 1731 (broad, C=O α,β-unsat-
urated lactone), 1647, 1050 cm–1. HRMS (ESI): calcd. for
C6H8NaO3 [M + Na]+ 151.0371; found 151.0375.
Supporting Information (see footnote on the first page of this arti-
cle): 1H and 13C NMR spectra.
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a b s t r a c t
A novel approach to the synthesis of purine nucleoside analogues, featuring the reaction of the C6eN1eO!
aldonitrone moiety of 9-ribosyl-purine (nebularine) N1-oxide with some representative dipolarophiles, as
well as Grignard reagents, is reported. Addition of Grignard reagents to the electrophilic C-6 carbon of the
substrate allows a facile access to C-6 C-substituted purine nucleosides without using metal catalysts. 1,3-
Dipolar cycloaddition processes lead to novel nucleoside analogues via opening, degradation or ring-
enlargement of the pyrimidine ring of the base system of the ﬁrst-formed isoxazoline or isoxazolidine
cycloadduct.
! 2011 Elsevier Ltd. All rights reserved.
1. Introduction
In the last decades many research groups have focused their
attention to the preparation of new modiﬁed nucleosides and nu-
cleotides with the aim of expanding the pool of molecules with
potential antineoplastic, antihypertensive and antiviral activities.1
In this context, efforts have been directed to the synthesis of
sugar2 and/or base3-modiﬁed nucleosides. A large number of
nucleobase analogues exist and several nucleoside analogues have
been employed against cancer and viral diseases. In addition, base-
modiﬁed nucleosides often show ﬂuorescent properties,4 and can
be used as ﬂuorescent probes for the analysis of DNA and RNA
structures as well as for analysing the interaction of DNA and RNA
with binding proteins. Purine bases and nucleosides bearing a C- or
N-substituent at C-6 represent an important class of compounds
possessing a broad spectrum of biological effects including cyto-
static, antiviral, antibacterial as well as receptoremodulation ac-
tivity.5 The reactivity imparted to purines and related nucleosides
by halogenation at C-6 has opened the way to the construction of
new libraries of C-6 modiﬁed nucleosides generally through direct
aromatic nucleophilic substitution (SNAr),6 or metal-mediated
cross-coupling processes3a,7 (Fig. 1). The most reliable methods to
access C-6 C-substituted nucleosides use metal or organometal-
mediated reactions.3a However, there is still a great need for the
development of new methods for the introduction of C-sub-
stituents at C-6.
Nitrones are precious substrates used in organic synthesis for
the assembly of structurally complex nitrogen-containing com-
pounds. Their most well-studied reactions are the 1,3-dipolar cy-
cloadditions (1,3-DC) and the nucleophilic addition of
organometallic reagents.8 We reasoned that 9-ribosyl-purine
(nebularine) N1-oxide (1a, Fig. 1), embodying a potentially reactive
C6eN1eO! nitronemoiety, could allow the C-6 functionalization of
the purine base. To probe this concept the reactivity of sugar-
protected 1b and 1c (Fig. 1) towards some representative
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dipolarophiles as well as Grignard reagents, respectively, was ex-
plored. The results obtained are described in the present paper.
2. Results and discussion
20,30,50-Tri-O-acetyl-nebularine N1-oxide (1b, Fig. 1) was used as
starting material for 1,3-DC processes whereas 20,30,50-tri-O-(tert-
butyldimethylsilyl)-nebularine N1-oxide (1c, Fig. 1) was employed
to test the addition of Grignard reagents. Compounds 1b and 1c
were synthesised from 20,30,50-tri-O-acetyl-nebularine and 20,30,50-
tri-O-(tert-butyldimethylsilyl)-nebularine, respectively,9 by re-
action of nebularine with catalytic amounts of methyltrioxo-
rhenium (MeReO3) in the presence of H2O2, as described in the
literature for the preparation of the corresponding purine N1-
oxide.10 Though the cycloaddition of aromatic N-oxides of various
heterocyclic systems has extensively been investigated,11 to our
knowledge no report exists in the literature on the reactivity of N-
oxides of purine nucleosides in cycloaddition reactions.
Reaction of compound 1b with some representative dipolar-
ophiles was carried out as shown in Table 1 and Scheme 1, to give
the novel nucleoside analogues 2 and 4e7, the structure of which
was determined by high-ﬁeld 2D-NMR analyses. As expected,12 in
all the analysed cases, we observed that the ﬁrst-formed
isoxazoline or isoxazolidine adduct did not survive. Therefore, the
nucleoside products obtained from such processes are all derived
from the cleavage of the N1eO bond in the cycloadduct followed in
some cases by further evolution of the ﬁrst-formed C-6 substituted
purine system. In particular, reaction of 1b with an equimolar
amount of dimethyl acetylenedicarboxylate in THF gave the two
unusual nucleoside analogues 2 (25%) and 4 (40%) (Table 1, entry 1)
possessing modiﬁed heterocyclic base systems. Compound 2
proved unstable as such giving a mixture of partially deacetylated
products on standing. However, its fully deacetylated derivative 3,
obtained by treatment of 2 with NH4OH (concd) in MeOH, was
a stable product, which was used for NMR characterisation. Com-
pound 4 contains the 5:7-fused imidazo[4,5-d][1,3]diazepine ring
system. The 1H NMR spectrum of 4 recorded in CD3OD showed it to
be a mixture of two tautomers in a 7:3 ratio. 2D-NMR studies car-
ried out in this solvent gave no conclusive evidences on the
structure of 4 that was eventually solved by performing NMR
analyses in DMSO-d6 where the major tautomer 4 was present in
88% amount. Few examples of nucleoside analogues based on this
base framework (ring-expanded nucleosides, RENs) exist all dis-
playing signiﬁcant biological activities.13 The interest towards this
type of substances is keen and the facile access to this framework is
particularly appealing. In particular, compound 4 is the ﬁrst ex-
ample of a C-7 analogue of coformycin,13c (Fig. 2) a highly potent
inhibitor of adenosine deaminase (ADA), an enzyme playing a key
role in purine metabolism.14
Table 1
Reaction of 1b with dipolarophiles
Entry Dipolarophile Conditions
(solvent)
Products
(yield %)
1 Dimethyl
acetylenedicarboxylate
rt, 2 h (THF) 2 (25%),
4 (40%)
2 3-Phenyl-2-propynenitrile rt, 16 h (THF) NR
3 3-Phenyl-2-propynenitrile Reﬂux, 4 h (dioxane) 5 (45%),
6 (30%)
4 N-Methylmaleimide rt, 5 h or reﬂux,
overnight (THF)
NR
5 N-Methylmaleimide Reﬂux, 5 h,
(dioxane/toluene, 1:1)
7 (60%)
6 Diphenylacetylene Reﬂux, overnight
(THF or dioxane)
NR
7 Dimethyl maleate or
dimethyl fumarate
Reﬂux, overnight
(toluene)
NR
NR: no reaction.
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A tentative explanation for the formation of 2 and 4 is depicted
in Scheme 2. Generation of their base system calls for the extrusion
of a two-carbon fragment from the initially-formed isoxazoline
adduct 8. In particular, formation of 2 can be explained via iso-
xazoline opening with concomitant base aromatization, to give the
C-6 substituted species 9 (route a) followed by loss of a COeCO2Me
fragment with formation of a two-carbon chain at C-6 (10).12
Evolution of 9 towards the conjugated species 10 via attack of
a nucleophile at the ketone carbonyl seems logical and would well
explain formation of the exocyclic double bond in 10. Trans-
formation of dimethyl a-ketosuccinates, such as 9 into methyl ac-
etates by loss of this structural fragment has previously been
reported.15 The electron-withdrawing effect of the exocyclic un-
saturated ester moiety in the latter may then be responsible for the
opening of the pyrimidine ring through attack of MeOH at C-2,
possibly in the work-up and/or puriﬁcation step, to eventually give
2. This type of reactivity at C-2 in 10 is strongly reminiscent of that
exhibited by the N1-2,4-dinitrophenyl-inosine derivatives, pre-
viously studied in our group, leading to formation of AICAR de-
rivatives.16 The imidazo 4-substituted framework of 2 is
unprecedented.
Scheme 2. A mechanistic hypothesis for the formation of 2 and 4.
As for compound 4, Stauss et al.17 reported formation of 2-
methyl-4-phenyl-5H-benzo[d][1,3]diazepin-5-carboxylic acid es-
ters as by-products of the reaction of 2-methyl-4-phenyl-quina-
zoline 3-oxide with dimethyl and diethyl acetylenedicarboxylates
and a plausible mechanistic hypothesis was given for the reaction
path leading to the benzodiazepine system. In particular, formation
of a cyclopropane-containing intermediate was postulated to be
responsible for the pyrimidine ring enlargement. In a similar way, it
is conceivable that the seven-membered ring in 4 can originate
from the electrocyclic opening of an aziridine-containing in-
termediate (11, Scheme 2), in turn formed by the fragmentation/
rearrangement of the initial adduct 8 (route b). The ring-enlarged
compound 12 would once again undergo elimination of the a-
ketoester side-chain possibly via nucleophilic attack at the ketone
carbonyl during work-up.
Non-symmetric 3-phenyl-2-propynenitrile failed to react with
1b at room temperature in THF (Table 1, entry 2) but gave a mixture
of C-6 substituted nucleosides 5 (45%) and 6 (30%) when the pro-
cess was conducted in dioxane at reﬂux (entry 3). Compound 5 is
likely derived from the opening of isoxazoline ring in one of the two
expected diastereomeric adducts 13 (Scheme 3) induced by loss of
the C6-H proton and aromatization of the heterocyclic system. On
the other hand, it seems hazardous trying to hypothesize a mech-
anistic route to C-6 benzoylated 6. However, it can be envisaged
that the oxidative cleavage of the double bond in the other adduct
(13, X¼Ph, Y¼CN), with loss of a two-carbon fragment and aro-
matization, should occur to generate 6. As far aswe know, the direct
introduction of acyl substituents at C-6 of the purine nucleoside
system has never been reported before, and this type of substances
is still rather rare.
5
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Scheme 3. A mechanistic hypothesis for the formation of 5 and 6.
Early attempts to induce reaction of 1b with N-methyl-
maleimide in THF, both at room temperature and at reﬂux (Table 1,
entry 4), were unsuccessful. However, when the process was car-
ried out in dioxane/toluene (1:1) at reﬂux (entry 5) the C-6 de-
rivative 7 was obtained in a 60% yield as a 1:1 mixture of
diastereomers, once again through isoxazoline opening and oxi-
dation at the maleimide portion. The ratio of isomers in the ini-
tially-formed mixture varied with HPLC puriﬁcation (silica column)
and/or on standing up to ca. 1:2, likely as a consequence of the
acidity of the C-6 proton next to the maleimide moiety. NMR data
could not provide unambiguous evidence on which is the major
diastereomer. Considering that the maleimide portion in 7 is sus-
ceptible to further synthetic modiﬁcations,18 access to C-6 mal-
eimido-derivatives, such as 7 opens the way to the preparation of
more complex and functionalised C-6 nucleoside derivatives.
Maleimido- or N-methylmaleimido-containing substances, both of
natural and non-natural origin, usually display signiﬁcant bi-
ological properties. For example, showdomycin19 is a potent nu-
cleoside antibiotic isolated from Streptomyces showdoensis, while
bisindolylmaleimides are known to be potent protein kinase C
(PKC) inhibitors.20
Finally, diphenylacetylene failed to react with 1b also on pro-
longed reﬂux both in THF and dioxane (Table 1, entry 6). Similar
results were obtained with dimethyl maleate and dimethyl fuma-
rate on reﬂux in toluene, also using excess reagents (Table 1, entry
7). The above results showed that nebularine oxide derivative 1b
displays the characteristic reactivity of nitrones towards electron-
poor dienophiles.
To further test the nitrone reactivity showed by 1a, we next
investigated the reaction of sugar-silylated 1c with some repre-
sentative Grignard reagents. It is known that nitrones smoothly
undergo nucleophilic addition of organometallic reagents. Indeed,
treatment of 1c with a 2-fold excess of a Grignard reagent afforded
the C-6 C-substituted N1-hydroxy adducts 14 as single products
(Table 2 and Scheme 4). These substances slowly decomposed on
standing, partly giving dehydration to C-6 substituted nebularine
derivatives 15e18. This process was pushed towards the latter
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substances in nearly quantitative yields, by treatment of the crude
C6-adducts with Ac2O in pyridine (6:4) at 50 $C. Formation of
15e18 indicated, as reported in the literature,21 the more electro-
philic nature of the C-6 atom of the nucleobase when compared to
the C-2 atom. The structure of the obtained compounds was
ascertained by high-ﬁeld 2D NMR and comparison with literature
data (see Experimental section).
Overall, reaction of 1c with Grignard reagents is of general ap-
plicability, working well with various types of substituents on the
organometallic partner, leading to compounds 15e18 in good yields
comparable22 to, or better7,23 than, those reported in the literature.
It is worth noting that our process allows the direct introduction of
a C-substituent on C-6 without using a metal catalyst. Based on
both the facile reaction and puriﬁcation procedures it is conceivable
that the process can be easily performed on gram scale opening the
way to obtain large amounts of C-6 C-substituted nucleosides
without employing different reaction conditions.
3. Conclusions
In conclusion, an unprecedented approach to the C-6 C-func-
tionalization of the purine nucleoside base system has been ex-
plored. In some cases, 1,3-DC reactions led to unexpected,
structurally intriguing, products through new reaction pathways.
Studies are in progress to investigate the scope of the described
processes as well as to further explore the synthetic potential of
nebularine N1-oxide. Since purine nucleosides, such as 14, em-
bodying the 6,9-dihydro-1H-purin-1-ol moiety are unprecedented,
future efforts will also focus on using these addition products to
prepare nucleoside analogues possessing novel modiﬁcations on
the base system. We believe that the developed procedures may
have future synthetic applications.
4. Experimental section
4.1. General methods
All reagents were obtained from commercial sources (Sigmae
Aldrich) and were used without further puriﬁcation. 1H and 13C
NMR spectra were performed on a Varian Mercury Plus 400 MHz
and Varian Unity Inova 700 MHz in CDCl3, CD3OD or DMSO-d6
solvents. Chemical shifts are reported in parts per million (d) rela-
tive to the residual solvent signals: CHCl3 7.27, CD2HOD 3.31,
CD2HSOCD3 2.49 for 1H NMR; CDCl3 77.0, CD2HOD 49.0,
CD2HSOCD3 39.5 for 13C NMR. 1H NMR chemical shifts were
assigned by 2D-NMR experiments. The abbreviations s, br s, d, dd
and m stand for singlet, broad singlet, doublet, doublet of doublets
and multiplet, respectively. HPLC analyses and puriﬁcations were
carried out on a Jasco UP-2075 Plus pump equipped with a Jasco
UV-2075 Plus UV detector using a 4.60%150 mm LUNA (Phenom-
enex) silica column (particle size 5 mm) eluted with a linear gra-
dient of AcOEt in hexane (from 50 to 100% in 30 min, ﬂow
1.0 mL min!1, system A; from 80 to 100% in 30 min, ﬂow
1.0 mL min!1, system B; from 50 to 100% in 60 min, ﬂow
1.0 mLmin!1, system C) or using a 4.8%150 mm C-18 reverse-phase
column (particle size 5 mm) eluted with a linear gradient of MeOH
in H2O (from 0 to 100% in 60 min, ﬂow 1.0 mL min!1, system D). UV
spectra were recorded on a Jasco V-530 UV spectrophotometer.
High Resolution MS spectra were recorded on a Bruker APEX II FT-
ICR mass spectrometer using electrospray ionization (ESI) tech-
nique in positive mode. IR spectra were recorded on a Jasco FT-
IRFTIR 430 spectrophotometer. Optical rotations were determined
on a Jasco polarimeter using a 1 dm cell at 20 $C; concentrations are
in g/100 mL. Column chromatography was performed on silica gel
(Merck, Kieselgel 60, 0.063e0.200 mm). Analytical TLC analyses
were performed using F254 silica gel plates (0.2 mm, Merck). TLC
spots were detected under UV light (254 nm).
4.2. Synthesis of 20,30,50-tri-O-acetyl-nebularine N1-oxide (1b)
Nebularine was acetylated overnight with Ac2Oepyridine under
standard conditions to give essentially pure triacetate. A mixture of
MeReO3 (5 mg, 0.02 mmol) and 30% aqueous H2O2 (0.4 mL,
4.0 mmol) in methanol (6 mL) was stirred at room temperature for
10 min. Then crude 20,30,50-tri-O-acetyl-nebularine (378 mg,
1.0 mmol) in methanol (4 mL) was added dropwise while stirring.
Stirring was continued at room temperature overnight. Then the
solvent was removed under reduced pressure and the crude was
puriﬁed on a silica gel column eluted with increasing amounts of
MeOH in CHCl3 (from 0 to 10%) to afford pure 20,30,50-tri-O-acetyl-
nebularine N1-oxide 1b (315 mg, 80% over two steps).
Compound 1b: white foam; ½a'20D !16.1 (c 0.13, CH3OH), 1H NMR
(400 MHz, CD3OD) dH 9.16 (d, J¼1.8 Hz, 1H), 9.04 (d, J¼1.8 Hz, 1H),
8.76 (s, 1H), 6.34 (d, J¼5.0 Hz,1H), 6.03e5.98 (m,1H), 5.69e5.65 (m,
1H), 4.52e4.48 (m, 1H), 4.44 (dd, J¼12.2, 3.5 Hz, 1H), 4.39 (dd,
J¼12.2, 4.9 Hz, 1H), 2.14 (s, 3H), 2.07 (s, 3H), 2.06 (s, 3H); 13C NMR
(100 MHz, CD3OD) dC 172.1, 171.3, 171.1, 150.5, 146.4, 145.3, 139.3,
135.5, 88.5, 81.7, 74.2, 71.7, 64.0, 20.6, 20.4, 20.2; m/z (HRESIMS)
Table 2
Reaction of 1c with Grignard reagents
Entry Grignard reagent (equiv) Conditions
(solvent)
Products (yield%,
over two steps)
1 Methylmagnesium bromide (2) rt, 2 h (THF) 15 (82%)
2 Vinylmagnesium bromide (2) rt, 2 h (THF) 16 (71%)
3 Phenylmagnesium bromide (2) rt, 2 h (THF) 17 (82%)
4 Propinylmagnesium bromide (2) rt, 2 h (THF) 18 (80%)
N
N N
NO
RO OR
RO
-O
1c R=TBDMS
N
N N
NO
RO OR
RO
R'
R'MgBr, THF
(2 equiv.), 2h, r.t.
Ac2O-pyridine
(6:4), 1h, 50°C
N
N N
NO
RO OR
RO
HO R'
14 Mixture of C-6
diastereomers
15 R'= Me
16 R'= CH=CH2
17 R'= Ph
18 R'= C CMe
6
Scheme 4. Reaction of 1c with representative Grignard reagents.
S. D’Errico et al. / Tetrahedron 67 (2011) 6138e6144 6141
395.1212 ([MþH]þ, C16H19N4O8, requires 395.1203); IR (neat) nmax
1748, 1495, 1424, 1369, 1229 cm!1; UV (MeOH) lmax 242, shoulder
267 nm.
4.3. Reaction of 1b with dimethyl acetylenedicarboxylate.
Synthesis of 2e4
A solution of 1b (50 mg, 0.13 mmol) and dimethyl acetylene-
dicarboxylate (18 mg, 0.13 mmol) in dry THF (2.5 mL) was stirred at
room temperature. After 2 h the process was complete (TLC mon-
itoring, AcOEt/MeOH, 95:5) and the solvent was evaporated under
reduced pressure. The crude was puriﬁed on a silica gel column
eluted with increasing amounts of MeOH in AcOEt (from 0 to 20%)
affording two main products: compound 2 (16 mg, 25%) and 4
(23 mg, 40%). The purity of 4was checked by HPLC analysis (System
A, tR¼30.0 min see General methods). Compound 2 (10 mg,
0.021 mmol) was treated with a concentrated aqueous solution of
NH4OH (0.5 mL) in MeOH (0.5 mL) for 30 min at room temperature.
The solvent was removed in vacuo and the crude was desaliﬁed by
RP-HPLC (SystemD, tR¼18.8min, see General methods) to give pure
3 (7.4 mg, 99%).
Compound 3: white foam; ½a'20D !15.6 (c 0.50, CH3OH), 1H NMR
(400 MHz, CD3OD) dH 7.89 (s, 1H, H-2), 7.87 (s, 1H, HC]N), 7.71 (s,
1H, HC]C), 5.82 (d, J10,20¼4.8 Hz, 1H, H-10), 4.44e4.41 (m, 1H, H-20),
4.27e4.24 (m, 1H, H-30), 4.02e3.99 (m, 1H, H-40), 3.87 (s, 3H,
CH3OC]N), 3.82 (dd, J50a,50b¼12.1, J50a,40¼3.2 Hz, 1H, Ha-50), 3.72 (dd,
J50b,50a¼12.2, J50b,40¼3.8 Hz, 1H, Hb-50), 3.63 (s, 3H, CH3OC]O); 13C
NMR (100 MHz, CD3OD) dC 171.4, 158.9, 150.4, 134.7, 133.1, 118.9,
92.7, 89.3, 85.7, 76.0, 71.2, 62.3, 53.9, 51.2; m/z (HRESIMS) 357.1421
([MþH]þ, C14H21N4O7, requires 357.1410); IR (neat) nmax 3330, 1634,
1575 cm!1; UV (MeOH) lmax 271 nm.
Compound 4: oil; 1H NMR (700 MHz, DMSO-d6) dH (major
tautomer) 8.90 (s, 1H, H-5), 8.77 (s, 1H, H-2), 6.34 (d, J¼5.3 Hz, 1H,
H-10), 6.10e6.07 (m, 1H, H-20), 5.68e5.63 (m, 1H, H-30), 4.42e4.39
(complex signal, 2H, H-40 and Ha-50), 4.25 (dd, J50b,50a¼12.9,
J50b,40¼6.0 Hz,1H, Hb-50), 4.20 and 4.19 (br s,1H each, Ha,b-8), 3.63 (s,
3H, OCH3), 2.12 (s, 3H, CH3), 2.03 (s, 3H, CH3), 1.99 (s, 3H, CH3). 13C
NMR (175 MHz, CD3OD) dC 169.9, 169.4, 169.2 (two carbons), 154.5,
151.9, 150.3, 145.4, 132.9, 85.9, 79.5, 71.8, 69.9, 62.6, 51.9, 38.0, 20.4,
20.3, 20.1; IR (neat) nmax 1746, 1598, 1223 cm!1; m/z (HRESIMS)
451.1451 ([MþH]þ, C19H23N4O9, requires 451.1465); UV (MeOH)
lmax 263 nm.
4.4. Reaction of 1b with 3-phenyl-2-propynenitrile. Synthesis
of 5 and 6
A solution of 1b (50 mg, 0.13 mmol) and 3-phenyl-2-
propynenitrile (14 mg, 0.16 mmol), in dioxane (2.5 mL) was
reﬂuxed for 4 h (TLC monitoring, AcOEt/hexane, 8:2) and then the
solvent was evaporated under reduced pressure. The crude was
puriﬁed on a silica gel column eluted with increasing amounts of
AcOEt in hexane (from 50 to 100%) to give 5 (30 mg, 45%) and 6
(19 mg, 30%), the purity of which was checked by HPLC analysis
(System C, 5 tR¼22.3 min; 6 tR¼18.2 min, see General methods).
Compound 5: white solid mp 116e117 $C; ½a'20D !50.6 (c 0.11,
CH3OH), 1H NMR (400 MHz, CD3OD) dH 8.62 (s, 1H, H-2), 8.46 (s, 1H,
H-8), 7.83e7.78 (m, 2H, Ph ortho-H), 7.54e7.50 (m, 1H, Ph para-H),
7.49e7.44 (m, 2H, Ph meta-H), 6.33 (d, J10,20¼5.0 Hz, 1H, H-10),
6.00e5.96 (m, 1H, H-20), 5.69e5.66 (m, 1H, H-30), 4.52e4.36
(complex signal, 3H, H-40 and Ha,b-50), 2.14 (s, 3H, CH3), 2.08 (s, 3H,
CH3), 2.07 (s, 3H, CH3); 13C NMR (175 MHz, CD3OD) dC 194.7, 172.2,
171.4, 171.2, 152.2, 149.1, 145.3, 143.5, 140.7, 132.3, 129.0, 125.1, 121.7,
88.4, 81.8, 74.6, 71.8, 64.1, 20.6, 20.5, 20.3; IR (neat) nmax 2205, 1742,
1616, 1239 cm!1; m/z (HRESIMS) 522.1620 ([MþH]þ, C25H24N5O8,
requires 522.1625); UV (MeOH) lmax 364 nm.
Compound 6: oil; ½a'20D !6.33 (c 0.6, CH3OH), 1H NMR (400 MHz,
CD3OD) dH 9.10 (s, 1H, H-2), 8.71 (s, 1H, H-8), 8.00e7.95 (m, 2H, Ph
ortho-H), 7.73e7.67 (m, 1H, Ph para-H), 7.57e7.51 (m, 2H, Ph meta-
H), 6.41 (d, J10,20¼5.0 Hz, 1H, H-10), 6.16e6.12 (m, 1H, H-20),
5.78e5.75 (m, 1H, H-30), 4.53e4.39 (complex signal, 3H, H-40 and
Ha,b-50), 2.16 (s, 3H, CH3), 2.08 (s, 3H, CH3), 2.06 (s, 3H, CH3); 13C
NMR (100 MHz, CD3OD) dC 192.8, 172.3, 171.4, 171.1, 154.7, 154.0,
152.9, 148.3, 136.6, 135.6, 133.4, 131.8, 129.6, 88.8, 81.8, 74.5, 71.9,
64.1, 20.9, 20.5, 20.4; IR (neat) nmax 1747,1674,1582,1226 cm!1;m/z
(HRESIMS) 483.1522 ([MþH]þ, C23H23N4O8, requires 483.1516); UV
(MeOH) lmax 265 nm.
4.5. Reaction of 1b with N-methylmaleimide. Synthesis of 7
A solution of 1b (5 mg, 0.013 mmol) and N-methylmaleimide
(14 mg, 0.13 mmol), in dioxane/toluene (1:1, v/v, 2.5 mL) was
reﬂuxed. After 5 h the process was complete (TLC monitoring,
AcOEt/MeOH, 95:5) and the solvent was removed under reduced
pressure. The crude was puriﬁed by HPLC (System B, tR¼16.0 min,
see General methods) affording 7 (4.0 mg, 60%) as an inseparable
mixture of diastereomers.
Compound 7: oil; 1H NMR (400 MHz, CD3OD) dH (mixture of di-
astereomers) 8.95 (s, 0.3H), 8.64 (s, 0.3H), 8.23 (s, 0.7H), 8.09 (s, 0.7H),
6.36 (d, J¼4.5 Hz, 0.3H), 6.19 (d, J¼5.1 Hz, 0.7H), 6.15e6.11 (m, 1H,
0.3H), 5.98e5.92 (m,0.7H), 5.80e5.73 (m,0.3H), 5.69e5.62 (m,0.7H),
5.29 (s, 0.7H), 5.16 (d, J¼2.7Hz, 0.3H), 4.51e4.32 (complex signal, 3H),
3.06 (s, 0.9H), 3.01 (s, 2.1H), 2.14 (s, 3H, CH3), 2.08 (s, 3H, CH3), 2.07 (s,
3H, CH3); 13C NMR (100 MHz, CD3OD) dC 177.4, 172.2, 171.3, 171.2,
153.7, 147.0, 146.2, 145.0, 141.4, 123.9, 89.0, 88.4, 88.2, 81.7, 74.6, 74.2,
73.9, 71.8, 69.1, 64.1, 25.4, 24.1, 20.7, 20.4, 20.3; IR (neat) nmax 3335,
1740, 1699, 1584 cm!1; m/z (HRESIMS) 506.1531 ([MþH]þ,
C21H24N5O10, requires 506.1523); UV (MeOH) lmax 267, 346 nm.
4.6. Preparation of 20,30,50-tri-O-(tert-butyldimethylsilyl)-
nebularine N1-oxide
20,30,50-Tri-O-(tert-butyldimethylsilyl)-nebularine was prepared
as described.9b A mixture of MeReO3 (5 mg, 0.02 mmol) and 30%
aqueous H2O2 (0.4 mL, 4.0 mmol) in methanol (6 mL) was stirred at
room temperature for 10 min. Then 20,30,50-tri-O-(tert-butyldime-
thylsilyl)-nebularine9b (595 mg, 1.0 mmol) in methanol (6 mL) was
dropwise added while stirring. The stirring was continued at room
temperature overnight. Then the solvent was removed under re-
duced pressure and the crude was puriﬁed on a silica gel column
eluted with increasing amounts of AcOEt in hexane (up to 20%) to
afford pure 20,30,50-tri-O-(tert-butyldimethylsilyl)-nebularine N1-
oxide 1c (513 mg, 84% yield).
Compound 1c: white solid, mp 126e127 $C; ½a'20D !16.1 (c 0.80,
CHCl3), 1H NMR (400 MHz, CD3OD) dH 9.16 (br s, 1H), 9.02 (br s, 1H),
8.88 (s, 1H), 6.12 (d, J¼4.7 Hz, 1H), 4.91e4.87 (m,1H), 4.75e4.70 (m,
1H), 4.44e4.40 (m, 1H), 4.06 (dd, J¼11.5, 4.1 Hz, 1H), 3.86 (dd,
J¼11.5, 2.4 Hz, 1H), 0.95 (br s, 18H), 0.82 (s, 9H), 0.15 (br s, 9H), 0.13
(s, 3H), 0.03 (s, 3H), !0.18 (s, 3H); 13C NMR (100 MHz, CD3OD) dC
150.0,146.4,145.6,139.2,135.2, 90.1, 87.0, 77.2, 72.9, 63.4, 26.5, 26.4,
26.2, 19.3, 18.9, 18.7, !4.0, !4.3, !4.7, !5.1, !5.3; m/z (HRESIMS)
633.3312 ([MþH]þ, C28H54N4NaO5Si3, requires 633.3300); IR (neat)
nmax 2930, 2858, 1255, 1139, 837, 778 cm!1; UV (CHCl3) lmax 280,
253 nm.
4.7. General procedure for reaction of 1c with Grignard
reagents. Synthesis of 15e18
In a ﬂamed round-bottomed ﬂask charged with dry nitrogen, 1c
(50 mg, 0.082 mmol), dissolved in dry THF (0.5 mL), was added via
cannula. To the ﬂask the Grignard reagent (2 equiv) in THF was
slowly added and the mixture was stirred for 2 h (TLC monitoring:
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hexane/AcOEt, 4:6) at room temperature. The reaction was
quenched by addition of a 1 M solution of NH4Cl (1 mL), diluted
with AcOEt (10 mL) and extracted with brine (1 mL). The organic
layer was separated, dried (Na2SO4), ﬁltered and concentrated
under rotary evaporation. The crude was dissolved in a mixture of
Ac2Oepyridine (6:4, 0.5 mL) and the solution was kept at 50 $C for
1 h. The crudewas evaporated in vacuo and puriﬁed over a silica gel
column eluted with increasing amounts of EtOAc in hexane (up to
20%). The fractions containing the product were collected and
evaporated to afford pure 15e18.
4.7.1. 20,30,50-Tri-O-(tert-butyldimethylsilyl)-6-methyl nebularine 15.
Compound 15: white solid (41 mg, 82% yield), ½a'20D !36.8 (c 0.50,
CH3OH), mp 74e76 $C; 1H NMR (400 MHz, CDCl3) dH 8.83 (s, 1H, H-
2), 8.38 (s, 1H, H-8), 6.11 (d, J¼5.2 Hz,1H, H-10), 4.72e4.66 (m,1H, H-
20), 4.34e4.32 (m,1H, H-30), 4.17e4.12 (m,1H, H-40), 4.02 (dd, J¼11.4,
3.9 Hz, 1H, H-5a0), 3.79 (dd, J¼11.4, 2.5 Hz, 1H, H-5b0), 2.87 (s, 3H,
CH3), 0.99 (s, 9H, C(CH3)3), 0.94 (s, 9H, C(CH3)3), 0.78 (s, 9H, C(CH3)3),
0.15 (s, 3H, CH3), 0.14 (s, 3H, CH3), 0.11 (br s, 6H, 2% CH3), 0.05 (s, 3H,
CH3), !0.28 (s, 3H, CH3); 13C NMR (100 MHz, CDCl3) dC 159.2, 152.2,
150.4, 142.7, 133.5, 88.2, 85.6, 75.8, 72.0, 62.5, 19.5, 18.5, 18.1, 17.8,
!4.4, !4.6, !4.7, !5.1, !5.4; m/z (HRESIMS) 609.3679 ([MþH]þ,
C29H57N4O4Si3, requires 609.3688); IR (neat) nmax 2955, 2930, 2859,
1599, 1256, 837, 777 cm!1; UV (CHCl3) lmax 260 nm.
4.7.2. 20,30,50-Tri-O-(tert-butyldimethylsilyl)-6-vinyl nebularine 16.
Compound 16: colourless oil22 (37 mg, 71% yield); ½a'20D !44.6 (c
0.51, CH3OH), 1H NMR and 13C NMR data are in agreement with
reported data;22 m/z (HRESIMS) 621.3681 ([MþH]þ, C30H57N4O4Si3,
requires 621.3688); IR (neat) nmax 2931, 2859, 1583, 1256, 837,
778 cm!1; UV (CHCl3) lmax 285 nm.
4.7.3. 20,30,50-Tri-O-(tert-butyldimethylsilyl)-6-phenyl nebularine 17.
Compound 17: colourless oil (45 mg, 82% yield); ½a'20D !96.4 (c 0.11,
CH3OH) 1H NMR (400 MHz, CDCl3) dH 9.01 (s, 1H, H-2), 8.82e8.75
(m, 2H, HPh), 8.46 (s, 1H, H-8), 7.61e7.49 (m, 3H, HPh), 6.18 (d,
J¼5.4 Hz,1H, H-10), 4.78e4.72 (m,1H, H-20), 4.38e4.32 (m,1H, H-30),
4.19e4.14 (m, 1H, H-40), 4.05 (dd, J¼11.3, 4.1 Hz, 1H, H-5a0), 3.82 (dd,
J¼11.3, 2.8 Hz, 1H, H-5b0), 0.97 (s, 9H, C(CH3)3), 0.96 (s, 9H, C(CH3)3),
0.79 (s, 9H, C(CH3)3), 0.16 (s, 3H, CH3), 0.15 (s, 3H, CH3), 0.13 (br s, 6H,
2% CH3), 0.03 (s, 3H, CH3), !0.25 (s, 3H, CH3); 13C NMR (100 MHz,
CDCl3) dC 154.9, 152.3, 143.3, 135.7, 131.6, 130.9, 129.8, 128.6, 88.2,
85.7, 75.7, 72.1, 62.6, 26.1, 25.8, 25.6, 18.5, 18.1, 17.8, !4.4, !4.6, !4.7,
!5.0, !5.3, !5.4; m/z (HRESIMS) 693.3649 ([MþNa]þ,
C34H58N4NaO4Si3, requires 693.3664); IR (neat) nmax 2954, 2930,
2858, 1579, 1567, 1256, 836, 777 cm!1; UV (CHCl3) lmax 291 nm.
4.7.4. 20,30,50-Tri-O-(tert-butyldimethylsilyl)-6-propynyl nebularine
18. Compound 18: colourless oil (41 mg, 80% yield); ½a'20D !61.3 (c
0.12, CH3OH) 1H NMR (700 MHz, CDCl3) dH 8.88 (s, 1H, H-2), 8.46 (s,
1H, H-8), 6.12 (d, J¼5.2 Hz, 1H, H-10), 4.66e4.62 (m, 1H, H-20),
4.31e4.28 (m, 1H, H-30), 4.16e4.13 (m, 1H, H-40), 4.01 (dd, J¼11.4,
3.9 Hz, 1H, H-5a0), 3.80 (dd, J¼11.4, 2.5 Hz, 1H, H-5b0), 2.25 (s, 3H,
CH3), 0.95 (s, 9H, C(CH3)3), 0.93 (s, 9H, C(CH3)3), 0.77 (s, 9H,
C(CH3)3), 0.15 (s, 3H, CH3), 0.14 (s, 3H, CH3), 0.10 (br s, 6H, 2% CH3),
0.05 (s, 3H, CH3), !0.29 (s, 3H, CH3); 13C NMR (175 MHz, CDCl3) dC
152.5, 151.2, 143.9, 142.2, 134.7, 97.1, 88.1, 85.8, 76.0, 75.3, 72.0, 62.5,
26.0, 25.8, 25.6, 18.5, 18.0, 17.8, 5.1, !4.4, !4.6, !4.7, !5.1, !5.3;m/z
(HRESIMS) 655.3519 ([MþNa]þ, C31H56N4NaO4Si3, requires
655.3507); IR (neat) nmax 2956, 2859, 2243, 1580, 1259, 837,
776 cm!1; UV (CHCl3) lmax 286 nm.
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a b s t r a c t
Three novel inosine-based dinuclear platinum complexes have been synthesized via a solid-phase strat-
egy. In these compounds, the metal is linked both to the N-7 of the purine nucleus and to the terminal
amine group of a hexylamine side chain installed on N-1. Cis- or trans- diamine as well as ethylenedia-
mine ligands are coordinated to platinum along with a chloride. The synthesised complexes were tested
against four different human tumor cell lines. One of these complexes proved to be more cytotoxic than
cisplatin against the MCF7 cancer cell line in a short-term exposure assay.
! 2011 Elsevier Ltd. All rights reserved.
Studies conducted during the last two decades demonstrated
that cross-resistance to cisplatin and its analogs can be overcome
using polynuclear platinum complexes.1,2 This finding prompted
efforts to design and synthesize new polynuclear platinum com-
plexes containing a chloro-leaving group3–6 on each terminal plat-
inum, generally with trans geometry7–9 respect to an aliphatic
unbranched amine-linking ligand that can contain either a central
inert charged platinum moiety or a functional group capable of
forming hydrogen bonds with DNA. Like mono-nuclear complexes,
polynuclear analogs induce cell death through apoptosis, but, un-
like the former, they are able to inhibit cancer cell growth
in vitro at concentrations much lower than cisplatin.10
New Pt-based compounds have recently been produced by con-
jugating biologically important substances or drugs with Pt-con-
taining subunits, such as Pt-amine units with heterocyclic
ligands11 or flat aromatic molecules with cisplatin-based
fragments.12,13 Moreover, Reedijk et al. were able to synthesize
mono14,15 and dinuclear16 platinum complexes by attaching plati-
num moieties to small peptides using solid-phase synthesis. Dif-
ferently, very few studies have investigated the conjugation of
Pt-amine subunits with nucleoside or nucleotide scaffolds.17
Nucleoside and nucleotide antimetabolites and their base ana-
logs are able to inhibit specific pathways of cancer cell metabolism
by blocking the biosynthesis or the function of nucleic acids.18–22
For example, the combination of cisplatin and 5-fluorouracil, a
chemotherapic agent that inhibits thymidylate synthase, has been
extensively used in clinical practice to treat various types of cancer.
Acyclovir, a guanosine nucleoside analog containing an open-chain
sugar surrogate, was used as ligand for platinum and the corre-
sponding complex exhibited high in vitro activity against various
herpes viruses.23 In this context, we asked whether nucleosides
could act as platinum carriers to obtain a higher drug concentration
in tumor cells.
Here we report the synthesis of the first examples of bis-
platinated nucleoside complexes in which the metal is linked both
to N-7 of the purine nucleus of inosine and to the terminal amino-
group of a hexylamine side chain installed on N-1, via a solid-phase
approach. We first focused on inosine as the nucleoside because we
have recently developed an efficient solid-phase strategy by which
an aminoalkyl chain of variable length can be attached to N-1 of
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the base.24–26 The new complexes are characterized by a rigid pla-
nar purine substructure and a flexible hexylamine chain. These
structural features confer semi-rigidity to the molecule that could,
in principle, confer a different reactivity to the two platinum cen-
ters towards DNA. The presence of hydroxyl groups belonging to
the sugar moiety could confer both water solubility, which is
important for oral administration, and hydrogen-bonding ability,
which is relevant for the initial preassociation with DNA.
Dinuclear platinum complexes 8a–cwere synthesized as shown
in Scheme 1. As an extension of our previously reported proce-
dure,24–26 inosine 1was bound to the commercially available poly-
styrene monomethoxytrityl chloride (MMTCl, 1.3 mmol/g) resin by
the selective formation of a 50-O-trityl ether linkage, to give solid
support 2 in an almost quantitative yield. Ribose moiety in 5 was
acetylated under standard conditions (Ac2O/pyridine) and then
the resin was subjected to N-1 dinitrophenylation by reaction with
2,4-dinitrochlorobenzene (DNCB) in the presence of K2CO3 in DMF,
to give support 3. As previously demonstrated,26,27 the reaction of
such a support with a diamine of suitable chain length furnishes N-
1-x-alkylinosine derivatives via opening-reclosure of the purine
ring. In this way, the N-1-derivatised support 4 was obtained by
reacting 3 with excess 1,6-diaminohexane in DMF that also caused
the concomitant deacetylation of the hydroxyl groups at the 20/30
positions. Acidic treatment of support 4 (2% TFA in DCM) furnished
the nucleoside material 5 in a yield of 76% over four steps (see Sup-
plementary data).
Next, the platinum-containingmoietieswere installed. In partic-
ular, treatment of support 4 with a five-fold excess of the suitable
platinating complex (6a–c), activated by overnight reaction with
AgNO3 (0.9 equiv) in DMF,28 furnished the bis-platinated supports
7a–cwhere the metal is coordinated with the N-7 and the N-1 ami-
noalkyl nitrogens. Finally, dinuclear platinum complexes 8a–c,
including trans- or cis-diamino ligands, as well as an ethylenedia-
mine ligand, around the metal center, were delivered by the usual
acidic treatment of the resin. Purification of these substances could
be accomplished by reverse-phase HPLC only using a gradient of
CH3CN in 0.1 M triethylammonium bicarbonate buffer (TEAB) (pH
7) as solvent mixture, whereas complex chromatographic patterns
resulted in the absence of the TEAB. The structures of complexes
8a–c (yields 67–70%) were confirmed by 2D-nuclear magnetic res-
onance (NMR) and high resolution mass spectrometry (HRMS)
data.29 In particular, the presence of the N(7)-Pt bond in these sub-
stanceswas demonstrated both by the high field shift of the C-5 and
C-8 resonances in their 13C NMR spectra and by the downfield shift
of H-8 in their proton spectra.30,31 Platination of the side-chain
amino group was evident from the high field shift of the methylene
protons next to metallated NH2.16 Further evidence of metallation
at N-7 comes from an increased acidity of the C(8)-H proton as indi-
cated by the disappearance of the pertinent signal in the proton
spectra of 8a–c when these substances were dissolved in D2O.32
We then comparatively evaluated the cellular response to com-
pounds 8a–c versus cisplatin in short-term exposure assays using
four human tumor cell lines, namely ovarian A2780, cervical HeLa,
breastMCF-7 and lung A549 cells by determining their ATP levels in
terms of relative light units (RLUs). The A549 cellular model was
chosen because, to our knowledge, it is relatively resistant to cis-
platin and expresses high endogenous levels of the ATP Binding
Cassette G2 (ABCG2) efflux pump.33 Standard curves of all cell lines
demonstrated the linearity and sensitivity of the method used to
detect the cytotoxic effects of the complexes (data not shown). In
A2780, HeLa and A549 cell lines, the cytotoxicity of 8a–c did not dif-
fer significantly from that of cisplatin (Table 1, Supplementary
data). Differently, in theMCF-7 cell line, 8a, 8c and cisplatin exerted
a similarly potent cytotoxic effect, whereas compound 8b was sig-
nificantly more cytotoxic than cisplatin (Fig. 1, panel A) and, more-
over, its 50% inhibitory concentration (IC50) was two-fold lower
than that obtained in the A549 cell line (Table 1 and Fig. 1, panel
B). The pattern of MCF-7 response to compound 8b in the short-
term exposure assay is particularly, especially considering that this
breast cancer cell line was derived from a metastatic pleural
effusion of a 69-year-old woman with an invasive ductal carci-
noma,34 one of the most aggressive and potentially lethal types of
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breast cancer.35 Therefore, we believe that further investigations
should be conducted to evaluate the potential of 8b as a therapeutic
strategy for breast tumors with poor prognosis, such as those histo-
logically and phenotypically similar to the MCF-7 cellular model.
In summary, in this Letter we describe the synthesis of three no-
vel inosine-based dinuclear platinum complexes using a fast and
flexible solid-phase strategy. These compounds were tested
against four human tumor cell lines. Compound 8b proved to be
more cytotoxic than cisplatin in short-term exposure assays in
the MCF-7 cancer cell line, and it exerted its cytotoxic effect in just
1 h. Consequently, it is likely that compound 8b is able to cross the
cellular membrane more readily than cisplatin. This encouraging
result prompts us to carry out further studies on the cytotoxicity
of this substance as well as on its structural modifications in the at-
tempt to obtain other representatives of this new class of bis-
platinated complexes. In these studies, we will focus, inter alia,
on modification of the sugar moiety and on modulation of the N-
1-alkyl chain length that separates the metal centers.
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Figure 1. Activity of 8b against MCF7 human breast cancer cells in short-term (1 h) exposure assays (see also Supplementary data). Panel A: The columns height represents
the mean relative light units (RLUs) value; the upper ticks indicate the standard deviation (P refers to t-test). Panel B: IC50 values were obtained starting from RLUs values of
the ViaLight# assay by dose–response curves; the upper ticks indicate the standard deviation.
Table 1
Cytotoxic effects of 8a, 8b, 8c compounds and cisplatin in MCF-7 and A549 cell lines
in short-term exposure assays
Cell Model IC50 (mM)a
Drug
8a 8b 8c cisplatin
MCF-7 0.84 ± 0.38 0.47 ± 0.14 3.26 ± 3.4 2.36 ± 1.4
A549 4.5 ± 3.4 1.27 ± 0.28 4.16 ± 4.3 0.9 ± 0.23
a IC50 values (±SD) were deduced from dose–response curves following cyto-
toxicity studies as described in Supplementary data.
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28. General procedure for the preparation of dinuclear platinum complexes 8a–c: In a
representative experiment Pt(en)Cl2 (24 mg, 0.075 mmol) was activated by
treatment with AgNO3 (11 mg, 0.067 mmol) in DMF (0.5 mL) in the dark
(overnight, rt). AgCl was removed by filtration and the resulting solution of
[Pt(en)(Cl)dmf]+(NO3)! in DMF was added to resin 7 (20 mg, 0.015 mmol) in
the presence of TEA (15 lL, 0.10 mmol). The suspension was shaken overnight
in the dark and then the resin 7a was filtered, washed with DMF (3 " 5 mL),
DMF/MeOH (1:1, v/v, 3 " 5 mL), MeOH (3 " 5 mL) and dried under reduced
pressure. The solid-phase platination yields, were evaluated by analysing the
nucleosidic material released from weighed amounts of 7a–c by treatment
with 2% (v/v) TFA in DCM for 8 min at rt followed by H2O washings (collected).
HPLC purifications [System A for 7a (tR: 35.2 min) and System B for 7b,c (tR:
30.5 and 19.3 min, respectively); see general procedures in the Supplementary
data] furnished bis-platinated nucleosides 8a–c (yields 67–70%), the structure
of which was confirmed by spectroscopic data.
29. Complex 8a: Bis-bicarbonate salt, yield: 68% (from 2). El. Anal. Calcd for
C22H43Cl2N9O11Pt2: C, 24.68; H, 4.05; N, 11.77. Found: C, 24.75; H, 4.08; N,
11.82. 1H NMR (500 MHz, D2O, assignments by a homonuclear COSY
experiment) d 8.87, 8.52 (s0s, 1H each, H-8 and H-2), 6.18 (d, J = 4.4 Hz, 1H,
H-10), 4.74 (m, 1H, H-20), 4.45 (m, 1H, H-30), 4.37–4.27 (m, 1H, H-40), 4.21 (t,
J = 7.0 Hz, 1H, CH2N), 3.98 (dd, J = 12.9, 2.6 Hz, 2H, H! 50a), 3.88 (dd, J = 12.9,
3.9 Hz, 1H, H! 50b), 2.82-2.72 (m, 2H, CH2NH2, ethylendiamine moiety), 2.68 (t,
J = 6.5 Hz, 2H, CH2NH2), 2.63–2.58 (m, 2H, CH2NH2, ethylendiamine moiety),
1.91–1.82 (m, 2H, CH2), 1.74–1.65 (m, 2H, CH2), 1.50–1.36 (m, 4H, 2 " CH2);
13C NMR (125 MHz, D2O, assignments by HSQC and HMBC experiments) d
162.4 and 163.2 (2"HCO!3 ), 156.1 (C@O), 150.1 (C-2), 146.8 (C-4), 142.7 (C-8),
121.8 (C-5), 89.3 (C-10), 83.3 (C-40), 73.4 (C-20), 69.5 (C-30), 60.5 (C-50), 48.3
(2 " CH2, ethylendiamine moiety), 47.8 (CH2N), 48.1 and 47.2 (2 " CH2,
ethylendiamine moiety), 46.06 (CH2NH2, aminohexyl chain), 29.9, 28.5, 25.1,
24.9 (4 " CH2, aminohexyl chain); UV (H2O) kmax 255 nm; HRESI-MS: (m/z)
473.5921, Calcd [M]2+ 473.5936.
Complex 8b: Bis-bicarbonate salt, yield: 70% (from 2). El. Anal. Calcd for
C18H39Cl2N9O11Pt2: C, 21.22; H, 3.86; N, 12.38. Found: C, 21.28; H, 3.88; N,
12.43. 1H NMR (500 MHz, D2O, assignments by a homonuclear COSY
experiment) d 8.86, 8.50 (s0s, 1H each, H-8 and H-2), 6.18 (d, J = 4.5 Hz, 1H,
H-10), 4.71 (m, 1H, H-20), 4.42 (m, 1H, H-30), 4.30–4.28 (m, 1H, H-40), 4.10 (t,
J = 7.0 Hz, 2H, CH2N), 3.95 (dd, J = 12.8, 2.7 Hz, 2H, H! 50a), 3.85 (dd, J = 12.9,
3.9 Hz, 1H, H! 50b), 2.65 (t, J = 7.4 Hz, 2H, CH2NH2), 1.87–1.80 (m, 2H, CH2),
1.71–1.64 (m, 2H, CH2), 1.46–1.35 (m, 4H, 2 " CH2); 13C NMR (125 MHz, D2O,
assignments by HSQC and HMBC experiments) d 162.8 and 163.0 (2" HCO!3 ),
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